17003041-302	<protein-id="O76090,O88870,Q21973,Q6UY87,Q8WMR7">Bestrophin-1</protein-id> enables Ca2+-activated <compound-id="312">Cl</compound-id>-conductance in epithelia.	Cl__Bestrophin-1__interaction
17003041-304	Calcium-dependent <compound-id="312">Cl</compound-id> (-) currents were activated by <compound-id="5957">ATP</compound-id> in HEK293 cells expressing <protein-id="O76090,Q6UY87,Q8WMR7">BEST1</protein-id>.	ATP__BEST1__no_interaction	Cl__BEST1__interaction
17321121-703	The absorption spectrum of the <protein-id="P80509,P80510">hydrogenase</protein-id> enzyme showed an absorption peak at 425nm indicating that the enzyme had iron-<compound-id="402">sulfur</compound-id> clusters.	sulfur__hydrogenase__interaction
17403602-1067	When Vitreoscilla were grown in medium containing 60mM <compound-id="23668193">sodium nitrite</compound-id> under both normal and limited aeration conditions, the levels of Vitreoscilla <protein-id="P15160,P17724,P73925,Q03459">hemoglobin</protein-id> (VHb) were decreased by greater than 90%, while the levels of the terminal respiratory oxidase, cytochrome bo, were increased 350% under normal aeration and 7-23% under limited aeration.	sodium nitrite__hemoglobin__interaction
17590240-1233	<compound-id="65064">Epigallocatechin gallate (EGCG</compound-id>) suppresses beta-amyloid-induced neurotoxicity through inhibiting c-<protein-id="P00520,P00522">Abl</protein-id>/<protein-id="O00213">FE65</protein-id> nuclear translocation and <protein-id="P18266,P49841,Q5YJC2,Q9WV60">GSK3 beta</protein-id> activation.	Epigallocatechin gallate (EGCG__GSK3 beta__interaction	Epigallocatechin gallate (EGCG__Abl__interaction	Epigallocatechin gallate (EGCG__FE65__interaction
17590240-1234	Here, we used a human neuronal cell line MC65 conditional expression of an amyloid precursor protein fragment (<protein-id="P12023">APP-C99</protein-id>) to investigate the protection mechanism of <compound-id="65064">epigallocatechin gallate (EGCG</compound-id>), the main constituent of <compound-id="4630">green tea</compound-id>.	green tea__APP-C99__interaction	epigallocatechin gallate (EGCG__APP-C99__interaction
17616381-938	The <protein-id="O41798,O89290,O89940,O91080,O93215,P03311,P03353,P03355,P03356,P03362,P03363,P03366,P03367,P03369,P03370,P04023,P04024,P04323,P04584,P04585,P04587,P04588,P04589,P05959,P05960,P05961,P05962,P07570,P0C210,P0C211,P10210,P10265,P10270,P10271,P10272,P10273,P10274,P10394,P10978,P11227,P11365,P12451,P12497,P12498,P12499,P14074,P14078,P15833,P16046,P16423,P16901,P17757,P18042,P18096,P18802,P19028,P19199,P19560,P19561,P20825,P20875,P20876,P20892,P21407,P21414,P24107,P24740,P26808,P26809,P26810,P27502,P28936,P31822,P35956,P35963,P51518,P63119,P63120,P63121,P63122,P63123,P63124,P63125,P63127,P63128,P63129,P63131,P84454,Q09SZ9,Q0R5R2,Q0R5R3,Q1A249,Q1A267,Q4U0X6,Q73368,Q74120,Q75002,Q76634,Q77373,Q79666,Q89928,Q8AII1,Q8I7P9,Q9IDV9,Q9Q720,Q9QBY3,Q9QBZ1,Q9QBZ5,Q9QSR3,Q9WC54,Q9WC63,Q9Y6I0">protease</protein-id> was purified to homogeneity using <compound-id="223">ammonium</compound-id> <compound-id="1117">sulfate</compound-id> precipitation, and ion exchange chromatography with a fold purification of 1.8 and a recovery of 49%.	sulfate__protease__interaction	ammonium__protease__interaction
17629591-228	In addition, we demonstrated that Hsp20, <protein-id="O35878,Q16082,Q99PR8">HspB2</protein-id> and <protein-id="Q5EAC9,Q5RAB0,Q6SJQ8,Q8MJ36,Q9EPX0,Q9JK92,Q9UJY1">HspB8</protein-id> induced <protein-id="P41693">interleukin-6</protein-id> production in cultured pericytes and astrocytes, which could be antagonized by <compound-id="5743">dexamethasone</compound-id>, whereas other sHsps and A beta were inactive, suggesting that sHsps may be among the key mediators of the local inflammatory response associated with HCHWA-D and AD lesions.	dexamethasone__HspB2__interaction	dexamethasone__interleukin-6__interaction	dexamethasone__HspB8__interaction
17692997-193	Furthermore, <compound-id="19001,439196,446094">dithiothreitol</compound-id> was found to be capable of significantly preventing the inhibitory effect of <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> on Abeta oligomer formation.	dithiothreitol__insulin__interaction
17719144-1171	The scavenger receptor, <protein-id="P21988,P21989,P21990,P21991,P21992">class B</protein-id>, type I (<protein-id="O18824,P97943,Q60417,Q61009,Q8SQC1,Q8WTV0">SR-BI</protein-id>) is critical in maintaining the homeostasis of <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> and <compound-id="2116,14985">alpha-tocopherol</compound-id>.	alpha-tocopherol__class B__interaction	alpha-tocopherol__SR-BI__interaction	cholesterol__SR-BI__interaction	cholesterol__class B__interaction
17719144-1172	<protein-id="O18824,P97943,Q60417,Q61009,Q8SQC1,Q8WTV0">SR-BI</protein-id> binds <protein-id="P81182">high-density lipoproteins</protein-id> (HDL) and mediates the selective transfer of cholesteryl esters and <compound-id="2116,14985">alpha-tocopherol</compound-id> from circulating HDL to cells.	alpha-tocopherol__high-density lipoproteins__interaction	alpha-tocopherol__SR-BI__interaction
17719144-1173	Thus, <protein-id="O18824,P97943,Q60417,Q61009,Q8SQC1,Q8WTV0">SR-BI</protein-id> influences neural and cognitive processes, a finding that highlights the contribution of <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> and <compound-id="2116,14985">alpha-tocopherol</compound-id> homeostasis in proper cognitive function.	cholesterol__SR-BI__no_interaction	alpha-tocopherol__SR-BI__no_interaction
17768029-984	<compound-id="5781">Alloxan</compound-id> is believed to confer its diabetogenic effect by inhibiting pancreatic <protein-id="O25731,P0A4E1,P0A4E2,P0A6V8,P0A6V9,P17712,P21908,P35557,P52792,P54495,P58616,P58617,P58618,P58619,P64253,P64254,P82680,Q55855,Q56198,Q59171,Q668N7,Q6D7C4,Q7N6Y0,Q83K86,Q87EG6,Q8FFD4,Q8FV09,Q8P8U7,Q8PKU2,Q8UIV7,Q8YDC6,Q92407,Q92T27,Q93IM5,Q98DM2,Q9A6N3,Q9HZ46,Q9KCZ4,Q9PEG4,Q9ZKB0">glucokinase</protein-id> activity, leading to pancreatic beta-cell death.	Alloxan__glucokinase__interaction
17882129-602	<compound-id="2116,14985">Alpha-tocopherol</compound-id> supplementation prevents the exercise-induced reduction of serum paraoxonase 1/<protein-id="P22862">arylesterase</protein-id> activities in healthy individuals.	Alpha-tocopherol__arylesterase__interaction
17888544-779	Although ApoE4 has been repeatedly associated with altered sphingomyelin and <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> levels in tissue culture and rodent models, there has not been a direct quantification of sphingomyelin or sterol levels in the brains of patients with different forms of <protein-id="P02649,P02650,P05770,P08226,P10517,P18287,P18649,P18650,P23529,Q03247,Q28502,Q28995,Q7M2U7,Q7M2U8,Q9GJU3,Q9GLC0,Q9GLM6,Q9GLM7,Q9GLM8">ApoE</protein-id>.	cholesterol__ApoE__no_interaction
17888546-781	<protein-id="P02649,P02650,P05770,P08226,P10517,P18287,P18649,P18650,P23529,Q03247,Q28502,Q28995,Q7M2U7,Q7M2U8,Q9GJU3,Q9GLC0,Q9GLM6,Q9GLM7,Q9GLM8">ApoE</protein-id> modified the association between <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> and cognitive decline, and the association between the ratio of <compound-id="99470,123976,50990021">27-hydroxycholesterol</compound-id> to <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> and cognitive functioning.	27-hydroxycholesterol__ApoE__interaction	cholesterol__ApoE__interaction
17890844-955	Here we show that during growth in media containing <compound-id="206,5793,64689,79025">glucose</compound-id> and in complex medium without <compound-id="206,5793,64689,79025">glucose</compound-id> RamB activates expression of the <protein-id="P0AFG8,P0AFG9,P45119,P57301,Q10504,Q59637,Q89AR0,Q8K9T9">aceE</protein-id> gene, encoding the E1p subunit of the pyruvate dehydrogenase complex.	glucose__aceE__no_interaction
17925795-1037	The mood stabilizers <compound-id="28486,3028194">lithium</compound-id> and <compound-id="3121">valproate</compound-id> selectively activate the promoter IV of <protein-id="P25430,P25431,P25432,Q06225">brain-derived neurotrophic factor</protein-id> in neurons.	lithium__brain-derived neurotrophic factor__interaction	valproate__brain-derived neurotrophic factor__interaction
17925795-1038	Treatment of cultured rat cortical neurons with therapeutic concentrations of <compound-id="433294">LiCl</compound-id> or VPA selectively increased the levels of exon IV (formerly rat exon III)-containing <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id> mRNA, and the activity of <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id> promoter IV.	LiCl__BDNF__interaction
17925795-1039	We showed that <compound-id="28486,3028194">lithium</compound-id>-induced activation of promoter IV was mimicked by pharmacological inhibition of <protein-id="P51136,P83101">GSK-3</protein-id> or short interfering RNA (siRNA)-mediated gene silencing of <protein-id="P18265,P49840">GSK-3alpha</protein-id> or <protein-id="P18266,P49841,Q5YJC2,Q9WV60">GSK-3beta</protein-id> isoforms.	lithium__GSK-3alpha__interaction	lithium__GSK-3beta__interaction	lithium__GSK-3__interaction
17925795-1040	Furthermore, treatment with other HDAC inhibitors, <compound-id="264">sodium butyrate</compound-id> and <compound-id="444732">trichostatin A</compound-id>, or transfection with an HDAC1-specific siRNA also activated <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id> promoter IV.	sodium butyrate__BDNF__no_interaction	trichostatin A__BDNF__no_interaction
17925795-1041	Our study demonstrates for the first time that <protein-id="P51136,P83101">GSK-3</protein-id> and HDAC are respective initial targets for <compound-id="28486,3028194">lithium</compound-id> and VPA to activate <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id> promoter IV, and that this <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id> induction involves a novel responsive region in promoter IV of the <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id> gene.	lithium__GSK-3__interaction	lithium__BDNF__no_interaction
17941873-845	Addition of biphasic <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> aspart 30 to optimized <compound-id="4091">metformin</compound-id> and <compound-id="4829">pioglitazone</compound-id> treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">Insulin</protein-id> plus Oral ageNts).	pioglitazone__insulin__no_interaction	metformin__insulin__no_interaction	pioglitazone__Insulin__no_interaction	metformin__Insulin__no_interaction
17941873-846	Efficacy and safety of biphasic <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> aspart (BIAsp 30, 30% short-acting and 70% intermediate-acting <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> aspart) added to an optimized treatment of <compound-id="4091">metformin</compound-id> and <compound-id="4829">pioglitazone</compound-id> (met/pio) were compared with treatment with optimized met/pio in type 2 diabetes patients.	pioglitazone__insulin__no_interaction	metformin__insulin__no_interaction
17943458-544	<compound-id="65065">N-acetylaspartic acid</compound-id> (NAA) is converted into <compound-id="5960">aspartate</compound-id> and <compound-id="53627460">acetate</compound-id> by <protein-id="P45381,P46446,Q60HH2,Q8R3P0,Q9R1T5">aspartoacylase</protein-id>.	N-acetylaspartic acid__aspartoacylase__interaction	aspartate__aspartoacylase__interaction	acetate__aspartoacylase__interaction
17950491-1121	In addition, treatment with <compound-id="77999">rosiglitazone</compound-id> increased interleukin-4 (<protein-id="O77762,P05112,P07750,P20096,P30367,P30368,P42202,P46652,P47966,P51492,P51744,P55030,P79155,P79339,Q04745,Q2PE74,Q3S4V6,Q58M18,Q60440,Q7YS71,Q865X5,Q865Y0,Q8HYB1,Q9MZR8,Q9XS58">IL-4</protein-id>) mRNA and reversed the age-related decrease in hippocampal <protein-id="O77762,P05112,P07750,P20096,P30367,P30368,P42202,P46652,P47966,P51492,P51744,P55030,P79155,P79339,Q04745,Q2PE74,Q3S4V6,Q58M18,Q60440,Q7YS71,Q865X5,Q865Y0,Q8HYB1,Q9MZR8,Q9XS58">IL-4</protein-id> concentration.	rosiglitazone__IL-4__interaction
17965987-545	Serum <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id> levels were increased and plasma levels of <compound-id="1738">HVA</compound-id> and <compound-id="10805">MHPG</compound-id> were decreased according to the recovery from the active phase of the disease.	HVA__BDNF__no_interaction	MHPG__BDNF__no_interaction
17965987-546	These results suggest that dysfunctions of catecholaminergic neurons and <protein-id="P18280,P20181,P20783,P25433,P25434,P25435,Q9TST2">neurotrophic factors</protein-id> might exist in Sydenham's chorea, and the decreasing catecholamine activities in response to <compound-id="5073">risperidone</compound-id> might be associated with the improvement of the disease.	risperidone__neurotrophic factors__no_interaction
17968352-734	Based on these validities we identified alterations in the <protein-id="O76024,P56695">Wolframin</protein-id> gene in the CA1 and amygdala regions, specifically in exposed PTSD-like rats, which were normalized after treatment with <compound-id="2771,146570">citalopram</compound-id>.	citalopram__Wolframin__interaction
17968676-958	<protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">Cyclooxygenase-2</protein-id> (<protein-id="P00411,P24894,P35355,Q05769,Q8HEC3,Q8SEM9">Cox-2</protein-id>) is a key enzyme in the conversion of <compound-id="444899">arachidonic acid</compound-id> to prostaglandins that has been shown to have a particular importance in the progression of several malignancies including nasopharyngeal carcinoma (NPC).	arachidonic acid__Cyclooxygenase-2__interaction	arachidonic acid__Cox-2__interaction
17976762-900	Other potential treatments discussed for possible use with long-acting <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> overdoses include incision and drainage of the injection site, <protein-id="O12956,O42143,O42144,P01272,P01273,P01274,P01275,P04093,P05110,P06883,P07449,P09566,P09567,P09682,P09686,P0C235,P13189,P15438,P18108,P22890,P29794,P31297,P33528,P55095,P68259,P68260,P68273,P68274,P68275,P68952,P68953,P68954,P68955,P68956,P68957,P79695,P81880,Q8MJ25,Q9PRQ9">glucagon</protein-id>, and <compound-id="383414,448601">octreotide</compound-id>.	octreotide__insulin__no_interaction	octreotide__glucagon__no_interaction
18037312-321	<compound-id="23973">Cadmium</compound-id> inhalation induced: (1) a transient bronchial inflammation, dominated by neutrophils; (2) a neutrophilia of the blood that persisted for up to 4 weeks; (3) a transient increased bronchial reactivity, and (4) a significant increase in <protein-id="O18733,P14780,P41245,P41246,P50282,P52176">MMP-9</protein-id> activity in the BALF.	Cadmium__MMP-9__interaction
18042181-811	To assess whether follicle-stimulating hormone (FSH) and <protein-id="P03969,P09038,P12226,P13109,P15655,P20003,P48798,P48799,P48800,Q60487">basic fibroblast growth factor</protein-id> (bFGF) modulate <compound-id="124886">GSH</compound-id> production in Sertoli cells by regulating the expression of <protein-id="P48506">GCLC</protein-id>, <protein-id="P48507,Q2T9Y6">GCLM</protein-id> and/or GR, we performed in vitro studies using rat Sertoli cells in primary culture.	GSH__GCLM__interaction	GSH__basic fibroblast growth factor__interaction	GSH__GCLC__interaction
18042181-812	In conclusion, our results show that FSH and bFGF increase <compound-id="124886">GSH</compound-id> levels in Sertoli cells through stimulation of the de novo synthesis and recycling by upregulating <protein-id="P48507,Q2T9Y6">GCLM</protein-id> and GR expression respectively.	GSH__GCLM__interaction
18061671-207	Compared to the control, both the stresses individually and in combination led to in reductions in growth, photosynthetic pigments, <compound-id="54670067,54690394">ascorbic acid</compound-id>, <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id> (<protein-id="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7">CAT</protein-id>) activity and yield, whereas a reverse trend was observed for flavonoids, thiols and <compound-id="614,8988,145742">proline</compound-id> contents, <protein-id="O50258">superoxide dismutase</protein-id> (<protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id>) and <protein-id="P15984,P16147,P84714">peroxidase</protein-id> (<protein-id="P59097,P79076,Q5B2E9,Q5G234,Q6QWR1,Q6UG02,Q75ZP8,Q8J136,Q8J2V8">POD</protein-id>) activities, and <protein-id="P22079,P80025">LPO</protein-id>.	ascorbic acid__peroxidase__no_interaction	proline__peroxidase__no_interaction	proline__CAT__no_interaction	ascorbic acid__catalase__no_interaction	proline__SOD__no_interaction	ascorbic acid__POD__no_interaction	ascorbic acid__CAT__no_interaction	ascorbic acid__SOD__no_interaction	proline__LPO__no_interaction	proline__superoxide dismutase__no_interaction	proline__POD__no_interaction	proline__catalase__no_interaction	ascorbic acid__LPO__no_interaction	ascorbic acid__superoxide dismutase__no_interaction
18068270-465	Selenium and <compound-id="5359268">aluminum</compound-id> levels were not associated to <protein-id="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481">CSF</protein-id> Abeta42.	aluminum__CSF__no_interaction
18068270-466	In vitro, the degradation of synthetic Abeta substrate added to <protein-id="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481">CSF</protein-id> was markedly accelerated by low levels (2microM) of exogenous zinc and <compound-id="23978">copper</compound-id>.	copper__CSF__interaction
18068871-859	<protein-id="O12976,P49768,P49769,P79802,P97887,Q4JIM4,Q5R780,Q6RH31,Q8HXW5,Q9W6T7,Q9XT97">Presenilin-1</protein-id> mutation impairs cholinergic modulation of synaptic plasticity and suppresses <compound-id="22880">NMDA</compound-id> currents in hippocampus slices.	NMDA__Presenilin-1__interaction
18068871-860	Similarly, mutant <protein-id="P49768,P79802,Q8HXW5,Q9W6T7">PS1</protein-id> impairs the ability of the cholinesterase inhibitor <compound-id="192706,9905831,10337156">phenserine</compound-id> to enhance LTP.	phenserine__PS1__no_interaction
18077014-827	It was found that the expression of <protein-id="P21673,P48026,P49431,Q01612,Q28999,Q3T0Q0,Q8AXL1,Q9JHW6">SSAT</protein-id> and <protein-id="O22616,P00860,P07805,P08432,P09057,P11926,P14019,P27116,P27117,P27118,P27119,P27121,P40807,P40808,P41931,P43099,P49725,P50134,P78599,Q5RFB7,Q8S3N2,Q92445,Q9BQT8,Q9UQW9">ODC</protein-id> were upregulated after reperfusion and the concentrations of <compound-id="1102">spermidine</compound-id> and <compound-id="1103">spermine</compound-id> were significantly decreased, while <compound-id="1045">putrescine</compound-id> concentration was significantly increased.	spermine__ODC__no_interaction	putrescine__SSAT__no_interaction	spermine__SSAT__no_interaction	putrescine__ODC__no_interaction	spermidine__SSAT__no_interaction	spermidine__ODC__no_interaction
18079026-797	In the present study, we investigated the effects of <compound-id="5002">quetiapine</compound-id> on memory impairment and pathological changes in an amyloid precursor protein (<protein-id="O73683,O93279,P05067,P08592,P0A3Z1,P0A3Z2,P0A3Z3,P0A3Z4,P12023,P29216,P47566,P53601,P75313,P79307,Q11207,Q28053,Q28280,Q28748,Q28757,Q29149,Q5IS80,Q60495,Q95241">APP</protein-id>)/<protein-id="O12976,P49768,P49769,P79802,P97887,Q4JIM4,Q5R780,Q6RH31,Q8HXW5,Q9W6T7,Q9XT97">presenilin-1</protein-id> (<protein-id="P49768,P49769,P79802,P84566,P97887,Q5R780,Q6RH31,Q8HXW5,Q9XT97">PS-1</protein-id>) double transgenic mouse model of Alzheimer's disease (AD).	quetiapine__presenilin-1__interaction	quetiapine__PS-1__interaction	quetiapine__APP__interaction
18079026-798	<compound-id="5002">Quetiapine</compound-id> also decreased brain Abeta peptides, beta-secretase activity and expression, and the level of <protein-id="P05067,P08592,P12023,P53601,P79307,Q5IS80,Q95241">C99</protein-id> (an <protein-id="O73683,O93279,P05067,P08592,P0A3Z1,P0A3Z2,P0A3Z3,P0A3Z4,P12023,P29216,P47566,P53601,P75313,P79307,Q11207,Q28053,Q28280,Q28748,Q28757,Q29149,Q5IS80,Q60495,Q95241">APP</protein-id> C-terminal fragment following cleavage by beta-secretase) in the transgenic mice.	Quetiapine__C99__interaction	Quetiapine__APP__interaction
18079026-799	Furthermore, <compound-id="5002">quetiapine</compound-id> attenuated anxiety-like behavior, up-regulated cerebral <protein-id="P10417,P49950">Bcl-2</protein-id> protein, and decreased cerebral nitrotyrosine in the transgenic mice.	quetiapine__Bcl-2__interaction
18162361-61	<compound-id="446157">Rosuvastatin</compound-id> rapidly phosphorylated <protein-id="P31750,Q8INB9">Akt</protein-id> and endothelial <protein-id="O61309,O61608,Q27571,Q9I9M2">nitric oxide synthase</protein-id> (<protein-id="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600">eNOS</protein-id>) in human endothelial cells.	Rosuvastatin__nitric oxide synthase__interaction	Rosuvastatin__eNOS__interaction	Rosuvastatin__Akt__interaction
18162361-62	Our findings indicate that <compound-id="446157">rosuvastatin</compound-id> protects endothelial cells from death with phosphorylation of <protein-id="P31750,Q8INB9">Akt</protein-id> and <protein-id="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600">eNOS</protein-id>.	rosuvastatin__eNOS__interaction	rosuvastatin__Akt__interaction
18164165-377	<protein-id="O50258">Superoxide dismutase</protein-id> and <protein-id="O32770,O59858,Q00277,Q9CFV1">glutathione peroxidase</protein-id> antioxidant enzyme activities and <compound-id="10964">malondialdehyde</compound-id> levels were found to be increased; however, <compound-id="5280489">beta-carotene</compound-id>, <compound-id="445354">retinol</compound-id>, <compound-id="54670067">vitamin C</compound-id>, <compound-id="2116,14985,1548900,1742129">vitamin E</compound-id>, <compound-id="124886">reduced glutathione</compound-id>, and albumin levels were observed to be significantly decreased.	retinol__Superoxide dismutase__no_interaction	vitamin C__Superoxide dismutase__no_interaction	malondialdehyde__glutathione peroxidase__no_interaction	reduced glutathione__Superoxide dismutase__no_interaction	vitamin E__glutathione peroxidase__no_interaction	vitamin E__Superoxide dismutase__no_interaction	vitamin C__glutathione peroxidase__no_interaction	retinol__glutathione peroxidase__no_interaction	reduced glutathione__glutathione peroxidase__no_interaction	malondialdehyde__Superoxide dismutase__no_interaction	beta-carotene__Superoxide dismutase__no_interaction	beta-carotene__glutathione peroxidase__no_interaction
18172601-392	Structure-function studies of nitrated <protein-id="O46674,O55143,P11507,P11607,P16615,P20647,Q00779,Q03669">SERCA2</protein-id> in aging heart and skeletal muscle demonstrate stoichiometric nitration of vicinal tyrosines, Tyr (294) and Tyr (295), on the lumenal side of the membrane-spanning helix, <compound-id="16682741">M4</compound-id>, which correlates with partial inhibition of Ca(2+)-ATPase activity suggesting a possible regulatory function in down-regulating mitochondrial energy production and the associated generation of reactive <compound-id="977">oxygen</compound-id>/<compound-id="947,123329">nitrogen</compound-id> species.	M4__SERCA2__no_interaction	oxygen__SERCA2__no_interaction	nitrogen__SERCA2__no_interaction
18177531-936	<compound-id="281">Carbon monoxide</compound-id> is an endogenous vasodilator gas produced by the enzyme <protein-id="O19998,O73688,O78497,P51271,P71119">heme oxygenase</protein-id> (HO).	Carbon monoxide__heme oxygenase__interaction
18179560-930	The long pentraxin 3 (<protein-id="O75364,P26022">PTX3</protein-id>) is a multifunctional soluble pattern recognition receptor, involved in several processes ranging from innate resistance and inflammation to clearance of apoptotic cells and organization of <compound-id="24759,453618,3084050,24728612">hyaluronic acid</compound-id>-rich extracellular matrices.	hyaluronic acid__PTX3__interaction
18180755-369	The <protein-id="P0C1J7,Q13451,Q5RF88,Q95L05,Q9XSH5,Q9XSI2,Q9XT11">FKBP5</protein-id> gene product forms part of a complex with the <protein-id="O13186,O46567,O73673,P04150,P06536,P06537,P35547,P49115,P49843,P49844,P59667,P79269,P79686,Q5R9P5,Q6XLJ0,Q95267,Q9N1U3">glucocorticoid receptor</protein-id> and can modulate <compound-id="5754">cortisol</compound-id>-binding affinity.	cortisol__FKBP5__interaction	cortisol__glucocorticoid receptor__interaction
18190985-361	Several studies have shown that <protein-id="P05463">epsilon</protein-id> 2 carriers have lower low-density lipoprotein and apo B levels and higher <protein-id="P81182">high-density lipoprotein</protein-id> <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> and apo A-I levels than <protein-id="P05463">epsilon</protein-id> 3 carriers.	cholesterol__high-density lipoprotein__interaction	cholesterol__epsilon__interaction
18191451-670	Toxicity and characterization of <protein-id="P32749,P32750,P32751,P32752,P32753,P81908">cholinesterase</protein-id>-inhibition induced by <compound-id="5936">diisopropyl fluorophosphate</compound-id> in Artemia salina larvae.	diisopropyl fluorophosphate__cholinesterase__interaction
18195714-756	<compound-id="11970143">Lipopolysaccharide</compound-id>-induced depressive-like behavior is mediated by <protein-id="P14902,P28776">indoleamine 2,3-dioxygenase</protein-id> activation in mice.	Lipopolysaccharide__indoleamine 2,3-dioxygenase__interaction
18195714-757	We report that peripheral administration of <compound-id="11970143">lipopolysaccharide</compound-id> (LPS) activates <protein-id="P14902,P28776">IDO</protein-id> and culminates in a distinct depressive-like behavioral syndrome, measured by increased duration of immobility in both the forced-swim and tail suspension tests.	lipopolysaccharide__IDO__interaction
18195714-758	Administration of L-<compound-id="846">kynurenine</compound-id>, a metabolite of <compound-id="1148,6305,9060,5460840">tryptophan</compound-id> that is generated by <protein-id="P14902,P28776">IDO</protein-id>, to naive mice dose dependently induces depressive-like behavior.	kynurenine__IDO__interaction	tryptophan__IDO__interaction
18198986-243	Serum adipocyte <protein-id="O42494,O45035,O76821,P80547,Q17284,Q8MUC1,Q9U5P1">fatty acid binding protein</protein-id> levels in patients with type 2 diabetes mellitus and obesity: the influence of <compound-id="3339">fenofibrate</compound-id> treatment.	fenofibrate__fatty acid binding protein__interaction
18198986-245	Serum <protein-id="P80565">FABP</protein-id> levels were 2.5-fold higher in T2DM group relative to C and were not affected by <compound-id="3339">fenofibrate</compound-id> treatment (C: 20.6+/-2.1 microg/l, T2DM before F: 55.6+/-5.7 microg/l, T2DM after F: 54.2+/-5.4 microg/l, p 0.0001 for C vs. T2DM before F).	fenofibrate__FABP__no_interaction
18198986-246	<protein-id="P80565">FABP</protein-id> levels positively correlated with BMI, triglyceride levels, blood <compound-id="206,5793,64689,79025">glucose</compound-id>, glycated <protein-id="P15160,P17724,P73925,Q03459">hemoglobin</protein-id>, atherogenic index and <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> levels.	glucose__hemoglobin__no_interaction	glucose__FABP__interaction	glucose__insulin__no_interaction
18198997-256	<compound-id="264">Butyrate</compound-id> enemas upregulate <protein-id="P0A9M0">Muc</protein-id> genes expression but decrease adherent mucus thickness in mice colon.	Butyrate__Muc__interaction
18198997-257	We demonstrated that <compound-id="264">butyrate</compound-id> stimulated the gene expression of both secreted (<protein-id="Q62635">Muc2</protein-id>) and membrane-linked (<protein-id="Q02496">Muc1</protein-id>, Muc3, Muc4) mucins.	butyrate__Muc2__interaction	butyrate__Muc1__interaction
18198997-258	<compound-id="264">Butyrate</compound-id> especially induced a 6-fold increase in <protein-id="Q62635">Muc2</protein-id> gene expression in proximal colon.	Butyrate__Muc2__interaction
18198997-259	However, <compound-id="264">butyrate</compound-id> enemas did not modify the number of epithelial cells containing the protein <protein-id="Q62635">Muc2</protein-id>, and caused a 2-fold decrease in the thickness of adherent mucus layer.	butyrate__Muc2__no_interaction
18204887-141	We examined the association of <protein-id="P42898,Q5I598,Q60HE5">MTHFR</protein-id> C677T and A1298C, and changes in plasma <compound-id="778">homocysteine</compound-id> in 352 Tunisian patients with angiographically-demonstrated CAD, and 390 age and gender-matched healthy subjects.	homocysteine__MTHFR__no_interaction
18205042-213	However, we also observed that <compound-id="2812">clotrimazol</compound-id> (1alpha-hydroxylase inhibitor) enhanced 25(OH)D(3)-induced <protein-id="Q07973">CYP24</protein-id> expression in breast cancer cells.	clotrimazol__CYP24__interaction
18207583-646	Expression of senescence-associated <protein-id="O33815,O52629,O52847,P00722,P00723,P06219,P0C1Y0,P14288,P22498,P23989,P24131,P26257,P30812,P50388,P70753,P77989,P81650,Q1G9Z4,Q47077,Q48727,Q56307,Q59140,Q59750,Q9K9C6">beta-galactosidase</protein-id> (SA-beta-<protein-id="P10683,P11886,P47212">Gal</protein-id>) by human skin fibroblasts, effect of advanced glycation end-products and <compound-id="840,17106,19466,94270,439554">fucose</compound-id> or rhamnose-rich polysaccharides.	fucose__Gal__interaction	fucose__beta-galactosidase__interaction
18221806-436	Short-term withdrawal of <compound-id="54454,4677798">simvastatin</compound-id> induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial <protein-id="O61309,O61608,Q27571,Q9I9M2">nitric oxide synthase</protein-id>.	simvastatin__nitric oxide synthase__interaction
18222028-559	It has been shown that the removal efficiency of <protein-id="P14678">COD</protein-id> increased with the increasing applied current density and increasing PAC and <compound-id="923,373840">Na</compound-id> (2)SO(4) dosage and the most effective removal capacity was achieved at the pH 7.	Na__COD__interaction
18222543-918	The protective effects of novel synthetic organoselenium compounds (Se I and Se II) against <compound-id="6001">DMBA</compound-id>-induced changes in levels of some [<protein-id="O50258">superoxide dismutase</protein-id> (<protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id>), <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id> (<protein-id="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7">CAT</protein-id>), <protein-id="O32770,O59858,Q00277,Q9CFV1">glutathione peroxidase</protein-id> (GPx), and <protein-id="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655">glutathione reductase</protein-id> (GR) activities and total <compound-id="124886">glutathione</compound-id> (<compound-id="124886">GSH</compound-id>), malonedialdehyde (MDA)] parameters in rat lung and kidney were investigated.	glutathione__CAT__no_interaction	DMBA__glutathione peroxidase__interaction	GSH__SOD__no_interaction	GSH__glutathione peroxidase__no_interaction	glutathione__SOD__no_interaction	DMBA__glutathione reductase__interaction	glutathione__glutathione peroxidase__no_interaction	GSH__superoxide dismutase__no_interaction	DMBA__SOD__interaction	DMBA__superoxide dismutase__interaction	DMBA__catalase__interaction	GSH__CAT__no_interaction	glutathione__superoxide dismutase__no_interaction	glutathione__glutathione reductase__no_interaction	GSH__catalase__no_interaction	GSH__glutathione reductase__no_interaction	DMBA__CAT__interaction	glutathione__catalase__no_interaction
18226951-1110	Abnormally high CSF 3-OMD occurs frequently for RLS patients indicating either increased <compound-id="6047">l-dopa</compound-id> synthesis, limitations in <compound-id="6047">l-dopa</compound-id> decarboxylation or increased <protein-id="O50163,O67222,O83772,P0A817,P0A818,P0A819,P0A820,P24752,P43762,P47293,P50307,P54419,P56460,P56878,P57486,P57897,P61945,P61946,P66764,P66765,P66766,P66767,P72871,P77899,P78003,Q1QCH2,Q21NJ5,Q21RM4,Q28UI9,Q2A1N2,Q2FFV6,Q2GBP1,Q2IM98,Q2IZR2,Q2JIN3,Q2JV74,Q2NRD1,Q2NZF1,Q2RK28,Q2RYY4,Q2SLT3,Q2SS11,Q2T267,Q2VYQ2,Q2Y5Z1,Q2YTK1,Q30PN0,Q311V1,Q31CL7,Q31EL0,Q31KC6,Q31WK4,Q32C11,Q38YF8,Q39BZ1,Q39W48,Q3A388,Q3AFS4,Q3AME2,Q3AQC3,Q3AWE6,Q3B531,Q3BXB7,Q3IDQ1,Q3IW86,Q3J7R5,Q3JX94,Q3K1M7,Q3K5E8,Q3MF32,Q3SFY2,Q3YXS9,Q3Z943,Q3ZZN7,Q46H57,Q476V0,Q47JN4,Q47R14,Q486L6,Q48CH3,Q48SU7,Q493F2,Q49YL6,Q4A5F4,Q4FNN1,Q4FTH7,Q4JVH7,Q4K4I7,Q4L7C7,Q4QLC5,Q4UR08,Q4ZM01,Q57K26,Q5E7R2,Q5FAC0,Q5FIN8,Q5FSK6,Q5GW76,Q5HEY9,Q5HNB8,Q5KW02,Q5LJ26,Q5LLL2,Q5LZI0,Q5M434,Q5N1I9,Q5NIC7,Q5NQV7,Q5P2V5,Q5PJJ2,Q5QVM7,Q5SHT8,Q5WDZ8,Q5WV18,Q5X3N0,Q5XBJ6,Q5YTN0,Q5ZTY6,Q60CG7,Q62EZ1,Q632S5,Q63YH5,Q650L4,Q65FV8,Q65UT4,Q661P3,Q666P5,Q67T90,Q6A8H3,Q6AF79,Q6AQ43,Q6D081,Q6F1M6,Q6FAQ6,Q6G8E3,Q6GFR6,Q6HCB4,Q6LMM8,Q6MPK2,Q6MTB6,Q71Z03,Q729A3,Q72I53,Q72SM5,Q72YV6,Q73JR4,Q741G5,Q74KS4,Q7M7Z2,Q7MHK6,Q7MTQ0,Q7N119,Q7NHG0,Q7NZF9,Q7U051,Q7U4S6,Q7URU7,Q7V2Y8,Q7V5A2,Q7VDM7,Q7VFY5,Q7VNG7,Q7VRG5,Q7VUL5,Q7W200,Q7WQX8,Q7WYG5,Q7WYN1,Q816Q8,Q81KI0,Q827Q0,Q82WL2,Q837P9,Q83A78,Q83GE4,Q83HT7,Q84FD3,Q87AY6,Q87LK6,Q88AK7,Q88D60,Q88XB8,Q898W7,Q89HP5,Q8A2T6,Q8CNT5,Q8CXS7,Q8D2N8,Q8DCA3,Q8DK88,Q8DQH0,Q8DT23,Q8E0A3,Q8E5Y0,Q8EIB4,Q8EP05,Q8FT48,Q8G3H4,Q8K715,Q8K9E5,Q8KEG7,Q8NVZ9,Q8P0G6,Q8PCH3,Q8PP75,Q8RCE4,Q8RGE5,Q8Y347,Q8Y6M0,Q8ZHG7,Q92AZ5,Q938W7,Q97F85,Q97RN9,Q98A80,Q98PM0,Q99Z77,Q9CCQ4,Q9CEE0,Q9I5Z0,Q9JVV6,Q9JY09,Q9K5E4,Q9K7Q9,Q9KUP3,Q9L0Y3,Q9PGB0,Q9RL99,Q9RWM6,Q9X1Y8,Q9X4Q2,Q9ZMN5">MAT</protein-id>/<protein-id="O23760,O81646,O82054,P21964,P28002,P46484,Q06509,Q06528,Q43239,Q43609,Q6ZD89,Q8GU25,Q8LL87,Q8W013,Q99028,Q9FQY8,Q9SWC2">COMT</protein-id> activity, or some combination of these.	l-dopa__MAT__no_interaction	l-dopa__COMT__no_interaction
18227836-349	To test this hypothesis, we investigated whether disruption of the <protein-id="P01175,P01176,P01177,P01178,P01179,P13389,P32005,P35454,P69043,P69044,P69056,P69057,P69058">oxytocin</protein-id> gene (<protein-id="P01179,P35454,Q5QQ53,Q7KVA1">Oxt</protein-id>-/-) made mice more susceptible to the psychosis-related effects of <compound-id="3007,5826,32893">amphetamine</compound-id> (<compound-id="6083">Amp</compound-id>), <compound-id="6005">apomorphine</compound-id> (Apo) and <compound-id="6468">phencyclidine</compound-id> (PCP).	apomorphine__Oxt__interaction	Amp__oxytocin__interaction	apomorphine__oxytocin__interaction	amphetamine__oxytocin__interaction	amphetamine__Oxt__interaction	phencyclidine__Oxt__interaction	phencyclidine__oxytocin__interaction	Amp__Oxt__interaction
18227838-352	The mood stabilizers <compound-id="28486,3028194">lithium</compound-id> and <compound-id="3121">valproate</compound-id> activate the <protein-id="P29323">ERK</protein-id> pathway in prefrontal cortex and hippocampus and potentiate <protein-id="P29323">ERK</protein-id> pathway-mediated neurite growth, neuronal survival and hippocampal neurogenesis.	lithium__ERK__interaction	valproate__ERK__interaction
18227970-442	In the root soluble fraction, the suicide inhibitor alpha-<compound-id="137670">difluoromethyl</compound-id>-<compound-id="866,5962">lysine</compound-id> suppressed the activity of <protein-id="P05033">lysine decarboxylase</protein-id> and of <protein-id="O22616,P00860,P07805,P08432,P09057,P11926,P14019,P27116,P27117,P27118,P27119,P27121,P41931,P44317,P49725,P50134,P78599,Q8S3N2,Q92445,Q9UQW9">ornithine decarboxylase</protein-id> to the same extent, but had no effect on <protein-id="O81160,O82475,P21885,P22220,P49726,Q39827,Q43075,Q819L4,Q81MS2,Q96412,Q96A70,Q9K9K5,Q9SNN0">arginine decarboxylase</protein-id> activity.	difluoromethyl__arginine decarboxylase__no_interaction	lysine__arginine decarboxylase__no_interaction	difluoromethyl__ornithine decarboxylase__interaction	lysine__ornithine decarboxylase__interaction	difluoromethyl__lysine decarboxylase__interaction	lysine__lysine decarboxylase__interaction
18228136-547	RT(2) Profiler PCR Array was used to identify differentially expressed genes in Dox and/or <compound-id="10903">2ME</compound-id> treatment groups, based on significance of results 4 genes were selected: <protein-id="P08183,P13568,P16875,P28873,P53258,Q06034,Q9LJX0,Q9ZR72">MDR1</protein-id>, <protein-id="P10417,P49950">Bcl2</protein-id>, <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">P53</protein-id> and <protein-id="O01377,O16852,P04961,P12004,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P61074,Q00265,Q00268">Cyclin</protein-id> D1.	2ME__Cyclin__no_interaction	2ME__P53__no_interaction	2ME__MDR1__no_interaction	2ME__Bcl2__no_interaction
18228136-548	The array and western blotting showed that <protein-id="P10417,P49950">Bcl2</protein-id> and <protein-id="O01377,O16852,P04961,P12004,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P61074,Q00265,Q00268">Cyclin</protein-id> D1 expression were down regulated; <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">P53</protein-id> expression was not affected while <protein-id="P08183,P13568,P16875,P28873,P53258,Q06034,Q9LJX0,Q9ZR72">MDR1</protein-id> was over expressed by combination of <compound-id="10903">2ME</compound-id> with Dox.	2ME__Cyclin__interaction	2ME__MDR1__interaction	2ME__P53__no_interaction	2ME__Bcl2__interaction
18228136-549	In conclusion, <compound-id="10903">2ME</compound-id> chemosensitizes resistant breast cancer cells to Dox cytotoxicity by down regulating expression of <protein-id="P10417,P49950">Bcl2</protein-id> and <protein-id="O01377,O16852,P04961,P12004,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P61074,Q00265,Q00268">Cyclin</protein-id> D1, augmenting caspase 3 activity as well as inducing cell cycle block in G(1) and S phases.	2ME__Cyclin__interaction	2ME__Bcl2__interaction
18230627-837	Randomised trials have demonstrated that the efficacy of anti-tumour necrosis factor (<protein-id="O35734,O77510,O77764,P01375,P04924,P13296,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF</protein-id>) agents is significantly increased by concomitant <compound-id="126941">methotrexate</compound-id> (MTX) in rheumatoid arthritis (RA).	methotrexate__TNF__interaction
18243311-231	Neither <protein-id="P52914">apyrase</protein-id> nor <compound-id="5957">ATP</compound-id> altered production of reactive <compound-id="977">oxygen</compound-id> intermediates (ROI) or reactive <compound-id="947,123329">nitrogen</compound-id> intermediates (RNI) by bovine monocytes.	nitrogen__apyrase__no_interaction	oxygen__apyrase__no_interaction	ATP__apyrase__no_interaction
18243368-1130	In this systematic review, we have analyzed the results of 52 clinical trials, including 72 intervention groups and 6290 patients, on <compound-id="5280795">vitamin D</compound-id> supplementation in order to evaluate the experimental evidence and the effects of age and chronic immobility on responses of parathyroid hormone (<protein-id="O27732,O28185,O66677,O74017,O74806,O83975,O84806,O85235,P01268,P01269,P01270,P04089,P0A281,P0A282,P0A7D1,P0A7D2,P0A7D3,P15743,P37470,P38876,P44682,P47329,P47714,P49607,P52212,P56077,P57287,P57820,P59490,P61234,P61235,P61414,P65863,P65864,P65865,P65866,P65867,P65868,P65869,P78034,Q27IM2,Q57NM8,Q59989,Q5F9L4,Q5FFA3,Q5FMA9,Q5FRT7,Q5GTI9,Q5GWR6,Q5HC85,Q5HIH3,Q5HRQ3,Q5HWF9,Q5JDB8,Q5L3U7,Q5LV91,Q5M222,Q5M6L4,Q5N2J4,Q5NGZ6,Q5NL75,Q5P722,Q5P9A6,Q5PCR7,Q5QV03,Q5SHZ2,Q5V1D3,Q5WAD6,Q5WTE7,Q5X1N7,Q5XEM3,Q5YPZ6,Q5ZS66,Q601M5,Q60363,Q60A14,Q62FC1,Q63HI2,Q63XM0,Q64X30,Q65PG8,Q65V47,Q65ZY7,Q66AY1,Q67JD0,Q68WD4,Q6AAC7,Q6ADQ8,Q6AJL9,Q6D557,Q6F240,Q6F8I7,Q6G0F9,Q6G2L1,Q6GBY6,Q6GJG9,Q6HPW6,Q6KHA3,Q6LNA9,Q6MJR3,Q6MS28,Q6N1P9,Q6NI78,Q6YP15,Q6YR64,Q724K0,Q72BR1,Q72IA8,Q72RZ0,Q73FF7,Q73II8,Q73Q01,Q741V9,Q74FE6,Q74LA8,Q7M7U8,Q7MMZ2,Q7MXK9,Q7N5A1,Q7NN75,Q7NQT1,Q7U9I5,Q7UKV0,Q7V342,Q7V4V4,Q7VDT7,Q7VG29,Q7VMI1,Q7VUH3,Q7W179,Q7WNY2,Q81J96,Q81VY9,Q821W6,Q82HE5,Q82TQ6,Q839C0,Q83AP0,Q83FR1,Q83HD8,Q83LE1,Q86Y79,Q877G5,Q87A24,Q87RN9,Q888C8,Q88PX8,Q88Z39,Q899I4,Q89DJ9,Q89YZ2,Q8BW00,Q8CQU9,Q8CXP8,Q8D2K4,Q8DFF4,Q8DJ45,Q8DRQ2,Q8DWN5,Q8E2I1,Q8E7Y8,Q8EHN5,Q8EWQ8,Q8F3Q2,Q8FQV6,Q8G5I6,Q8K8Z7,Q8K9V3,Q8KD05,Q8P327,Q8PC61,Q8PNT8,Q8Q0M4,Q8R757,Q8RIJ5,Q8RLD7,Q8TKX4,Q8TV04,Q8U0N0,Q8UD97,Q8XHJ8,Q8Y2E3,Q8YAD1,Q8YYK4,Q8ZEY4,Q8ZYM4,Q92F62,Q92H41,Q92N67,Q976I0,Q97CB4,Q97E97,Q97TD1,Q980V1,Q98HV6,Q98PE2,Q9A206,Q9AAV9,Q9AEQ5,Q9CD49,Q9CJI1,Q9F8Q3,Q9GL67,Q9HLW6,Q9HVC3,Q9J5H2,Q9JV42,Q9K029,Q9K3T8,Q9KGJ3,Q9KQ21,Q9PA78,Q9PII7,Q9PR67,Q9RRW3,Q9V108,Q9X1W1,Q9XT35,Q9YBD6,Q9Z6V6,Q9ZCV4,Q9ZJC3">PTH</protein-id>).	vitamin D__PTH__interaction
18243368-1131	The <compound-id="5280795">vitamin D</compound-id> supplementation of the chronically immobile patients resulted in a smaller decrease in <protein-id="O27732,O28185,O66677,O74017,O74806,O83975,O84806,O85235,P01268,P01269,P01270,P04089,P0A281,P0A282,P0A7D1,P0A7D2,P0A7D3,P15743,P37470,P38876,P44682,P47329,P47714,P49607,P52212,P56077,P57287,P57820,P59490,P61234,P61235,P61414,P65863,P65864,P65865,P65866,P65867,P65868,P65869,P78034,Q27IM2,Q57NM8,Q59989,Q5F9L4,Q5FFA3,Q5FMA9,Q5FRT7,Q5GTI9,Q5GWR6,Q5HC85,Q5HIH3,Q5HRQ3,Q5HWF9,Q5JDB8,Q5L3U7,Q5LV91,Q5M222,Q5M6L4,Q5N2J4,Q5NGZ6,Q5NL75,Q5P722,Q5P9A6,Q5PCR7,Q5QV03,Q5SHZ2,Q5V1D3,Q5WAD6,Q5WTE7,Q5X1N7,Q5XEM3,Q5YPZ6,Q5ZS66,Q601M5,Q60363,Q60A14,Q62FC1,Q63HI2,Q63XM0,Q64X30,Q65PG8,Q65V47,Q65ZY7,Q66AY1,Q67JD0,Q68WD4,Q6AAC7,Q6ADQ8,Q6AJL9,Q6D557,Q6F240,Q6F8I7,Q6G0F9,Q6G2L1,Q6GBY6,Q6GJG9,Q6HPW6,Q6KHA3,Q6LNA9,Q6MJR3,Q6MS28,Q6N1P9,Q6NI78,Q6YP15,Q6YR64,Q724K0,Q72BR1,Q72IA8,Q72RZ0,Q73FF7,Q73II8,Q73Q01,Q741V9,Q74FE6,Q74LA8,Q7M7U8,Q7MMZ2,Q7MXK9,Q7N5A1,Q7NN75,Q7NQT1,Q7U9I5,Q7UKV0,Q7V342,Q7V4V4,Q7VDT7,Q7VG29,Q7VMI1,Q7VUH3,Q7W179,Q7WNY2,Q81J96,Q81VY9,Q821W6,Q82HE5,Q82TQ6,Q839C0,Q83AP0,Q83FR1,Q83HD8,Q83LE1,Q86Y79,Q877G5,Q87A24,Q87RN9,Q888C8,Q88PX8,Q88Z39,Q899I4,Q89DJ9,Q89YZ2,Q8BW00,Q8CQU9,Q8CXP8,Q8D2K4,Q8DFF4,Q8DJ45,Q8DRQ2,Q8DWN5,Q8E2I1,Q8E7Y8,Q8EHN5,Q8EWQ8,Q8F3Q2,Q8FQV6,Q8G5I6,Q8K8Z7,Q8K9V3,Q8KD05,Q8P327,Q8PC61,Q8PNT8,Q8Q0M4,Q8R757,Q8RIJ5,Q8RLD7,Q8TKX4,Q8TV04,Q8U0N0,Q8UD97,Q8XHJ8,Q8Y2E3,Q8YAD1,Q8YYK4,Q8ZEY4,Q8ZYM4,Q92F62,Q92H41,Q92N67,Q976I0,Q97CB4,Q97E97,Q97TD1,Q980V1,Q98HV6,Q98PE2,Q9A206,Q9AAV9,Q9AEQ5,Q9CD49,Q9CJI1,Q9F8Q3,Q9GL67,Q9HLW6,Q9HVC3,Q9J5H2,Q9JV42,Q9K029,Q9K3T8,Q9KGJ3,Q9KQ21,Q9PA78,Q9PII7,Q9PR67,Q9RRW3,Q9V108,Q9X1W1,Q9XT35,Q9YBD6,Q9Z6V6,Q9ZCV4,Q9ZJC3">PTH</protein-id> 0.001).	vitamin D__PTH__interaction
18243368-1132	Our results also suggest that <protein-id="O27732,O28185,O66677,O74017,O74806,O83975,O84806,O85235,P01268,P01269,P01270,P04089,P0A281,P0A282,P0A7D1,P0A7D2,P0A7D3,P15743,P37470,P38876,P44682,P47329,P47714,P49607,P52212,P56077,P57287,P57820,P59490,P61234,P61235,P61414,P65863,P65864,P65865,P65866,P65867,P65868,P65869,P78034,Q27IM2,Q57NM8,Q59989,Q5F9L4,Q5FFA3,Q5FMA9,Q5FRT7,Q5GTI9,Q5GWR6,Q5HC85,Q5HIH3,Q5HRQ3,Q5HWF9,Q5JDB8,Q5L3U7,Q5LV91,Q5M222,Q5M6L4,Q5N2J4,Q5NGZ6,Q5NL75,Q5P722,Q5P9A6,Q5PCR7,Q5QV03,Q5SHZ2,Q5V1D3,Q5WAD6,Q5WTE7,Q5X1N7,Q5XEM3,Q5YPZ6,Q5ZS66,Q601M5,Q60363,Q60A14,Q62FC1,Q63HI2,Q63XM0,Q64X30,Q65PG8,Q65V47,Q65ZY7,Q66AY1,Q67JD0,Q68WD4,Q6AAC7,Q6ADQ8,Q6AJL9,Q6D557,Q6F240,Q6F8I7,Q6G0F9,Q6G2L1,Q6GBY6,Q6GJG9,Q6HPW6,Q6KHA3,Q6LNA9,Q6MJR3,Q6MS28,Q6N1P9,Q6NI78,Q6YP15,Q6YR64,Q724K0,Q72BR1,Q72IA8,Q72RZ0,Q73FF7,Q73II8,Q73Q01,Q741V9,Q74FE6,Q74LA8,Q7M7U8,Q7MMZ2,Q7MXK9,Q7N5A1,Q7NN75,Q7NQT1,Q7U9I5,Q7UKV0,Q7V342,Q7V4V4,Q7VDT7,Q7VG29,Q7VMI1,Q7VUH3,Q7W179,Q7WNY2,Q81J96,Q81VY9,Q821W6,Q82HE5,Q82TQ6,Q839C0,Q83AP0,Q83FR1,Q83HD8,Q83LE1,Q86Y79,Q877G5,Q87A24,Q87RN9,Q888C8,Q88PX8,Q88Z39,Q899I4,Q89DJ9,Q89YZ2,Q8BW00,Q8CQU9,Q8CXP8,Q8D2K4,Q8DFF4,Q8DJ45,Q8DRQ2,Q8DWN5,Q8E2I1,Q8E7Y8,Q8EHN5,Q8EWQ8,Q8F3Q2,Q8FQV6,Q8G5I6,Q8K8Z7,Q8K9V3,Q8KD05,Q8P327,Q8PC61,Q8PNT8,Q8Q0M4,Q8R757,Q8RIJ5,Q8RLD7,Q8TKX4,Q8TV04,Q8U0N0,Q8UD97,Q8XHJ8,Q8Y2E3,Q8YAD1,Q8YYK4,Q8ZEY4,Q8ZYM4,Q92F62,Q92H41,Q92N67,Q976I0,Q97CB4,Q97E97,Q97TD1,Q980V1,Q98HV6,Q98PE2,Q9A206,Q9AAV9,Q9AEQ5,Q9CD49,Q9CJI1,Q9F8Q3,Q9GL67,Q9HLW6,Q9HVC3,Q9J5H2,Q9JV42,Q9K029,Q9K3T8,Q9KGJ3,Q9KQ21,Q9PA78,Q9PII7,Q9PR67,Q9RRW3,Q9V108,Q9X1W1,Q9XT35,Q9YBD6,Q9Z6V6,Q9ZCV4,Q9ZJC3">PTH</protein-id> decreases quite linearly during <compound-id="5280795">vitamin D</compound-id> supplementation at any given 25-OHD level.	vitamin D__PTH__interaction
18248398-140	<protein-id="O02750,O93416,Q28603,Q95189,Q95234">Leptin</protein-id> did not show any effect in long photoperiod but decreased proliferation by stimulating <compound-id="896">melatonin</compound-id> in short photoperiod.	melatonin__Leptin__interaction
18249383-1046	To compare the changes in body composition and in <protein-id="O02750,O93416,Q28603,Q95189,Q95234">leptin</protein-id> levels in postmenopausal women receiving hormone therapy (HT) or <compound-id="444008">tibolone</compound-id>.	tibolone__leptin__no_interaction
18249399-1054	Common 677C--&gt;T mutation of the <protein-id="O54235,O67422,P0AEZ1,P0AEZ2,P11003,P45208,P57154,P71319,Q89B13,Q8KA62">5,10-methylenetetrahydrofolate reductase</protein-id> gene affects follicular <compound-id="5757">estradiol</compound-id> synthesis.	estradiol__5,10-methylenetetrahydrofolate reductase__interaction
18253022-733	Surprisingly, a deletion of the <protein-id="Q00934">pilR</protein-id> gene affected not only insoluble <compound-id="29936">Fe(III</compound-id>) reduction, which requires pili, but also soluble <compound-id="29936">Fe(III</compound-id>) reduction, which, in contrast, does not require pili.	Fe(III__pilR__interaction
18253697-765	Furthermore, the suppressive effects of P on <protein-id="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3">cytochrome c</protein-id> release and caspase-9 and caspase-3 activation in serum-deprived MC3T3-E1 cells were also reversed by <compound-id="55245">RU486</compound-id>.	RU486__cytochrome c__interaction
18256928-624	Therapeutic <compound-id="4091">metformin</compound-id>/<protein-id="P54646,Q09136,Q9Y478">AMPK</protein-id> activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model.	metformin__AMPK__no_interaction
18256928-625	However, when ERalpha negative MDA-MB-435 cells were treated with <compound-id="4091">metformin</compound-id>, they demonstrated increased expression of vascular endothelial growth factor (<protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id>) in an <protein-id="P54646,Q09136,Q9Y478">AMPK</protein-id> dependent manner; while the ERalpha positive MCF-7 cells did not.	metformin__AMPK__interaction	metformin__VEGF__interaction
18256928-626	The <compound-id="4091">metformin</compound-id>-treated group showed increased <protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id> expression, intratumoral microvascular density and reduced necrosis.	metformin__VEGF__interaction
18256928-627	<compound-id="4091">Metformin</compound-id> treatment was sufficient, however, to reduce systemic <protein-id="Q95222">IGF-1</protein-id> and the proliferation rate of tumor cells in vascularized regions.	Metformin__IGF-1__interaction
18260130-109	<protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id>, <protein-id="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3">MCP-1</protein-id>, <protein-id="P10147,P10855,P50229,Q5I1Z0,Q8HYQ3,Q8SQA6">MIP-1alpha</protein-id>, <protein-id="O62812,P08317,P10145,P19874,P26894,P36925,P41324,P46653,P49113,P67813,P67814,P79255,Q102R3,Q7YRB5,Q9XSX5">IL-8</protein-id>, <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id>, <protein-id="P01584,P09428,P10749,P14628,P21621,P26889,P41687,P46648,P48090,P51493,P51745,P79162,P79182,Q28292,Q28386,Q2HZH0,Q2MH07,Q63264,Q6PUD2,Q6R2X3,Q865X8,Q8WNR2,Q9WVG1,Q9XS77">IL-1beta</protein-id>, <protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id>, <protein-id="O18999,O77482,P18510,P25085,P25086,P26890,Q29056,Q866R8,Q9BEH0,Q9GMZ4">IL-1ra</protein-id>, and <protein-id="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5">IL-10</protein-id> were measured from monocyte/macrophage cultures at different stages of activation and differentiation seeded onto polyethylene, <compound-id="12254">polyurethane</compound-id>, expanded polytetrafluoroethylene, <compound-id="6658">polymethyl methacrylate</compound-id>, and a hydrogel copolymer of <compound-id="13360">2-hydroxyethyl methacrylate</compound-id>, <compound-id="6917">1-vinyl-2-pyrrolidinone</compound-id>, and polyethylene glycol acrylate in tissue culture <compound-id="7501">polystyrene</compound-id> (TCPS) plates.	polymethyl methacrylate__TNF-alpha__no_interaction	1-vinyl-2-pyrrolidinone__IL-10__no_interaction	polyurethane__VEGF__no_interaction	polyurethane__IL-6__no_interaction	polymethyl methacrylate__MCP-1__no_interaction	polystyrene__IL-1ra__no_interaction	1-vinyl-2-pyrrolidinone__TNF-alpha__no_interaction	2-hydroxyethyl methacrylate__MIP-1alpha__no_interaction	2-hydroxyethyl methacrylate__MCP-1__no_interaction	polystyrene__MCP-1__no_interaction	polymethyl methacrylate__IL-1ra__no_interaction	polystyrene__IL-6__no_interaction	polystyrene__VEGF__no_interaction	polyurethane__MCP-1__no_interaction	1-vinyl-2-pyrrolidinone__IL-1beta__no_interaction	polyurethane__IL-10__no_interaction	polyurethane__IL-8__no_interaction	polystyrene__TNF-alpha__no_interaction	1-vinyl-2-pyrrolidinone__VEGF__no_interaction	polystyrene__IL-10__no_interaction	polymethyl methacrylate__IL-1beta__no_interaction	polymethyl methacrylate__IL-6__no_interaction	polymethyl methacrylate__MIP-1alpha__no_interaction	1-vinyl-2-pyrrolidinone__MIP-1alpha__no_interaction	1-vinyl-2-pyrrolidinone__IL-1ra__no_interaction	polyurethane__IL-1ra__no_interaction	polymethyl methacrylate__VEGF__no_interaction	polyurethane__TNF-alpha__no_interaction	2-hydroxyethyl methacrylate__IL-1beta__no_interaction	polyurethane__MIP-1alpha__no_interaction	2-hydroxyethyl methacrylate__VEGF__no_interaction	polymethyl methacrylate__IL-10__no_interaction	1-vinyl-2-pyrrolidinone__IL-8__no_interaction	2-hydroxyethyl methacrylate__IL-6__no_interaction	polyurethane__IL-1beta__no_interaction	2-hydroxyethyl methacrylate__TNF-alpha__no_interaction	polymethyl methacrylate__IL-8__no_interaction	1-vinyl-2-pyrrolidinone__MCP-1__no_interaction	2-hydroxyethyl methacrylate__IL-8__no_interaction	1-vinyl-2-pyrrolidinone__IL-6__no_interaction	polystyrene__IL-1beta__no_interaction	2-hydroxyethyl methacrylate__IL-1ra__no_interaction	polystyrene__IL-8__no_interaction	polystyrene__MIP-1alpha__no_interaction	2-hydroxyethyl methacrylate__IL-10__no_interaction
18262559-301	Systemic administration of <protein-id="P15160,P17724,P73925,Q03459">hemoglobin</protein-id> vesicle elevates tumor tissue <compound-id="977">oxygen</compound-id> tension and modifies tumor response to irradiation.	oxygen__hemoglobin__interaction
18262738-416	The participation of <protein-id="Q05608,Q9RI12">protein kinase A</protein-id> (PKA), <protein-id="P13678,Q25378">protein kinase C</protein-id> (<protein-id="P05130,P13677,P13678,P34722">PKC</protein-id>) and protein tyrosine kinase (PTK) in capacitation induced by <compound-id="5460609">ONOO</compound-id> (-) was evaluated by incubation with specific inhibitors (50 microM H-89, 0.1 microM <compound-id="2396">bisindolylmaleimide I</compound-id>, and 3 microM <compound-id="5280961">genistein</compound-id>, respectively).	bisindolylmaleimide I__PKC__interaction	bisindolylmaleimide I__protein kinase A__interaction	ONOO__protein kinase A__interaction	ONOO__protein kinase C__interaction	genistein__protein kinase A__interaction	genistein__protein kinase C__interaction	ONOO__PKC__interaction	genistein__PKC__interaction	bisindolylmaleimide I__protein kinase C__interaction
18266054-1214	At the time, <protein-id="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655">glutathione reductase</protein-id> activity was significantly inhibited and gamma-glutamyl <compound-id="594,5862,5360637">cysteine</compound-id> increased by ACA exposure.	cysteine__glutathione reductase__no_interaction
18268501-1260	The effect of the polymorphism is non-conservative and results in a <compound-id="738,5961">glutamine</compound-id> to <compound-id="232,4367,6322">arginine</compound-id> change (Gln460Arg), which is likely to affect <protein-id="Q99572">P2RX7</protein-id> dimerization and protein-protein interactions.	arginine__P2RX7__interaction	glutamine__P2RX7__interaction
18270841-348	Increased <compound-id="16129681,16129706">somatostatin</compound-id> tone and decreased <protein-id="Q6BEG6,Q6BEG7,Q9BDJ6,Q9BEF8,Q9EQX0,Q9GKY5,Q9QYH7,Q9UBU3">ghrelin</protein-id> concentrations may also contribute to reduced GH levels.	somatostatin__ghrelin__no_interaction
18272254-1258	Inhibition of LTP by beta-amyloid is prevented by activation of <protein-id="O70431,P04274,P07550,P10608,P18762,P54833,Q28044,Q28509,Q28997,Q4KWL2,Q8UUY8,Q9TST5">beta2 adrenoceptors</protein-id> and stimulation of the <compound-id="6076">cAMP</compound-id>/PKA signalling pathway.	cAMP__beta2 adrenoceptors__no_interaction
18274872-320	) <compound-id="977,5359597">O2</compound-id> (-) and <compound-id="784">H2O2</compound-id> in H. plumaeforme was respectively related to the low activity of <protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id> and the decreased activity of <protein-id="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7">CAT</protein-id>.	O2__SOD__interaction	H2O2__CAT__interaction	H2O2__SOD__interaction	O2__CAT__interaction
18279956-684	A novel oligodeoxynuleotides containing 11 <compound-id="6804">CpG</compound-id> motifs was synthesized and inserted into the VR1020 plasmid containing pig <protein-id="P41693">interleukin-6</protein-id> (<protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id>) gene (VPIL6) to construct recombinant plasmid, VPIL6C.	CpG__interleukin-6__no_interaction	CpG__IL-6__no_interaction
18280595-101	Furthermore, it has also been reported that <compound-id="1548943">capsaicin</compound-id>-treated pigs significantly increase mean arterial blood pressure compared with controls and that the decrease in <protein-id="P10286,P30880,P30881,P31888,P80511">CGRP</protein-id> synthesis and release contributes to the elevated blood pressure.	capsaicin__CGRP__interaction
18283487-569	Since then, the efforts of numerous investigators have led to the following conclusions: (a) This enzyme is indeed the molecular machine for the <compound-id="5957">ATP</compound-id>-dependent and-coupled transport of <compound-id="923,373840">Na</compound-id> (+) and K(+) across the plasma membrane of a living cell in which such a process (<protein-id="P13607,P17326,P28774,P35317">sodium pump</protein-id>) is detected.	ATP__sodium pump__interaction	Na__sodium pump__interaction
18286621-29	Affinity electrophoresis analysis provided evidence that carboxymethylated <compound-id="4125253,5460037">dextran</compound-id> polymers grafted with high amounts of <compound-id="10391">benzylamide</compound-id> groups (named DMCB) interact with <protein-id="O19006,O46564,P12643,P21274,P49001,Q804S2,Q90751">BMP-2</protein-id>.	benzylamide__BMP-2__interaction	dextran__BMP-2__interaction
18286621-30	A screening study provided evidence that the potentiating effects of the <compound-id="4125253,5460037">dextran</compound-id> derivatives on the <protein-id="O19006,O46564,P12643,P21274,P49001,Q804S2,Q90751">BMP-2</protein-id>-induced <protein-id="O60109,P81800,P83456">alkaline phosphatase</protein-id> activity improved with their <compound-id="10391">benzylamide</compound-id> groups content and, therefore, with their affinity for the growth factor.	benzylamide__alkaline phosphatase__interaction	dextran__BMP-2__interaction	dextran__alkaline phosphatase__interaction	benzylamide__BMP-2__interaction
18294936-104	Since <compound-id="40400,644073,5311033,6321408,24838065">buprenorphine</compound-id> is metabolized through <protein-id="P08684">cytochrome P450 3A4</protein-id>, we genotyped six genetic polymorphisms previously described in poor metabolizers but could not confirm these pharmacogenetic bases in this case.	buprenorphine__cytochrome P450 3A4__interaction
18295378-334	Mitochondrial dysfunction was associated with higher levels of reactive <compound-id="977">oxygen</compound-id> species, an altered Bcl-xL/<protein-id="P27297,Q07813,Q63690">Bax</protein-id> ratio and reduction of <protein-id="P11353,P36551,P36552,Q9UTE2,Q9V3D2">COX</protein-id> IV activity.	oxygen__COX__no_interaction	oxygen__Bax__no_interaction
18298568-1058	Peripheral venous levels of <compound-id="6013">testosterone</compound-id>, <protein-id="P10765,P22393,P33089,P33090,P33091,P43001">prolactin</protein-id>, follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), <compound-id="10964">malondialdehyde</compound-id> and glycosylated haemoglobin (HbA(1)c) were obtained in all subjects.	testosterone__prolactin__no_interaction	malondialdehyde__prolactin__no_interaction
18298570-1059	Our results showed that <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id> abolished the effect of the oxidant, protecting spermatozoa against reactive <compound-id="977">oxygen</compound-id> species, and improving both sperm motility and chromatin status during incubation.	oxygen__catalase__interaction
18298659-1127	Intranasal and intravenous administration of live Cpn and Aa, respectively induced an accumulation of activated mast cells in the aortic sinus of apolipoprotein E-deficient mice, however, with varying responses in the systemic levels of <compound-id="11970143">lipopolysaccharide</compound-id> (LPS) and <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id>.	lipopolysaccharide__TNF-alpha__no_interaction
18304632-1001	<protein-id="P00448,P66828,P66829,Q8Z2V9,Q9RUV2">MnSOD</protein-id> and two additional <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id> isozymes were induced by <compound-id="91739">quinclorac</compound-id> or <compound-id="54960">bensulfuron-methyl</compound-id> in S. maltophilia WZ2, but not in E. coli K12.	quinclorac__MnSOD__interaction	quinclorac__catalase__interaction	bensulfuron-methyl__MnSOD__interaction	bensulfuron-methyl__catalase__interaction
18304632-1002	Results indicate that <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id> has a much weakly role in the defense against <compound-id="91739">quinclorac</compound-id> or <compound-id="54960">bensulfuron-methyl</compound-id> induced oxidative stress, whereas <protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id> could be critical.	quinclorac__catalase__interaction	bensulfuron-methyl__SOD__interaction	bensulfuron-methyl__catalase__interaction	quinclorac__SOD__interaction
18304748-1077	Moreover, <protein-id="Q99JR5">TARPs</protein-id> (except gamma4) reduce the ion channel block by the synthetic <compound-id="119582,5311197">Joro spider toxin</compound-id> analog <compound-id="129695">1-naphthylacetyl spermine</compound-id> (NASP).	1-naphthylacetyl spermine__TARPs__interaction	Joro spider toxin__TARPs__no_interaction
18306310-763	SMC cultured on P(100/0) films modified by covalently attached <protein-id="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400">fibronectin</protein-id> or fibrin layers proliferated at a rate comparable to that observed on control tissue culture <compound-id="7501">polystyrene</compound-id>.	polystyrene__fibronectin__no_interaction
18306310-764	However, prewetting P(70/30) with a <compound-id="1061,167704,644102">phosphate</compound-id> buffer prior to aminolysis significantly improved cell numbers following immobilization of <protein-id="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400">fibronectin</protein-id>.	phosphate__fibronectin__no_interaction
18308488-862	The dose of <protein-id="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5">ACTH</protein-id> (2.5 microg/kg) was chosen to mimic the <compound-id="5754">cortisol</compound-id> concentrations seen during mixing of unfamiliar sows.	cortisol__ACTH__no_interaction
18311594-236	Our data suggest HumDN1 genotypes are related to total <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> levels in Han Chinese MI patients, but <protein-id="O18998,O42446,P00639,P11936,P11937,P21704,P24855,P49183,Q4AEE3,Q767J3,Q9YGI5">deoxyribonuclease I</protein-id> gene polymorphisms are not associated with susceptibility to MI in Han Chinese.	cholesterol__deoxyribonuclease I__no_interaction
18314895-1018	Specifically, <compound-id="8172">TEG</compound-id> was shown to alter S. mutans gene expression levels of <protein-id="P08987">gtfB</protein-id>, a known virulence factor, and yfiV, a putative <protein-id="Q9CJ45">transcriptional regulator</protein-id> of cell-surface fatty acid genes.	TEG__transcriptional regulator__interaction	TEG__gtfB__interaction
18314898-1022	Degradation analysis over 8 weeks in the presence of 10 mg/L <protein-id="O64362,O80288,O80292,P00720,P03706,P07540,P09963,P10439,P11187,P13656,P15057,P19385,P19386,P21270,P23472,P23473,P27359,P33486,P37715,P39046,P51771,P62692,P62693,P68920,P68921,P81241,P82174,P82175,P83673,Q27650,Q37875,Q37896,Q48603,Q7SID7,Q9CIT4,Q9T1X2,Q9ZXB7">lysozyme</protein-id> showed a 50% decrease in total weight and an 80% decrease in <compound-id="36797">PLGA</compound-id> molecular weight.	PLGA__lysozyme__interaction
18317936-346	Fluo-3 staining used in flow cytometry and video microscopy revealed an oxysterol-induced <compound-id="271">Ca(2</compound-id>+) influx, varying according to the oxysterol studied, leading to the activation of the MEK/<protein-id="P27361,P28869,P42525,Q07176">ERK1</protein-id>/2 pathway as demonstrated by Western blot analysis.	Ca(2__ERK1__interaction
18327670-82	To determine if response to endocrine therapy of breast cancer can be predicted by either a metabolic "flare reaction" detected by positron emission tomography (PET) with 2-[(18)F]-fluoro-<compound-id="108223">2-deoxyglucose</compound-id> (FDG), induced by an <compound-id="5757">estradiol</compound-id> challenge, or by <protein-id="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7">estrogen-receptor</protein-id> (ER) status, determined by PET with the estrogen analog 16alpha-[(18)F]fluoroestradiol-17beta (FES).	2-deoxyglucose__estrogen-receptor__no_interaction	estradiol__estrogen-receptor__no_interaction
18328561-582	Depletion of <compound-id="124886">GSH</compound-id> levels was accompanied by the induction of <protein-id="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655">glutathione reductase</protein-id> (GR) after 24h exposure with each of the four carbamates to CHO-K1 cells.	GSH__glutathione reductase__interaction
18330498-512	<compound-id="2719">Chloroquine</compound-id> and <compound-id="312145">wortmannin</compound-id> inhibited the upregulation induced by <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> stimulation and amino acid deprivation but not that induced by osmotic shock.	Chloroquine__insulin__interaction	wortmannin__insulin__interaction
18330498-513	Moreover, <compound-id="4713">PD98059</compound-id> and <compound-id="8515">SP600125</compound-id> inhibited only amino acid deprivation-induced upregulation and <compound-id="5353940">SB202190</compound-id> inhibited only <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>-induced upregulation.	SB202190__insulin__interaction	SP600125__insulin__no_interaction	PD98059__insulin__no_interaction
18331557-1201	The role of phosphorylated <protein-id="P31750,Q8INB9">Akt</protein-id> (p-<protein-id="P31750,Q8INB9">Akt</protein-id>) in oral carcinogenesis induced by <compound-id="942,89594,157672">nicotine</compound-id> and alkaline environments was investigated.	nicotine__Akt__interaction
18336537-456	Sera from a population sample of infants with cryptorchidism (n = 43), hypospadias (n = 41) and controls (n = 113) were analyzed for inhibin B, anti-Müllerian hormone (<protein-id="P03971,P03972,P27106,P49000,P79295">AMH</protein-id>), <compound-id="6013">testosterone</compound-id>, luteinizing hormone (LH), follicle stimulating hormone (FSH) and sex hormone binding globulin (<protein-id="P04278,P08689,P15196,P97497,Q62588">SHBG</protein-id>).	testosterone__AMH__no_interaction	testosterone__SHBG__no_interaction
18340529-389	Myeloperoxidase (<protein-id="P05164,P11247">MPO</protein-id>) is an endogenous oxidant enzyme that generates reactive <compound-id="977">oxygen</compound-id> species (ROS).	oxygen__MPO__interaction
18343629-1064	In present study, we investigated the combined effect of <compound-id="3220">emodin</compound-id> and <compound-id="64982">baicalin</compound-id> on pancreatic damage and pancreatitis associated lung injury, as well as tissue <protein-id="O00206,P58727,Q2V898,Q68Y56,Q8SPE8,Q8SPE9,Q9GL65,Q9MYW3,Q9TSP2,Q9TTN0,Q9WV82">TLR4</protein-id> expression in the setting of AP.	emodin__TLR4__no_interaction	baicalin__TLR4__no_interaction
18343629-1065	The results showed that combination of <compound-id="3220">emodin</compound-id> and <compound-id="64982">baicalin</compound-id> significantly reduced serum amylase, <protein-id="Q8JFG3">tumor necrosis factor</protein-id>-alpha and <protein-id="P41693">interleukin-6</protein-id>, attenuated pancreatic and pulmonary damage, also suppressed <protein-id="O00206,P58727,Q2V898,Q68Y56,Q8SPE8,Q8SPE9,Q9GL65,Q9MYW3,Q9TSP2,Q9TTN0,Q9WV82">TLR4</protein-id> expression in pancreas and lung.	baicalin__TLR4__interaction	emodin__TLR4__interaction	emodin__tumor necrosis factor__interaction	baicalin__interleukin-6__interaction	emodin__interleukin-6__interaction	baicalin__tumor necrosis factor__interaction
18346857-498	Results showed that a moderate dose of <protein-id="O02750,O93416,Q28603,Q95189,Q95234">leptin</protein-id> (250 microg/kg body weight/day) injected during the re-feeding period: (i) promoted the recovery of the regressed ovary as evidenced by an increase in ovary weight and recovery of yellow hierarchical follicles; (ii) elevated the plasma <compound-id="5757">17beta-estradiol</compound-id> (E(2)) level; (iii) increased the mRNA levels of ovary follicle-stimulating hormone receptor (<protein-id="P23945,P32212,P35376,P35379,P47799,P49059,P79763,Q5GJ04,Q6R6L8,Q6YNB6,Q7ZTV5,Q8R428,Q95179">FSHR</protein-id>), <protein-id="O02721,P16235,P16582,P22888,P30730,Q28005,Q28585,Q90674">luteinizing hormone receptor</protein-id> (<protein-id="P16070,P22888,Q28585">LHR</protein-id>) and <protein-id="O08537,O13012,O93511,P57781,P57782,Q62986,Q92731,Q95171,Q9IAK1,Q9PTU5,Q9PVE2,Q9TTE5,Q9TU15,Q9W6M2,Q9XSB5,Q9XSW2,Q9YH32">estrogen receptor-beta</protein-id> (<protein-id="O08537,O13012,O93511,P57781,P57782,Q62986,Q92731,Q95171,Q9IAK1,Q9PTU5,Q9PVE2,Q9TTE5,Q9TU15,Q9W6M2,Q9XSB5,Q9XSW2,Q9YH32">ER-beta</protein-id>).	17beta-estradiol__LHR__no_interaction	17beta-estradiol__estrogen receptor-beta__no_interaction	17beta-estradiol__luteinizing hormone receptor__no_interaction	17beta-estradiol__ER-beta__no_interaction	17beta-estradiol__FSHR__no_interaction	17beta-estradiol__leptin__interaction
18357521-771	The anti-neoplastic drug <compound-id="4666,36314,441276">taxol</compound-id> binds to <protein-id="O04386,O42786,O44388,O59837,P02554,P02556,P02557,P04107,P05219,P05220,P05304,P08562,P10875,P10876,P10878,P11482,P11833,P11857,P12457,P14140,P14643,P16040,P17938,P18699,P18700,P20365,P20802,P21148,P22012,P22852,P24637,P28551,P30668,P32256,P33127,P34108,P35394,P41352,P41385,P41386,P41387,P41388,P41741,P41742,P41799,P53373,P53374,P53375,P53376,P79008,P93176,Q00264,Q04709,Q08115,Q24829,Q27380,Q2U2U3,Q39445,Q3KVN1,Q4HZS8,Q4P235,Q4R9N3,Q4WA70,Q52NY7,Q5UBX3,Q6QDC9,Q7KQL5,Q86ZP5,Q8SS99,Q8WZE0,Q91240,Q92268,Q96TU8,Q9GSR5,Q9HFQ3,Q9LKI8,Q9N2N6,Q9UV72">beta-tubulin</protein-id> to prevent tumor cell division, promoting cell death.	taxol__beta-tubulin__interaction
18357521-772	In the current study, we knocked down <protein-id="P10417,P49950">Bcl-2</protein-id> expression using cognate siRNA during low-dose <compound-id="4666,36314,441276">taxol</compound-id> treatment to induce apoptosis in two human glioblastoma U138MG and U251MG cell lines.	taxol__Bcl-2__interaction
18357521-773	The cells were treated with either 100 nM <compound-id="4666,36314,441276">taxol</compound-id> or 100 nM Bcl-2 siRNA or both for 72 h. Immunofluorescent stainings for calpain and active caspase-3 showed increases in expression and co-localization of these <protein-id="O41798,O89290,O89940,O91080,O93215,P03311,P03353,P03355,P03356,P03362,P03363,P03366,P03367,P03369,P03370,P04023,P04024,P04323,P04584,P04585,P04587,P04588,P04589,P05959,P05960,P05961,P05962,P07570,P0C210,P0C211,P10210,P10265,P10270,P10271,P10272,P10273,P10274,P10394,P10978,P11227,P11365,P12451,P12497,P12498,P12499,P14074,P14078,P15833,P16046,P16423,P16901,P17757,P18042,P18096,P18802,P19028,P19199,P19560,P19561,P20825,P20875,P20876,P20892,P21407,P21414,P24107,P24740,P26808,P26809,P26810,P27502,P28936,P31822,P35956,P35963,P51518,P63119,P63120,P63121,P63122,P63123,P63124,P63125,P63127,P63128,P63129,P63131,P84454,Q09SZ9,Q0R5R2,Q0R5R3,Q1A249,Q1A267,Q4U0X6,Q73368,Q74120,Q75002,Q76634,Q77373,Q79666,Q89928,Q8AII1,Q8I7P9,Q9IDV9,Q9Q720,Q9QBY3,Q9QBZ1,Q9QBZ5,Q9QSR3,Q9WC54,Q9WC63,Q9Y6I0">proteases</protein-id> in apoptotic cells.	taxol__proteases__interaction
18357521-774	Our current study demonstrated that Bcl-2 siRNA significantly augmented <compound-id="4666,36314,441276">taxol</compound-id> mediated apoptosis in different human glioblastoma cells through induction of <protein-id="P27730">calpain</protein-id> and caspase proteolytic activities.	taxol__calpain__interaction
18357522-775	Based on these findings, altered expression of <protein-id="P04116,P23289,P23294,P47789,P47790,P60201,Q04004,Q08868,Q8HXW7">PLP1</protein-id> in most areas of the striatum suggests that widespread changes to the myelin structure could be associated with the adaptive changes following chronic <compound-id="2826,5760,439497,446220,644017,54613779">cocaine</compound-id> abuse.	cocaine__PLP1__interaction
18359113-478	No correlation was detected between serum <protein-id="O02750,O93416,Q28603,Q95189,Q95234">leptin</protein-id> level and <compound-id="5280795">vitamin D</compound-id>-25(OH)D3, which was under normal range in 60% of the patients.	vitamin D__leptin__no_interaction
18359113-479	The higher <protein-id="O02750,O93416,Q28603,Q95189,Q95234">leptin</protein-id> levels in women was accompanied by higher serum levels of <compound-id="206,5793,64689,79025">glucose</compound-id>, albumin, Ca, <compound-id="304,5997,6432564,11025495">cholesterol</compound-id>, <compound-id="923,373840">Na</compound-id> and FT4.	cholesterol__leptin__no_interaction	Na__leptin__no_interaction	glucose__leptin__no_interaction
18359113-480	Comparison of 50 patients with the lowest <protein-id="O02750,O93416,Q28603,Q95189,Q95234">leptin</protein-id> levels (mean of 3.4ng/ml) to 50 patients with highest <protein-id="O02750,O93416,Q28603,Q95189,Q95234">leptin</protein-id> levels (mean of 34ng/ml), did not indicate differences in both <compound-id="5283731">25(OH)D3</compound-id> and ICTP between these two populations in spite of the highly significant difference in <protein-id="O02750,O93416,Q28603,Q95189,Q95234">leptin</protein-id> levels.	25(OH)D3__leptin__no_interaction
18363836-902	The effects on the early secretory pathway in HEK293 cells were: reduction of the rate of ER-to-Golgi transport of the vesicular stomatitis virus <protein-id="P08163">glycoprotein</protein-id> (VSVG), slowed accumulation of a Golgi marker plasmid in pre-Golgi structures after <compound-id="5287620">Brefeldin A</compound-id> treatment and inhibition of cargo concentration of the neuronal glutamate transporter <protein-id="P31597,P43005,P51906,P51907,Q95135">excitatory amino-acid carrier 1</protein-id> (<protein-id="P31597,P43005,Q95135">EAAC1</protein-id>) into transpor complexes in HEK293 cells, an effect that could be completely reversed in the presence of an excess of <protein-id="P62821,Q4UB16,Q6NYB7,Q9TVU5">Rab1</protein-id>.	Brefeldin A__excitatory amino-acid carrier 1__no_interaction	Brefeldin A__glycoprotein__no_interaction	Brefeldin A__Rab1__no_interaction	Brefeldin A__EAAC1__no_interaction
18367388-537	<compound-id="445154">Resveratrol</compound-id> did not attenuate GA-induced generation of <compound-id="784">hydrogen peroxide</compound-id>, but it did block GA-induced phosphorylation of <protein-id="O57474,P08050,P14154,P16863,P17302,P18246,P23242,Q29101,Q6S9C0">connexin 43</protein-id> (<protein-id="O57474,P08050,P14154,P16863,P17302,P18246,P23242,Q29101,Q6S9C0">Cx43</protein-id>), a key modulator of GJIC.	hydrogen peroxide__Cx43__no_interaction	Resveratrol__Cx43__interaction	hydrogen peroxide__connexin 43__no_interaction	Resveratrol__connexin 43__interaction
18367388-538	Furthermore, <compound-id="445154">resveratrol</compound-id> down-regulated GA-induced phosphorylation of extracellular signal-regulated kinase (<protein-id="P29323">ERK</protein-id>)1/2, one of the critical regulators of <protein-id="O57474,P08050,P14154,P16863,P17302,P18246,P23242,Q29101,Q6S9C0">Cx43</protein-id>.	resveratrol__ERK__interaction	resveratrol__Cx43__interaction
18368465-1220	<compound-id="3009">DFMO</compound-id> accumulated cells in S phase of the cell cycle and reduced <protein-id="P20248,P30274,P37881,P43449,P51943,Q92161">cyclin A</protein-id> expression.	DFMO__cyclin A__interaction
18368485-1240	Indeed, treatment of cells with 1 muM <compound-id="444795">all-trans retinoic acid</compound-id> (<compound-id="444795">ATRA</compound-id>) or 1 muM 13-cis <compound-id="444795">retinoic acid</compound-id> (13-CRA) for 7 days induced astrocytic differentiation with upregulation of glial fibrillary <protein-id="P01538,P01543,P01544,P01545,P08772,P08943,P09617,P09618,P21742,P32032,Q05806,Q42596,Q42597,Q42838,Q8H0Q5,Q8VZK8,Q9C8D6,Q9SBK8">acidic protein</protein-id> (<protein-id="P03995,P14136,P47819,Q28115">GFAP</protein-id>) and down regulation of telomerase activity.	all-trans retinoic acid__acidic protein__interaction	retinoic acid__GFAP__interaction	all-trans retinoic acid__GFAP__interaction	ATRA__acidic protein__interaction	retinoic acid__acidic protein__interaction	ATRA__GFAP__interaction
18368485-1241	Wright staining and ApopTag assay showed, respectively, morphological and biochemical features of apoptosis in glioblastoma cells following exposure to 200 units/ml <protein-id="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9">IFN-gamma</protein-id> for 48 h. Induction of differentiation was associated with decreases in levels of nuclear factor kappa B (NFkappaB), inducible <protein-id="O61309,O61608,Q27571,Q9I9M2">nitric oxide synthase</protein-id> (<protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id>), and production of <compound-id="145068">nitric oxide</compound-id> (NO) so as to increase sensitivity to <protein-id="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9">IFN-gamma</protein-id> for apoptosis.	nitric oxide__nitric oxide synthase__no_interaction	nitric oxide__IFN-gamma__no_interaction	nitric oxide__iNOS__no_interaction
18371961-849	Because <protein-id="P08758,P14668,P17153,P48036,P70075,P81287,Q4R4H7,Q5R1W0">annexin V</protein-id> binds <compound-id="445141,6323481,44147587">phosphatidylserine</compound-id>, this study is using this feature to select functional spermatozoa.	phosphatidylserine__annexin V__interaction
18373731-672	<compound-id="65137">Cyclo(His-Pro</compound-id>) promotes cytoprotection by activating <protein-id="O54968,Q60795">Nrf2</protein-id>-mediated up-regulation of antioxidant defence.	Cyclo(His-Pro__Nrf2__interaction
18373731-674	Here, we addressed this issue and found that <compound-id="65137">cyclo(His-Pro</compound-id>) triggered nuclear accumulation of <protein-id="O54968,Q16236,Q60795">NF-E2-related factor-2</protein-id> (<protein-id="O54968,Q60795">Nrf2</protein-id>), a transcription factor that up-regulates antioxidant-/electrophile-responsive element (ARE-EpRE)-related genes, in PC12 cells.	cyclo(His-Pro__NF-E2-related factor-2__interaction	cyclo(His-Pro__Nrf2__interaction
18374997-195	In women, <protein-id="P20918,Q01177">Plg</protein-id> levels were higher in individuals with diagnosed ischemic heart disease (IHD) and increased with triglycerides (TG) and <compound-id="206,5793,64689,79025">glucose</compound-id> level.	glucose__Plg__interaction
18375536-500	To investigate overnight variations in absolute values and patterns of cytokines including <protein-id="P41693">interleukin 6</protein-id> (<protein-id="O35736,P05231,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL6</protein-id>) and tumour necrosis factor alpha (<protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNFalpha</protein-id>) in rheumatoid arthritis (RA), and to relate any changes to those occurring in blood <compound-id="5754">cortisol</compound-id>.	cortisol__IL6__interaction	cortisol__TNFalpha__interaction	cortisol__interleukin 6__interaction
18378405-1044	Using a cell culture model of synaptic NMDA receptor-dependent synaptic potentiation, we find that this is mediated exclusively by NR2B-containing <protein-id="P35439,Q9R1M7">N-methyl-D-aspartate receptors</protein-id>, as implicated by NR2B-specific antagonists and the use of selective vs. non-selective doses of the NR2A-preferring antagonist <compound-id="4463">NVP</compound-id>-AAM077.	NVP__N-methyl-D-aspartate receptors__no_interaction
18379782-593	<compound-id="30623,71384">Dexrazoxane</compound-id> protects against doxorubicin-induced cardiomyopathy: upregulation of <protein-id="P31750,Q8INB9">Akt</protein-id> and Erk phosphorylation in a rat model.	Dexrazoxane__Akt__no_interaction
18380536-252	Intracellular oxidative status was assessed by analysis of <compound-id="124886">GSH</compound-id>/<compound-id="65359">GSSG</compound-id> levels and time course of ROS production and <protein-id="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655">glutathione reductase</protein-id> (GR) activity.	GSH__glutathione reductase__no_interaction	GSSG__glutathione reductase__no_interaction
18380539-1099	A recently discussed cardiovascular risk factor, <compound-id="123831">asymmetric dimethylarginine</compound-id> (<compound-id="123831">ADMA</compound-id>), is known to act as an endogenous inhibitor of endothelial <protein-id="O61309,O61608,Q27571,Q9I9M2">nitric oxide synthase</protein-id>.	ADMA__nitric oxide synthase__interaction	asymmetric dimethylarginine__nitric oxide synthase__interaction
18380542-1100	The net exercise-induced increase in 6-keto-<protein-id="P49763,Q9XS47">PGF</protein-id> (1alpha) concentration, expressed as the difference between the end-exercise minus pre-exercise concentration positively correlated with VO(2max) (r=0.78, p=0.004) as well as with the net VO(2) increase at exhaustion (r=0.81, p=0.003), but not with other respiratory, cardiac, metabolic or inflammatory parameters of the exercise (minute ventilation, heart rate, plasma <compound-id="612">lactate</compound-id>, <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> or <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id> concentrations).	lactate__TNF-alpha__no_interaction	lactate__IL-6__no_interaction	lactate__PGF__no_interaction
18380545-1104	Adenosine A(3) receptor agonist N(6)-(3-iodobenzyl) adenosine-5 '-N-methyluronamide (<compound-id="123683">IB-MECA</compound-id>) has been tested from the point of view of potentiating the effects of <protein-id="P01586,P04823,P06740,P08700,P25140,P49875,P51445,Q06435,Q28334,Q28809,Q9BDX4">hematopoietic growth factors</protein-id> interleukin-3 (<protein-id="P01586,P04823,P06740,P08700,P25140,P49875,P51445,Q06435,Q28334,Q28809,Q9BDX4">IL-3</protein-id>), <protein-id="P20826,P21581,P21583,P79169,P79368,Q06220,Q09108,Q28132,Q29030,Q90314,Q95M19,Q95MD2,Q95N18">stem cell factor</protein-id> (<protein-id="P20826,P21581,P21583,P79169,P79368,Q06220,Q09108,Q28132,Q29030,Q90314,Q95M19,Q95MD2,Q95N18">SCF</protein-id>), <protein-id="P48750">granulocyte-macrophage colony-stimulating factor</protein-id> (<protein-id="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481">GM-CSF</protein-id>), and <protein-id="P35834,Q28746">granulocyte colony-stimulating factor</protein-id> (<protein-id="O02708,O02837,P09919,P09920,P35833,P35834,Q28746">G-CSF</protein-id>) on the growth of hematopoietic progenitor cells for granulocytes and macrophages (GM-CFC) in suspension of normal mouse bone marrow cells in vitro.	IB-MECA__granulocyte-macrophage colony-stimulating factor__interaction	IB-MECA__hematopoietic growth factors__interaction	IB-MECA__G-CSF__interaction	IB-MECA__granulocyte colony-stimulating factor__interaction	IB-MECA__IL-3__interaction	IB-MECA__SCF__interaction	IB-MECA__stem cell factor__interaction	IB-MECA__GM-CSF__interaction
18380545-1105	Significant elevation of numbers of GM-CFC evoked by the combinations of <compound-id="123683">IB-MECA</compound-id> with <protein-id="P01586,P04823,P06740,P08700,P25140,P49875,P51445,Q06435,Q28334,Q28809,Q9BDX4">IL-3</protein-id>, <protein-id="P20826,P21581,P21583,P79169,P79368,Q06220,Q09108,Q28132,Q29030,Q90314,Q95M19,Q95MD2,Q95N18">SCF</protein-id>, or GM-CSF as compared with these growth factors alone has been noted.	IB-MECA__SCF__no_interaction	IB-MECA__IL-3__no_interaction
18380545-1106	Combination of <compound-id="123683">IB-MECA</compound-id> with <protein-id="O02708,O02837,P09919,P09920,P35833,P35834,Q28746">G-CSF</protein-id> did not induce significantly higher numbers of GM-CFC in comparison with <protein-id="O02708,O02837,P09919,P09920,P35833,P35834,Q28746">G-CSF</protein-id> alone.	IB-MECA__G-CSF__no_interaction
18380545-1107	Joint action of three drugs, namely of <compound-id="123683">IB-MECA</compound-id>+ <protein-id="P01586,P04823,P06740,P08700,P25140,P49875,P51445,Q06435,Q28334,Q28809,Q9BDX4">IL-3</protein-id>+ <protein-id="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481">GM-CSF</protein-id>, produced significantly higher numbers of GM-CFC in comparison with the combinations of <compound-id="123683">IB-MECA</compound-id>+ <protein-id="P01586,P04823,P06740,P08700,P25140,P49875,P51445,Q06435,Q28334,Q28809,Q9BDX4">IL-3</protein-id>, <compound-id="123683">IB-MECA</compound-id>+ <protein-id="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481">GM-CSF</protein-id>, or <protein-id="P01586,P04823,P06740,P08700,P25140,P49875,P51445,Q06435,Q28334,Q28809,Q9BDX4">IL-3</protein-id>+ <protein-id="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481">GM-CSF</protein-id>.	IB-MECA__GM-CSF__no_interaction	IB-MECA__IL-3__no_interaction
18381637-476	Rabbit marrow mesenchymal stem cells (MSCs) and gelatin microparticles (MPs) loaded with <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>-like growth factor-1 (<protein-id="Q95222">IGF-1</protein-id>), transforming growth factor-beta1 (<protein-id="O19011,O93449,P01137,P04202,P07200,P09531,P09533,P16176,P17246,P18341,P50414,P54831,Q38HS2,Q9PTQ2,Q9Z1Y6">TGF-beta1</protein-id>), or a combination of both growth factors were mixed with OPF, a <compound-id="16212859">poly(ethylene glycol)-diacrylate</compound-id> crosslinker and the radical initiators ammonium persulfate and <compound-id="8037">N,N,N',N'-tetramethylethylenediamine</compound-id>, and then crosslinked at 37 degrees C for 8 min to form hydrogel composites.	N,N,N',N'-tetramethylethylenediamine__TGF-beta1__interaction	N,N,N',N'-tetramethylethylenediamine__IGF-1__interaction	poly(ethylene glycol)-diacrylate__TGF-beta1__no_interaction	N,N,N',N'-tetramethylethylenediamine__insulin__interaction	poly(ethylene glycol)-diacrylate__IGF-1__no_interaction	poly(ethylene glycol)-diacrylate__insulin__no_interaction
18381638-477	<protein-id="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400">Fibronectin</protein-id> modulates osteoblast behavior on <compound-id="3081502">Nitinol</compound-id>.	Nitinol__Fibronectin__interaction
18384163-783	Real-time RT-PCR showed that the expression of osteoblast marker genes such as <protein-id="Q08775,Q13950,Q9XSB7,Q9Z2J9">CBFalpha1</protein-id> and <protein-id="O60109,P81800,P83456">alkaline phosphatase</protein-id> was increased in <compound-id="24759,453618,3084050,24728612">hyaluronic acid</compound-id>-based hydrogel, and the expression level was dependent on the molecular weight of <compound-id="24759,453618,3084050,24728612">hyaluronic acid</compound-id>, <compound-id="104802">RGD peptide</compound-id>, and <protein-id="O19006,O46564,P12643,P21274,P49001,Q804S2,Q90751">BMP-2</protein-id>.	RGD peptide__alkaline phosphatase__interaction	RGD peptide__BMP-2__no_interaction	hyaluronic acid__alkaline phosphatase__interaction	RGD peptide__CBFalpha1__interaction	hyaluronic acid__BMP-2__no_interaction	hyaluronic acid__CBFalpha1__interaction
18386138-732	Treatment of H9c2 cell with low concentrations of Dox causes alterations in fibrous <protein-id="Q04765,Q04766">structural proteins</protein-id> including the nuclear lamina and sarcomeric cardiac myosin, as well as mitochondrial depolarization and fragmentation, membrane blebbing with cell shape changes, and <compound-id="445141,6323481,44147587">phosphatidylserine</compound-id> externalization.	phosphatidylserine__structural proteins__no_interaction
18387753-460	We monitored <protein-id="P28246,P45123">bcr</protein-id>-<protein-id="P00520,P00522">abl</protein-id> transcript levels by quantitative real time PCR in 50 tunisian patients treated with <compound-id="5291">imatinib</compound-id> for chronic myeloid leukemia in chronic phase for a median of 29 months (3-60) after they started <compound-id="5291">imatinib</compound-id>.	imatinib__abl__no_interaction	imatinib__bcr__no_interaction
18389169-121	The non-covalent interaction of <compound-id="5483782,6085493">brilliant red</compound-id> (BR) with <protein-id="O64362,O80288,O80292,P00720,P03706,P07540,P09963,P10439,P11187,P13656,P15057,P19385,P19386,P21270,P23472,P23473,P27359,P33486,P37715,P39046,P51771,P62692,P62693,P68920,P68921,P81241,P82174,P82175,P83673,Q27650,Q37875,Q37896,Q48603,Q7SID7,Q9CIT4,Q9T1X2,Q9ZXB7">lysozyme</protein-id> was investigated by the UV spectrometry, circular dichroism (CD) and isothermal titration calorimetry (ITC).	brilliant red__lysozyme__interaction
18390571-968	Recent studies suggest that crystals of <compound-id="1175">monosodium urate</compound-id> (MSU), deposited in joints of patients with acute gouty arthritis, activate the NACHT domain, <compound-id="857,6106,439524">leucine</compound-id>-rich repeat and <protein-id="O15553,Q9JJ25,Q9JJ26">pyrin</protein-id> domain-containing protein (NALP)3 inflammasome.	leucine__pyrin__no_interaction	monosodium urate__pyrin__interaction
18393628-298	<compound-id="942,89594,157672">Nicotine</compound-id>, <compound-id="9308">muscarine</compound-id>, and <compound-id="2730">chlorpyrifos</compound-id> induced the phosphorylation of <protein-id="P21708,P27361,P28869,P42525,Q63844">extracellular signal-regulated kinases 1</protein-id> and 2.	muscarine__extracellular signal-regulated kinases 1__interaction	chlorpyrifos__extracellular signal-regulated kinases 1__interaction	Nicotine__extracellular signal-regulated kinases 1__interaction
18393672-326	Adult bone marrow (BM)-derived <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>-producing cells (IPCs) are capable of regulating blood <compound-id="206,5793,64689,79025">glucose</compound-id> levels in chemically induced hyperglycemic mice.	glucose__insulin__interaction
18393672-328	Treatment with <compound-id="3032771">benfotiamine</compound-id> activated glucose metabolism in INS-1 cells in high-<compound-id="206,5793,64689,79025">glucose</compound-id> culture conditions, and appeared to maximize the BM-derived IPCs ability to synthesize <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>.	benfotiamine__insulin__interaction	glucose__insulin__no_interaction
18393672-329	<compound-id="3032771">Benfotiamine</compound-id> was not shown to induce the glucose receptor <protein-id="P12336,P14246">Glut-2</protein-id>, however it was shown to activate <protein-id="O25731,P0A4E1,P0A4E2,P0A6V8,P0A6V9,P17712,P21908,P35557,P52792,P54495,P58616,P58617,P58618,P58619,P64253,P64254,P82680,Q55855,Q56198,Q59171,Q668N7,Q6D7C4,Q7N6Y0,Q83K86,Q87EG6,Q8FFD4,Q8FV09,Q8P8U7,Q8PKU2,Q8UIV7,Q8YDC6,Q92407,Q92T27,Q93IM5,Q98DM2,Q9A6N3,Q9HZ46,Q9KCZ4,Q9PEG4,Q9ZKB0">glucokinase</protein-id>, the enzyme responsible for conversion of glucose to <compound-id="5958,439284,439427,439958">glucose-6-phosphate</compound-id>.	glucose-6-phosphate__glucokinase__interaction	glucose-6-phosphate__Glut-2__interaction	Benfotiamine__glucokinase__no_interaction	Benfotiamine__Glut-2__no_interaction
18393672-330	However, in cells where the pentose phosphate pathway was blocked by <compound-id="8682">oxythiamine</compound-id> treatment, there was a clear downregulation of <protein-id="P12336,P14246">Glut-2</protein-id>, <protein-id="O25731,P0A4E1,P0A4E2,P0A6V8,P0A6V9,P17712,P21908,P35557,P52792,P54495,P58616,P58617,P58618,P58619,P64253,P64254,P82680,Q55855,Q56198,Q59171,Q668N7,Q6D7C4,Q7N6Y0,Q83K86,Q87EG6,Q8FFD4,Q8FV09,Q8P8U7,Q8PKU2,Q8UIV7,Q8YDC6,Q92407,Q92T27,Q93IM5,Q98DM2,Q9A6N3,Q9HZ46,Q9KCZ4,Q9PEG4,Q9ZKB0">glucokinase</protein-id>, <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>, and <protein-id="O01360,O13507,O27090,O28542,O32755,O34425,O42259,O52631,O57479,O57672,O59494,O59841,O67161,O83816,O96423,P00355,P00356,P00357,P00361,P00362,P04406,P04797,P08439,P09124,P09316,P09317,P0A1P0,P0A1P1,P0C0G6,P0C0G7,P10096,P10097,P10618,P15115,P16858,P17244,P17721,P19089,P19314,P19315,P20287,P20445,P22512,P22513,P23722,P24163,P24164,P24166,P24746,P24748,P24749,P24750,P24751,P24753,P25861,P26518,P26519,P26520,P26521,P26988,P27726,P28844,P29272,P29497,P32637,P32638,P34783,P35143,P39460,P44304,P46406,P46713,P46795,P46796,P47543,P48812,P51009,P51469,P51640,P52694,P52987,P53429,P53430,P54117,P54118,P54226,P55070,P55071,P55971,P56649,P57384,P58839,P61879,P61880,P64178,P64179,P68777,P70685,P75358,P80447,P80534,P83601,P87197,P94915,Q00301,Q00584,Q00640,Q01558,Q01597,Q01651,Q01982,Q05025,Q07234,Q12552,Q1DTF9,Q27652,Q27890,Q28259,Q28554,Q2NEN0,Q3IUT3,Q46450,Q48335,Q4J940,Q4KYY3,Q58546,Q59199,Q59309,Q59800,Q59906,Q5JHB5,Q5R2J2,Q5RAB4,Q5V061,Q5XDW3,Q6BMK0,Q6CCU7,Q6L125,Q6M0E6,Q757I2,Q89AK1,Q8J1H3,Q8K8M9,Q8NK47,Q8PTD3,Q8TFJ2,Q8WZN0,Q8X1X3,Q8ZWK7,Q92211,Q92243,Q92263,Q94469,Q96US8,Q971K2,Q97BJ8,Q9HFX1,Q9HGY7,Q9HJ69,Q9HSS7,Q9N2D5,Q9N655,Q9P8C0,Q9PJN6,Q9UR38,Q9UVC0,Q9UW96,Q9V1P1,Q9Y796,Q9Y8E9,Q9YFS9,Q9Z518,Q9Z7T0,Q9ZKT0">GAPDH</protein-id>.	oxythiamine__GAPDH__interaction	oxythiamine__glucokinase__interaction	oxythiamine__insulin__interaction	oxythiamine__Glut-2__interaction
18394828-1061	) and two <compound-id="977">oxygen</compound-id> tensions (5 and 20%) were compared for their ability to sustain blastocyst survival and <protein-id="O46633,P28171,P28172,Q95187">IFNT</protein-id> production from days 8 to 11 post-insemination.	oxygen__IFNT__interaction
18394828-1062	In conclusion, culturing blastocysts of cattle in a 5% <compound-id="977">oxygen</compound-id> environment with M199 containing serum sustains embryo viability and permits constitutive and inducible <protein-id="O46633,P28171,P28172,Q95187">IFNT</protein-id> production.	oxygen__IFNT__interaction
18394828-1063	Incubation in 20% <compound-id="977">oxygen</compound-id> increases <protein-id="O46633,P28171,P28172,Q95187">IFNT</protein-id> production.	oxygen__IFNT__interaction
18395421-172	Histologic examination investigated deposition of extracellular matrix (<protein-id="Q13201">ECM</protein-id>) including collagen, <protein-id="P11547">elastin</protein-id>, <compound-id="24759,453618,3084050,24728612">hyaluronic acid</compound-id> (HA), <protein-id="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400">fibronectin</protein-id>, and decorin in the lamina propria of the scarred vocal folds.	hyaluronic acid__fibronectin__no_interaction	hyaluronic acid__elastin__no_interaction	hyaluronic acid__ECM__no_interaction
18396353-715	A series of novel bis-pyridinium oximes connected by bis-<compound-id="10869">methoxymethyl benzene</compound-id>, 1,4-bis-methoxymethyl (cis)-but-2-ene and 1,4-bis-methoxymethyl but-2-yne linkers were synthesized and their in vitro reactivation efficacy was evaluated against <compound-id="5936">diisopropyl phosphorofluoridate</compound-id> (DFP) inhibited <protein-id="Q867X2,Q867X3,Q86GC9,Q92081">acetylcholinesterase</protein-id> (<protein-id="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3">AChE</protein-id>) and compared with the established antidote 2-PAM and <compound-id="107688">obidoxime</compound-id>.	methoxymethyl benzene__acetylcholinesterase__no_interaction	methoxymethyl benzene__AChE__no_interaction	diisopropyl phosphorofluoridate__AChE__no_interaction	obidoxime__acetylcholinesterase__no_interaction	obidoxime__AChE__no_interaction	diisopropyl phosphorofluoridate__acetylcholinesterase__no_interaction
18396355-716	In-vitro regeneration of <compound-id="7871">sarin</compound-id> inhibited electric eel <protein-id="Q867X2,Q867X3,Q86GC9,Q92081">acetylcholinesterase</protein-id> by bis-pyridinium oximes bearing <compound-id="7237">xylene</compound-id> linker.	sarin__acetylcholinesterase__interaction	xylene__acetylcholinesterase__no_interaction
18396355-717	A series of bis-pyridinium oximes connected by <compound-id="7237">xylene</compound-id> linker were synthesized and their in-vitro reactivation potential was evaluated against <protein-id="Q867X2,Q867X3,Q86GC9,Q92081">acetylcholinesterase</protein-id> (<protein-id="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3">AChE</protein-id>) inhibited by nerve agent, <compound-id="7871">sarin</compound-id>.	xylene__acetylcholinesterase__no_interaction	sarin__acetylcholinesterase__interaction	xylene__AChE__no_interaction	sarin__AChE__interaction
18396355-718	Among the synthesized compounds, alpha,alpha'xylene-bis-[3,3'-(hydroxyiminomethyl) pyridinium] dibromide (3b) was found to be most potent reactivator for <protein-id="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3">AChE</protein-id> inhibited by <compound-id="7871">sarin</compound-id>.	sarin__AChE__interaction
18396356-720	Of the compounds synthesized, <compound-id="398803">compound 2a</compound-id>, which has a primary amide at warhead region of the inhibitor most potently inhibited mu-<protein-id="P27730">calpain</protein-id> with an IC(50) value of 2.81+/-1.26 microM, which is ca.	compound 2a__calpain__interaction
18397836-365	Recent studies have focused on possible functional disorders of the enteric nervous system within the abomasal wall, since cattle with abomasal displacement have an increased activity of neuronal <protein-id="O61309,O61608,Q27571,Q9I9M2">nitric oxide synthase</protein-id>, as well as decreased <compound-id="187">acetylcholine</compound-id> sensitivity.	acetylcholine__nitric oxide synthase__no_interaction
18397960-447	Earlier publications have suggested a possible role for the efflux transporter <protein-id="Q9UNQ0">breast cancer resistance protein</protein-id> (<protein-id="Q9UNQ0">BCRP</protein-id>) in acquired resistance to disease-modifying antirheumatic drugs (DMARDs) such as <compound-id="3899">leflunomide</compound-id> and its metabolite <compound-id="54684141">A771726</compound-id> (<compound-id="54684141">teriflunomide</compound-id>).	teriflunomide__BCRP__interaction	leflunomide__BCRP__interaction	A771726__breast cancer resistance protein__interaction	leflunomide__breast cancer resistance protein__interaction	teriflunomide__breast cancer resistance protein__interaction	A771726__BCRP__interaction
18398609-866	Inhibition of <protein-id="P0ABF6,P0ABF7,P19079,P32320,P44325,P47298,P47718,P56389,P75051,Q06549,Q322V3,Q32EM3,Q3IBX5,Q3Z062,Q4QK60,Q57MF5,Q5E4R6,Q5PE68,Q65RG8,Q66C79,Q6D3B4,Q6LRI0,Q7MK48,Q7N6K3,Q7VMJ6,Q87Q52,Q8DA31,Q8EDG1,Q8FFV3,Q8X648,Q8Z5A8,Q8ZG08,Q8ZNM0,Q9CP11,Q9KD53,Q9KSM5,Q9S3M0">cytidine deaminase</protein-id> by <compound-id="100016,328839,16760709,46783268">zebularine</compound-id> enhances the antineoplastic action of <compound-id="451668">5-aza-2'-deoxycytidine</compound-id>.	5-aza-2'-deoxycytidine__cytidine deaminase__interaction	zebularine__cytidine deaminase__interaction
18398611-867	An individual's response to <compound-id="657237">fludarabine</compound-id> may be influenced by the amount of <protein-id="P01730,P05542,P16003,P16004,P33705,P46630,P79184,P79185,Q08336,Q08338,Q08339,Q08340,Q29037,Q9XS78">CD4</protein-id> (+) and CD8(+) T-lymphocyte suppression.	fludarabine__CD4__interaction
18398624-876	We hypothesise that <compound-id="24325">arginine aspartate</compound-id> acts as a chemical or pharmacological chaperone, and suggest amino acid supplementation as a possible therapy in <protein-id="P08559,P29804,P49823,Q5R490,Q8HXW9">PDHA1</protein-id> mutations with mild phenotypes.	arginine aspartate__PDHA1__no_interaction
18400050-469	mRNA expressions of matrix metallopeptidase-9, inducible <protein-id="O61309,O61608,Q27571,Q9I9M2">nitric oxide synthase</protein-id> and pro-inflammatory cytokines interleukin-1 beta and tumour necrosis factor-alpha in EAN sciatic nerves were greatly decreased by administration of <compound-id="54675783">minocycline</compound-id> as well.	minocycline__nitric oxide synthase__interaction
18400404-699	Then the review evaluates the involvement of <protein-id="O70503,Q4R5G7,Q53GQ0,Q5E9H7,Q6P7R8">KARs</protein-id> activated by the endogenous agonist <compound-id="611,23327,33032">glutamate</compound-id> in the generation and propagation of epileptiform activity.	glutamate__KARs__interaction
18403016-272	<protein-id="O68838,P0A6W9,P0A6X0,P32477,P57485,P58994,P61379,Q09768,Q20117,Q57KV3,Q5E7F8,Q5LYY5,Q5M3J8,Q5PF10,Q65RX0,Q66E64,Q6ANW2,Q6D1T4,Q6LMV1,Q71VZ1,Q72RD4,Q7MHS5,Q7N7A4,Q7W3F2,Q7WES2,Q82ZG8,Q87LS2,Q88AR1,Q88R90,Q88UW5,Q89AD8,Q8D2V5,Q8DC38,Q8DW15,Q8DXM9,Q8E399,Q8EBF9,Q8F4D5,Q8X0X0,Q8X900,Q8XK30,Q8Y3R3,Q8Z4D6,Q8ZBU2,Q926X7,Q97IV1,Q9CM00,Q9HF78,Q9HTY6,Q9KUG5,Q9NFN6,Q9W3K5">Glutamate cysteine ligase</protein-id> (<protein-id="P28676,Q8NEA9,Q96IK5">GCL</protein-id>), synthesizing <compound-id="123938">gamma-glutamylcysteine</compound-id> from <compound-id="611,23327,33032">glutamate</compound-id> and <compound-id="594,5862,5360637">cysteine</compound-id>, is the rate-limiting enzyme in <compound-id="124886">glutathione</compound-id> (<compound-id="124886">GSH</compound-id>) biosynthesis.	cysteine__GCL__interaction	GSH__GCL__interaction	glutamate__Glutamate cysteine ligase__interaction	gamma-glutamylcysteine__GCL__interaction	gamma-glutamylcysteine__Glutamate cysteine ligase__interaction	glutamate__GCL__interaction	cysteine__Glutamate cysteine ligase__interaction	glutathione__Glutamate cysteine ligase__interaction	glutathione__GCL__interaction	GSH__Glutamate cysteine ligase__interaction
18403053-226	We observed that <compound-id="3870,3034764,6610292">lactacystin</compound-id> inhibited the proteasome activities and increased the level and insolubility of different <protein-id="P10637,P16525,P19332,P58384">tau</protein-id> species, including phosphorylated <protein-id="P10637,P16525,P19332,P58384">tau</protein-id>.	lactacystin__tau__interaction
18404246-532	Serine and cysteine <protein-id="O41798,O89290,O89940,O91080,O93215,P03311,P03353,P03355,P03356,P03362,P03363,P03366,P03367,P03369,P03370,P04023,P04024,P04323,P04584,P04585,P04587,P04588,P04589,P05959,P05960,P05961,P05962,P07570,P0C210,P0C211,P10210,P10265,P10270,P10271,P10272,P10273,P10274,P10394,P10978,P11227,P11365,P12451,P12497,P12498,P12499,P14074,P14078,P15833,P16046,P16423,P16901,P17757,P18042,P18096,P18802,P19028,P19199,P19560,P19561,P20825,P20875,P20876,P20892,P21407,P21414,P24107,P24740,P26808,P26809,P26810,P27502,P28936,P31822,P35956,P35963,P51518,P63119,P63120,P63121,P63122,P63123,P63124,P63125,P63127,P63128,P63129,P63131,P84454,Q09SZ9,Q0R5R2,Q0R5R3,Q1A249,Q1A267,Q4U0X6,Q73368,Q74120,Q75002,Q76634,Q77373,Q79666,Q89928,Q8AII1,Q8I7P9,Q9IDV9,Q9Q720,Q9QBY3,Q9QBZ1,Q9QBZ5,Q9QSR3,Q9WC54,Q9WC63,Q9Y6I0">proteases</protein-id> proved to be suitable tools for the production of amino acids and peptides conjugated to <compound-id="2151">4-aminoantipyrine</compound-id>, whereas metalloproteases do not seem to be very qualified for accepting this nucleophile.	4-aminoantipyrine__proteases__interaction
18405417-151	Role of serotonin <protein-id="P08908,P19327,P28285,Q64264,Q6XXX9,Q6XXY0,Q98998,Q9N296,Q9N297,Q9N298">5-HT1A</protein-id> receptors in the antidepressant-like effect and the antinociceptive effect of <compound-id="5656">venlafaxine</compound-id> in mice.	venlafaxine__5-HT1A__interaction
18405417-152	The present study was undertaken to evaluate the potential role of <protein-id="P08908,P19327,P28285,Q64264,Q6XXX9,Q6XXY0,Q98998,Q9N296,Q9N297,Q9N298">5-HT1A</protein-id> receptors in the antidepressant-like effect and antinociceptive effect of <compound-id="5656">venlafaxine</compound-id>.	venlafaxine__5-HT1A__interaction
18405417-154	These findings show that <protein-id="P08908,P19327,P28285,Q64264,Q6XXX9,Q6XXY0,Q98998,Q9N296,Q9N297,Q9N298">5-HT1A</protein-id> receptors play differing roles in modulating the antidepressant-like and antinociceptive effects of <compound-id="5656">venlafaxine</compound-id> in the models investigated.	venlafaxine__5-HT1A__interaction
18405417-155	In contrast, the antinociceptive effect of <compound-id="5656">venlafaxine</compound-id> is probably potentiated due to the blockade of somatodendritic <protein-id="P08908,P19327,P28285,Q64264,Q6XXX9,Q6XXY0,Q98998,Q9N296,Q9N297,Q9N298">5-HT1A</protein-id> receptors in the same raphe nuclei, facilitating the descending monoaminergic pain control system.	venlafaxine__5-HT1A__interaction
18407279-655	Moreover, <protein-id="P05804">beta-glucuronidase</protein-id> hydrolysis of <compound-id="64982">baicalin</compound-id> sequentially yielded glucuronic acid and <compound-id="5281605">baicalein</compound-id> as confirmed by co-TLC with authentic samples.	baicalein__beta-glucuronidase__interaction	baicalin__beta-glucuronidase__interaction
18407527-68	The effect of this diet alone or after 2 weeks of treatment with <compound-id="77999">rosiglitazone</compound-id> or <compound-id="3476">glimepiride</compound-id> on glucose homeostasis, lipid profile, and levels of resistin and <protein-id="O02750,O93416,Q28603,Q95189,Q95234">leptin</protein-id> was studied.	rosiglitazone__leptin__interaction	glimepiride__leptin__interaction
18407527-71	<compound-id="77999">Rosiglitazone</compound-id> corrected the altered parameters measured, except for liver <compound-id="2724387">TGs</compound-id> ; similarly, <compound-id="3476">glimepiride</compound-id> reinstated the inverted parameters but raised <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> level and, consequently, the HOMA index.	glimepiride__insulin__interaction	Rosiglitazone__insulin__no_interaction	TGs__insulin__no_interaction
18409068-1012	<compound-id="10302451">AZD0530</compound-id> inhibited tumor growth in a manner independent of dose and inhibited phosphorylation of <protein-id="Q00944,Q05397">FAK</protein-id> and <protein-id="P49023,P49024,Q5R7I1,Q66H76,Q8VI36">paxillin</protein-id> in a dose-dependent manner in a Calu-6 xenograft model.	AZD0530__FAK__interaction	AZD0530__paxillin__interaction
18409071-995	Activation of ErbB3, <protein-id="P00533,P13387,P55245">EGFR</protein-id> and Erk is essential for growth of human breast cancer cell lines with acquired resistance to <compound-id="104741">fulvestrant</compound-id>.	fulvestrant__EGFR__no_interaction
18409071-997	Treatment with the EGFR inhibitor <compound-id="123631">gefitinib</compound-id> preferentially inhibited growth and reduced the S phase fraction in the resistant cell lines concomitant with inhibition of Erk and unaltered <protein-id="P31750,Q8INB9">Akt</protein-id> activation.	gefitinib__Akt__no_interaction
18410309-540	<compound-id="896">Melatonin</compound-id> protects from hepatic reperfusion injury through inhibition of IKK and <protein-id="P92208,Q966Y3">JNK</protein-id> pathways and modification of cell proliferation.	Melatonin__JNK__interaction
18410309-541	<compound-id="896">Melatonin</compound-id> significantly improved animal survival and decreased transaminase levels, the indices for necrosis, liver damage, leukocyte infiltration, and <protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id> expression.	Melatonin__iNOS__interaction
18410309-542	At the same time, <compound-id="896">melatonin</compound-id> reduced the expression of both <protein-id="O01377,O02115,O10308,O16852,O27367,O29912,O58398,O73947,O82134,O82797,P04961,P11038,P12004,P15873,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P57761,P61074,P61258,Q00265,Q00268,Q03392,Q43124,Q43266,Q57697,Q6B6N4,Q6KZF1,Q6LWJ8,Q74MV1,Q7T6Y0,Q8PX25,Q8TUF7,Q8TWK3,Q979S2,Q9DDF1,Q9DEA3,Q9HJQ0,Q9HN45,Q9M7Q7,Q9MAY3,Q9P9H8,Q9PTP1,Q9UWR9,Q9UYX8,Q9W644">PCNA</protein-id> 0.05).	melatonin__PCNA__interaction
18410309-543	<compound-id="896">Melatonin</compound-id> is hepatoprotective most likely via mechanisms including inhibition of IKK and <protein-id="P92208,Q966Y3">JNK</protein-id> pathways and regulation of cell proliferation.	Melatonin__JNK__interaction
18410522-611	Here, we report that the citrus <compound-id="5280805">bioflavonoid</compound-id> <compound-id="5280445">luteolin</compound-id> reduces amyloid-beta (Abeta) peptide generation in both human 'Swedish' mutant <protein-id="O73683,O93279,P05067,P08592,P0A3Z1,P0A3Z2,P0A3Z3,P0A3Z4,P12023,P29216,P47566,P53601,P75313,P79307,Q11207,Q28053,Q28280,Q28748,Q28757,Q29149,Q5IS80,Q60495,Q95241">APP</protein-id> transgene-bearing neuron-like cells and primary neurons.	luteolin__APP__no_interaction	bioflavonoid__APP__no_interaction
18410522-612	We also find that <compound-id="5280445">luteolin</compound-id> induces changes consistent with <protein-id="P51136,P83101">GSK-3</protein-id> inhibition that (i) decrease amyloidogenic gamma-secretase <protein-id="O73683,O93279,P05067,P08592,P0A3Z1,P0A3Z2,P0A3Z3,P0A3Z4,P12023,P29216,P47566,P53601,P75313,P79307,Q11207,Q28053,Q28280,Q28748,Q28757,Q29149,Q5IS80,Q60495,Q95241">APP</protein-id> processing, and (ii) promote <protein-id="O12976,P49768,P49769,P79802,P97887,Q4JIM4,Q5R780,Q6RH31,Q8HXW5,Q9W6T7,Q9XT97">presenilin-1</protein-id> (<protein-id="P49768,P79802,Q8HXW5,Q9W6T7">PS1</protein-id>) carboxyl-terminal fragment (CTF) phosphorylation.	luteolin__APP__interaction	luteolin__presenilin-1__interaction	luteolin__PS1__interaction	luteolin__GSK-3__interaction
18410522-613	As validation of these findings in vivo, we find that <compound-id="5280445">luteolin</compound-id>, when applied to the Tg2576 mouse model of AD, decreases soluble Abeta levels, reduces <protein-id="P51136,P83101">GSK-3</protein-id> activity, and disrupts <protein-id="P49768,P79802,Q8HXW5,Q9W6T7">PS1</protein-id>-<protein-id="O73683,O93279,P05067,P08592,P0A3Z1,P0A3Z2,P0A3Z3,P0A3Z4,P12023,P29216,P47566,P53601,P75313,P79307,Q11207,Q28053,Q28280,Q28748,Q28757,Q29149,Q5IS80,Q60495,Q95241">APP</protein-id> association.	luteolin__APP__interaction	luteolin__PS1__interaction	luteolin__GSK-3__interaction
18410527-619	Since <compound-id="5280353,5315455,5353439,6183357">biliverdin</compound-id> and <compound-id="5280352">bilirubin</compound-id> are downstream products of <compound-id="4971">heme</compound-id> degradation by <protein-id="O19998,O73688,O78497,P51271,P71119">heme oxygenase</protein-id> (HO), it has been suggested that HO-activity protects against curcumin-induced apoptosis.	bilirubin__heme oxygenase__interaction	heme__heme oxygenase__interaction	biliverdin__heme oxygenase__interaction
18410529-629	Here, we examine the effect of resistin on <compound-id="206,5793,64689,79025">glucose</compound-id> uptake in human trophoblast cells and we demonstrate that transplacental glucose transport is mediated by <protein-id="P23586">glucose transporter</protein-id> (GLUT)-1.	glucose__glucose transporter__no_interaction
18410529-630	<protein-id="P27361,P28869,P42525,Q07176">ERK1</protein-id> and 2 activation stimulated <protein-id="P79365">GLUT-1</protein-id> synthesis and resulted in increase of placental <compound-id="206,5793,64689,79025">glucose</compound-id> uptake.	glucose__GLUT-1__interaction	glucose__ERK1__interaction
18410529-631	High resistin levels (50-100 ng/ml) seem able to affect <compound-id="206,5793,64689,79025">glucose</compound-id>-uptake, presumably by decreasing the cell surface <protein-id="P23586">glucose transporter</protein-id>.	glucose__glucose transporter__interaction
18410530-134	<compound-id="6804">CpG</compound-id> methylation as well as histone H3 methylation of lysines 9 and 27 contribute independently to <protein-id="O48920,P34727,P34728,P51823,Q94650">ARF</protein-id> gene silencing in adenocarcinoma cell lines and can be reversed by <compound-id="451668">5-aza-2'-deoxycytidine</compound-id>.	CpG__ARF__interaction	5-aza-2'-deoxycytidine__ARF__interaction
18410982-929	<compound-id="79101">Gly-Pro</compound-id>-, <compound-id="79101">Gly-Pro</compound-id>-Met- and Ala-Ala-Phe-N'-(2-hexyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)-hydrazides are synthesized by <compound-id="3520">guanidinium</compound-id>/uronium type condensing reagent and used as fluorogenic substrates to localize <protein-id="P14740,P22411,P27487,P28843,P81425,Q9N2I7">dipeptidyl peptidase IV</protein-id> and <protein-id="O14773,O89023,Q5IS74,Q5RFL1,Q60HH1,Q71JP6,Q9EQV6,Q9XSB8">tripeptidyl peptidase I</protein-id> activities in mammalian tissue sections.	Gly-Pro__dipeptidyl peptidase IV__interaction	guanidinium__dipeptidyl peptidase IV__interaction	Gly-Pro__tripeptidyl peptidase I__interaction	guanidinium__tripeptidyl peptidase I__interaction
18413191-1010	However, increased blood <compound-id="206,5793,64689,79025">glucose</compound-id> (200 mg/dl) significantly impaired the inhibitory effect of ASA (84% for <protein-id="P08514,P53711,Q9QUM0">GPIIb</protein-id>.005; 48% for P-selectin, P=NS).	glucose__GPIIb__no_interaction
18413206-1026	The expressions of <protein-id="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3">MCP-1</protein-id> mRNA in renal tissues were markedly up-regulated in untreated diabetic rats, and these could be notably reduced by <compound-id="77999">rosiglitazone</compound-id> treatment.	rosiglitazone__MCP-1__interaction
18413206-1027	In conclusion, <compound-id="77999">rosiglitazone</compound-id> may have a potential therapeutic target in DN, which may be partly attributed to lowering of the expression of <protein-id="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3">MCP-1</protein-id> in the local kidney and the urinary excretion of <protein-id="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3">MCP-1</protein-id>.	rosiglitazone__MCP-1__interaction
18414844-751	The homomeric <protein-id="P13900,P16604">P2X</protein-id> (7) receptor is extraordinary in that in addition to distinctive localization and biological functions it exhibits several hallmark properties, for example, the receptor is potently inhibited by divalent cations such as calcium, <compound-id="5462224">magnesium</compound-id>, zinc and <compound-id="23978">copper</compound-id>.	copper__P2X__interaction	magnesium__P2X__interaction
18414894-793	Replacement doses of <compound-id="5754">hydrocortisone</compound-id> (HC) (10 mg/m2/day) failed to produce a feedback inhibition of <protein-id="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5">adrenocorticotropic hormone</protein-id> (<protein-id="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5">ACTH</protein-id>), and <compound-id="6013">testosterone</compound-id> levels remained high.	testosterone__adrenocorticotropic hormone__no_interaction	hydrocortisone__ACTH__no_interaction	testosterone__ACTH__no_interaction	hydrocortisone__adrenocorticotropic hormone__no_interaction
18414974-853	<compound-id="23973">Cadmium</compound-id> exposure diminished the activities of enzymatic antioxidants, <protein-id="O50258">superoxide dismutase</protein-id> (<protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id>), <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id> (<protein-id="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7">CAT</protein-id>), <protein-id="O04437,O18598,P0A9D2,P0A9D3,P30116,P44521,P46088,P46419,P46423,P46426,P46428,P46437,P48438,P80894,P81065,P82996,P82997,P82998,P82999,P83000,P83001,P83246,Q04522,Q08392,Q08393,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52,Q96324">glutathione-S-transferase</protein-id> (<protein-id="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52">GST</protein-id>), <protein-id="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655">glutathione reductase</protein-id> (GR), <protein-id="O32770,O59858,Q00277,Q9CFV1">glutathione peroxidase</protein-id> (GPx) and glucose-6-phosphate dehydrogenase (<protein-id="O00091,O24357,O51581,O54537,O55044,O68282,O83491,O84188,P05370,P0A584,P0A585,P0A586,P0A587,P0AC53,P0AC54,P11410,P11411,P11412,P11413,P12646,P15588,P21907,P29686,P37830,P37986,P41571,P41764,P44311,P48826,P48828,P48848,P48992,P54547,P54996,P56110,P57405,P73411,P77809,P80619,P97324,Q00612,Q23711,Q24625,Q25019,Q25537,Q27464,Q27638,Q29492,Q42919,Q43793,Q43839,Q7YS37,Q89AI7,Q8K9M2,Q8XCJ6,Q9PKK8,Q9X0N9,Q9Z3S2,Q9Z8U6,Q9ZKB2">G6PD</protein-id>) as well as non-enzymatic antioxidant, <compound-id="124886">reduced glutathione</compound-id> (<compound-id="124886">GSH</compound-id>) and total thiols.	GSH__GST__no_interaction	reduced glutathione__GST__no_interaction	Cadmium__catalase__interaction	GSH__superoxide dismutase__no_interaction	reduced glutathione__glutathione-S-transferase__no_interaction	reduced glutathione__CAT__no_interaction	reduced glutathione__catalase__no_interaction	reduced glutathione__SOD__no_interaction	GSH__CAT__no_interaction	Cadmium__GST__interaction	GSH__glutathione reductase__no_interaction	Cadmium__G6PD__interaction	GSH__SOD__no_interaction	Cadmium__SOD__interaction	GSH__glutathione peroxidase__no_interaction	reduced glutathione__G6PD__no_interaction	reduced glutathione__superoxide dismutase__no_interaction	Cadmium__superoxide dismutase__interaction	reduced glutathione__glutathione peroxidase__no_interaction	Cadmium__glutathione reductase__interaction	Cadmium__glutathione peroxidase__interaction	GSH__glutathione-S-transferase__no_interaction	Cadmium__glutathione-S-transferase__interaction	reduced glutathione__glutathione reductase__no_interaction	Cadmium__CAT__interaction	GSH__catalase__no_interaction	GSH__G6PD__no_interaction
18414974-854	On the other hand, the levels of <compound-id="975,65359">oxidized glutathione</compound-id> (<compound-id="65359">GSSG</compound-id>), lipid peroxidation, protein carbonylation, DNA fragmentation, concentration of <compound-id="5359597">superoxide</compound-id> radicals and activities of <protein-id="O08469">cytochrome P450</protein-id> enzymes (<protein-id="P21568,P21569,P24525,P34887,Q26551">CYP</protein-id> P450s) have been found to increase due to <compound-id="23973">cadmium</compound-id> intoxication.	GSSG__CYP__no_interaction	cadmium__CYP__interaction	GSSG__cytochrome P450__no_interaction	oxidized glutathione__cytochrome P450__no_interaction	cadmium__cytochrome P450__interaction	superoxide__CYP__no_interaction	oxidized glutathione__CYP__no_interaction	superoxide__cytochrome P450__no_interaction
18415015-878	This paper describes (1) the preparation of the intact oligosaccharides from <protein-id="P48648">GM1</protein-id> (II(3)NeuAcGgOse(4) Cer) and GbOse(4) Cer as examples to show the use of CGase to prepare intact <compound-id="871">glycan</compound-id> chains from GSLs, and (2) the specificity and detergent requirements of Rhodococcal EGCases for the release of <compound-id="871">glycan</compound-id> chains from different GSLs.	glycan__GM1__no_interaction
18415121-949	The discovery of the <protein-id="P26677,P26678,P61012,P61013,P61015">PLN</protein-id>/<protein-id="O00165,O35387">HAX-1</protein-id> interaction therefore unveils an important new link between <compound-id="271">Ca(2</compound-id>+) homeostasis and cell survival, with significant therapeutic potential.	Ca(2__HAX-1__interaction	Ca(2__PLN__interaction
18418358-391	<compound-id="25081457">UFP-101</compound-id> alone evoked effects similar to low N/<protein-id="Q13519">OFQ</protein-id> doses, suggesting tonic inhibitory control over forelimb movement by endogenous N/<protein-id="Q13519">OFQ</protein-id>.	UFP-101__OFQ__no_interaction
18418709-605	Treating MCF-7 cells with <compound-id="16070039">AVE</compound-id>-1642 Qdots, but not unconjugated Qdots alone, downregulated <protein-id="P08069,Q05688,Q29000">IGF1R</protein-id> levels and rendered cells refractory to <protein-id="P05017,P07455,P08025,P10763,P16545,P17085,P17647,P18254,P33712,P51457,P51458,P51462,Q02815,Q28933,Q68LC0,Q6GUL6,Q6IVA5,Q6JLX1,Q95222">IGF-I</protein-id> stimulation.	AVE__IGF1R__interaction	AVE__IGF-I__interaction
18418709-606	Our data suggest that <compound-id="16070039">AVE</compound-id>-1642 Qdots can be used to detect <protein-id="P08069,Q05688,Q29000">IGF1R</protein-id> expression and measure changes in cell surface receptor levels.	AVE__IGF1R__interaction
18420260-309	Although previous studies indicated reduced levels of <compound-id="906,444885,445063">sialic acid</compound-id> residues during apoptosis, elevated Sambucus nigra <protein-id="P02872,P05046,P11218,P11219,P30617,P42088,P49329,P82859,P82953">agglutinin</protein-id> (SNA) reactivity might be due to the degradation of high molecular weight <protein-id="P08163">glycoproteins</protein-id> (probably including cadherin) that masked the SNA-binding residues of the plasma membrane prior to apoptosis.	sialic acid__glycoproteins__no_interaction	sialic acid__agglutinin__no_interaction
18423787-1115	We detected a marked decrease in target mRNA, an accumulation of short interfering RNAs (siRNAs), and a decrease in <compound-id="5280343">quercetin content</compound-id> relative to <compound-id="5280863">kaempferol</compound-id> in leaf tissues, indicating that sequence-specific mRNA degradation of the <protein-id="Q9SD85">F3'H</protein-id> gene was induced.	kaempferol__F3'H__interaction	quercetin content__F3'H__interaction
18423943-93	Polyhydroxy phenolic compounds, such as flavonoids, <compound-id="2116,14985,1548900,1742129">vitamin E</compound-id>, <compound-id="5281792">rosmarinic acid</compound-id> and <compound-id="2236">aristolochic acid</compound-id>, are able to inhibit <protein-id="P0C1C0,Q01172,Q6CZT4">PLA</protein-id> (2) from different sources.	rosmarinic acid__PLA__interaction	vitamin E__PLA__interaction	aristolochic acid__PLA__interaction
18425600-1102	Analysis of the protein domain features indicated typical conserved <compound-id="594,5862,5360637">cysteine</compound-id> residues containing a single <protein-id="P09837">whey acidic protein</protein-id> (<protein-id="O46655,P01173,P01174,P09412,P09837,Q9N0L8">WAP</protein-id>) domain at the C-terminus.	cysteine__WAP__no_interaction	cysteine__whey acidic protein__no_interaction
18427801-1197	Cross-linked <protein-id="P13900,P16604">P2X</protein-id> (1/2) heteromers showed strongly reduced or absent function that was selectively recovered upon treatment with <compound-id="439196,439352,446094">DTT</compound-id>.	DTT__P2X__interaction
18431601-998	Permeabilization of K. marxianus cells in relation to <protein-id="O33815,O52629,O52847,P00722,P00723,P06219,P0C1Y0,P14288,P22498,P23989,P24131,P26257,P30812,P50388,P70753,P77989,P81650,Q1G9Z4,Q47077,Q48727,Q56307,Q59140,Q59750,Q9K9C6">beta-galactosidase</protein-id> activity was carried out using cetyltrimethyl <compound-id="25514">ammonium bromide</compound-id> (<compound-id="2681">CTAB</compound-id>) to avoid the problem of enzyme extraction.	CTAB__beta-galactosidase__interaction	ammonium bromide__beta-galactosidase__interaction
18431759-1114	Although the levels of <protein-id="O77762,P05112,P07750,P20096,P30367,P30368,P42202,P46652,P47966,P51492,P51744,P55030,P79155,P79339,Q04745,Q2PE74,Q3S4V6,Q58M18,Q60440,Q7YS71,Q865X5,Q865Y0,Q8HYB1,Q9MZR8,Q9XS58">IL-4</protein-id>, <protein-id="P20109,P35225,P42203,P61126,Q5I6E4,Q864V6,Q865W5,Q865X3,Q95J68,Q9N0W9,Q9XSV9">IL-13</protein-id>, <protein-id="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5">IL-10</protein-id>, and <protein-id="O46678,O55235,P09340,P09341">GRO</protein-id>/KC were affected by polymer implantation, but not dependent on a specific polymer, <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> and <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNFalpha</protein-id> were significantly greater in those animals implanted with <compound-id="5327147">PEU</compound-id> and SR, materials that do not promote fusion.	PEU__GRO__no_interaction	PEU__IL-4__no_interaction	PEU__IL-13__no_interaction	PEU__TNFalpha__no_interaction	PEU__IL-10__no_interaction	PEU__IL-6__no_interaction
18431773-1123	Incorporation of <compound-id="6035">bromodeoxyuridine</compound-id> into newly synthesized DNA and the concentration of <protein-id="O46037,P12003,P18206,P19826,P26234,Q04615,Q17162,Q64727">vinculin</protein-id>, <protein-id="O18840,O42161,O93400,P15475,P29751,P48975,P60706,P60707,P60708,P60709,P60710,P60711,P60712,P60713,P68143,P79818,P83750,P83751,P84336,P84856,Q0PGG4,Q4L0Y2,Q5R1X3,Q711N9,Q71FK5,Q76N69,Q91ZK5,Q9Y702">beta-actin</protein-id>, osteopontin, and <protein-id="P02819,P02821,P02823,P0C225,P0C226,P15504,P28317,P39056,P81455,P83005,P83238,P83473,P83489,P84348,P84349,P84350,P84351,Q7LZI4,Q8HYY9">osteocalcin</protein-id> in cells on the scaffolds of all pore sizes were similar to the values obtained on standard tissue culture <compound-id="7501">polystyrene</compound-id>, which indicated good biocompatibility of the scaffolds.	polystyrene__osteocalcin__no_interaction	bromodeoxyuridine__vinculin__no_interaction	polystyrene__vinculin__no_interaction	bromodeoxyuridine__beta-actin__no_interaction	bromodeoxyuridine__osteocalcin__no_interaction	polystyrene__beta-actin__no_interaction
18431776-1124	To determine the capabilities of previously used microsphere scaffold to deliver growth factors simultaneously, this work investigated a long-term (about three months) release of bovine <protein-id="P21847,P83517">serum albumin</protein-id> (<protein-id="P02769">BSA</protein-id>) from microsphere scaffolds fabricated by using two different polymers, <compound-id="107801">poly(3-hydroxybutyrate-co-3-hydroxyvalerate</compound-id>) (PHBV, 8% PHV), <compound-id="23111554">poly(lactide-co-glycolide</compound-id>) acid (<compound-id="36797">PLGA</compound-id>, 5050) and a blend of <compound-id="36797">PLGA</compound-id> and PHBV.	PLGA__BSA__interaction	poly(3-hydroxybutyrate-co-3-hydroxyvalerate__serum albumin__interaction	PLGA__serum albumin__interaction	poly(lactide-co-glycolide__BSA__interaction	poly(3-hydroxybutyrate-co-3-hydroxyvalerate__BSA__interaction	poly(lactide-co-glycolide__serum albumin__interaction
18433938-1194	Prediction of <protein-id="O62743,O97878,O97879,O97880,O97881,O97882,O97883,O97962,O97975,P51681,P56439,P56440,P56493,P60574,P61755,P61756,P61757,P61813,P61814,P61815,P68269,P68270,Q1ZY22,Q2HJ17,Q5ECR9,Q6WN98,Q71UI8,Q8HZT9,Q95NC0,Q95NC1,Q95NC2,Q95NC3,Q95NC4,Q95NC5,Q95NC6,Q95NC7,Q95NC8,Q95NC9,Q95ND0,Q95ND1,Q95ND2,Q95NE8,Q9BGN6,Q9TV42,Q9TV43,Q9TV45,Q9TV47,Q9TV48,Q9TV49,Q9XT76">CCR5</protein-id> receptor binding affinity of substituted 1-(3,3-diphenylpropyl)-<compound-id="5376415">piperidinyl</compound-id> amides and ureas based on the heuristic method, support vector machine and projection pursuit regression.	piperidinyl__CCR5__interaction
18433938-1195	Quantitative structure-activity relationship (QSAR) models were developed to predict for <protein-id="O62743,O97878,O97879,O97880,O97881,O97882,O97883,O97962,O97975,P51681,P56439,P56440,P56493,P60574,P61755,P61756,P61757,P61813,P61814,P61815,P68269,P68270,Q1ZY22,Q2HJ17,Q5ECR9,Q6WN98,Q71UI8,Q8HZT9,Q95NC0,Q95NC1,Q95NC2,Q95NC3,Q95NC4,Q95NC5,Q95NC6,Q95NC7,Q95NC8,Q95NC9,Q95ND0,Q95ND1,Q95ND2,Q95NE8,Q9BGN6,Q9TV42,Q9TV43,Q9TV45,Q9TV47,Q9TV48,Q9TV49,Q9XT76">CCR5</protein-id> binding affinity of substituted 1-(3,3-diphenylpropyl)-<compound-id="5376415">piperidinyl</compound-id> amides and ureas using linear free energy relationship (LFER).	piperidinyl__CCR5__interaction
18434046-291	It is suggested that <compound-id="119">GABA</compound-id> acting through the <protein-id="P26714,Q08832,Q9BLY8">GABA(A) receptor</protein-id> mechanism on the expression of <protein-id="P27429">GnRH</protein-id> gene and <protein-id="O18821,P30968,P30969,P32236,P32237,P49922,Q01776,Q19PY9,Q8CH60,Q8SPZ1,Q9MZI6,Q9TTI8">GnRH-R</protein-id> gene in the hypothalamus may be involved in two processes: the biosynthesis of <protein-id="P27429">GnRH</protein-id> and the release of this neurohormone in the hypothalamus.	GABA__GnRH-R__interaction	GABA__GnRH__interaction	GABA__GABA(A) receptor__interaction
18435693-994	TT-induced increases in <compound-id="5754">cortisol</compound-id>, <protein-id="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5">adrenocorticotropic hormone</protein-id> and <protein-id="P10765,P22393,P33089,P33090,P33091,P43001">prolactin</protein-id> were reduced only after 3-h <protein-id="Q9UIJ5">REC</protein-id>.	cortisol__REC__no_interaction	cortisol__adrenocorticotropic hormone__no_interaction	cortisol__prolactin__no_interaction
18436224-84	<compound-id="5280343">Quercetin</compound-id> inhibits vascular <compound-id="5359597">superoxide</compound-id> production induced by <protein-id="P05305,Q28469">endothelin-1</protein-id> : Role of NADPH oxidase, uncoupled <protein-id="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600">eNOS</protein-id> and <protein-id="P05130,P13677,P13678,P34722">PKC</protein-id>.	Quercetin__PKC__no_interaction	Quercetin__eNOS__no_interaction	superoxide__PKC__no_interaction	superoxide__eNOS__no_interaction	superoxide__endothelin-1__interaction	Quercetin__endothelin-1__interaction
18436224-85	We have investigated the effects of <compound-id="5280343">quercetin</compound-id> and its methylated metabolite <compound-id="5281654">isorhamnetin</compound-id> (1-10microM) on endothelial dysfunction and <compound-id="5359597">superoxide</compound-id> (O(2*)(-)) production induced by <protein-id="P05305,Q28469">endothelin-1</protein-id> (<protein-id="P05305,P09558,P13206,P17322,P22387,P22388,P29560,P97740,Q28469,Q5NRP9,Q5NRQ1,Q9BG76">ET-1</protein-id>, 10nM).	superoxide__ET-1__interaction	isorhamnetin__ET-1__interaction	superoxide__endothelin-1__interaction	quercetin__ET-1__interaction	quercetin__endothelin-1__interaction	isorhamnetin__endothelin-1__interaction
18436224-86	<protein-id="P05305,P09558,P13206,P17322,P22387,P22388,P29560,P97740,Q28469,Q5NRP9,Q5NRQ1,Q9BG76">ET-1</protein-id> increased the contractile response induced by phenylephrine and reduced the relaxant responses to <compound-id="187">acetylcholine</compound-id> in phenylephrine contracted intact aorta, and these effects were prevented by co-incubation with <compound-id="5280343">quercetin</compound-id>, <compound-id="5281654">isorhamnetin</compound-id> or <compound-id="2703,411938">chelerythrine</compound-id> (protein kinase C (PKC) inhibitor).	acetylcholine__ET-1__interaction	isorhamnetin__ET-1__interaction	quercetin__ET-1__interaction	chelerythrine__ET-1__interaction
18436224-87	Furthermore, <protein-id="P05305,P09558,P13206,P17322,P22387,P22388,P29560,P97740,Q28469,Q5NRP9,Q5NRQ1,Q9BG76">ET-1</protein-id> increased intracellular O(2*)(-) production in all layers of the vessel, protein expression of NADPH oxidase subunit <protein-id="O10300,P08567,P26642,P34051,Q12802,Q91375,Q9SZB9,Q9Y240">p47</protein-id> (phox) without affecting <protein-id="O75935,P03304,P11691,P15961,P16342,P17593,P17594,P19751,P23169,P24102,P50629,P50630,P50631,P50632,P50633,P50634,P82796,Q05903,Q66198,Q8V439,Q8V6W7,Q91A29,Q9PYA3">p22</protein-id> (phox) expression and lucigenin-enhanced chemiluminescence signal stimulated by <compound-id="1959,11957499">calcium ionophore A23187</compound-id>.	calcium ionophore A23187__p47__no_interaction	calcium ionophore A23187__ET-1__no_interaction	calcium ionophore A23187__p22__no_interaction
18436224-88	Moreover, <compound-id="2214">apocynin</compound-id>, endothelium denudation and <compound-id="4367,440005">N(G)-nitro-l-arginine</compound-id> methylester (l-NAME, nitric oxide synthase inhibitor) suppressed the <protein-id="P05305,P09558,P13206,P17322,P22387,P22388,P29560,P97740,Q28469,Q5NRP9,Q5NRQ1,Q9BG76">ET-1</protein-id>-induced increase in A23187-stimulated O(2*)(-) generation.	N(G)-nitro-l-arginine__ET-1__interaction	apocynin__ET-1__interaction
18436224-89	Moreover, <compound-id="5280343">quercetin</compound-id> but not <compound-id="5281654">isorhamnetin</compound-id>, inhibited the increased <protein-id="P05130,P13677,P13678,P34722">PKC</protein-id> activity induced by <protein-id="P05305,P09558,P13206,P17322,P22387,P22388,P29560,P97740,Q28469,Q5NRP9,Q5NRQ1,Q9BG76">ET-1</protein-id>.	isorhamnetin__PKC__no_interaction	quercetin__PKC__interaction	isorhamnetin__ET-1__no_interaction	quercetin__ET-1__interaction
18436224-90	Taken together these results indicate that <protein-id="P05305,P09558,P13206,P17322,P22387,P22388,P29560,P97740,Q28469,Q5NRP9,Q5NRQ1,Q9BG76">ET-1</protein-id>-induced NADPH oxidase up-regulation and <protein-id="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600">eNOS</protein-id> uncoupling via <protein-id="P05130,P13677,P13678,P34722">PKC</protein-id> leading to endothelial dysfunction and these effects were prevented by <compound-id="5280343">quercetin</compound-id> and <compound-id="5281654">isorhamnetin</compound-id>.	isorhamnetin__ET-1__interaction	isorhamnetin__eNOS__interaction	isorhamnetin__PKC__interaction	quercetin__eNOS__interaction	quercetin__ET-1__interaction	quercetin__PKC__interaction
18436227-91	We hypothesized that variants in <protein-id="Q8NBP7">PCSK9</protein-id> that lower LDL <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> levels are associated with reduced prevalence and incidence of peripheral artery disease (PAD).	cholesterol__PCSK9__interaction
18436346-156	A series of 2-aryl-naphtho[1,2-d] <compound-id="9255">oxazole</compound-id> derivatives have been synthesized and evaluated for <protein-id="O13016,P18031,P20417,P35821">PTP-1B</protein-id> inhibitory activity.	oxazole__PTP-1B__interaction
18436348-931	A new series of <compound-id="6735">indanone</compound-id> and aurone derivatives have been synthesized and tested for in vitro <protein-id="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3">AChE</protein-id> inhibitory activity by modified Ellman method.	indanone__AChE__interaction
18436399-180	<compound-id="56842239">Polyunsaturated fatty acids</compound-id> differentially alter <protein-id="P49763,Q9XS47">PGF</protein-id> (2alpha) and <protein-id="Q29458">PGE</protein-id> (2) release from bovine trophoblast and endometrial tissues during short-term culture.	Polyunsaturated fatty acids__PGF__interaction	Polyunsaturated fatty acids__PGE__interaction
18436399-181	Two studies tested the hypothesis that eicosapentaenoic (20:5omega3; EPA), <compound-id="6433873">docosahexaenoic acids</compound-id> (22:6omega3; DHA) or <compound-id="5280450">linoleic acid</compound-id> (C18 :2omega6; <compound-id="96">LIN</compound-id>) reduced bovine endometrial and trophoblast prostaglandin F(2alpha) (<protein-id="P49763,Q9XS47">PGF</protein-id> (2alpha)) and prostaglandin E(2) (<protein-id="Q29458">PGE</protein-id> (2)) release during short-term culture.	LIN__PGE__interaction	LIN__PGF__interaction	docosahexaenoic acids__PGE__interaction	linoleic acid__PGE__interaction	linoleic acid__PGF__interaction	docosahexaenoic acids__PGF__interaction
18437529-872	<protein-id="O25121,O67036,O83796,O84335,P0A554,P0A555,P26242,P45205,P54523,P57536,P57848,P73067,P77488,Q0S1H1,Q0SS05,Q0TKM1,Q0TPD8,Q0VMI4,Q11KE0,Q11NY7,Q12CQ9,Q13RX1,Q18B68,Q1BLY7,Q1C4I9,Q1CL87,Q1CUF6,Q1D3G4,Q1GCG4,Q1GQK9,Q1GZD7,Q1IZP0,Q1LK34,Q1LTI9,Q1MKN4,Q1MRB3,Q1QE74,Q1QQ40,Q1R1E5,Q1RFC0,Q21A74,Q21F93,Q21UG7,Q24V05,Q253R7,Q2A3D3,Q2GC13,Q2IPZ2,Q2IRL7,Q2JDD9,Q2JK64,Q2JTX2,Q2KBR2,Q2KZ15,Q2LUA7,Q2NV94,Q2P472,Q2RIB9,Q2SA08,Q2T7N5,Q2W367,Q2YCH7,Q2YMF0,Q30TC5,Q30Z99,Q31AZ2,Q325I1,Q32JH8,Q393P4,Q3A3Z6,Q3AAN0,Q3AJP8,Q3AXZ4,Q3B5P3,Q3BRW8,Q3II09,Q3JAD1,Q3JKA3,Q3K660,Q3KM28,Q3M4F6,Q3SKF1,Q3SUZ1,Q3Z4Y9,Q3Z8G9,Q3ZXC2,Q46L36,Q474C2,Q47BJ0,Q47NL9,Q487D3,Q48NX0,Q493G7,Q4FN07,Q4FV64,Q4JVB5,Q4K5A5,Q4QKG6,Q4UW29,Q4ZYU8,Q50000,Q57ET1,Q57SE2,Q5E6Z0,Q5FAI2,Q5FUB1,Q5H1A0,Q5HWF0,Q5L6H4,Q5LH44,Q5LX42,Q5NG39,Q5P228,Q5PFR6,Q5QVE8,Q5SMD7,Q5WF63,Q5YTA2,Q60AN1,Q62DU1,Q635A7,Q63JF4,Q64Y02,Q65HJ2,Q65TP4,Q66DV4,Q67NB6,Q6A8V3,Q6AFD5,Q6AJQ1,Q6D844,Q6F7N5,Q6G0D4,Q6G4D1,Q6HDY8,Q6LU07,Q6MDK6,Q6NB76,Q6NGV3,Q71ZV7,Q72CD3,Q72H81,Q72U01,Q731B7,Q73LF4,Q73W57,Q75TB7,Q7M7Z0,Q7MN49,Q7MSZ3,Q7N0J7,Q7NP63,Q7NUK5,Q7U6P6,Q7UWB7,Q7V1G6,Q7V7Q3,Q7VC14,Q7VIJ7,Q7VNP7,Q7VRH9,Q7VV87,Q7W7Q0,Q7WL37,Q818R9,Q81M54,Q823V1,Q82VD3,Q83G46,Q83I20,Q83SG2,Q87C03,Q87RU0,Q889Q1,Q88QG7,Q894H0,Q89RW1,Q8A0C2,Q8D357,Q8DFA3,Q8DL74,Q8EGR9,Q8EWX7,Q8F153,Q8FKB9,Q8FPI2,Q8G292,Q8GAA0,Q8K9A1,Q8KFI9,Q8NPB2,Q8P815,Q8PJG7,Q8R639,Q8RAC5,Q8UHD7,Q8XE76,Q8XJE1,Q8XX95,Q8Y7C1,Q8YFM2,Q8YZ80,Q8Z8X3,Q8ZC45,Q8ZRD1,Q92BZ0,Q92RJ1,Q97HD5,Q985Y3,Q9A6M5,Q9JW13,Q9JXV7,Q9K971,Q9KGU7,Q9KTL3,Q9PB95,Q9PIH8,Q9PK62,Q9R6S7,Q9RBN6,Q9RUB5,Q9X291,Q9Z6J9,Q9ZM94">1-Deoxy-D-xylulose-5-phosphate synthase</protein-id> (DXS) catalyses the first committed step of the 2C-methyl-<compound-id="192838,3262721">D-erythritol-4-phosphate</compound-id> (<compound-id="7728">MEP</compound-id>) pathway, which is an alternative isoprenoids biosynthetic route that has been recently discovered.	MEP__1-Deoxy-D-xylulose-5-phosphate synthase__interaction	D-erythritol-4-phosphate__1-Deoxy-D-xylulose-5-phosphate synthase__interaction
18437557-896	To get insight into the underlying mechanisms, we compared the ability of recombinant wild type and variant (D327N) <protein-id="P04278,P08689,P15196,P97497,Q62588">SHBG</protein-id> to influence <compound-id="5757">estradiol</compound-id> effects in MCF-7 breast cancer cells.	estradiol__SHBG__interaction
18437557-897	D327N <protein-id="P04278,P08689,P15196,P97497,Q62588">SHBG</protein-id> was more effective than wild type protein in inhibiting <compound-id="5757">estradiol</compound-id>-induced cell proliferation and anti-apoptosis.	estradiol__SHBG__interaction
18437699-978	Our results suggest that <compound-id="934">Ni(II</compound-id>)-induced changes in cytokine secretion by monocytes are diverse and may be influenced by <protein-id="O54968,Q60795">Nrf2</protein-id> but are not likely influenced by changes in whole-cell <protein-id="O14463,P29445,Q8KEA4">Trx1</protein-id> levels.	Ni(II__Trx1__no_interaction	Ni(II__Nrf2__interaction
18439591-271	To test the hypothesis that increasing <compound-id="12594">DHEAS</compound-id> levels is associated with improved <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> resistance in patients with polycystic ovary syndrome (PCOS).	DHEAS__insulin__interaction
18440842-362	Packed cell volume, total protein, <compound-id="588">creatinine</compound-id>, blood <compound-id="1176,265993">urea</compound-id> <compound-id="947,123329">nitrogen</compound-id>, and <protein-id="P07846,P27867,Q00796,Q02912,Q06004,Q29318,Q4R639,Q58D31,Q59787,Q64442,Q9Z9U1">sorbitol dehydrogenase</protein-id> concentrations decreased while foals were on PN, while serum <compound-id="312">chloride</compound-id> concentration increased.	urea__sorbitol dehydrogenase__no_interaction	chloride__sorbitol dehydrogenase__no_interaction	nitrogen__sorbitol dehydrogenase__no_interaction	creatinine__sorbitol dehydrogenase__no_interaction
18442069-1161	The gene expressions of <protein-id="O42231,O42430,O42457,P00185,P04798,P05176,P33616,P56590,P56591,P79716,P98181,Q00557,Q06367,Q3LFU0,Q5KQT7,Q6GUR1,Q6JZS3,Q92039,Q92095,Q92100,Q92109,Q92110,Q92116,Q92148,Q9W683,Q9YH64">CYP1A1</protein-id> and <protein-id="O18963,P05181,P08682,P33266,P51581,P79383,Q6GUQ4">CYP2E1</protein-id> in the placenta increased significantly in <compound-id="942,89594,157672">nicotine</compound-id>-treated groups on GD 15 and GD 18, but returned to the level similar to the corresponding control on GD 21.	nicotine__CYP2E1__interaction	nicotine__CYP1A1__interaction
18442069-1162	In <compound-id="942,89594,157672">nicotine</compound-id> group, there was a decrease of <protein-id="P21447">mdr1a</protein-id> expression on GD 15, GD 18, and GD 21, with the most significant decrease on GD 15.	nicotine__mdr1a__interaction
18442070-1163	The present study was designed to understand the effects of sublethal concentrations of <compound-id="3039">dichlorvos</compound-id> (DIC) on hematological constituent [red blood corpuscles, white blood corpuscles (WBC), mean cell volume, mean corpuscular <protein-id="P15160,P17724,P73925,Q03459">hemoglobin</protein-id>, mean corpuscular <protein-id="P15160,P17724,P73925,Q03459">hemoglobin</protein-id> concentration, platelet counts, <protein-id="P15160,P17724,P73925,Q03459">hemoglobin</protein-id> and hematocrite levels] and serum damage marker enzymes (<protein-id="O33822,O58489,O67781,O86459,O93744,P00509,P14909,P23034,P44425,P53001,P58661,P72173,Q4J8X2,Q55128,Q56114,Q56232,Q59228,Q60013,Q92JE7,Q972A2,Q9V0L2,Q9X0Y2,Q9ZE56">aspartate aminotransferase</protein-id>, alanin aminotransferase, <protein-id="O60109,P81800,P83456">alkaline phosphatase</protein-id>, and lactate dehydrogenase) in rats at subacute period under laboratory conditions.	dichlorvos__aspartate aminotransferase__interaction	dichlorvos__alkaline phosphatase__interaction	dichlorvos__hemoglobin__interaction
18442075-634	<compound-id="896">Melatonin</compound-id> altered <compound-id="7516">PHZ</compound-id>-induced responses significantly to a greater degree than <compound-id="2116,14985,1548900,1742129">vitamin E</compound-id> as evidenced by <protein-id="P22079,P80025">LPO</protein-id> status, <protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id> activity, and <compound-id="5464076">ABTS radical cation</compound-id> scavenging activity of antioxidants.	vitamin E__SOD__no_interaction	Melatonin__SOD__no_interaction	Melatonin__LPO__no_interaction	PHZ__SOD__no_interaction	ABTS radical cation__LPO__no_interaction	ABTS radical cation__SOD__no_interaction	PHZ__LPO__no_interaction	vitamin E__LPO__no_interaction
18443829-973	The hydrolysis reaction of <compound-id="75834">p-nitrophenyl butyrate</compound-id> catalyzed by <protein-id="Q7M4U7">lipases</protein-id> was followed with in situ UV/vis diode array spectrophotometry.	p-nitrophenyl butyrate__lipases__interaction
18443829-974	Five enzymes-Candida antarctica <protein-id="Q7M4U7">lipase</protein-id> B and Fusarium solani pisi cutinase wild-type and three single-mutation variants-were tested as catalysts in homogeneous conditions and immobilized on zeolite <compound-id="445523">NaY</compound-id>, on a <compound-id="6581">polyacrylate</compound-id> support and as cross-linked aggregates.	polyacrylate__lipase__no_interaction	NaY__lipase__no_interaction
18443843-1157	At term, the impact of their coexposure was assessed by evaluating lipid peroxidation (<protein-id="P22079,P80025">LPO</protein-id>), activities of <protein-id="O50258">superoxide dismutase</protein-id> (<protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id>), <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id>, <protein-id="O32770,O59858,Q00277,Q9CFV1">glutathione peroxidase</protein-id> (GPx), <protein-id="O04437,O18598,P0A9D2,P0A9D3,P30116,P44521,P46088,P46419,P46423,P46426,P46428,P46437,P48438,P80894,P81065,P82996,P82997,P82998,P82999,P83000,P83001,P83246,Q04522,Q08392,Q08393,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52,Q96324">glutathione-S-transferase</protein-id> (<protein-id="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52">GST</protein-id>), different ATPases and <protein-id="Q867X2,Q867X3,Q86GC9,Q92081">acetylcholinesterase</protein-id> (<protein-id="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3">AChE</protein-id>) in erythrocytes, serum <compound-id="206,5793,64689,79025">glucose</compound-id>, and levels of <compound-id="124886">glutathione</compound-id> (<compound-id="124886">GSH</compound-id>) and glycosylated <protein-id="P15160,P17724,P73925,Q03459">hemoglobin</protein-id> (GHb) in blood.	GSH__GST__no_interaction	glutathione__GST__no_interaction	glucose__catalase__no_interaction	GSH__superoxide dismutase__no_interaction	GSH__hemoglobin__no_interaction	GSH__SOD__no_interaction	glutathione__AChE__no_interaction	GSH__LPO__no_interaction	glucose__glutathione-S-transferase__no_interaction	glucose__acetylcholinesterase__no_interaction	glutathione__SOD__no_interaction	glucose__superoxide dismutase__no_interaction	glucose__glutathione peroxidase__no_interaction	glutathione__catalase__no_interaction	glutathione__acetylcholinesterase__no_interaction	glucose__hemoglobin__no_interaction	GSH__glutathione peroxidase__no_interaction	glutathione__LPO__no_interaction	glucose__AChE__no_interaction	GSH__glutathione-S-transferase__no_interaction	glutathione__superoxide dismutase__no_interaction	glutathione__glutathione peroxidase__no_interaction	glucose__SOD__no_interaction	glucose__LPO__no_interaction	GSH__acetylcholinesterase__no_interaction	GSH__AChE__no_interaction	glutathione__glutathione-S-transferase__no_interaction	glutathione__hemoglobin__no_interaction	GSH__catalase__no_interaction	glucose__GST__no_interaction
18443843-1158	<protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">Catalase</protein-id> was decreased with <compound-id="3224">endosulfan</compound-id> and the coexposure, but not with arsenic, whereas <compound-id="124886">GSH</compound-id> was decreased with arsenic and <compound-id="3224">endosulfan</compound-id>, but not with the coexposure.	endosulfan__Catalase__no_interaction	GSH__Catalase__no_interaction
18443843-1159	<protein-id="P13607,P17326,P28774,P35317">Na+-K+-ATPase</protein-id> activity was decreased in the <compound-id="3224">endosulfan</compound-id>-treated and the coexposed birds.	endosulfan__Na+-K+-ATPase__interaction
18443897-1003	mRNA and protein levels of <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id>, <protein-id="P25446,Q63199">Fas</protein-id>, and caspase-8, which are closely related to cell apoptosis by a death ligand/receptor-dependent apoptosis pathway, were increased by <compound-id="10918">L-carnitine</compound-id> treatment.	L-carnitine__TNF-alpha__interaction	L-carnitine__Fas__interaction
18443897-1004	In addition, <compound-id="10918">L-carnitine</compound-id> treatment regulated mitochondria-dependent apoptosis pathways by inducing the up-regulation of caspase-9 and caspase-3 and the down-regulation of <protein-id="P10417,P49950">Bcl-2</protein-id> in hepa1c1c 7 cells.	L-carnitine__Bcl-2__interaction
18443897-1005	Taken together, the findings of this study have demonstrated that <compound-id="10918">L-carnitine</compound-id> could induce apoptosis in hepa1c1c7 cells by regulating <protein-id="P36940,P41047,P48023,P63306,P63307,P63308,Q861W5,Q9BDN1,Q9BEA8">Fas ligands</protein-id> and inhibiting the expression of <protein-id="P10417,P49950">Bcl-2</protein-id>.	L-carnitine__Fas ligands__interaction	L-carnitine__Bcl-2__interaction
18445079-363	<compound-id="84098">Merlin</compound-id> is known to bind <protein-id="P49023,P49024,Q5R7I1,Q66H76,Q8VI36">paxillin</protein-id>, beta1 integrin and focal adhesion kinase, members of focal contacts, multi-protein complexes that mediate cell adhesion to the extracellular matrix.	Merlin__paxillin__interaction
18445307-585	Furthermore, free radical overproduction and oxidative stress were associated with a significant decrease in hepatic <compound-id="124886">glutathione</compound-id> levels in septic mice, and with an excessive NO production attributed to the induction of the inducible isoform of NO synthase (<protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id>).	glutathione__iNOS__no_interaction
18445307-586	In fact, hepatic <compound-id="124886">glutathione</compound-id> levels were significantly increased in the group of mice receiving the probiotic, and the increased <protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id> expression both in the colon and lungs was down-regulated in those mice treated with L. fermentum.	glutathione__iNOS__no_interaction
18448193-1146	Furthermore, supplementation of specific inhibitors of <protein-id="O03979,O04058,O93967,P10248,P10731,P11544,P14166,P14717,P14925,P19021,P26600,P35511,P35512,P45726,P45727,P45730,P45731,P45735,P52777,P83388,P91268,P97467,Q42609,Q43210,Q9P2V4,Q9PSN0">PAL</protein-id>, <protein-id="O24312,O81928,P37114,P37115,P48522,P92994,Q04468,Q42797,Q43033,Q43054,Q43067,Q43240,Q96423,Q9AR74">C4H</protein-id> and <protein-id="O11451,O11452,O11453,O24540,O54075,O69140,P17814,P41636,P42516,P68763,P68764,P68765,P69180,P69181,P69182,P69183,P69184">4CL</protein-id> in elicited cell cultures led to suppressed accumulation of <compound-id="135">p-hydroxybenzoic acid</compound-id>, which opens up interesting questions regarding the probable route of the biosynthesis of this phenolic acid in C. nucifera.	p-hydroxybenzoic acid__PAL__no_interaction	p-hydroxybenzoic acid__4CL__no_interaction	p-hydroxybenzoic acid__C4H__no_interaction
18449471-648	<compound-id="5291">Imatinib</compound-id> is transported by P-<protein-id="P08163">glycoprotein</protein-id> (P-gp) and <protein-id="Q9UNQ0">Breast Cancer Resistance Protein</protein-id> (<protein-id="Q9UNQ0">BCRP</protein-id>), however, the exact impact of these transporters on absorption, distribution, metabolism and excretion (ADME) of <compound-id="5291">imatinib</compound-id> is not fully understood due to incomplete data.	imatinib__BCRP__interaction	imatinib__Breast Cancer Resistance Protein__interaction	Imatinib__glycoprotein__interaction	Imatinib__BCRP__interaction	Imatinib__Breast Cancer Resistance Protein__interaction	imatinib__glycoprotein__interaction
18449471-650	In conclusion, P-gp and <protein-id="Q9UNQ0">BCRP</protein-id> have only a modest effect on the ADME of <compound-id="5291">imatinib</compound-id> in comparison to metabolic elimination.	imatinib__BCRP__interaction
18449471-651	The considerable drug-drug interaction observed with <compound-id="119373">elacridar</compound-id> or <compound-id="4679">pantoprazole</compound-id> is only partly mediated by inhibition of P-gp and <protein-id="Q9UNQ0">BCRP</protein-id> and far more by the inhibition of other elimination pathways.	pantoprazole__BCRP__interaction	elacridar__BCRP__interaction
18449536-687	There is clear evidence for <protein-id="O95069">TREK</protein-id>-1 and <protein-id="O14649">TASK</protein-id>-1 in the heart and these channels are likely to regulate cardiac action potential duration through their regulation by stretch, <compound-id="56842239">polyunsaturated fatty acids</compound-id>, pH, and neurotransmitters.	polyunsaturated fatty acids__TASK__interaction	polyunsaturated fatty acids__TREK__interaction
18449536-688	<protein-id="O95069">TREK</protein-id>-1 may also have a critical role in mediating the vasodilator response of resistance arteries to <compound-id="56842239">polyunsaturated fatty acids</compound-id>, thus contributing to their protective effect on the cardiovascular system.	polyunsaturated fatty acids__TREK__interaction
18449944-953	Alumina ceramic particles, in comparison with <compound-id="23963">titanium</compound-id> particles, hardly affect the expression of <protein-id="Q9Y6Q6">RANK</protein-id>-, <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id>-, and <protein-id="O00300">OPG</protein-id>-mRNA in the THP-1 human monocytic cell line.	titanium__TNF-alpha__interaction	titanium__RANK__interaction	titanium__OPG__interaction
18450412-1248	<compound-id="5326739">Indirubin-3-oxime</compound-id>-induced growth inhibition was associated with induction of Cdk inhibitor p21, inhibition of <protein-id="O01377,O16852,P04961,P12004,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P61074,Q00265,Q00268">cyclin</protein-id> D1 and activation of caspase-3.	Indirubin-3-oxime__cyclin__interaction
18452177-145	Three proteins, porcine <protein-id="P10766,P20391,P20392,P33092,P34005,P34006,P34747,P37885,P55755">somatotropin</protein-id>, bovine <protein-id="P21847,P83517">serum albumin</protein-id>, and immunoglobulin, as well as materials with a strong calorimetric glass transition (T(g)), that is, <compound-id="3715">indomethacin</compound-id> and poly(vinypyrrolidone) (PVP), were studied by both TSC and differential scanning calorimetry (DSC).	indomethacin__serum albumin__no_interaction	indomethacin__somatotropin__no_interaction
18454352-1155	The recombinant protein exhibited high <protein-id="O03979,O04058,O93967,P10248,P10731,P11544,P14166,P14717,P14925,P19021,P26600,P35511,P35512,P45726,P45727,P45730,P45731,P45735,P52777,P83388,P91268,P97467,Q42609,Q43210,Q9P2V4,Q9PSN0">PAL</protein-id> activity and could catalyze the conversion of L:-Phe to <compound-id="444539">trans-cinnamic acid</compound-id>.	trans-cinnamic acid__PAL__no_interaction
18456422-1170	Only the <protein-id="P80298,P80545,P81173">beta-lactamases</protein-id> of pI 5.4 and superior to 7.6 hydrolyze the <compound-id="5479527,5742673,6540461">cefotaxime</compound-id>.	cefotaxime__beta-lactamases__interaction
18457934-815	To investigate this relationship, we used actively growing young Sprague-Dawley rats and <compound-id="6918502">CKD-732</compound-id>, one of the angiogenesis inhibitor (AI) to reveal the relationship of angiogenesis in the effect of <protein-id="O27732,O28185,O66677,O74017,O74806,O83975,O84806,O85235,P01268,P01269,P01270,P04089,P0A281,P0A282,P0A7D1,P0A7D2,P0A7D3,P15743,P37470,P38876,P44682,P47329,P47714,P49607,P52212,P56077,P57287,P57820,P59490,P61234,P61235,P61414,P65863,P65864,P65865,P65866,P65867,P65868,P65869,P78034,Q27IM2,Q57NM8,Q59989,Q5F9L4,Q5FFA3,Q5FMA9,Q5FRT7,Q5GTI9,Q5GWR6,Q5HC85,Q5HIH3,Q5HRQ3,Q5HWF9,Q5JDB8,Q5L3U7,Q5LV91,Q5M222,Q5M6L4,Q5N2J4,Q5NGZ6,Q5NL75,Q5P722,Q5P9A6,Q5PCR7,Q5QV03,Q5SHZ2,Q5V1D3,Q5WAD6,Q5WTE7,Q5X1N7,Q5XEM3,Q5YPZ6,Q5ZS66,Q601M5,Q60363,Q60A14,Q62FC1,Q63HI2,Q63XM0,Q64X30,Q65PG8,Q65V47,Q65ZY7,Q66AY1,Q67JD0,Q68WD4,Q6AAC7,Q6ADQ8,Q6AJL9,Q6D557,Q6F240,Q6F8I7,Q6G0F9,Q6G2L1,Q6GBY6,Q6GJG9,Q6HPW6,Q6KHA3,Q6LNA9,Q6MJR3,Q6MS28,Q6N1P9,Q6NI78,Q6YP15,Q6YR64,Q724K0,Q72BR1,Q72IA8,Q72RZ0,Q73FF7,Q73II8,Q73Q01,Q741V9,Q74FE6,Q74LA8,Q7M7U8,Q7MMZ2,Q7MXK9,Q7N5A1,Q7NN75,Q7NQT1,Q7U9I5,Q7UKV0,Q7V342,Q7V4V4,Q7VDT7,Q7VG29,Q7VMI1,Q7VUH3,Q7W179,Q7WNY2,Q81J96,Q81VY9,Q821W6,Q82HE5,Q82TQ6,Q839C0,Q83AP0,Q83FR1,Q83HD8,Q83LE1,Q86Y79,Q877G5,Q87A24,Q87RN9,Q888C8,Q88PX8,Q88Z39,Q899I4,Q89DJ9,Q89YZ2,Q8BW00,Q8CQU9,Q8CXP8,Q8D2K4,Q8DFF4,Q8DJ45,Q8DRQ2,Q8DWN5,Q8E2I1,Q8E7Y8,Q8EHN5,Q8EWQ8,Q8F3Q2,Q8FQV6,Q8G5I6,Q8K8Z7,Q8K9V3,Q8KD05,Q8P327,Q8PC61,Q8PNT8,Q8Q0M4,Q8R757,Q8RIJ5,Q8RLD7,Q8TKX4,Q8TV04,Q8U0N0,Q8UD97,Q8XHJ8,Q8Y2E3,Q8YAD1,Q8YYK4,Q8ZEY4,Q8ZYM4,Q92F62,Q92H41,Q92N67,Q976I0,Q97CB4,Q97E97,Q97TD1,Q980V1,Q98HV6,Q98PE2,Q9A206,Q9AAV9,Q9AEQ5,Q9CD49,Q9CJI1,Q9F8Q3,Q9GL67,Q9HLW6,Q9HVC3,Q9J5H2,Q9JV42,Q9K029,Q9K3T8,Q9KGJ3,Q9KQ21,Q9PA78,Q9PII7,Q9PR67,Q9RRW3,Q9V108,Q9X1W1,Q9XT35,Q9YBD6,Q9Z6V6,Q9ZCV4,Q9ZJC3">PTH</protein-id>.	CKD-732__PTH__no_interaction
18458677-190	Functional polymorphisms in the <protein-id="P41693">interleukin-6</protein-id> and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and <compound-id="37542">ribavirin</compound-id> treatment.	ribavirin__interleukin-6__interaction
18458952-1204	An alpha-numeric code for representing N-linked <compound-id="871">glycan</compound-id> structures in secreted <protein-id="P08163">glycoproteins</protein-id>.	glycan__glycoproteins__interaction
18458952-1205	Towards this end, we propose a fixed-length alpha-numeric code for representing N-linked <compound-id="871">glycan</compound-id> structures commonly found in secreted <protein-id="P08163">glycoproteins</protein-id> from mammalian cell cultures.	glycan__glycoproteins__interaction
18458994-119	There was a significant increase in <protein-id="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3">cytochrome-c</protein-id> oxidase activity at 2.5 mg/L, which might indicate <compound-id="91590">irgarol</compound-id>'s disruption of the mitochondrial membrane and subsequently <compound-id="5957">ATP</compound-id> synthesis.	irgarol__cytochrome-c__interaction	ATP__cytochrome-c__interaction
18459128-282	Treatment of A549, which express wild-type <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id>, and H1299, which are <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id>-deficient, human lung cancer cells with <compound-id="2353">berberine</compound-id> resulted in inhibition of cell proliferation and an increase in apoptotic cell death ; however, A549 cells were more sensitive to the <compound-id="2353">berberine</compound-id>-induced cytotoxic effects than H1299 cells.	berberine__p53__no_interaction
18459941-785	Furthermore <compound-id="60823">atorvastatin</compound-id> treatment markedly decreased the levels of <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id>, <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> and <protein-id="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3">MCP-1</protein-id>, reduced myocardial infiltration of macrophages and significantly increased myocardial and serum levels of the anti-inflammatory cytokine <protein-id="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5">IL-10</protein-id>.	atorvastatin__IL-10__interaction	atorvastatin__MCP-1__interaction	atorvastatin__IL-6__interaction	atorvastatin__TNF-alpha__interaction
18459941-787	Our study suggests that the modulation of the balance between pro- and anti-inflammatory cytokines towards the anti-inflammatory cytokine <protein-id="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5">IL-10</protein-id> is one salutary mechanism underlying how <compound-id="60823">atorvastatin</compound-id> influences post-MI remodelling and thus improves LV function.	atorvastatin__IL-10__no_interaction
18459944-788	In addition, <compound-id="10069117">AUDA</compound-id> treatment attenuated macrophage infiltration and inhibited urinary excretion of <protein-id="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3">MCP-1</protein-id> (<protein-id="P10148,P13500,P14844,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3">monocyte chemoattractant protein-1</protein-id>) and kidney cortex <protein-id="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3">MCP-1</protein-id> gene expression.	AUDA__MCP-1__interaction	AUDA__monocyte chemoattractant protein-1__interaction
18462831-74	Exogenous <compound-id="1102">spermidine</compound-id>, arsenic and <compound-id="10932">beta-aminobutyric acid</compound-id> modulate tobacco resistance to tobacco mosaic virus, and affect local and systemic glucosylsalicylic acid levels and <protein-id="O81160,O82475,P21885,P22220,P49726,Q39827,Q43075,Q819L4,Q81MS2,Q96412,Q96A70,Q9K9K5,Q9SNN0">arginine decarboxylase</protein-id> gene expression in tobacco leaves.	beta-aminobutyric acid__arginine decarboxylase__interaction	spermidine__arginine decarboxylase__interaction
18462831-75	Moreover, this phenotypic response was correlated with changes in the endogenous concentration of the SAR-related molecule <compound-id="338">salicylic acid</compound-id> and in transcript levels of some pathogenesis/stress-related genes (<protein-id="P83834">pathogenesis-related proteins</protein-id> PR-1a and <protein-id="P33157,P51525">PR-2</protein-id> and <protein-id="O81160,O82475,P21885,P22220,P49726,Q39827,Q43075,Q819L4,Q81MS2,Q96412,Q96A70,Q9K9K5,Q9SNN0">arginine decarboxylase</protein-id> (<protein-id="O81160,O82475,P21170,P22220,P23670,P28629,P49726,P60658,P60659,P81336,Q39827,Q43075,Q7MK24,Q7N121,Q7NE10,Q7NSA6,Q7NU27,Q7TUJ9,Q7U3S0,Q7UTS2,Q7V3M9,Q7VEG4,Q83Q93,Q87F25,Q87JS8,Q87VU3,Q88QC7,Q8A2B1,Q8BVM4,Q8DA54,Q8DHY6,Q8EFU5,Q8FE34,Q8P448,Q8PFQ5,Q8XCX9,Q8XR10,Q8YRP3,Q8ZHG8,Q96412,Q96A70,Q9CL60,Q9EYI7,Q9HUX1,Q9JT25,Q9K0U3,Q9KLD1,Q9PH02,Q9RPK1,Q9RXR4,Q9SNN0">ADC</protein-id>)).	salicylic acid__arginine decarboxylase__no_interaction	salicylic acid__pathogenesis-related proteins__no_interaction	salicylic acid__ADC__no_interaction	salicylic acid__PR-2__no_interaction
18462962-149	She had a mutation in <protein-id="Q9BZ23">PANK2</protein-id> gene consisting of an aminoacid change of <compound-id="602,4580,5950,71080">Alanine</compound-id> to <compound-id="6287">Valine</compound-id> in exon 5 (A382V).	Valine__PANK2__interaction	Alanine__PANK2__interaction
18466349-969	Decreased hepatic <protein-id="P02753,P06912,P18902,P27485,P41263,P61641,Q28369">RBP4</protein-id> secretion is correlated with reduced hepatic <compound-id="206,5793,64689,79025">glucose</compound-id> production but is not associated with <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> resistance in patients with liver cirrhosis.	glucose__RBP4__interaction	glucose__insulin__no_interaction
18466352-971	<compound-id="6442177">RAD001</compound-id>-induced growth suppression was associated with inactivation of downstream targets of <protein-id="P42345,P42346,Q9JLN9">mTOR</protein-id>, reduction in <protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id> expression and microvessel density, inhibition of cell proliferation, up-regulation of <protein-id="O11451,O11452,O11453,O39927,O39928,O39929,O91936,O92529,O92530,O92531,O92532,P06934,P16342,P19751,P25880,P25881,P25882,P25884,P25989,P26660,P26661,P26662,P26663,P26664,P27958,P29833,P29846,P29996,P29997,P40305,P68763,P68764,P68765,P69180,P69181,P69182,P69183,P69184,P69618,P69619,Q00269,Q43735,Q5I2N3,Q66198,Q68749,Q68798,Q68801,Q81258,Q81487,Q81495,Q81754,Q81835,Q81842,Q8V439,Q8V6W7,Q913D4,Q91A29,Q91DH7,Q91DH8,Q91DH9,Q99IB8,Q9DHD6,Q9E925,Q9PYA3,Q9QAX1,Q9WMX2">p27</protein-id> (Kip1) and down-regulation of <protein-id="O19002,O39927,O39928,O39929,O91936,O92529,O92530,O92531,O92532,P26660,P26661,P26662,P26663,P26664,P27954,P27955,P27956,P27957,P27958,P27959,P27960,P27961,P29846,P38936,P39689,P61585,P63028,Q00269,Q01403,Q01404,Q07828,Q11118,Q42580,Q5EG65,Q5I2N3,Q62092,Q68749,Q68798,Q68801,Q81258,Q81487,Q81495,Q81754,Q913D4,Q99IB8,Q9DHD6,Q9QAX1,Q9WMX2">p21</protein-id> (<protein-id="O42923,P39689">Cip1</protein-id>/<protein-id="P39689">Waf1</protein-id>), <protein-id="O05982">Cdk</protein-id>-6, <protein-id="O05982">Cdk</protein-id>-2, <protein-id="O05982">Cdk</protein-id>-4, cdc-25C, <protein-id="O01377,O16852,P04961,P12004,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P61074,Q00265,Q00268">cyclin</protein-id> B1 and <protein-id="P01109,P06646,P49709,P52160,Q17103">c-Myc</protein-id>.	RAD001__Cip1__interaction	RAD001__p27__interaction	RAD001__VEGF__interaction	RAD001__Cdk__interaction	RAD001__c-Myc__interaction	RAD001__Waf1__interaction	RAD001__p21__interaction	RAD001__cyclin__interaction	RAD001__mTOR__interaction
18467006-128	A series of <compound-id="7370">benzenesulfonamide</compound-id>-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles have been synthesized and evaluated for their <protein-id="P36897">ALK5</protein-id> inhibitory activity in cell-based luciferase reporter assays.	benzenesulfonamide__ALK5__interaction
18468607-1101	Genetic variation in <protein-id="P11597,P22687,P25914,P47896">CETP</protein-id> (<protein-id="P25914">cholesteryl ester transfer protein</protein-id>) has been clearly associated with HDL <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> levels but its association with cardiovascular disease and related phenotypes has been more controversial, possibly due to variability of polymorphisms and their frequencies across different ethnic populations.	cholesterol__CETP__interaction	cholesterol__cholesteryl ester transfer protein__interaction
18470629-1072	However, <compound-id="5353758">methomyl</compound-id> exhibited more potency in reducing <protein-id="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3">AChE</protein-id> activity than <compound-id="16248">methiocarb</compound-id>.	methomyl__AChE__interaction	methiocarb__AChE__interaction
18470874-1230	Early and late 2-cell and late 4-cell stage embryos, prepared by in vitro fertilization (IVF), parthenogenetic activation (PG), and nuclear transfer of mouse embryonic fibroblast (MEF) and mouse HM1 embryonic stem cells (HM1), were processed for autoradiography following (3)H-<compound-id="6029">uridine</compound-id> incubation (transcriptional activity), transmission electron microscopy (ultrastructure) and immunofluorescence (nucleolar proteins; upstream binding factor, <protein-id="P17480">UBF</protein-id> and <protein-id="P06748,P07222,P13084,P16039,Q3T160,Q61937">nucleophosmin</protein-id>, <protein-id="P51472">B23</protein-id>).	uridine__nucleophosmin__no_interaction	uridine__UBF__no_interaction	uridine__B23__no_interaction
18471929-584	Furthermore, among the ROS scavenging antioxidant defense genes studied here, mRNA levels of salicylic acid-binding (SAbind) <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id> (<protein-id="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7">CAT</protein-id>) and lignin-forming <protein-id="P15984,P16147,P84714">peroxidase</protein-id> (<protein-id="P07003,P37063,P92983,Q54970">POX</protein-id>) were found to be increased by <compound-id="614,8988,145742">proline</compound-id> and <compound-id="248">betaine</compound-id> under salt stress.	betaine__peroxidase__interaction	proline__POX__interaction	proline__peroxidase__interaction	proline__CAT__interaction	betaine__CAT__interaction	proline__catalase__interaction	betaine__catalase__interaction	betaine__POX__interaction
18472163-737	Significant <protein-id="P03973,P12547,P22298,P28296,P29118,P35211,P83610,P97430,Q03420,Q53GG5,Q9H0A0,Q9PU47,Q9Z1X0">ALP</protein-id> activity changes, sensitivity of isozyme patterns (Mr of 60, 64, and 85kDa) and increased variation in <protein-id="P03973,P12547,P22298,P28296,P29118,P35211,P83610,P97430,Q03420,Q53GG5,Q9H0A0,Q9PU47,Q9Z1X0">ALP</protein-id> plasticity during acute exposure to <compound-id="23973">cadmium</compound-id> point to its possible aplication as an exposure biomarker.	cadmium__ALP__interaction
18472187-928	To decrease the level of androgen <compound-id="6013">testosterone</compound-id> in the prostate, we are interested in developing inhibitors of <protein-id="P42330,Q5R7C9">17beta-hydroxysteroid dehydrogenase type 5</protein-id> (<protein-id="P42330,P70694,Q5R7C9">17beta-HSD5</protein-id>).	testosterone__17beta-HSD5__interaction	testosterone__17beta-hydroxysteroid dehydrogenase type 5__interaction
18472342-221	A role for <compound-id="24316">guanosine 3',5'-cyclic monophosphate</compound-id> (<compound-id="24316">cGMP</compound-id>) and the <protein-id="P00513,P25848">protein kinase</protein-id> G (PKG) pathway in synaptic long-term depression (LTD) in the hippocampal CA1 region has been proposed, based on observations in vitro, where, for example, increases of [<compound-id="24316">cGMP</compound-id>] result in short-term depression (STD) coupled with a reduction in presynaptic <compound-id="611,23327,33032">glutamate</compound-id> release.	glutamate__protein kinase__no_interaction	guanosine 3',5'-cyclic monophosphate__protein kinase__no_interaction	cGMP__protein kinase__no_interaction
18472342-222	Application of an inhibitor of soluble guanylate <protein-id="O94303,P33734,Q9P4P9,Q9SZ30">cyclase</protein-id> prevented LTD induced by low-frequency stimulation (<protein-id="P59082">LFS</protein-id>), and impaired <protein-id="P59082">LFS</protein-id>-<protein-id="P50234,P52842,Q06520">STD</protein-id> elicited in the presence of <compound-id="5722">Zaprinast</compound-id>.	Zaprinast__cyclase__no_interaction	Zaprinast__STD__no_interaction	Zaprinast__LFS__no_interaction
18473163-133	<protein-id="O60502,P44955,P49010,P58067,P75949,P96155,P96157,Q04786,Q0TR53,Q2KXM7,Q2P4L0,Q2Y863,Q31G32,Q31ZG4,Q32EW7,Q3BVU6,Q3J953,Q3SKU2,Q3Z310,Q4QLU8,Q4USG7,Q57QE6,Q5FA94,Q5H1Q0,Q5P081,Q5PGT0,Q5QUZ5,Q606N2,Q65VK7,Q669N5,Q6D674,Q6LJ30,Q7N397,Q7NWB7,Q7UCW4,Q7VNI8,Q7VWV8,Q7W9J5,Q7WH65,Q82SJ8,Q87BR5,Q89ZI2,Q8EEW2,Q8FIN2,Q8PB42,Q8PMU1,Q8VIJ5,Q8XL08,Q8Z7I6,Q8ZFS3,Q8ZQ06,Q9CPH0,Q9EQQ9,Q9HZK0,Q9JVT3,Q9K0Q4,Q9KU37,Q9PAZ0">beta-Hexosaminidases</protein-id> (EC 3.2.1.52) are lysosomal enzymes that remove terminal beta-glycosidically bound <compound-id="24139">N-acetylglucosamine</compound-id> and <compound-id="899,35717,84265,439174">N-acetylgalactosamine</compound-id> residues from a number of glycoconjugates.	N-acetylgalactosamine__beta-Hexosaminidases__interaction	N-acetylglucosamine__beta-Hexosaminidases__interaction
18473182-143	Overexpression of <protein-id="O18963,P05181,P08682,P33266,P51581,P79383,Q6GUQ4">CYP2E1</protein-id> induces HepG2 cells death by the AMP kinase activator <compound-id="16078949">5'-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside</compound-id> (AICAR).	5'-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside__CYP2E1__interaction
18474445-915	Distribution of the <protein-id="O97775,O97776,O97952,O97960,P10275,P15207,P19091,P49699,Q6QT55,Q7T1K4,Q8MIK0,Q9GKL7,Q9TT90">androgen receptor</protein-id> in the diencephalon and the pituitary gland in goats: Co-localisation with corticotrophin releasing hormone, <compound-id="8230,644077,44285245">arginine vasopressin</compound-id> and corticotrophs.	arginine vasopressin__androgen receptor__no_interaction
18475288-1020	<compound-id="2375">Bicalutamide</compound-id> induced apoptosis in androgen-dependent PWR-1E cells via a caspase-dependent and <protein-id="P27730">calpain</protein-id>-independent mechanism.	Bicalutamide__calpain__no_interaction
18475288-1021	In androgen-independent PC-3 cells, <compound-id="2375">bicalutamide</compound-id> also induced apoptosis by mechanisms that were partially inhibited by pan-caspase inhibition but were partially <protein-id="P27730">calpain</protein-id> dependent.	bicalutamide__calpain__interaction
18477686-347	A differential regulation of the two <compound-id="119">GABA</compound-id> synthesizing enzymes (<protein-id="P48321,Q05329,Q4PRC2">GAD65</protein-id> and <protein-id="P14748,P48319,Q5IS68,Q99259">GAD67</protein-id>) parallels GABAergic neuron differentiation.	GABA__GAD67__interaction	GABA__GAD65__interaction
18479249-96	The results showed that portal pressure and IHR, hepatic levels of PIIINP, hepatic collagen deposition, mRNA expression of PIIIP-<protein-id="Q08398">alpha1</protein-id> and <protein-id="O19011,O93449,P01137,P04202,P07200,P09531,P09533,P16176,P17246,P18341,P50414,P54831,Q38HS2,Q9PTQ2,Q9Z1Y6">TGF-beta1</protein-id>, protein expression of <protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id> and <protein-id="P24557,P36423,P47787,P49430,Q2KIG5">TXS</protein-id>, and production of <compound-id="5280497">TXA2</compound-id> in liver perfusates were significantly decreased in UDCA-treated BDL rats.	TXA2__iNOS__no_interaction	TXA2__alpha1__no_interaction	TXA2__TGF-beta1__no_interaction	TXA2__TXS__no_interaction
18479249-97	The increased levels of hepatic <compound-id="124886">GSH</compound-id> and <protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id> activity and decreased levels of TBARS and nitrite were also observed in UDCA-treated BDL rats.	GSH__SOD__no_interaction
18479251-501	The production of rhG-<protein-id="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481">CSF</protein-id> was induced by switching from growth on <compound-id="753">glycerol</compound-id> to growth on <compound-id="887,19314">methanol</compound-id>.	glycerol__CSF__no_interaction	methanol__CSF__interaction
18479251-502	In the induction phase, the <compound-id="887,19314">methanol</compound-id> feed rate had a significant effect on the specific expression rate of rhG-<protein-id="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481">CSF</protein-id>.	methanol__CSF__interaction
18479251-503	Under this condition, a maximum concentration of 300 mg/l of rhG-<protein-id="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481">CSF</protein-id> and the expression yield of 0.6 mg of rhG-<protein-id="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481">CSF</protein-id>/g of <compound-id="887,19314">methanol</compound-id> were attained.	methanol__CSF__interaction
18479251-504	Among seven additives tested, <compound-id="443314">Tween 20</compound-id>, Tween 80 and <compound-id="248">betaine</compound-id> exhibited the best results in respect of preventing the formation of rhG-<protein-id="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481">CSF</protein-id> protein aggregates.	Tween 20__CSF__interaction	betaine__CSF__interaction
18479686-323	<compound-id="150311">Ezetimibe</compound-id> potently reduces vascular inflammation and arteriosclerosis in <protein-id="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600">eNOS</protein-id>-deficient ApoE ko mice.	Ezetimibe__eNOS__no_interaction
18479686-324	Hypercholesterolemia is associated with decreased vascular <compound-id="145068">nitric oxide</compound-id> bioavailability and deletion of endothelial <protein-id="O61309,O61608,Q27571,Q9I9M2">nitric oxide synthase</protein-id> (<protein-id="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600">eNOS</protein-id>) markedly accelerates atherosclerosis development in apolipoprotein E knockout (apoE ko) mice.	nitric oxide__eNOS__no_interaction	nitric oxide__nitric oxide synthase__no_interaction
18479896-454	<compound-id="445580">Docosahexaenoic acid</compound-id> induces apoptosis in colorectal carcinoma cells by modulating the <protein-id="P42347,P42348,P54673,P54674,P54675,P54676">PI3 kinase</protein-id> and <protein-id="O62618">p38 MAPK</protein-id> pathways.	Docosahexaenoic acid__PI3 kinase__interaction	Docosahexaenoic acid__p38 MAPK__interaction
18479896-455	The protein inhibitors <compound-id="312145">wortmannin</compound-id> (<compound-id="16738692">phosphoinositide</compound-id> 3 kinase inhibitor), <compound-id="4713">PD 98059</compound-id> (MEK inhibitor) and <compound-id="176155">SB 203580</compound-id> (p38 inhibitor) as well as silencing RNA [small interfering RNA (siRNA)] of the <protein-id="O62618">p38 MAPK</protein-id> protein, were used to investigate cross-talk between signalling pathways.	SB 203580__p38 MAPK__no_interaction	phosphoinositide__p38 MAPK__no_interaction	wortmannin__p38 MAPK__no_interaction	PD 98059__p38 MAPK__no_interaction
18479897-371	Feeding long-chain n-3 <compound-id="56842239">polyunsaturated fatty acids</compound-id> during gestation increases intestinal <compound-id="206,5793,64689,79025">glucose</compound-id> absorption potentially via the acute activation of <protein-id="P54646,Q09136,Q9Y478">AMPK</protein-id>.	glucose__AMPK__interaction	polyunsaturated fatty acids__AMPK__interaction
18479897-373	Furthermore, adding <compound-id="445580">docosahexaenoic acid</compound-id> (DHA) or an <protein-id="O24006">AMP</protein-id>-activated <protein-id="P00513,P25848">protein kinase</protein-id> (<protein-id="P54646,Q09136,Q9Y478">AMPK</protein-id>.05) in intestinal preparations obtained from the offspring fed the control diet, devoid of the PFO product and containing minimal concentrations of n-3 PUFA.	docosahexaenoic acid__AMPK__no_interaction	docosahexaenoic acid__protein kinase__no_interaction	docosahexaenoic acid__AMP__no_interaction
18479950-485	Prior to <compound-id="2116,14985,1548900,1742129">vitamin E</compound-id> supplementation, exercise induced a significant decrease in <protein-id="P27169,P27170">PON1</protein-id> activity, <compound-id="23644574">EMF</compound-id>, <compound-id="2116,14985,1548900,1742129">vitamin E</compound-id> concentration and a significant increase in MDA concentration at t+1d.	vitamin E__PON1__no_interaction	EMF__PON1__no_interaction
18479950-486	After a 10 week <compound-id="2116,14985,1548900,1742129">vitamin E</compound-id> supplementation period, these exercise-induced changes in <protein-id="P27169,P27170">PON1</protein-id> activity, <compound-id="23644574">EMF</compound-id> and MDA concentration were still significant in the control group, but not in the supplemented group.	EMF__PON1__no_interaction	vitamin E__PON1__interaction
18481266-77	In adulthood, <compound-id="6013">testosterone</compound-id> secreted by the testes is converted into estrogens by the preoptic <protein-id="O42145,O46512,P11511,P19098,P22443,P28649,P46194,P70091,P79304,P79430,P79699,Q29605,Q29624,Q5QQX7,Q69FB6,Q6QHT9,Q6YI21,Q92087,Q92111,Q92112,Q95M61,Q9XS28">aromatase</protein-id>.	testosterone__aromatase__interaction
18481276-83	The model was used to investigate how on-treatment <protein-id="O19062,P02741,P02742,P08462,P18151,P21291,P41964,P47875,P49254,P49262,P52753,P67966,P67967,P97315,Q07203">CRP</protein-id> related to baseline <protein-id="O19062,P02741,P02742,P08462,P18151,P21291,P41964,P47875,P49254,P49262,P52753,P67966,P67967,P97315,Q07203">CRP</protein-id> and estimated treatment effects with <compound-id="446157">rosuvastatin</compound-id>.	rosuvastatin__CRP__interaction
18481313-107	Hepatocyte growth factor, keratinocyte growth factor or <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> prevented the effect of <compound-id="702">ethanol</compound-id> on cell permeability, but not on <protein-id="Q29458">PGE</protein-id> (2) release.	ethanol__insulin__interaction	ethanol__PGE__no_interaction
18481313-108	<protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">Cyclooxygenase-2</protein-id> stimulated <protein-id="Q29458">PGE</protein-id> (2) release mediated the reversible effect of <compound-id="702">ethanol</compound-id> on tight junctions and, meanwhile, contributed to cell survival.	ethanol__Cyclooxygenase-2__interaction	ethanol__PGE__no_interaction
18482727-966	Interestingly, <compound-id="60823">atorvastatin</compound-id> inhibited the expression of ICAM and <protein-id="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3">MCP-1</protein-id>, followed by the suppression of macrophage recruitment into the aortic wall at 1 week after operation.	atorvastatin__MCP-1__interaction
18482727-967	In addition, synthesis of collagen and <protein-id="P11547">elastin</protein-id> in the vascular wall were significantly increased by <compound-id="60823">atorvastatin</compound-id>.	atorvastatin__elastin__interaction
18484100-516	Organic cations (<compound-id="72886">OCs</compound-id>) are primarily excreted via vectorial transport by various renal organic cation transporters (<protein-id="O75051">OCTs</protein-id>).	OCs__OCTs__interaction
18484100-517	In a rat ARF model, induction of ARF by <compound-id="24933">uranyl nitrate</compound-id> (UN) treatment significantly decreased the levels of <protein-id="Q00196">Oct2</protein-id> (slc22a2) mRNA and protein in the kidney medulla.	uranyl nitrate__Oct2__interaction
18484622-1118	In all final products, <compound-id="679">dimethylsulfoxide</compound-id> used to prepare the <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>/lipid mixture was below 20 ppm.	dimethylsulfoxide__insulin__interaction
18485500-951	Platelet reactivity and <compound-id="2806,60606">clopidogrel</compound-id> resistance are associated with the H2 haplotype of the <protein-id="Q95KC3,Q9CPV9,Q9EPX4,Q9H244">P2Y12</protein-id>-<protein-id="P02783">ADP</protein-id> receptor gene.	clopidogrel__ADP__interaction	clopidogrel__P2Y12__interaction
18486150-336	<compound-id="2909,5280754,5284373,5458585,5497195,6435893,24883466,49867938">Cyclosporin A</compound-id> up-regulates and activates <protein-id="P13678,Q25378">protein kinase C</protein-id>-zeta in EBV-infected and EBV-transformed human B-cells.	Cyclosporin A__protein kinase C__interaction
18486150-337	We have proposed that <compound-id="2909,5280754,5284373,5458585,5497195,6435893,24883466,49867938">cyclosporin A</compound-id> (CsA), despite being a <protein-id="O88480,Q9Y6J0">calcineurin inhibitor</protein-id>, will activate <protein-id="P05130,P13677,P13678,P34722">PKC</protein-id> in B cells, thus promoting Epstein-Barr virus (EBV)-induced transformation.	cyclosporin A__calcineurin inhibitor__interaction	cyclosporin A__PKC__interaction
18486994-189	Our results showed 2a, 2d and 2g as the most active compounds that inhibited the HIV-1 reverse <protein-id="O55528,O89344,P03523,P06447,P06829,P11205,P11213,P12576,P12577,P13179,P13615,P16289,P16379,P20894,P24658,P26676,P28887,P30929,P31332,P31352,P35262,P35341,P35946,P35975,P41357,Q03396,Q05318,Q06996,Q5XX01,Q66802,Q6V1Q2,Q88434,Q8JPX5,Q91DD4,Q997F0,Q9DUD8">transcriptase</protein-id> catalytic activity with cytotoxicity lower than <compound-id="35370">AZT</compound-id> and SI higher than DDC and DDI.	AZT__transcriptase__interaction
18487053-332	<compound-id="445154">Resveratrol</compound-id> (4,3',5'-trihydroxystilbene) is a naturally occurring antioxidant that inhibits <protein-id="O62664,O97554,P05979,P22437,P23219,Q63921">cyclooxygenase-1</protein-id> (<protein-id="O62664,O97554,P05979,P22437,P23219,Q63921,Q9T0N8">COX-1</protein-id>), <protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">cyclooxygenase-2</protein-id> (<protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">COX-2</protein-id>) and the transcription factor NF-kappaB.	Resveratrol__cyclooxygenase-2__interaction	Resveratrol__cyclooxygenase-1__interaction	Resveratrol__COX-1__interaction	Resveratrol__COX-2__interaction
18489490-99	After <compound-id="22880">NMDA</compound-id> stimulation of SV-FHAS and neoplastic astrocytes, real-time polymerase chain reaction showed an increase of the CPE, containing <protein-id="O73691,O73692,O73693,O73694,P08046,P08154,P18146,P26632,Q29W20">EGR-1</protein-id> splice variant only in astrocytoma cells.	NMDA__EGR-1__no_interaction
18489909-317	Using both physiologically achievable (2 microM) and supraphysiological (10 microM) concentrations, we investigated the ability of <compound-id="5280343">quercetin</compound-id> and its predominant human metabolites to attenuate the expression of vascular cell adhesion molecule-1 (<protein-id="P19320,P29533,P29534,Q28260">VCAM-1</protein-id>), intercellular adhesion molecule-1 (<protein-id="P05362,P13597,P33729,Q00238,Q28806,Q5NKV4,Q5NKV6,Q5NKV9,Q95132">ICAM-1</protein-id>) and <protein-id="P10148,P13500,P14844,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3">monocyte chemoattractant protein-1</protein-id> (<protein-id="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3">MCP-1</protein-id>) in human umbilical artery smooth muscle cells (HUASMC) activated by <protein-id="Q8JFG3">tumor necrosis factor</protein-id>-alpha (<protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNFalpha</protein-id>).	quercetin__TNFalpha__interaction	quercetin__monocyte chemoattractant protein-1__interaction	quercetin__tumor necrosis factor__interaction	quercetin__ICAM-1__interaction	quercetin__MCP-1__interaction	quercetin__VCAM-1__interaction
18489909-318	<compound-id="5280343">Quercetin</compound-id> was able to reduce <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNFalpha</protein-id>-induced upregulation of <protein-id="P19320,P29533,P29534,Q28260">VCAM-1</protein-id>, <protein-id="P05362,P13597,P33729,Q00238,Q28806,Q5NKV4,Q5NKV6,Q5NKV9,Q95132">ICAM-1</protein-id> and <protein-id="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3">MCP-1</protein-id> at both the protein and transcript (mRNA) level in HUASMC.	Quercetin__TNFalpha__interaction	Quercetin__ICAM-1__interaction	Quercetin__MCP-1__interaction	Quercetin__VCAM-1__interaction
18489909-319	However the quercetin metabolites, <compound-id="5280362">quercetin 3'-sulfate</compound-id>, quercetin 3-glucuronide and 3'-methylquercetin 3-glucuronide, had no effect on <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNFalpha</protein-id>-induced up regulation of adhesion molecule or chemokine expression, at either concentration tested.	quercetin 3'-sulfate__TNFalpha__no_interaction
18490188-482	In its active form, <compound-id="1132">thiamin pyrophosphate</compound-id> (TPP), it is a co-enzyme for several enzymes, including <protein-id="O06811,O67642,O83571,P29277,P29401,P34736,P40142,P43757,P45694,P46708,P47312,P50137,P51010,P56900,P57195,P58333,P59956,P66962,P66963,P75611,P84540,P99161,Q12630,Q52723,Q5HG77,Q5HPJ9,Q5R1W6,Q5R4C1,Q60HC7,Q6B855,Q6G9L6,Q6GH64,Q89AY2,Q8CPC7,Q8KA26,Q9KAD7">transketolase</protein-id>.	thiamin pyrophosphate__transketolase__interaction
18492032-354	Coexpression pattern with <protein-id="O13124,O42392,P11473,P13053,P48281,P49701,Q28037,Q95MH5">VDR</protein-id> provides an indication that <compound-id="5280453">calcitriol</compound-id> could be the modulator of these adaptive responses to involution and dietary P restriction.	calcitriol__VDR__interaction
18492301-527	Dietary chia seed (Salvia hispanica L.) rich in <compound-id="5280934">alpha-linolenic acid</compound-id> improves adiposity and normalises hypertriacylglycerolaemia and <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> resistance in dyslipaemic rats.	alpha-linolenic acid__insulin__interaction
18492301-528	The present study investigates the benefits of the dietary intake of chia seed (Salvia hispanica L.) rich in <compound-id="5280934">alpha-linolenic acid</compound-id> and fibre upon dyslipidaemia and <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> resistance (IR), induced by intake of a <compound-id="5988">sucrose</compound-id>-rich (62.5 %) diet (SRD).	alpha-linolenic acid__insulin__interaction	sucrose__insulin__interaction
18492302-529	Pigs fed the high-<compound-id="866,5962">lysine</compound-id> diet moreover had an increased concentration of <compound-id="440121">trimethyllysine</compound-id> (TML), a reduced mRNA abundance of <protein-id="Q0VC74,Q5F4B3,Q91ZE0,Q91ZW6,Q96UB1,Q9NVH6">TML dioxygenase</protein-id> and reduced concentrations of <compound-id="134">gamma-butyrobetaine</compound-id> (BB) in muscle, indicating that the conversion of TML into BB in muscle was impaired.	lysine__TML dioxygenase__no_interaction	trimethyllysine__TML dioxygenase__no_interaction	gamma-butyrobetaine__TML dioxygenase__no_interaction
18494609-496	The cells exposed to 10 microM (<compound-id="5280893">15S)-HPETE</compound-id> for 3 h or to 40 microM (<compound-id="5280724">15S)-HETE</compound-id> for 6 h showed increased expression of <protein-id="P36940,P41047,P48023,P63306,P63307,P63308,Q861W5,Q9BDN1,Q9BEA8">Fas ligand</protein-id> and <protein-id="P46310,Q13158">FADD</protein-id> (<protein-id="P25446,Q63199">Fas</protein-id>-associated death domain), caspase 8 activation, Bid (<protein-id="P55957,P70444,Q4JHS0,Q8JGM8,Q9JLT6">BH3-interacting domain death agonist</protein-id>) cleavage, decrease in mitochondrial membrane potential, <protein-id="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3">cytochrome c</protein-id> release, caspase 3 activation, <protein-id="P09874,P11103,P18493,P26446,P27008,Q7EYV7,Q9R152,Q9ZP54,Q9ZSV1">PARP-1</protein-id> [poly(<protein-id="P02783">ADP</protein-id>-ribose) polymerase-1] cleavage and DNA fragmentation, suggesting the involvement of both extrinsic and intrinsic death pathways.	15S)-HPETE__FADD__interaction	15S)-HPETE__Fas__interaction	15S)-HETE__BH3-interacting domain death agonist__interaction	15S)-HETE__Fas__interaction	15S)-HETE__ADP__interaction	15S)-HETE__cytochrome c__interaction	15S)-HETE__Fas ligand__interaction	15S)-HPETE__Fas ligand__interaction	15S)-HETE__FADD__interaction	15S)-HPETE__ADP__interaction	15S)-HETE__PARP-1__interaction	15S)-HPETE__cytochrome c__interaction	15S)-HPETE__BH3-interacting domain death agonist__interaction	15S)-HPETE__PARP-1__interaction
18495128-1028	<compound-id="1651,23190">3-Deazaadenosine</compound-id> inhibits vasa vasorum neovascularization in aortas of <protein-id="P02649,P02650,P05770,P08226,P10517,P18287,P18649,P18650,P23529,Q03247,Q28502,Q28995,Q7M2U7,Q7M2U8,Q9GJU3,Q9GLC0,Q9GLM6,Q9GLM7,Q9GLM8">ApoE</protein-id> (-/-)/LDL(-/-) double knockout mice.	3-Deazaadenosine__ApoE__no_interaction
18495129-1029	<compound-id="145858">Anthocyanin</compound-id> attenuates <protein-id="P25942,Q28203,Q3LRP1,Q3ZTK5,Q7YRL5,Q8SQ34">CD40</protein-id>-mediated endothelial cell activation and apoptosis by inhibiting <protein-id="P25942,Q28203,Q3LRP1,Q3ZTK5,Q7YRL5,Q8SQ34">CD40</protein-id>-induced <protein-id="O42781,P27638,Q00859">MAPK</protein-id> activation.	Anthocyanin__MAPK__interaction	Anthocyanin__CD40__interaction
18495129-1030	Treatment of ECs with anthocyanins cyanidin-3-O-beta-glucoside (Cy-3-g) and <compound-id="53398755">peonidin-3-O-beta-glucoside</compound-id> (Pn-3-g) prevents <protein-id="P25942,Q28203,Q3LRP1,Q3ZTK5,Q7YRL5,Q8SQ34">CD40</protein-id>-induced endothelial activation by inhibiting production of proinflammatory cytokines and matrix metalloproteinases (MMPs).	peonidin-3-O-beta-glucoside__CD40__interaction
18495129-1031	Collectively, our findings suggested that the inhibition of <protein-id="P92208,Q966Y3">JNK</protein-id> and <protein-id="O24473,O75791,O95433,O97628,P46108,P80350,P82869,Q01552,Q04929,Q63768,Q64010,Q9LDA4,Q9Y2S7">p38</protein-id> activation interrupts <protein-id="P25942,Q28203,Q3LRP1,Q3ZTK5,Q7YRL5,Q8SQ34">CD40</protein-id> induced endothelial cell activation and apoptosis, which thereby may represent a mechanism that would explain the anti-inflammatory response of <compound-id="145858">anthocyanin</compound-id> and its athero-protective function.	anthocyanin__p38__interaction	anthocyanin__JNK__interaction	anthocyanin__CD40__interaction
18495357-1187	Postsynaptic action of <compound-id="5957">ATP</compound-id> is mediated through metabotropic P2Y and ionotropic <protein-id="P13900,P16604">P2X</protein-id> receptors abundantly expressed in neural cells.	ATP__P2X__interaction
18495456-706	However, the <protein-id="P42898,Q5I598,Q60HE5">MTHFR</protein-id> C677T genotype, alone or together with a diet, influenced <compound-id="248">betaine</compound-id> (P=.03) and phosphatidylcholine (P=.03).	betaine__MTHFR__interaction
18495456-707	In addition, the <protein-id="P42898,Q5I598,Q60HE5">MTHFR</protein-id> C677T genotype appears to influence the direction and use of <compound-id="305">choline</compound-id> moieties in this group of women.	choline__MTHFR__interaction
18495458-1236	<compound-id="1203,72276,182232">Epicatechin</compound-id>-induced survival was a rapid event that was accompanied by early and sustained activation of major survival signaling proteins, such as AKT/phosphatidylinositol 3-kinase and extracellular-regulated kinase (activated from 5 min to 18 h), as well as <protein-id="P13678,Q25378">protein kinase C</protein-id> (<protein-id="P05130,P13677,P13678,P34722">PKC</protein-id>)-alpha (30 min to 18 h), in concert with unaltered c-<protein-id="P05627,P17325,P18289">jun</protein-id> N-amino terminal kinase levels and early inactivation of key death-related signals like <protein-id="P10829">PKC-delta</protein-id> (5 min to 18 h).	Epicatechin__jun__interaction	Epicatechin__PKC__interaction	Epicatechin__PKC-delta__interaction	Epicatechin__protein kinase C__interaction
18495460-1238	Phospholipidosis and down-regulation of the <protein-id="P19957">PI3</protein-id>-K/<protein-id="P22221,Q42736">PDK</protein-id>-1/<protein-id="P31750,Q8INB9">Akt</protein-id> signalling pathway are <compound-id="2116,14985,1548900,1742129">vitamin E</compound-id> inhibitable events associated with 7-ketocholesterol-induced apoptosis.	vitamin E__PI3__interaction	vitamin E__Akt__interaction	vitamin E__PDK__interaction
18495461-1165	Lack of <compound-id="445354">vitamin A</compound-id> significantly changed mucin (MUC) dynamics, as reflected by the enlarged goblet-cell "cup" area relative to controls; decreased <protein-id="Q02817">MUC2</protein-id> mRNA expression in the jejunum, ileum and colon of VAD rats and increased <protein-id="Q02505">MUC3</protein-id> mRNA expression in the ileum and colon of these rats.	vitamin A__MUC2__interaction	vitamin A__MUC3__interaction
18495461-1166	In addition, <compound-id="445354">vitamin A</compound-id> deficiency down-regulated <protein-id="P17722,P37364,P80154,P80407,P81462,Q10745">defensin</protein-id> 6 mRNA expression while up-regulating toll-like receptors 2 and 5 mRNA expressions.	vitamin A__defensin__interaction
18495463-1243	<compound-id="969516">Curcumin</compound-id>, <compound-id="5324476">demethoxycurcumin</compound-id> and <compound-id="5315472">bisdemethoxycurcumin</compound-id> differentially inhibit cancer cell invasion through the down-regulation of MMPs and <protein-id="P00749,P04185,P06869,P15120,P16227,P29598,Q05589">uPA</protein-id>.	Curcumin__uPA__interaction	bisdemethoxycurcumin__uPA__interaction	demethoxycurcumin__uPA__interaction
18496518-35	<protein-id="O13186,O46567,O73673,P04150,P06536,P06537,P35547,P49115,P49843,P49844,P59667,P79269,P79686,Q5R9P5,Q6XLJ0,Q95267,Q9N1U3">Glucocorticoid receptor</protein-id> antagonism augments <compound-id="3386">fluoxetine</compound-id>-induced downregulation of the 5-HT transporter.	fluoxetine__Glucocorticoid receptor__interaction
18496518-37	In contrast, chronic <compound-id="3386">fluoxetine</compound-id> markedly decreased 5-<protein-id="P31645">HTT</protein-id> levels in all regions.	fluoxetine__HTT__interaction
18496518-38	This downregulation of 5-<protein-id="P31645">HTT</protein-id> by <compound-id="3386">fluoxetine</compound-id> and its enhancement by Org 34850 can explain our recent observation that GR antagonists augment the SSRI-induced increase in extracellular <compound-id="5202">5-HT</compound-id>.	5-HT__HTT__interaction	fluoxetine__HTT__interaction
18496650-691	Moreover, intestinal, colonic and caecal TBARS, LOOH, CD and also the antioxidants <protein-id="O50258">superoxide dismutase</protein-id> (<protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id>), <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id> (<protein-id="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7">CAT</protein-id>), <protein-id="O04437,O18598,P0A9D2,P0A9D3,P30116,P44521,P46088,P46419,P46423,P46426,P46428,P46437,P48438,P80894,P81065,P82996,P82997,P82998,P82999,P83000,P83001,P83246,Q04522,Q08392,Q08393,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52,Q96324">glutathione S-transferase</protein-id> (<protein-id="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52">GST</protein-id>), <protein-id="O32770,O59858,Q00277,Q9CFV1">glutathione peroxidase</protein-id> (GPx), <protein-id="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655">glutathione reductase</protein-id> (GR) and <compound-id="124886">reduced glutathione</compound-id> (<compound-id="124886">GSH</compound-id>) were significantly diminished in DMH 0.05) elevated on simultaneous <compound-id="5281670">morin</compound-id> supplementation.	GSH__GST__no_interaction	morin__GST__interaction	morin__CAT__interaction	GSH__superoxide dismutase__no_interaction	morin__glutathione reductase__interaction	GSH__SOD__no_interaction	reduced glutathione__CAT__no_interaction	GSH__glutathione S-transferase__no_interaction	reduced glutathione__catalase__no_interaction	reduced glutathione__SOD__no_interaction	reduced glutathione__GST__no_interaction	GSH__CAT__no_interaction	GSH__glutathione reductase__no_interaction	morin__catalase__interaction	reduced glutathione__glutathione S-transferase__no_interaction	morin__glutathione S-transferase__interaction	GSH__glutathione peroxidase__no_interaction	reduced glutathione__superoxide dismutase__no_interaction	morin__superoxide dismutase__interaction	reduced glutathione__glutathione peroxidase__no_interaction	morin__glutathione peroxidase__interaction	reduced glutathione__glutathione reductase__no_interaction	morin__SOD__interaction	GSH__catalase__no_interaction
18496767-753	Using in vitro binding assays we have demonstrated that <protein-id="O70494,Q02447,Q90WR8">transcription factors Sp3</protein-id>, ZBP-89 and NF-Y are capable of binding to the <protein-id="P35713">SOX18</protein-id> promoter region spanning the sequence-200 to-162 relative to ATG and that formation of complexes could be efficiently reduced by <compound-id="29051,163659,230076,6326719">mithramycin A</compound-id>.	mithramycin A__SOX18__interaction	mithramycin A__transcription factors Sp3__interaction
18496861-830	Treatment with <protein-id="P15316,P26831,P49370,P49371,Q08169,Q53591,Q54699,Q54873,Q59634,Q59801,Q9U6V9">hyaluronidase</protein-id> indicates that the dimensions of the small fibrils may be dependent upon the presence of <compound-id="24759">hyaluronan</compound-id> within the matrix.	hyaluronan__hyaluronidase__no_interaction
18496865-833	<compound-id="8925">Tetraglyme</compound-id> coatings reduce <protein-id="P22775,P81070">fibrinogen</protein-id> and <protein-id="Q62935">von Willebrand factor</protein-id> adsorption and platelet adhesion under both static and flow conditions.	Tetraglyme__fibrinogen__interaction	Tetraglyme__von Willebrand factor__interaction
18496865-834	Previous studies have showed that radio-frequency plasma deposited <compound-id="8925">tetraglyme</compound-id> coatings greatly reduced <protein-id="P22775,P81070">fibrinogen</protein-id> adsorption (Gamma(Fg)) from highly diluted plasmas (0.1 and 1%) and subsequent platelet adhesion under static conditions.	tetraglyme__fibrinogen__interaction
18497703-873	Effects of inhibition of <protein-id="O54705,O61309,O61608,Q26240,Q28969,Q9I9M2">NOS</protein-id>, <protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id>, and <protein-id="O19132,O61309,P29475,P29476,Q9Z0J4">nNOS</protein-id> by N-nitro-<compound-id="92932,550788">L-arginine methyl ester</compound-id> (L-NAME), <compound-id="2146">aminoguanidine</compound-id>, and <compound-id="1893">7-nitroindazole</compound-id>, respectively, were determined on the antigen-induced systemic hypotension and portal hypertension in conscious Sprague-Dawley rats sensitized with the ovalbumin antigen.	7-nitroindazole__NOS__interaction	aminoguanidine__iNOS__interaction	L-arginine methyl ester__NOS__interaction	L-arginine methyl ester__nNOS__interaction	aminoguanidine__nNOS__interaction	aminoguanidine__NOS__interaction	L-arginine methyl ester__iNOS__interaction	7-nitroindazole__nNOS__interaction	7-nitroindazole__iNOS__interaction
18497707-589	Differential gene expression of <protein-id="P51617,Q62406">interleukin-1 receptor associated kinase-1</protein-id> and interleukin-1 receptor associated kinase-M in peripheral blood mononuclear cells of young and aged rats following preconditioning with <compound-id="44268108">endotoxin</compound-id>.	endotoxin__interleukin-1 receptor associated kinase-1__interaction
18497707-590	The IL-1 receptor-associated kinase 1 (<protein-id="P51617,Q62406">IRAK-1</protein-id>) and <protein-id="Q8K4B2,Q9Y616">IRAK-M</protein-id> are key signaling molecules in cellular responses to <compound-id="44268108">endotoxin</compound-id> initiated through the Toll-like receptors (<protein-id="P23799">TLRs</protein-id>).	endotoxin__IRAK-M__interaction	endotoxin__TLRs__interaction	endotoxin__IRAK-1__interaction
18497707-591	The aim of this study was to evaluate the effect of age on the modulation of <protein-id="P23799">TLRs</protein-id> and <protein-id="P51617,Q62406">IRAK-1</protein-id> and <protein-id="Q8K4B2,Q9Y616">IRAK-M</protein-id> in peripheral blood mononuclear cells (PBMCs) exposed in vitro to <compound-id="44268108">endotoxin</compound-id> under conditions that could induce <compound-id="44268108">endotoxin</compound-id> tolerance.	endotoxin__IRAK-M__interaction	endotoxin__IRAK-1__interaction	endotoxin__TLRs__interaction
18497709-959	We also previously demonstrated that <compound-id="738,5961">glutamine</compound-id> (GLN) significantly induced <protein-id="P06762,P09601,P14791,P14901,P32394,Q5E9F2">HO-1</protein-id> in the lower intestinal tract.	glutamine__HO-1__interaction
18497709-961	<compound-id="738,5961">Glutamine</compound-id> treatment before <compound-id="5047209,46173182">HS</compound-id> (MAP of 30 mmHg for 60 min) significantly ameliorated <compound-id="5047209,46173182">HS</compound-id>-induced mucosal inflammation and apoptotic cell death in the ileum, as judged by significant decreases in gene expression of <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id>, <protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id>, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1, myeloperoxidase activity, the number of infiltrated neutrophils, DNA fragmentation by in situ oligo ligation assay, and activated caspase-3 expression, and by increases in gene expression of <protein-id="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5">IL-10</protein-id> and <protein-id="P10417,P49950">Bcl-2</protein-id>.	Glutamine__IL-10__interaction	Glutamine__TNF-alpha__interaction	HS__IL-10__interaction	Glutamine__iNOS__interaction	HS__iNOS__interaction	Glutamine__Bcl-2__interaction	HS__Bcl-2__interaction	HS__TNF-alpha__interaction
18497709-964	<compound-id="738,5961">Glutamine</compound-id> treatment may thus protect mucosal cells from HS-induced oxidative damage via the anti-inflammatory and antiapoptotic properties of <protein-id="P06762,P09601,P14791,P14901,P32394,Q5E9F2">HO-1</protein-id>.	Glutamine__HO-1__interaction
18498083-305	In this work, we identified a high affinity and potency metallocene-containing <compound-id="67516">triazole</compound-id> peptide conjugate that suppresses the interactions of HIV-1 envelope <protein-id="O12164,O41803,O70902,O89292,O91086,P03375,P03377,P03378,P04577,P04578,P04579,P04580,P04581,P04582,P04583,P04624,P05877,P05878,P05879,P05880,P05881,P05882,P05883,P05884,P05885,P05886,P08810,P11267,P12449,P12487,P12488,P12489,P12490,P12491,P12492,P15831,P17281,P17755,P18040,P18094,P18799,P19503,P19549,P19550,P19551,P20871,P20872,P20888,P22380,P24105,P27757,P27977,P31819,P31872,P32536,P35961,Q02837,Q1A243,Q1A261,Q70626,Q73372,Q74126,Q75008,Q76638,Q77377,Q79670,Q89607,Q8AIH5,Q9IDV2,Q9Q714,Q9QBY2,Q9QBZ0,Q9QBZ4,Q9QBZ8,Q9QSQ7,Q9WC60,Q9WC69">gp120</protein-id> at both its <protein-id="P01730,P05542,P16003,P16004,P33705,P46630,P79184,P79185,Q08336,Q08338,Q08339,Q08340,Q29037,Q9XS78">CD4</protein-id> and co-receptor binding sites.	triazole__CD4__interaction	triazole__gp120__interaction
18498083-306	Surface plasmon resonance interaction analysis revealed that, compared to a previously reported phenyl-containing <compound-id="67516">triazole</compound-id> conjugate <compound-id="25085904">HNG-105</compound-id> (105), peptide 156 had a higher direct binding affinity for several subtypes of HIV-1 gp120 due mainly to the decreased dissociation rate of the conjugate-<protein-id="O12164,O41803,O70902,O89292,O91086,P03375,P03377,P03378,P04577,P04578,P04579,P04580,P04581,P04582,P04583,P04624,P05877,P05878,P05879,P05880,P05881,P05882,P05883,P05884,P05885,P05886,P08810,P11267,P12449,P12487,P12488,P12489,P12490,P12491,P12492,P15831,P17281,P17755,P18040,P18094,P18799,P19503,P19549,P19550,P19551,P20871,P20872,P20888,P22380,P24105,P27757,P27977,P31819,P31872,P32536,P35961,Q02837,Q1A243,Q1A261,Q70626,Q73372,Q74126,Q75008,Q76638,Q77377,Q79670,Q89607,Q8AIH5,Q9IDV2,Q9Q714,Q9QBY2,Q9QBZ0,Q9QBZ4,Q9QBZ8,Q9QSQ7,Q9WC60,Q9WC69">gp120</protein-id> complex.	HNG-105__gp120__no_interaction	triazole__gp120__no_interaction
18498083-307	The ferrocene <compound-id="67516">triazole</compound-id> conjugate bound to <protein-id="O12164,O41803,O70902,O89292,O91086,P03375,P03377,P03378,P04577,P04578,P04579,P04580,P04581,P04582,P04583,P04624,P05877,P05878,P05879,P05880,P05881,P05882,P05883,P05884,P05885,P05886,P08810,P11267,P12449,P12487,P12488,P12489,P12490,P12491,P12492,P15831,P17281,P17755,P18040,P18094,P18799,P19503,P19549,P19550,P19551,P20871,P20872,P20888,P22380,P24105,P27757,P27977,P31819,P31872,P32536,P35961,Q02837,Q1A243,Q1A261,Q70626,Q73372,Q74126,Q75008,Q76638,Q77377,Q79670,Q89607,Q8AIH5,Q9IDV2,Q9Q714,Q9QBY2,Q9QBZ0,Q9QBZ4,Q9QBZ8,Q9QSQ7,Q9WC60,Q9WC69">gp120</protein-id> of both clade A (92UG037-08) and clade B (YU-2 and SF162) virus subtypes with nanomolar KD in direct binding and inhibited the binding of <protein-id="O12164,O41803,O70902,O89292,O91086,P03375,P03377,P03378,P04577,P04578,P04579,P04580,P04581,P04582,P04583,P04624,P05877,P05878,P05879,P05880,P05881,P05882,P05883,P05884,P05885,P05886,P08810,P11267,P12449,P12487,P12488,P12489,P12490,P12491,P12492,P15831,P17281,P17755,P18040,P18094,P18799,P19503,P19549,P19550,P19551,P20871,P20872,P20888,P22380,P24105,P27757,P27977,P31819,P31872,P32536,P35961,Q02837,Q1A243,Q1A261,Q70626,Q73372,Q74126,Q75008,Q76638,Q77377,Q79670,Q89607,Q8AIH5,Q9IDV2,Q9Q714,Q9QBY2,Q9QBZ0,Q9QBZ4,Q9QBZ8,Q9QSQ7,Q9WC60,Q9WC69">gp120</protein-id> to soluble <protein-id="P01730,P05542,P16003,P16004,P33705,P46630,P79184,P79185,Q08336,Q08338,Q08339,Q08340,Q29037,Q9XS78">CD4</protein-id> and to antibodies that bind to HIV-1YU-2 gp120 at both the <protein-id="P01730,P05542,P16003,P16004,P33705,P46630,P79184,P79185,Q08336,Q08338,Q08339,Q08340,Q29037,Q9XS78">CD4</protein-id> binding site and <protein-id="P01730,P05542,P16003,P16004,P33705,P46630,P79184,P79185,Q08336,Q08338,Q08339,Q08340,Q29037,Q9XS78">CD4</protein-id>-induced binding sites.	triazole__CD4__no_interaction	triazole__gp120__interaction
18498357-470	Screening of risk factors for thromboembolism revealed that all patients carried a <protein-id="P42898,Q5I598,Q60HE5,Q9WU20">methylenetetrahydrofolate reductase</protein-id> 677C--&gt;T (<protein-id="P42898,Q5I598,Q60HE5">MTHFR</protein-id>) mutation in a gene involved in folate metabolism, and either borderline or elevated <compound-id="778">homocysteine</compound-id> levels.	homocysteine__methylenetetrahydrofolate reductase__no_interaction	homocysteine__MTHFR__no_interaction
18498673-382	Circulating <protein-id="O02750,O93416,Q28603,Q95189,Q95234">leptin</protein-id> was negatively correlated with mRNA expression of adiponectin, <protein-id="O02671,O15243,P48357,Q9MYL0">LEPR</protein-id> and <protein-id="O46647,P06858,P11151,P11152,P11153,P11602,P49060,P49923,P55031,Q06000,Q29524">LPL</protein-id>, whereas <compound-id="853,5819">thyroxine</compound-id> was positively correlated with levels of <protein-id="Q865B6,Q865B7,Q9UBK2">PPARGC1A</protein-id>.	thyroxine__LPL__no_interaction	thyroxine__leptin__no_interaction	thyroxine__PPARGC1A__interaction	thyroxine__LEPR__no_interaction
18500430-564	In the absence of exogenous <compound-id="271">Ca(2</compound-id>+) and Mg(2+) and in the presence of <compound-id="6207">EGTA</compound-id>, which favours the release of endogenous <compound-id="271">Ca(2</compound-id>+), the polyamine <compound-id="1103">spermine</compound-id> is able to stimulate the activity of pyruvate dehydrogenase complex (<protein-id="O77560,P06672,P19632,P20941,P28516,P34734,P41686,P51845,P51846,P51847,P51848,P51849,P51850,P51851,Q05326,Q05327,Q6FJA3,Q9XS39">PDC</protein-id>) of energized rat liver mitochondria (RLM).	spermine__PDC__interaction	Ca(2__PDC__no_interaction	EGTA__PDC__no_interaction
18500430-565	At concentrations higher than 0.5 mM, <compound-id="1103">spermine</compound-id> still stimulates <protein-id="O77560,P06672,P19632,P20941,P28516,P34734,P41686,P51845,P51846,P51847,P51848,P51849,P51850,P51851,Q05326,Q05327,Q6FJA3,Q9XS39">PDC</protein-id>, when compared with the control, but shows a slight dose-dependent decrease.	spermine__PDC__interaction
18500430-566	Changes in <protein-id="O77560,P06672,P19632,P20941,P28516,P34734,P41686,P51845,P51846,P51847,P51848,P51849,P51850,P51851,Q05326,Q05327,Q6FJA3,Q9XS39">PDC</protein-id> stimulation are very close to the phosphorylation level of the E(1alpha) subunit of <protein-id="O77560,P06672,P19632,P20941,P28516,P34734,P41686,P51845,P51846,P51847,P51848,P51849,P51850,P51851,Q05326,Q05327,Q6FJA3,Q9XS39">PDC</protein-id>, which regulates the activity of the complex, but it is also the target of <compound-id="1103">spermine</compound-id>.	spermine__PDC__interaction
18500430-567	These results provide the first evidence that, when transported in RLM, <compound-id="1103">spermine</compound-id> can interact in various ways with <protein-id="O77560,P06672,P19632,P20941,P28516,P34734,P41686,P51845,P51846,P51847,P51848,P51849,P51850,P51851,Q05326,Q05327,Q6FJA3,Q9XS39">PDC</protein-id>, showing dose-dependent behaviour.	spermine__PDC__interaction
18500522-58	This study assessed relationships between <protein-id="Q9P121">hNT</protein-id> levels and <compound-id="657237">fludarabine</compound-id> uptake and cytotoxicity in cultures of human renal proximal tubule cells (hRPTCs) that produce multiple transporter types.	fludarabine__hNT__interaction
18502597-1034	Multiple metabolic and neuroendocrine mechanisms are responsible for the CR-mediated anti-inflammatory effects, including reduced adiposity and secretion of pro-inflammatory adipokines, enhanced glucocorticoid production, reduced plasma <compound-id="206,5793,64689,79025">glucose</compound-id> and advanced glycation end-product concentrations, increased parasympathetic tone, and increased <protein-id="Q6BEG6,Q6BEG7,Q9BDJ6,Q9BEF8,Q9EQX0,Q9GKY5,Q9QYH7,Q9UBU3">ghrelin</protein-id> production.	glucose__ghrelin__interaction
18503570-926	From the known regulatory mechanisms of Arc expression, HFD reduced <protein-id="P35439,Q9R1M7">N-methyl-D-aspartate receptor</protein-id> (NMDAR) activity, as seen by decreases in <compound-id="1153,6057,5460803">tyrosine</compound-id> phosphorylation of <protein-id="P35436,Q00959,Q12879,Q5IS45">NMDAR2A</protein-id> and levels of <protein-id="Q05586,Q5R1P0">NMDAR1</protein-id>.	tyrosine__NMDAR2A__interaction	tyrosine__N-methyl-D-aspartate receptor__interaction	tyrosine__NMDAR1__no_interaction
18503570-927	Additionally, we demonstrated that <compound-id="99470,123976,50990021">27-hydroxycholesterol</compound-id>, a <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> metabolite that enters the brain from the blood, decreases Arc levels as well as NMDAR and <protein-id="P05480,Q9WUD9">Src</protein-id> kinase activities in rat primary hippocampal neurons.	cholesterol__Src__no_interaction	27-hydroxycholesterol__Src__interaction
18505747-21	<protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">Cyclooxygenase-2</protein-id>, an inducible enzyme important in inflammation, catalyzes the production of prostanoids from <compound-id="444899">arachidonic acid</compound-id>.	arachidonic acid__Cyclooxygenase-2__interaction
18506596-495	cDNA probes have been developed for subsequent use in monitoring the <compound-id="23973">cadmium</compound-id> exposure of the clam Ruditapes decussatus and the cockle Cerastoderma glaucum using <protein-id="O02033,O13257,O18842,O42152,O93571,P02807,P04358,P07216,P08002,P23038,P25127,P25128,P30331,P30565,P51902,P52723,P52725,P52726,P52728,P55945,P55946,P55948,P55951,P55952,P55953,P68494,P68495,P68497,P68498,P68499,P80367,P80593,P84865,Q05890,Q6J1T3,Q6S4N8,Q6XUW5,Q708T3,Q7ZZP9,Q800D3,Q8UVY1,Q94550,Q9IB50,Q9U568">metallothionein</protein-id> (MT) gene expression in different tissues of these species.	cadmium__metallothionein__no_interaction
18506630-727	Purified <protein-id="P06181,P11542,P11543,P20010,P20011,P20012,P20013,P21764,P31837,P31838,P49012,P50622">lignin peroxidase</protein-id> was able to oxidize a variety of substrates including <compound-id="27854">Mn2</compound-id>+, <compound-id="1148,6305,9060,5460840">tryptophan</compound-id>, <compound-id="3862">mimosine</compound-id>, <compound-id="6047">L-Dopa</compound-id>, <compound-id="785">hydroquinone</compound-id>, xylidine, <compound-id="1031">n-propanol</compound-id>, <compound-id="7118">veratryl alcohol</compound-id>, and ten textile dyes of various groups indicating as a versatile <protein-id="P15984,P16147,P84714">peroxidase</protein-id>.	n-propanol__lignin peroxidase__interaction	hydroquinone__peroxidase__no_interaction	hydroquinone__lignin peroxidase__interaction	Mn2__lignin peroxidase__interaction	veratryl alcohol__peroxidase__no_interaction	Mn2__peroxidase__no_interaction	L-Dopa__peroxidase__no_interaction	mimosine__lignin peroxidase__interaction	tryptophan__peroxidase__no_interaction	L-Dopa__lignin peroxidase__interaction	veratryl alcohol__lignin peroxidase__interaction	mimosine__peroxidase__no_interaction	n-propanol__peroxidase__no_interaction	tryptophan__lignin peroxidase__interaction
18506630-728	<compound-id="1148,6305,9060,5460840">Tryptophan</compound-id> stabilizes the <protein-id="P06181,P11542,P11543,P20010,P20011,P20012,P20013,P21764,P31837,P31838,P49012,P50622">lignin peroxidase</protein-id> activity during decolorization of dyes.	Tryptophan__lignin peroxidase__interaction
18506631-523	To achieve enzymatic production of <compound-id="5281">calcium-stearate</compound-id> at unfavorable conditions, i.e., pH 10 and 60 degrees C, suitable <protein-id="Q7M4U7">lipase</protein-id> was selected and reaction conditions were optimized using calcium <compound-id="961">hydroxide</compound-id> and hydrogenated beef tallow as substrates.	hydroxide__lipase__interaction	calcium-stearate__lipase__interaction
18506631-524	Under optimum conditions, 95% of beef tallow, in 2.5 h, was converted into <compound-id="5281">calcium-stearate</compound-id> by using commercial <protein-id="Q7M4U7">lipase</protein-id> SDL 451.	calcium-stearate__lipase__interaction
18506760-597	<compound-id="2662">Celecoxib</compound-id> could selectively inhibited <protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">COX-2</protein-id> expression and <compound-id="5280360">PGE2</compound-id> production.	Celecoxib__COX-2__interaction	PGE2__COX-2__no_interaction
18506760-598	<compound-id="2662">Celecoxib</compound-id> also inhibited p(473Ser) <protein-id="P31750,Q8INB9">Akt</protein-id>, <protein-id="P09560,P11345,Q80VX4,Q8C0C0">raf</protein-id> and <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id> expression, and induced apoptosis by release of <protein-id="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3">cytochrome c</protein-id> and activation of caspase 9, 3, and 6, which were more remarkably in HBx positive cells than in control cells.	Celecoxib__cytochrome c__interaction	Celecoxib__Akt__interaction	Celecoxib__raf__interaction	Celecoxib__p53__interaction
18506817-653	It has been proposed as a substrate of P-<protein-id="P08163">glycoprotein</protein-id> (P-gp), an efflux transporter, that may contribute to limit <compound-id="5362440">indinavir</compound-id> bioavailability.	indinavir__glycoprotein__interaction
18508255-264	We found that ZPDC <protein-id="P08163">glycoprotein</protein-id> has significant scavenging effect on the production of intracellular <compound-id="784">H2O2</compound-id> without cytotoxicity in G/GO-or HX/XO-treated in Chang liver cells.	H2O2__glycoprotein__interaction
18509327-948	However, the simultaneous presence of the <protein-id="P08684">CYP3A4</protein-id> *1B and <protein-id="P20815">CYP3A5</protein-id> *1A alleles was associated with a 64% increase in <compound-id="148124">docetaxel</compound-id> clearance (P = 0.0015), independent of both sex and CYP3A activity (as determined using the erythromycin breath test).	docetaxel__CYP3A4__interaction	docetaxel__CYP3A5__interaction
18509591-45	It was found that <compound-id="1123">taurine</compound-id> administration produced lower levels of <protein-id="O33822,O58489,O67781,O86459,O93744,P00509,P14909,P23034,P44425,P53001,P58661,P72173,Q4J8X2,Q55128,Q56114,Q56232,Q59228,Q60013,Q92JE7,Q972A2,Q9V0L2,Q9X0Y2,Q9ZE56">aspartate aminotransferase</protein-id> and alkaline aminotransferase than that of the untreated group.	taurine__aspartate aminotransferase__interaction
18509591-46	In addition, the levels of hepatic total protein, <compound-id="124886">glutathione</compound-id> and <protein-id="O50258">superoxide dismutase</protein-id> were higher in the <compound-id="1123">taurine</compound-id> treated groups than those in the untreated control or the <compound-id="1123">taurine</compound-id> depleted groups, while hepatic <compound-id="10964">malondialdehyde</compound-id> content exhibited the negative effect.	taurine__superoxide dismutase__interaction	malondialdehyde__superoxide dismutase__interaction	glutathione__superoxide dismutase__no_interaction
18509591-47	Moreover, the concentrations of hepatic <compound-id="825,5810,69248,440015">hydroxyproline</compound-id>, serum <compound-id="24759,453618,3084050,24728612">hyaluronic acid</compound-id>, interleukin-2, <protein-id="P41693">interleukin-6</protein-id>, <protein-id="Q8JFG3">tumor necrosis factor</protein-id>-alpha and <compound-id="44342165">laminin</compound-id> were all decreased in the <compound-id="1123">taurine</compound-id> treated groups.	laminin__interleukin-6__no_interaction	hyaluronic acid__interleukin-6__no_interaction	taurine__tumor necrosis factor__interaction	hydroxyproline__interleukin-6__no_interaction	taurine__interleukin-6__interaction	laminin__tumor necrosis factor__no_interaction	hydroxyproline__tumor necrosis factor__no_interaction	hyaluronic acid__tumor necrosis factor__no_interaction
18509644-1152	Pharmacological (<compound-id="5287969">flavopiridol</compound-id>) and molecular (shRNA) transcription inhibitor were used to impede formation of <protein-id="P08581,Q07DV8,Q07DY1,Q07DZ1,Q07E01,Q07E24,Q07E37,Q07E48,Q09YH7,Q09YI9,Q09YK0,Q09YL1,Q09YN5,Q108U6,Q2IBA6,Q2IBC0,Q2IBD8,Q2IBF2,Q2IBG7,Q2QL89,Q2QLA9,Q2QLC0,Q2QLE0,Q2QLF1,Q2QLG5,Q2QLH6,Q42662,Q75ZY9">MET</protein-id> transcripts.	flavopiridol__MET__interaction
18509748-1206	Effect of small interference RNA targeting <protein-id="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9">HIF-1alpha</protein-id> mediated by rAAV combined <compound-id="54690394">L:-ascorbate</compound-id> on pancreatic tumors in athymic mice.	L: -ascorbate__HIF-1alpha__interaction
18509748-1207	Moreover, rAAV-siHIF and <compound-id="54690394">L:-ascorbate</compound-id> could all inhibit the secretion of vascular <protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id>.	L: -ascorbate__VEGF__interaction
18509748-1208	These results suggest that rAAV-siHIF and <compound-id="54690394">L:-ascorbate</compound-id> can inhibit the growth of nude mice xenograft tumor and <protein-id="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9">HIF-1alpha</protein-id> could be a target of pancreatic cancer genetic and pharmacological therapy.	L: -ascorbate__HIF-1alpha__no_interaction
18511076-738	Changes in <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id> serum levels in patients with major depression disorder (MDD) after 6 months treatment with <compound-id="68617">sertraline</compound-id>, <compound-id="146570">escitalopram</compound-id>, or <compound-id="5656">venlafaxine</compound-id>.	venlafaxine__BDNF__interaction	sertraline__BDNF__interaction	escitalopram__BDNF__interaction
18511076-739	We assessed serum <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id> levels in 21 patients with major depressive episode treated with <compound-id="68617">sertraline</compound-id>, <compound-id="146570">escitalopram</compound-id>, or <compound-id="5656">venlafaxine</compound-id> and 20 healthy controls.	venlafaxine__BDNF__interaction	sertraline__BDNF__interaction	escitalopram__BDNF__interaction
18511076-740	<compound-id="68617">Sertraline</compound-id> increased <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id> levels after 5 weeks and 6 months of treatment.	Sertraline__BDNF__interaction
18511076-741	<compound-id="5656">Venlafaxine</compound-id> increased <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id> levels only after 6 months.	Venlafaxine__BDNF__interaction
18511076-742	<compound-id="146570">Escitalopram</compound-id> did not affect <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id> levels at either time point.	Escitalopram__BDNF__no_interaction
18513727-1142	The increase of <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> was accompanied by a marked posttranslational down-regulation of liver <protein-id="O18824,P97943,Q60417,Q61009,Q8SQC1,Q8WTV0">SR-BI</protein-id> expression.	cholesterol__SR-BI__interaction
18513727-1143	Taken together, a diet-induced increase of plasma and hepatic <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> levels leads to a posttranscriptional down-regulation of <protein-id="O18824,P97943,Q60417,Q61009,Q8SQC1,Q8WTV0">SR-BI</protein-id> in mouse liver via a mechanism likely involving <protein-id="Q3T0X8,Q5RCF7,Q5T2W1,Q865P3">PDZK1</protein-id>.	cholesterol__PDZK1__interaction	cholesterol__SR-BI__interaction
18513857-1213	A 5.5 kilobase-pair (kbp) <protein-id="Q09750">Pst1</protein-id>-Kpn1 fragment containing gene(s) encoding for <compound-id="5281576">zearalenone</compound-id> degradation was cloned.	zearalenone__Pst1__interaction
18514659-430	However, <compound-id="5280497">TXA(2</compound-id>) formation remains elevated in patients with cardiovascular disease on doses of <compound-id="2244">aspirin</compound-id> that fully suppress platelet <protein-id="O62664,O97554,P05979,P22437,P23219,Q63921,Q9T0N8">COX-1</protein-id>, suggesting other tissue sources for <compound-id="5280497">TXA(2</compound-id>) formation.	aspirin__COX-1__interaction	TXA(2__COX-1__no_interaction
18514900-1098	) production increased; <protein-id="O02033,O13257,O18842,O42152,O93571,P02807,P04358,P07216,P08002,P23038,P25127,P25128,P30331,P30565,P51902,P52723,P52725,P52726,P52728,P55945,P55946,P55948,P55951,P55952,P55953,P68494,P68495,P68497,P68498,P68499,P80367,P80593,P84865,Q05890,Q6J1T3,Q6S4N8,Q6XUW5,Q708T3,Q7ZZP9,Q800D3,Q8UVY1,Q94550,Q9IB50,Q9U568">metallothionein</protein-id> (MT) and <compound-id="124886">glutathione</compound-id> levels increased in most cases, and <protein-id="Q867X2,Q867X3,Q86GC9,Q92081">acetylcholinesterase</protein-id> (<protein-id="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3">AChE</protein-id>) activity decreased in summer.	glutathione__metallothionein__no_interaction	glutathione__AChE__no_interaction	glutathione__acetylcholinesterase__no_interaction
18515453-577	From these findings, it is suggested that <compound-id="3116">distigmine bromide</compound-id> may produce centrally mediated behavioural signs by increasing the ACh levels in the brain, resulting from its <protein-id="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3">AChE</protein-id> and BuChE inhibitions.	distigmine bromide__AChE__interaction
18515457-594	Using DBA/2OlaHsd mice, we investigated the effects of chronic social defeat and concomitant treatment with <compound-id="9821250">R121919</compound-id>/<compound-id="720051">NBI</compound-id> 30775 on 1) the behavioural profile in the modified hole board test and 2) in-situ hybridization analysis-based expression of arginine vasopressin (<protein-id="P01180,P01181,P01182,P01183,P01184,P01185,P10769,P31414,P81768">AVP</protein-id>) and <protein-id="P01142,P06296,P06850,P49926,Q95MI6,Q9PTS1">CRH</protein-id> mRNA in both the hypothalamic paraventricular nucleus and supraoptic nucleus.	NBI__AVP__interaction	NBI__CRH__interaction	R121919__CRH__interaction	R121919__AVP__interaction
18515973-10	<compound-id="91474">7-Ketocholesterol</compound-id> also enhanced <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> release from VSMC.	7-Ketocholesterol__IL-6__interaction
18515973-11	<protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> release by <compound-id="91474">7-ketocholesterol</compound-id>, although significant, was not as remarkable as that induced by <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id>.	7-ketocholesterol__IL-6__interaction	7-ketocholesterol__TNF-alpha__no_interaction
18515973-12	These data suggest that <compound-id="91474">7-ketocholesterol</compound-id> upregulates <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> via mechanisms distinct from <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id> and contributes to the intra- and extracellular <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> deposits within the vasculature.	7-ketocholesterol__IL-6__interaction	7-ketocholesterol__TNF-alpha__no_interaction
18515973-3	<compound-id="91474">7-Ketocholesterol</compound-id> upregulates <protein-id="P41693">interleukin-6</protein-id> via mechanisms that are distinct from those of <protein-id="Q8JFG3">tumor necrosis factor</protein-id>-alpha, in vascular smooth muscle cells.	7-Ketocholesterol__interleukin-6__interaction	7-Ketocholesterol__tumor necrosis factor__no_interaction
18515973-4	Among the 7 IL examined, only <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> transcript was increased by <compound-id="91474">7-ketocholesterol</compound-id> treatment in human aorta smooth muscle cells.	7-ketocholesterol__IL-6__interaction
18515973-5	<protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> transcripts increased up to 24 h after treatment with <compound-id="91474">7-ketocholesterol</compound-id>, and this effect was profoundly repressed by treatment with p38 MAPK inhibitors and to a lesser extent JNK inhibitors.	7-ketocholesterol__IL-6__interaction
18515973-6	<compound-id="107722">7alpha-Hydroxycholesterol</compound-id>, <compound-id="99470,123976,50990021">27-hydroxycholesterol</compound-id> or <compound-id="304,5997,6432564,11025495">cholesterol</compound-id>, however, did not induce <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> expression.	7alpha-Hydroxycholesterol__IL-6__no_interaction	cholesterol__IL-6__no_interaction	27-hydroxycholesterol__IL-6__no_interaction
18515973-7	Mechanisms of <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> induction by <compound-id="91474">7-ketocholesterol</compound-id> were investigated in comparison with <protein-id="Q8JFG3">tumor necrosis factor</protein-id> (<protein-id="O35734,O77510,O77764,P01375,P04924,P13296,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF</protein-id>)-alpha.	7-ketocholesterol__IL-6__interaction	7-ketocholesterol__TNF__no_interaction	7-ketocholesterol__tumor necrosis factor__no_interaction
18515973-8	Whereas <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id> activated <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> promoter, which was impaired by p38 MAPK inhibitors or by mutation in the NF-kappaB-binding site within the promoter region, <compound-id="91474">7-ketocholesterol</compound-id> did not affect <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> promoter activity.	7-ketocholesterol__TNF-alpha__no_interaction	7-ketocholesterol__IL-6__no_interaction
18515973-9	<compound-id="91474">7-ketocholesterol</compound-id> significantly increased the amount of intracellular <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> protein in the presence of <compound-id="5287620">brefeldin A</compound-id>.	7-ketocholesterol__IL-6__interaction	brefeldin A__IL-6__interaction
18521540-51	<compound-id="216325">AGI-1067</compound-id> is a novel, phenolic antioxidant, and vascular protectant which dose-dependently inhibits <protein-id="P0C1A8,P0C1A9">PEA</protein-id> biomarkers in vitro.	AGI-1067__PEA__interaction
18521605-224	<compound-id="3637">Hydralazine</compound-id> inhibits human cervical cancer cell growth in vitro in association with <protein-id="P25054">APC</protein-id> demethylation and re-expression.	Hydralazine__APC__interaction
18521605-225	Clinically, it has been approved that DNA methylation inhibitors, such as <compound-id="451668">5-aza-2'-deoxycytidine</compound-id> (<compound-id="451668">5-Aza-dC</compound-id>), can reverse <protein-id="P25054">APC</protein-id> promoter methylation, but widespread clinical use of these inhibitors is limited by their toxicity and instability in aqueous solution.	5-aza-2'-deoxycytidine__APC__interaction	5-Aza-dC__APC__interaction
18521740-1013	The androgen metabolite <compound-id="242332">5alpha- androstane-3beta,17beta-diol</compound-id> (3betaAdiol) induces breast cancer growth via <protein-id="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7">estrogen receptor</protein-id> : implications for aromatase inhibitor resistance.	5alpha-androstane-3beta,17beta-diol__estrogen receptor__interaction
18521740-1015	Lastly, we found that the downstream metabolite of <compound-id="10635">5alpha-dihydrotestosterone</compound-id>, <compound-id="242332">5alpha- androstane-3beta,17beta-diol</compound-id> (3betaAdiol), is estrogenic in breast cancer cells, and induces growth and ER-signaling via activation of <protein-id="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7">ERalpha</protein-id>.	5alpha-dihydrotestosterone__ERalpha__interaction	5alpha-androstane-3beta,17beta-diol__ERalpha__interaction
18521741-219	Here we demonstrate that an AR ligand, <compound-id="15,10635">5-alpha-dihydrotestosterone</compound-id> (<compound-id="10635">DHT</compound-id>), inhibits MCF-7 breast cancer cell growth induced by <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> like growth factor 1 (<protein-id="P05017,P07455,P08025,P10763,P16545,P17085,P17647,P18254,P33712,P51457,P51458,P51462,Q02815,Q28933,Q68LC0,Q6GUL6,Q6IVA5,Q6JLX1,Q95222">IGF-I</protein-id>).	5-alpha-dihydrotestosterone__IGF-I__interaction	DHT__insulin__interaction	5-alpha-dihydrotestosterone__insulin__interaction	DHT__IGF-I__interaction
18521748-1184	Here, we constructed variants to test whether any of these motifs may explain why <protein-id="O94759">TRPM2</protein-id>-DeltaN does not respond to stimulation with either ADP ribose or <compound-id="784">hydrogen peroxide</compound-id>.	hydrogen peroxide__TRPM2__no_interaction
18521846-1089	We found that <compound-id="66414">2-methoxyestradiol</compound-id> induced the activation of <protein-id="P92208,Q966Y3">JNK</protein-id>, <protein-id="P29323">ERK</protein-id>, and <protein-id="O62618">p38 MAPKs</protein-id>.	2-methoxyestradiol__ERK__interaction	2-methoxyestradiol__p38 MAPKs__interaction	2-methoxyestradiol__JNK__interaction
18521846-1090	<compound-id="66414">2-methoxyestradiol</compound-id>-induced <protein-id="P92208,Q966Y3">JNK</protein-id> activation was associated with the induction of apoptosis through the mitochondrial pathways as a result of increased phosphorylation (inactivation) of the anti-apoptotic <protein-id="P10417,P49950">Bcl-2</protein-id> and Bcl-xL proteins.	2-methoxyestradiol__Bcl-2__interaction	2-methoxyestradiol__JNK__interaction
18521846-1091	In comparison, <compound-id="66414">2-methoxyestradiol</compound-id>-induced activation of <protein-id="P29323">ERK</protein-id> and <protein-id="O24473,O75791,O95433,O97628,P46108,P80350,P82869,Q01552,Q04929,Q63768,Q64010,Q9LDA4,Q9Y2S7">p38</protein-id> in these cells was found to have a protective effect against 2-MeO-E(2)-induced apoptosis.	2-methoxyestradiol__ERK__interaction	2-methoxyestradiol__p38__interaction
18521846-1093	Mechanistically, inhibition of <protein-id="P29323">ERK</protein-id> and <protein-id="O24473,O75791,O95433,O97628,P46108,P80350,P82869,Q01552,Q04929,Q63768,Q64010,Q9LDA4,Q9Y2S7">p38</protein-id> activity was associated with activation of various caspases and <protein-id="O50017,P08469,P14043,P31669,P35875,P55057,Q08824,Q11208">PARP</protein-id> cleavage, and it also stabilized the pro-apoptotic <protein-id="P27297">proteins Bax</protein-id> and <protein-id="O54918,O88498">Bim</protein-id>, thereby preventing them from degradation during <compound-id="66414">2-methoxyestradiol</compound-id> treatment.	2-methoxyestradiol__ERK__no_interaction	2-methoxyestradiol__proteins Bax__no_interaction	2-methoxyestradiol__PARP__no_interaction	2-methoxyestradiol__Bim__no_interaction	2-methoxyestradiol__p38__no_interaction
18521859-1108	Accumulating evidence suggests that <compound-id="53477912">phosphatidylinositol</compound-id> (PI) pathways have been involved in the secretion of <compound-id="681">dopamine</compound-id> (DA) and the regulation of <protein-id="P23977,P27922,Q01959,Q03614,Q61327,Q9GJT6">DA transporter</protein-id>, which is a target of <compound-id="1206,10836,36604">methamphetamine</compound-id> (METH).	dopamine__DA transporter__no_interaction	methamphetamine__DA transporter__interaction	phosphatidylinositol__DA transporter__interaction
18522674-789	<compound-id="2662">Celecoxib</compound-id> caused a 60% reduction in testicular interstitial fluid (IF) prostaglandin E(2) (<protein-id="Q29458">PGE</protein-id> (2)) concentrations, accompanied by a compensatory increase in <protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">COX-2</protein-id> mRNA expression.	Celecoxib__COX-2__interaction	Celecoxib__PGE__interaction
18522674-790	However, <compound-id="2662">celecoxib</compound-id> had no effect on <protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">COX-2</protein-id> protein levels or LPS-induced expression of the inflammatory mediators interleukin-1beta, tumour necrosis factor-alpha or inducible <protein-id="O61309,O61608,Q27571,Q9I9M2">nitric-oxide synthase</protein-id>.	celecoxib__COX-2__no_interaction	celecoxib__nitric-oxide synthase__no_interaction
18522674-791	These data indicate that <compound-id="2662">celecoxib</compound-id> reduces intratesticular activity of <protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">COX-2</protein-id> (as indicated by <protein-id="Q29458">PGE</protein-id> (2) levels) and inhibits IF formation in the testis, but has no appreciable effect on steroidogenesis or spermatogenesis, at least in the short term.	celecoxib__COX-2__interaction	celecoxib__PGE__no_interaction
18522674-792	These results indicate significant roles for products of the <protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">COX-2</protein-id> pathway in testicular vascular control and steroidogenesis, which may have implications for men with marginal fertility taking <compound-id="2662">celecoxib</compound-id> for extended periods, but also highlight the potential of this drug to ameliorate testicular damage caused by systemic or local inflammation.	celecoxib__COX-2__interaction
18528683-286	At the end of the experiment (after 6 weeks), lung histological changes, collagen staining, the activity of <protein-id="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655">glutathione reductase</protein-id> (GR) and contents of <compound-id="124886">reduced glutathione</compound-id> (<compound-id="124886">GSH</compound-id>) and <compound-id="825,5810,69248,440015">hydroxyproline</compound-id> (Hpr) in the lung as well as serum level of <protein-id="Q8JFG3">tumor necrosis factor</protein-id>-alpha (<protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id>) were evaluated.	hydroxyproline__TNF-alpha__no_interaction	reduced glutathione__TNF-alpha__no_interaction	reduced glutathione__glutathione reductase__no_interaction	GSH__TNF-alpha__no_interaction	reduced glutathione__tumor necrosis factor__no_interaction	GSH__glutathione reductase__no_interaction	hydroxyproline__tumor necrosis factor__no_interaction	hydroxyproline__glutathione reductase__no_interaction	GSH__tumor necrosis factor__no_interaction
18528683-287	The obtained data revealed that <compound-id="2578">BCNU</compound-id> induced pathological changes and markedly increased lung collagen and level of <protein-id="P0AA04,P0AA07,P11065,P77335">Hpr</protein-id> but decreased <compound-id="124886">GSH</compound-id> content and GR activity and increased serum <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id> compared to both control and MT-administered rats.	GSH__Hpr__no_interaction	BCNU__Hpr__interaction	BCNU__TNF-alpha__interaction	GSH__TNF-alpha__no_interaction
18528747-574	Collectively, <protein-id="P06116">HMB</protein-id> supplementation increased concentrations of <compound-id="176">short-chain fatty acids</compound-id> in intestinal lumen, expression of proglucagon, <protein-id="O95838,Q9Z0W0">GLP-2R</protein-id>, and <protein-id="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600">eNOS</protein-id> genes, and net portal absorption of AA.	short-chain fatty acids__HMB__no_interaction	short-chain fatty acids__GLP-2R__no_interaction	short-chain fatty acids__eNOS__no_interaction
18528783-293	In search for the pharmacophore and to analyze structure-activity relationships we synthesized a series of truncated derivatives and analogs of <compound-id="656725">RB-2</compound-id>, including 1-amino-2-sulfo-4-ar(alk)ylaminoanthraquinones, 1-amino-2-methyl-4-arylaminoanthraquinones, <compound-id="22628">1-amino-4-bromoanthraquinone 2-sulfonic acid</compound-id> esters and sulfonamides, and bis-(1-amino-4-bromoanthraquinone) sulfonamides, and investigated them in preparations of rat <protein-id="O18956,O93295,P49961,P55772,P97687,Q9MYU4">NTPDase1</protein-id>, 2, and 3 using a capillary electrophoresis assay.	1-amino-4-bromoanthraquinone 2-sulfonic acid__NTPDase1__interaction	RB-2__NTPDase1__interaction
18533896-944	Plasma <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> 0.05) following ingestion of GluF than after Glu alone, without any differences between the effects of either intervention on plasma <compound-id="206,5793,64689,79025">glucose</compound-id> concentrations.	glucose__insulin__no_interaction
18534791-223	No significant differences were observed in plasma concentrations of <compound-id="206,5793,64689,79025">glucose</compound-id>, <protein-id="P80303">NEFA</protein-id>, and <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>-like growth factor or hepatic triglyceride content, but all supplements tended to decrease <compound-id="441">beta hydroxybutyrate</compound-id> postpartum compared to CTL cows.	glucose__NEFA__no_interaction	beta hydroxybutyrate__insulin__no_interaction	glucose__insulin__no_interaction	beta hydroxybutyrate__NEFA__no_interaction
18534811-234	The results showed that <compound-id="2833,6167,53278">colchicine</compound-id> augmented splenic-specific IgG1 and <protein-id="O77762,P05112,P07750,P20096,P30367,P30368,P42202,P46652,P47966,P51492,P51744,P55030,P79155,P79339,Q04745,Q2PE74,Q3S4V6,Q58M18,Q60440,Q7YS71,Q865X5,Q865Y0,Q8HYB1,Q9MZR8,Q9XS58">IL-4</protein-id> as well as cell proliferation but suppressed specific IgG2a and <protein-id="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9">IFN-gamma</protein-id> levels.	colchicine__IFN-gamma__interaction	colchicine__IL-4__interaction
18534874-957	<compound-id="5329102">Sunitinib malate</compound-id> (Pfizer, Inc.) is a multitargeted kinase inhibitor that inhibits vascular endothelial growth factor (<protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id>) receptor (R)-1, 2 and 3, platelet-derived growth factor receptors (PDGFR)-alpha and beta, <protein-id="Q00342">Flt3</protein-id>, <protein-id="P07949">RET</protein-id>, and Kit.	Sunitinib malate__RET__interaction	Sunitinib malate__Flt3__interaction	Sunitinib malate__VEGF__interaction
18536700-664	<protein-id="P97738">Narp</protein-id> deletion blocks extinction of <compound-id="5288826,5479215">morphine</compound-id> place preference conditioning.	morphine__Narp__interaction
18536700-665	Accordingly, to assess its potential role in the long-lasting behavioral effects of drugs of abuse, we have investigated the impact of <protein-id="P97738">Narp</protein-id> deletion on sustained behavioral responses elicited by repeated <compound-id="5288826,5479215">morphine</compound-id> administration.	morphine__Narp__no_interaction
18536704-162	Decreased <protein-id="P21917,P30729,P51436,Q6TLJ0">dopamine D4 receptor</protein-id> expression increases extracellular <compound-id="611,23327,33032">glutamate</compound-id> and alters its regulation in mouse striatum.	glutamate__dopamine D4 receptor__interaction
18536705-163	injection of <protein-id="O70176,P13589,P16613,P18509,P41535,P41585,P48144,P81039,Q29W19">PACAP</protein-id> provoked a significant increase in plasma <compound-id="206,5793,64689,79025">glucose</compound-id> level.	glucose__PACAP__interaction
18536954-285	In 17 adults on a fixed metabolic diet, an 11-day course of <compound-id="156419">cinacalcet</compound-id> increased serum <protein-id="O02686,P01350,P01351,P01352,P01353,P01354,P04563,P04564,P06885,P10034,P33713,P33714,P48757,P55885">gastrin</protein-id> and basal gastric acid output, but not maximal gastric acid output, compared with a placebo.	cinacalcet__gastrin__interaction
18537150-81	Since <compound-id="5281884">PSC-833</compound-id> was found to be a weak inhibitor of CYP 3A4 and to have no inhibitory effects on <protein-id="P16397,P18773">esterases</protein-id>, <protein-id="P17988,P50227,P52840,P52846,P82609,Q29476,Q80VR3">phenol sulfotransferases</protein-id>, and glucuronyltransferases, it is suggested <compound-id="5281884">PSC-833</compound-id> enhances intestinal mucosal permeation of these cyclic prodrugs by inhibiting their polarized efflux and not by inhibiting their metabolism.	PSC-833__phenol sulfotransferases__no_interaction	PSC-833__esterases__no_interaction
18538372-777	We showed that after treatment of HCT116 cells with a low dose of <compound-id="31703">doxorubicin</compound-id> most of them stopped proliferation as documented by SA-<protein-id="O33815,O52629,O52847,P00722,P00723,P06219,P0C1Y0,P14288,P22498,P23989,P24131,P26257,P30812,P50388,P70753,P77989,P81650,Q1G9Z4,Q47077,Q48727,Q56307,Q59140,Q59750,Q9K9C6">beta-galactosidase</protein-id> activity and the lack of Ki67 expression.	doxorubicin__beta-galactosidase__interaction
18538372-778	The vast majority of the <compound-id="31703">doxorubicin</compound-id>-treated cells did not enter mitoses, as evidenced by mitotic index analysis, as well as by the predominantly cytoplasmic localization of <protein-id="O01377,O16852,P04961,P12004,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P61074,Q00265,Q00268">cyclin</protein-id> B1 and a lack of separation of multiplied centrosomes.	doxorubicin__cyclin__no_interaction
18538450-1221	Molecular modeling of the binding of the <compound-id="7583">diphenyl ether</compound-id> derivatives on enoyl-<protein-id="O14561,O19921,O34163,O51647,O67611,O69475,O83786,O84239,P07088,P08971,P0A001,P0A002,P0A003,P0A199,P0A1A0,P0A2W0,P0A2W1,P0A2W2,P0A2W3,P0A4W6,P0A4W7,P0A6A8,P0A6A9,P0A6B0,P0A6B1,P0A6B2,P0A6B3,P10352,P10977,P11829,P11830,P11943,P12784,P12884,P12885,P17650,P19372,P20803,P20804,P23153,P25701,P25702,P27060,P29189,P32463,P32887,P41174,P43677,P43709,P47529,P48078,P49517,P51280,P52411,P52412,P52413,P52414,P52505,P53665,P56464,P57433,P58553,P59449,P61156,P63437,P63438,P63439,P63440,P63441,P63442,P63443,P63444,P63445,P63446,P63447,P63448,P63449,P63452,P63453,P75378,P80643,P80916,P80917,P80918,P80919,P80920,P80921,P80922,P80923,P94123,Q00663,Q02054,Q02570,Q05363,Q0MQC1,Q0MQC2,Q0MQC3,Q10217,Q1BBA1,Q49X16,Q4L5T4,Q56035,Q5HGK0,Q5HPV9,Q5WFM5,Q5XAE1,Q606L6,Q62LT9,Q636H6,Q63S86,Q64ZV7,Q65RC8,Q660G8,Q669L4,Q6B8U3,Q6D687,Q6FDT7,Q6G056,Q6G442,Q6G9Y1,Q6GHK3,Q6HEW5,Q6MAF8,Q6MLJ8,Q6YPI8,Q71YL0,Q732M0,Q73ZP6,Q74CR8,Q75FW6,Q7M9W1,Q7MLZ9,Q7MU10,Q7U9V9,Q7UYY2,Q7V4J6,Q7V9R0,Q7VI80,Q7VKH6,Q7VR21,Q7VW32,Q7W5I7,Q7WD23,Q819V7,Q81WI7,Q823D5,Q83N02,Q83NH7,Q85FZ0,Q88LL5,Q89MV8,Q8A2E6,Q8CPI2,Q8D3A9,Q8D8G9,Q8DHS3,Q8EDH4,Q8ER06,Q8EXX4,Q8K9J4,Q8KAN9,Q8R9W1,Q8RGX5,Q8UGE2,Q8XJN7,Q8Z495,Q8ZFT4,Q92GD8,Q94519,Q97HJ4,Q97IA5,Q984T3,Q98QK3,Q9A7P3,Q9CHF9,Q9CJS5,Q9CR21,Q9EZI1,Q9KA04,Q9KQH8,Q9PI64,Q9PKF8,Q9PPY4,Q9R6Z3,Q9RA32,Q9RG22,Q9RK61,Q9RT27,Q9WZD0,Q9Z8P3,Q9ZCH9,Q9ZLS1">ACP</protein-id> reductase, the molecular target site of <compound-id="5564">triclosan</compound-id>, indicated that these compounds fit within the binding domain occupied by <compound-id="5564">triclosan</compound-id>.	triclosan__ACP__interaction	diphenyl ether__ACP__interaction
18539357-492	Tumor <protein-id="P08640,P15941,Q29435,Q60528">MUC1</protein-id> differs from normal <protein-id="P08640,P15941,Q29435,Q60528">MUC1</protein-id> by modified <compound-id="871">glycan</compound-id> side chains.	glycan__MUC1__interaction
18539387-509	Mineralization and dehalogenation of <compound-id="6914">2,4,6-TCP</compound-id> was evidenced by high <protein-id="P14678">COD</protein-id> removal efficiencies (approximately 95%), and by the stoichiometric release of <compound-id="312">chloride</compound-id> ions from the halogenated compound (approximately 80%).	2,4,6-TCP__COD__interaction	chloride__COD__no_interaction
18539426-489	Studies in postmenopausal women showed that an <protein-id="O42145,O46512,P11511,P19098,P22443,P28649,P46194,P70091,P79304,P79430,P79699,Q29605,Q29624,Q5QQX7,Q69FB6,Q6QHT9,Q6YI21,Q92087,Q92111,Q92112,Q95M61,Q9XS28">aromatase</protein-id> inhibitor (AI) as initial, upfront treatment reduces early recurrence, including distant metastases, compared with <compound-id="2733526">tamoxifen</compound-id>.	tamoxifen__aromatase__no_interaction
18541345-459	<compound-id="3475">Gliclazide</compound-id> can change the conformation of the active sites and decrease obviously the affinities between <compound-id="3475">gliclazide</compound-id> in the active site and enzymes when it is docked in the second active sites in <protein-id="P11712">CYP2C9</protein-id> and <protein-id="P33261">CYP2C19</protein-id>.	Gliclazide__CYP2C19__interaction	gliclazide__CYP2C9__interaction	Gliclazide__CYP2C9__interaction	gliclazide__CYP2C19__interaction
18543297-399	Metabolism of <compound-id="3918,5360697">dextrorphan</compound-id> by <protein-id="P10635,Q2XNC8,Q2XNC9">CYP2D6</protein-id> in different recombinantly expressed systems and its implications for the in vitro assessment of <compound-id="3008,5360696,5362449,12305042">dextromethorphan</compound-id> metabolism.	dextrorphan__CYP2D6__interaction	dextromethorphan__CYP2D6__no_interaction
18543297-400	<protein-id="P10635,Q2XNC8,Q2XNC9">Cytochrome P450 2D6</protein-id> (<protein-id="P10635,Q2XNC8,Q2XNC9">CYP2D6</protein-id>) mediated formation of <compound-id="3918,5360697">dextrorphan</compound-id> (<compound-id="439216">DOR</compound-id>) from <compound-id="3008,5360696,5362449,12305042">dextromethorphan</compound-id> (DEX) is widely used as a marker to assess the activity of this enzyme both in vitro and in vivo.	dextromethorphan__Cytochrome P450 2D6__interaction	dextrorphan__Cytochrome P450 2D6__interaction	dextrorphan__CYP2D6__interaction	dextromethorphan__CYP2D6__interaction	DOR__Cytochrome P450 2D6__interaction	DOR__CYP2D6__interaction
18543297-401	The sequential metabolism of <compound-id="439216">DOR</compound-id> during in vitro studies, particularly using recombinant systems (rCYPs) expressing human <protein-id="P10635,Q2XNC8,Q2XNC9">CYP2D6</protein-id>, is assumed to be negligible.	DOR__CYP2D6__no_interaction
18543297-402	The extent of metabolism was investigated for a range of DEX and <compound-id="439216">DOR</compound-id> concentrations in microsomal preparations from three different rCYPs expressing human <protein-id="P10635,Q2XNC8,Q2XNC9">CYP2D6</protein-id> (yeast, Supersomes and Bactosomes) containing 10 pmol of the enzyme.	DOR__CYP2D6__interaction
18543297-403	Two novel <protein-id="P10635,Q2XNC8,Q2XNC9">CYP2D6</protein-id> related metabolites were identified in Bactosomes, and assigned as single hydroxylations in the phenyl rings of <compound-id="439216">DOR</compound-id> and <compound-id="11840954">HYM</compound-id> using ion-trap mass spectrometry.	DOR__CYP2D6__interaction	HYM__CYP2D6__interaction
18543330-427	The metal-coordinating residues in the active site of <protein-id="P54970">ILL2</protein-id> include a conserved <compound-id="594,5862,5360637">cysteine</compound-id> that clearly distinguishes this protein from previously structurally characterized members of the M20 peptidase family.	cysteine__ILL2__interaction
18543330-428	Finally, the active site of <protein-id="P54970">ILL2</protein-id> harbors an absolutely conserved <compound-id="611,23327,33032">glutamate</compound-id> (Glu172), which is well positioned to act as a general acid-base residue.	glutamate__ILL2__interaction
18544044-880	In this study, we tested the hypothesis that the Angiopoietin 1 (<protein-id="P21570">Ang1</protein-id>)/<protein-id="O73791,Q02858">Tie2</protein-id> pathway mediates <compound-id="54454,4677798">simvastatin</compound-id>-induced vascular integrity and migration of neuroblasts after stroke.	simvastatin__Tie2__interaction	simvastatin__Ang1__interaction
18544044-881	<compound-id="54454,4677798">Simvastatin</compound-id> treatment significantly decreased blood-brain barrier (BBB) leakage and concomitantly, increased <protein-id="P21570">Ang1</protein-id>, <protein-id="O73791,Q02858">Tie2</protein-id> and <protein-id="Q16625,Q28269,Q28793,Q5RFS5,Q61146,Q6P6T5,Q91049,Q9PUN1">Occludin</protein-id> expression in the ischaemic border (IBZ) compared to the MCAo control group.	Simvastatin__Tie2__interaction	Simvastatin__Occludin__interaction	Simvastatin__Ang1__interaction
18544044-882	<compound-id="54454,4677798">Simvastatin</compound-id> also significantly increased doublecortin (<protein-id="O43602">DCX</protein-id>, a marker of migrating neuroblasts) expression in the IBZ compared to control MCAo rats.	Simvastatin__DCX__interaction
18544044-883	The data show that <compound-id="54454,4677798">simvastatin</compound-id> treatment of RBMEC increased <protein-id="P21570">Ang1</protein-id> and <protein-id="O73791,Q02858">Tie2</protein-id> gene and protein expression and promoted phosphorylated-<protein-id="O73791,Q02858">Tie2</protein-id> activity.	simvastatin__Tie2__interaction	simvastatin__Ang1__interaction
18544044-884	<compound-id="54454,4677798">Simvastatin</compound-id> treatment of stroke increases <protein-id="P21570">Ang1</protein-id>/<protein-id="O73791,Q02858">Tie2</protein-id> expression and thereby reduces BBB leakage and promotes vascular stabilization.	Simvastatin__Tie2__interaction	Simvastatin__Ang1__interaction
18544044-885	<protein-id="P21570">Ang1</protein-id>/<protein-id="O73791,Q02858">Tie2</protein-id> expression induced by <compound-id="54454,4677798">simvastatin</compound-id> treatment promotes neuroblast micro-vascular coupling after stroke.	simvastatin__Tie2__interaction	simvastatin__Ang1__interaction
18544047-888	Suppressing the activity of <protein-id="O08580,P11474">ERRalpha</protein-id> in 3T3-L1 adipocytes reduces mitochondrial biogenesis but enhances glycolysis and basal <compound-id="206,5793,64689,79025">glucose</compound-id> uptake.	glucose__ERRalpha__interaction
18544047-889	Through suppressing the expression of another <protein-id="O08580,P11474">ERRalpha</protein-id> target gene <protein-id="O02623,P40530,P91622,Q02332,Q9P6P9">pyruvate dehydrogenase kinase</protein-id> 2 (<protein-id="Q15119">PDK2</protein-id>), we found that XCT-790 not only enhanced the conversion of <compound-id="1060">pyruvate</compound-id> to acetyl-CoA and hyper-activated the tricarboxylic acid (TCA) cycle, but also led to higher levels of mitochondrial membrane potential and reactive oxidant species (ROS) production.	pyruvate__PDK2__no_interaction	pyruvate__pyruvate dehydrogenase kinase__no_interaction	pyruvate__ERRalpha__no_interaction
18544047-891	Therefore, <protein-id="O08580,P11474">ERRalpha</protein-id> stands at the crossroad of <compound-id="206,5793,64689,79025">glucose</compound-id> and fatty acid utilization and acts as a homeostatic switch to regulate the flux of TCA cycle, mitochondrial membrane potential and glycolysis to maintain a steady level of <compound-id="5957">ATP</compound-id> production, particularly, when mitochondrial biogenesis is reduced.	ATP__ERRalpha__interaction	glucose__ERRalpha__interaction
18544592-1218	A significant decrease in mean total <compound-id="145068">nitric oxide</compound-id> (NOx), nitrite, and <compound-id="943">nitrate</compound-id> levels was also found after <protein-id="O02708,O02837,P09919,P09920,P35833,P35834,Q28746">G-CSF</protein-id> plus <compound-id="5743">dexamethasone</compound-id> administration.	nitrate__G-CSF__interaction	dexamethasone__G-CSF__no_interaction	nitric oxide__G-CSF__interaction
18544592-1219	Even if partially compensated with u-PA and <protein-id="O55527,O55779,P02810,P03314,P03424,P04861,P04862,P06022,P06164,P06165,P06941,P07602,P08097,P10030,P14253,P14254,P14340,P26035,P26779,P27384,P28055,P29165,P32533,P32534,P32535,P35940,P35948,P35977,P69738,Q00794,Q03339,Q074N0,Q1X880,Q1X881,Q6DV88,Q6J3P1,Q89277,Q98803,Q997F1,Q9DUE0,Q9WS38,Q9YRV3">protein C</protein-id>, increased FVIII and <protein-id="P04275,P80012,Q28295,Q28833,Q8CIZ8">vWF</protein-id> activity, and decreased <compound-id="145068">nitric oxide</compound-id> levels may still partially contribute to progress of thrombosis risk in rhG-CSF plus <compound-id="5743">dexamethasone</compound-id> administered healthy granulocyte donors.	dexamethasone__protein C__interaction	nitric oxide__vWF__no_interaction	dexamethasone__vWF__interaction	nitric oxide__protein C__no_interaction
18546023-135	<protein-id="Q7M4U7">Lipase</protein-id> immobilized on <compound-id="3485">glutaraldehyde</compound-id>-crosslinked chitosan yielded the highest efficiency in terms of total coupled protein and protein loading efficiency.	glutaraldehyde__Lipase__interaction
18547170-484	Amyloglucosidase from Rhizopus mould and <protein-id="P12614,P15885,P27034,P29091,P40740,Q03506,Q46684">beta-glucosidase</protein-id> from sweet almond were employed for the preparation of phenolic and vitamin glycosides of <compound-id="1183">vanillin</compound-id>, <compound-id="2998">N-vanillylnonanamide</compound-id>, <compound-id="836">DL-dopa</compound-id>, <compound-id="681">dopamine</compound-id>, <compound-id="969516">curcumin</compound-id>, <compound-id="2116,14985">alpha-tocopherol</compound-id> (<compound-id="2116,14985,1548900,1742129">vitamin E</compound-id>), <compound-id="1054">pyridoxine</compound-id> (vitamin B(6)), <compound-id="3249">ergocalciferol (vitamin D</compound-id> (2)), <compound-id="1130">thiamin</compound-id> (vitamin B(1)) and <compound-id="1072,6759,493570">riboflavin</compound-id> (vitamin B(2)).	thiamin__beta-glucosidase__interaction	dopamine__beta-glucosidase__interaction	alpha-tocopherol__beta-glucosidase__interaction	curcumin__beta-glucosidase__interaction	DL-dopa__beta-glucosidase__interaction	pyridoxine__beta-glucosidase__interaction	vitamin E__beta-glucosidase__interaction	N-vanillylnonanamide__beta-glucosidase__interaction	vanillin__beta-glucosidase__interaction	ergocalciferol (vitamin D__beta-glucosidase__interaction	riboflavin__beta-glucosidase__interaction
18547363-1222	<compound-id="442530">Ochratoxin A</compound-id> impairs <protein-id="O54968,Q60795">Nrf2</protein-id>-dependent gene expression in porcine kidney tubulus cells.	Ochratoxin A__Nrf2__interaction
18547363-1223	Therefore, in the present study, the effects of <compound-id="444766">OTA</compound-id> on the nuclear translocation and transactivation of the transcription factor <protein-id="O54968,Q60795">Nrf2</protein-id> as well as mRNA levels of <protein-id="O54968,Q60795">Nrf2</protein-id> target genes including <protein-id="O04437,O18598,P0A9D2,P0A9D3,P30116,P44521,P46088,P46419,P46423,P46426,P46428,P46437,P48438,P80894,P81065,P82996,P82997,P82998,P82999,P83000,P83001,P83246,Q04522,Q08392,Q08393,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52,Q96324">glutathione-S-transferase</protein-id> and gamma-glutamylcysteinyl synthetase have been studied in cultured porcine kidney tubulus cells (LLC-PK1).	OTA__Nrf2__interaction	OTA__glutathione-S-transferase__interaction
18547363-1224	<protein-id="O54968,Q60795">Nrf2</protein-id> was induced by <compound-id="5350">sulforaphane</compound-id>, a well-known activator of this transcription factor.	sulforaphane__Nrf2__interaction
18547363-1225	<compound-id="442530">Ochratoxin A</compound-id> significantly decreased gamma-glutamylcysteinyl synthetase and <protein-id="O04437,O18598,P0A9D2,P0A9D3,P30116,P44521,P46088,P46419,P46423,P46426,P46428,P46437,P48438,P80894,P81065,P82996,P82997,P82998,P82999,P83000,P83001,P83246,Q04522,Q08392,Q08393,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52,Q96324">glutathione-S-transferase</protein-id> mRNA levels in LLC-PK1 cells.	Ochratoxin A__glutathione-S-transferase__interaction
18547363-1226	Furthermore, <compound-id="444766">OTA</compound-id> also lowered <protein-id="O54968,Q60795">Nrf2</protein-id> mRNA levels.	OTA__Nrf2__interaction
18547363-1227	Current data indicate that <compound-id="444766">OTA</compound-id> nephrotoxicity may be, at least partly, mediated by an <protein-id="O54968,Q60795">Nrf2</protein-id>-dependent signal transduction pathway.	OTA__Nrf2__interaction
18547754-637	Parthenogenetic porcine blastocysts were generated by the following methods: (1) electroporation followed by blocking the activity of specific <protein-id="P00513,P25848">protein kinases</protein-id> with <compound-id="123740,5235506,51340302">butyrolactone I</compound-id> ; (2) electroporation followed by inhibition of protein synthesis using <compound-id="6197">cycloheximide</compound-id> ; and (3) electroporation only (control).	butyrolactone I__protein kinases__interaction	cycloheximide__protein kinases__no_interaction
18547755-125	The aim of the present study was to investigate differences in the expression of mRNAs for <protein-id="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7">ERalpha</protein-id>, <protein-id="O08537,O13012,O93511,P57781,P57782,Q62986,Q92731,Q95171,Q9IAK1,Q9PTU5,Q9PVE2,Q9TTE5,Q9TU15,Q9W6M2,Q9XSB5,Q9XSW2,Q9YH32">ERbeta</protein-id> and PR in the sow uterus at different stages of the estrous cycle as well as in inseminated sows at estrus and during early pregnancy by use of solution hybridization and in relation to plasma levels of <compound-id="5757">estradiol</compound-id> and <compound-id="5994">progesterone</compound-id>.	progesterone__ERalpha__interaction	estradiol__ERalpha__interaction	progesterone__ERbeta__interaction	estradiol__ERbeta__interaction
18547796-661	Increased incorporation of dietary plant sterols and <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> correlates with decreased expression of hepatic and intestinal <protein-id="Q99PE7,Q99PE8">Abcg5</protein-id> and <protein-id="P58428,Q9DBM0">Abcg8</protein-id> in diabetic BB rats.	cholesterol__Abcg8__interaction	cholesterol__Abcg5__interaction
18547796-662	This increase in <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> and plant sterols and stanols was associated with a marked decrease in hepatic and intestinal <protein-id="Q99PE7,Q99PE8">Abcg5</protein-id> (ATP-binding cassette transporter G5) and <protein-id="P58428,Q9DBM0">Abcg8</protein-id> (ATP-binding cassette transporter G8) expressions in diabetic rats, as well as decreased mRNA levels of several other genes involved in sterol regulation.	cholesterol__Abcg8__interaction	cholesterol__Abcg5__interaction
18547796-663	Therefore, lower expression levels of <protein-id="Q99PE7,Q99PE8">Abcg5</protein-id>/<protein-id="P58428,Q9DBM0">Abcg8</protein-id> in diabetic rats may account for the increased accumulation of plant sterols and <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> in these rats.	cholesterol__Abcg8__interaction	cholesterol__Abcg5__interaction
18547798-666	<compound-id="370">Gallic acid</compound-id>, <compound-id="445858">ferulic acid</compound-id> and <compound-id="637542">p-coumaric acid</compound-id> at a dosage of 100 mg kg(-1) body weight significantly increased the activities of cardiac <protein-id="O50258">superoxide dismutase</protein-id>, <protein-id="O32770,O59858,Q00277,Q9CFV1">glutathione peroxidase</protein-id> (GPx) and <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id> (<protein-id="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7">CAT</protein-id>.05).	ferulic acid__glutathione peroxidase__interaction	Gallic acid__glutathione peroxidase__interaction	p-coumaric acid__superoxide dismutase__interaction	p-coumaric acid__glutathione peroxidase__interaction	ferulic acid__CAT__interaction	Gallic acid__CAT__interaction	Gallic acid__catalase__interaction	Gallic acid__superoxide dismutase__interaction	p-coumaric acid__CAT__interaction	p-coumaric acid__catalase__interaction	ferulic acid__catalase__interaction	ferulic acid__superoxide dismutase__interaction
18547799-292	These effects of <compound-id="5280961">genistein</compound-id> during the differentiation period were associated with down-regulation of <protein-id="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7">ERalpha</protein-id> and <protein-id="O08537,O13012,O93511,P57781,P57782,Q62986,Q92731,Q95171,Q9IAK1,Q9PTU5,Q9PVE2,Q9TTE5,Q9TU15,Q9W6M2,Q9XSB5,Q9XSW2,Q9YH32">ERbeta</protein-id> expression.	genistein__ERalpha__interaction	genistein__ERbeta__interaction
18548182-922	Activities of microbial extracellular enzymes involved in carbon, <compound-id="947,123329">nitrogen</compound-id>, and <compound-id="24404,139579">phosphorus</compound-id> cycling declined appreciably with depth, the only exception being <protein-id="P15984,P16147,P84714">peroxidase</protein-id>.	nitrogen__peroxidase__no_interaction	phosphorus__peroxidase__no_interaction
18548275-801	<compound-id="104818">Sulfonylurea</compound-id> (SU) treatment restores <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> secretion in patients with <protein-id="O02822,Q14654,Q9JHJ9">KCNJ11</protein-id> mutations.	Sulfonylurea__KCNJ11__no_interaction	Sulfonylurea__insulin__interaction
18548615-1193	The purpose of this study was to investigate the effect of three zinc salts (i.e., <compound-id="14806">zinc oxide</compound-id>, <compound-id="767">zinc carbonate</compound-id>, and <compound-id="176">zinc acetate</compound-id>) on <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> encapsulation efficiency (EE), stability, and in vitro release kinetics from poly(lactic-co-<compound-id="757">glycolic acid</compound-id>) (<compound-id="36797">PLGA</compound-id>) microspheres.	zinc carbonate__insulin__interaction	zinc acetate__insulin__interaction	PLGA__insulin__interaction	glycolic acid__insulin__interaction	zinc oxide__insulin__interaction
18550063-794	<protein-id="Q8JFG3">Tumor necrosis factor</protein-id>-alpha inhibition protects against <compound-id="44268108">endotoxin</compound-id>-induced endothelial glycocalyx perturbation.	endotoxin__Tumor necrosis factor__interaction
18550063-795	In the present study, we investigated whether <compound-id="44268108">endotoxin</compound-id>-induced inflammatory reactions lead to a decrease of endothelial glycocalyx thickness in humans and whether <protein-id="Q8JFG3">tumor necrosis factor</protein-id>-alpha (<protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNFalpha</protein-id>) plays a role in this process.	endotoxin__tumor necrosis factor__no_interaction	endotoxin__TNFalpha__no_interaction
18550164-868	The amino acid sequence deduced from the coding sequence encodes for <protein-id="P03161,P03610,P03631,P03632,P07394,P15966,P25243,P25244,P35823,P98005">a protein</protein-id> of 73 amino acids containing 21 <compound-id="594,5862,5360637">cysteine</compound-id> residues.	cysteine__a protein__interaction
18550594-1147	Ultrastructural analysis in the macaque mediodorsal nucleus revealed that thalamic interneurons are a main postsynaptic target of <protein-id="P13483,P23977,P27922,Q01959,Q03614,Q61327,Q9GJT6">DAT</protein-id>-ir axons ; this suggests that the marked expansion of the <compound-id="681">dopamine</compound-id> innervation in the primate in comparison to the rodent thalamus may be related to the presence of a sizable interneuron population in primates.	dopamine__DAT__no_interaction
18550596-1150	<protein-id="Q24546">Synapsin</protein-id>-dependent facilitation in MF synapses of WT mice was attenuated by blocking F-<protein-id="O00937,O13419,O16808,O17320,O65314,O65315,O65316,O74258,O81221,P02577,P10365,P10989,P11426,P13363,P14235,P17128,P20904,P24902,P26182,P26183,P30161,P45520,P45521,P48465,P50138,P51775,P53455,P53476,P53477,P53491,P53498,P53499,P53500,P53502,P53689,P60009,P60010,P60011,P68555,P78711,P80709,P81085,P90689,P91754,Q05214,Q11212,Q24733,Q2U7A3,Q39596,Q39758,Q6TCF2,Q75D00,Q8SWN8,Q8X119,Q92192,Q92193,Q99023,Q9P4D1,Q9UVF3,Q9UVX4,Q9UVZ8">actin</protein-id> polymerization with <compound-id="2919,5311281,5368686,5836499,6364615,6433621">cytochalasin B</compound-id> in hippocampal slices.	cytochalasin B__Synapsin__interaction	cytochalasin B__actin__interaction
18551377-641	Transformation was achieved using a vector that targets genes to the rrn16/<protein-id="O14062,P02368,P06368,P11524,P13576,P14149,P17293,P17294,P19461,P29161,P39573,P41196,P42344,P46296,P46308,P47333,P47840,P48856,P49168,P49500,P51289,P52762,P56354,P59168,P61941,P62127,P63196,P63199,P63200,P63323,P63324,P74230,Q2JMY0,Q2JUX7,Q318N2,Q3AMT3,Q3AW56,Q3MDM2,Q46IW1,Q5F1R7,Q68S28,Q6B8X8,Q6ENC0,Q6L3C7,Q6YXM6,Q70XU7,Q7NAV1,Q7NEF4,Q7U4D4,Q7UZY4,Q7V503,Q7VA02,Q85BW6,Q85FG4,Q85X49,Q8KTP6,Q8MA18,Q8RUK6,Q8VMU2,Q8YP60,Q9AIG9,Q9CL86,Q9MUP2,Q9PPW5,Q9TJR0,Q9TKZ7,Q9TLV6,Q9XQE1">rps12</protein-id> intergenic region of the sugar beet plastome, employing the <protein-id="P08881,P0AG05,P0AG06">aadA</protein-id> gene as a selectable marker against <compound-id="15541">spectinomycin</compound-id> and the gfp gene for visual screening of plastid transformants.	spectinomycin__aadA__interaction	spectinomycin__rps12__no_interaction
18552508-1057	<compound-id="2662">Celecoxib</compound-id> inhibits serum amyloid a-induced <protein-id="O55123,P07152,P09238">matrix metalloproteinase-10</protein-id> expression in human endothelial cells.	Celecoxib__matrix metalloproteinase-10__interaction
18553142-185	This article investigated the effect of sulfite on total antioxidant capacity (TAC), total oxidant status, lipid <compound-id="784">hydroperoxide</compound-id> (LOOH), and total free sulfydryl groups (-SH) levels in normal and <protein-id="P79371,Q8JGM4,Q9S850">SOX</protein-id>-deficient male albino rat plasma.	hydroperoxide__SOX__no_interaction
18553142-186	<protein-id="P79371,Q8JGM4,Q9S850">SOX</protein-id> deficiency was established by feeding rats a low <compound-id="6422,23932">molybdenum</compound-id> diet and adding to their drinking water 200 ppm <compound-id="23964">tungsten</compound-id>.	tungsten__SOX__interaction	molybdenum__SOX__interaction
18553215-218	an " <protein-id="O00937,O13419,O16808,O17320,O65314,O65315,O65316,O74258,O81221,P02577,P10365,P10989,P11426,P13363,P14235,P17128,P20904,P24902,P26182,P26183,P30161,P45520,P45521,P48465,P50138,P51775,P53455,P53476,P53477,P53491,P53498,P53499,P53500,P53502,P53689,P60009,P60010,P60011,P68555,P78711,P80709,P81085,P90689,P91754,Q05214,Q11212,Q24733,Q2U7A3,Q39596,Q39758,Q6TCF2,Q75D00,Q8SWN8,Q8X119,Q92192,Q92193,Q99023,Q9P4D1,Q9UVF3,Q9UVX4,Q9UVZ8">actin</protein-id> binding domain", as a singlet and which, in addition, contain the conserved <compound-id="594,5862,5360637">cysteine</compound-id> rich double Zn finger possessing Lim domain, also as a singlet.	cysteine__actin__interaction
18554595-1071	To test the hypothesis that <compound-id="12594">DHEAS</compound-id> production from <compound-id="5881">DHEA</compound-id> occurs in hepatic cells and that this production is augmented by the presence of sex steroids or <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>.	DHEA__insulin__interaction	DHEAS__insulin__interaction
18554598-1073	Changes in <protein-id="Q8JFG3">tumor necrosis factor</protein-id> (<protein-id="O35734,O77510,O77764,P01375,P04924,P13296,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF</protein-id>) production by <compound-id="11970143">lipopolysaccharide</compound-id>-stimulated peripheral blood mononuclear cells significantly correlated with serum P levels in postmenopausal women subjected to estrogen/<compound-id="10631">medroxyprogesterone</compound-id> therapy.	medroxyprogesterone__tumor necrosis factor__no_interaction	lipopolysaccharide__TNF__interaction	lipopolysaccharide__tumor necrosis factor__interaction	medroxyprogesterone__TNF__no_interaction
18554690-393	The differences in tissue distribution and protein levels of <protein-id="O18473,O18531,P34021,P49880,P49881,P49882,P49883">EcR</protein-id>-B1 during the programmed cell death indicate that the receptor plays a major role in the modulation and function of <compound-id="19212,4233007,5316996">ecdysone</compound-id> activity in Bombyx anterior silk glands.	ecdysone__EcR__interaction
18555241-208	<compound-id="969516">Curcumin</compound-id>, a nutritional supplement with antineoplastic activity, enhances leiomyoma cell apoptosis and decreases <protein-id="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400">fibronectin</protein-id> expression.	Curcumin__fibronectin__interaction
18555557-379	Methylthioadenosine phosphorylase (<protein-id="Q13126">MTAP</protein-id>) is involved in the metabolism of purines and converts methylthioadenosine (MTA) to <compound-id="190">adenine</compound-id>.	adenine__MTAP__interaction
18555557-380	Methylation-specific primers were used to analyze methylation of the <protein-id="Q13126">MTAP</protein-id> promoter, using DNA treated with <compound-id="23665763">sodium bisulfite</compound-id>.	sodium bisulfite__MTAP__no_interaction
18555679-458	Long-chain <compound-id="62238">fatty alcohols</compound-id> also reduced <protein-id="Q8JFG3">tumor necrosis factor</protein-id>-alpha and prostaglandin E(2) production, although the potency of inhibition for the latter was lower.	fatty alcohols__tumor necrosis factor__interaction
18556000-671	<compound-id="4455">Neopterin</compound-id> is released from human monocyte-derived macrophages upon stimulation with <protein-id="Q9TTB0">interferon-gamma</protein-id> and is a sensitive indicator for cellular immune activation.	Neopterin__interferon-gamma__interaction
18556087-712	Both activity and expression of <protein-id="O70531,P50443,Q62273">sulfate transporters</protein-id> and <protein-id="O14492,P04802,P07288,P22325,P33619,P55228,Q12650,Q6DT45">APS</protein-id> reductase in plants are modulated by the <compound-id="402">sulfur</compound-id> status of the plant.	sulfur__sulfate transporters__interaction	sulfur__APS__interaction
18560889-729	<protein-id="Q07842">Complex I</protein-id> deficiency is a novel cause of secretory diarrhea and may act via disrupting the supply of <compound-id="5957">adenosine triphosphate</compound-id> (<compound-id="5957">ATP</compound-id>) needed for the maintenance of ion gradients across membranes.	adenosine triphosphate__Complex I__interaction	ATP__Complex I__interaction
18561093-53	This prospective cross-sectional study was performed to investigate the influence of GH excess on <protein-id="O02750,O93416,Q28603,Q95189,Q95234">leptin</protein-id> and <protein-id="Q6BEG6,Q6BEG7,Q9BDJ6,Q9BEF8,Q9EQX0,Q9GKY5,Q9QYH7,Q9UBU3">ghrelin</protein-id> levels at baseline and after <compound-id="206,5793,64689,79025">glucose</compound-id> load in a large group of acromegalic patients.	glucose__leptin__no_interaction	glucose__ghrelin__no_interaction
18561170-499	<protein-id="P23916,P24664,P35050,P83348,Q59149">Trypsin</protein-id> digestion, fluorescence anisotropy, and NMR experiments presented here were designed to resolve the issue and show that in arm-dimerization domain, the arms are structured, although differently, in the presence and absence of <compound-id="66308">arabinose</compound-id>.	arabinose__Trypsin__no_interaction
18561187-110	DNA array studies have revealed that <protein-id="P42624,P58115">YhaK</protein-id> is strongly up-regulated by nitroso-<compound-id="124886">glutathione</compound-id> (<compound-id="3514,104858,10404739">GSNO</compound-id>) and also displays a 12-fold increase in expression during biofilm growth of E. coli 83972 and VR50 in human urine.	glutathione__YhaK__interaction	GSNO__YhaK__interaction
18561187-111	We found that the third <compound-id="594,5862,5360637">cysteine</compound-id> in <protein-id="P42624,P58115">YhaK</protein-id>, Cys122, is oxidized to a <compound-id="447587">sulfenic acid</compound-id>.	cysteine__YhaK__interaction	sulfenic acid__YhaK__interaction
18561187-112	E. coli <protein-id="O14313,O22711,O30973,O32823,O43099,O66790,O69777,O83790,O84101,P0A9P4,P0A9P5,P0AE52,P0AE53,P0AE54,P0AE55,P14292,P14293,P21762,P26830,P30044,P34227,P39916,P40553,P43496,P43788,P44411,P44758,P46843,P47348,P49537,P50971,P51272,P51978,P52213,P52214,P52215,P55979,P56431,P56577,P56578,P56876,P57279,P57399,P61076,P65688,P65689,P66010,P66011,P73728,P75531,P80880,P80892,P81433,P94284,P99029,P99101,Q01116,Q05741,Q25861,Q53212,Q55624,Q5HHQ4,Q5HQW4,Q6BIS1,Q6C7L4,Q6FR39,Q6GB66,Q6GIM7,Q75CM8,Q7Z7S3,Q89AJ2,Q89AS1,Q8CPY8,Q8J0U0,Q8K9W0,Q8T6Z1,Q92375,Q928B5,Q92I02,Q98PK9,Q9BGI1,Q9GLW7,Q9GLW9,Q9KSS4,Q9M7T0,Q9PKT7,Q9PR71,Q9R063,Q9Z8M4,Q9ZD97,Q9ZHF0,Q9ZL18,Q9ZMU4">thioredoxin reductase</protein-id> and <compound-id="5884">NADPH</compound-id> produced ROS and caused oxidation and oligomerization of reduced <protein-id="P42624,P58115">YhaK</protein-id>.	NADPH__YhaK__interaction	NADPH__thioredoxin reductase__interaction
18562331-1081	In this report, we investigated the possible role of LA and vmPFC <protein-id="Q00960,Q01097,Q13224">NR2Bs</protein-id> in the consolidation of fear extinction using the <protein-id="Q00960,Q01097,Q13224">NR2B</protein-id>-selective antagonist <compound-id="3689,6604117,11198145,11771731">ifenprodil</compound-id>.	ifenprodil__NR2B__no_interaction	ifenprodil__NR2Bs__no_interaction
18562423-1156	Patients under <compound-id="2818">clozapine</compound-id>-<compound-id="5073">risperidone</compound-id> therapy developed a rise of serum <protein-id="P10765,P22393,P33089,P33090,P33091,P43001">prolactin</protein-id> levels.	risperidone__prolactin__interaction	clozapine__prolactin__interaction
18562442-1178	In experiment 3, administration of E(2) or <compound-id="926,5893,447862">DPN</compound-id> to ovariectomised wildtype, but not betaERKO, mice decreased immobility compared with vehicle administration, these data suggest that <protein-id="O08537,O13012,O93511,P57781,P57782,Q62986,Q92731,Q95171,Q9IAK1,Q9PTU5,Q9PVE2,Q9TTE5,Q9TU15,Q9W6M2,Q9XSB5,Q9XSW2,Q9YH32">ERbeta</protein-id> may be required for some of the anti-depressant-like effects of E(2).	DPN__ERbeta__no_interaction
18563306-164	<compound-id="54454,4677798">Simvastatin</compound-id> treatment significantly increased the number of peripheral blood CD34+ CD133+ cells, and serum concentration of vascular endothelial growth factor (<protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id>) and AKT was markedly increased in vivo.	Simvastatin__VEGF__interaction
18563306-165	In cultured EPC, <compound-id="54454,4677798">simvastatin</compound-id> increased the concentrations of <protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id>, AKT and <protein-id="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600">eNOS</protein-id>.	simvastatin__VEGF__interaction	simvastatin__eNOS__interaction
18563306-166	Western blots analysis showed that <compound-id="54454,4677798">simvastatin</compound-id> increased the phosphorylation of <protein-id="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600">eNOS</protein-id> and <protein-id="O43524">FKHRL1</protein-id>, which can be blocked by the PI3K/AKT pathway blocker <compound-id="3973">LY294002</compound-id>.	LY294002__eNOS__interaction	LY294002__FKHRL1__interaction	simvastatin__eNOS__interaction	simvastatin__FKHRL1__interaction
18563306-167	In in vitro study, <compound-id="54454,4677798">simvastatin</compound-id> increases the phosphorylation of <protein-id="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600">eNOS</protein-id> and of <protein-id="O43524">FKHRL1</protein-id> through the <protein-id="O00329,O02697,O35904,P23727,P26450,P27986,P32871,P42336,P42337,P42338,P42347,P42348,P48736,P54673,P54674,P54675,P54676,Q63787,Q8BTI9,Q8UUU2,Q9JHG7,Q9Z1L0">PI3K</protein-id>/AKT signaling pathway.	simvastatin__PI3K__interaction	simvastatin__eNOS__interaction	simvastatin__FKHRL1__interaction
18563517-342	Only the intracellular <protein-id="O62641,O77620,O97513,P04351,P05016,P17108,P19114,P26891,P36835,P37997,P46649,P51747,P60568,P60569,P68290,P68291,Q07885,Q08081,Q08867,Q1WM29,Q25BC3,Q29416,Q29615,Q2PE47,Q2PE78,Q4U313,Q5MBA8,Q5PXD0,Q7JFM2,Q7JFM3,Q7JFM4,Q7JFM5,Q865X2,Q865Y1,Q8MKH2,Q95KP3,Q9XS38,Q9XT83,Q9XT84">IL-2</protein-id> response in the lower tertile of <protein-id="O62641,O77620,O97513,P04351,P05016,P17108,P19114,P26891,P36835,P37997,P46649,P51747,P60568,P60569,P68290,P68291,Q07885,Q08081,Q08867,Q1WM29,Q25BC3,Q29416,Q29615,Q2PE47,Q2PE78,Q4U313,Q5MBA8,Q5PXD0,Q7JFM2,Q7JFM3,Q7JFM4,Q7JFM5,Q865X2,Q865Y1,Q8MKH2,Q95KP3,Q9XS38,Q9XT83,Q9XT84">IL-2</protein-id> production was improved with <compound-id="738,5961">glutamine</compound-id> indicating a small influence.	glutamine__IL-2__interaction
18563517-343	The elevation of <compound-id="738,5961">glutamine</compound-id> plasma levels by a perioperative intravenous infusion of L-alanyl-<compound-id="5961,145815">L-glutamine</compound-id> influenced the intracellular expression of <protein-id="O62641,O77620,O97513,P04351,P05016,P17108,P19114,P26891,P36835,P37997,P46649,P51747,P60568,P60569,P68290,P68291,Q07885,Q08081,Q08867,Q1WM29,Q25BC3,Q29416,Q29615,Q2PE47,Q2PE78,Q4U313,Q5MBA8,Q5PXD0,Q7JFM2,Q7JFM3,Q7JFM4,Q7JFM5,Q865X2,Q865Y1,Q8MKH2,Q95KP3,Q9XS38,Q9XT83,Q9XT84">IL-2</protein-id> in the lower tertile only slightly.	L-glutamine__IL-2__no_interaction	glutamine__IL-2__no_interaction
18563542-358	Determination of bioactive matter by affinity adsorption solid substrate-room temperature phosphorimetry based on <protein-id="P02871,P02873,P02874,P02875,P07386,P16108,P16349,P16351,P16352,P33888,P38662,P42088,P83410,P83511,P84987,Q41114">lectin</protein-id> labeled with self-ordered ring of <compound-id="11049,27020">eosin Y</compound-id>.	eosin Y__lectin__interaction
18563542-359	Specific affinity adsorption (AA) reactions could be carried out between the products of concanavalin <protein-id="P02872,P05046,P11218,P11219,P30617,P42088,P49329,P82859,P82953">agglutinin</protein-id> (<protein-id="P02866,P14894,P81460,P81461">Con A</protein-id>), triticum vulgaris <protein-id="P02871,P02873,P02874,P02875,P07386,P16108,P16349,P16351,P16352,P33888,P38662,P42088,P83410,P83511,P84987,Q41114">lectin</protein-id> (WGA) labeled with ESOR and alpha-fetoprotein variant (<protein-id="O80994,O80995,P02771,P05140,P07835,P09031,P23699,P28050,P49066,P83128,P84407,Q01758,Q08617,Q12899,Q28789,Q3SZ57,Q8MJU5">AFP</protein-id>-V), <protein-id="O60109,P81800,P83456">alkaline phosphatase</protein-id> (<protein-id="P03973,P12547,P22298,P28296,P29118,P35211,P83610,P97430,Q03420,Q53GG5,Q9H0A0,Q9PU47,Q9Z1X0">ALP</protein-id>), <compound-id="206,5793,64689,79025">glucose</compound-id> (G), respectively.	glucose__agglutinin__no_interaction	glucose__ALP__no_interaction	glucose__lectin__no_interaction	glucose__AFP__no_interaction	glucose__alkaline phosphatase__no_interaction	glucose__Con A__no_interaction
18563554-369	In this paper we demonstrate that hedgehog signaling antagonists, including <compound-id="442972">cyclopamine</compound-id>, and a second compound, CUR0199691, can inhibit growth of <protein-id="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7">estrogen receptor</protein-id> (ER)-positive and ER-negative tumorigenic breast cancer cells at elevated doses.	cyclopamine__estrogen receptor__no_interaction
18563559-375	The equality of K (D) of <compound-id="43815">paroxetine</compound-id> binding to blood platelet membranes and to membranes from nerve endings appears to encourage the use of such membranes as a model for brain <protein-id="P31645,Q9XT49">SERT</protein-id>.	paroxetine__SERT__no_interaction
18563560-376	With supplementation of <compound-id="1123">taurine</compound-id> in diet, lower expression of <protein-id="P03995,P14136,P47819,Q28115">GFAP</protein-id> and <protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id> while higher expression of <protein-id="P24942,P56564">GLAST</protein-id>, GS and <protein-id="P20228,P54767,Q04792,Q07346,Q42521,Q99259,Q9CG20">GAD</protein-id> in retina of diabetic rats were determinated by RT-PCR 0.05).	taurine__VEGF__interaction	taurine__GFAP__interaction	taurine__GAD__interaction	taurine__GLAST__interaction
18563560-377	<protein-id="P03995,P14136,P47819,Q28115">GFAP</protein-id>, <protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id>, <protein-id="P24942,P56564">GLAST</protein-id>, GS and <protein-id="P20228,P54767,Q04792,Q07346,Q42521,Q99259,Q9CG20">GAD</protein-id> expressions in normal controls were not altered by <compound-id="1123">taurine</compound-id> treatment.	taurine__GFAP__no_interaction	taurine__GLAST__no_interaction	taurine__GAD__no_interaction	taurine__VEGF__no_interaction
18563561-378	<compound-id="10964">Malondialdehyde</compound-id> (MDA), <compound-id="124886">glutathione</compound-id> (<compound-id="124886">GSH</compound-id>), <compound-id="145068">nitric oxide</compound-id> (NO) levels and myeloperoxidase activity (<protein-id="P05164,P11247">MPO</protein-id>) were examined in plasma, liver and brain tissues.	GSH__MPO__no_interaction	Malondialdehyde__MPO__no_interaction	nitric oxide__MPO__no_interaction	glutathione__MPO__no_interaction
18563616-418	<protein-id="O23970,P00435,P04041,P07203,P11352,P11909,P36014,Q4AEI1,Q4AEI2,Q4AEI3,Q865R2,Q8MJ14">Glutathione peroxidase 1</protein-id> (<protein-id="O48646,P00435,P07203,P11909,P36014,P52032,Q00277,Q4AEI1,Q4AEI2,Q4AEI3,Q865R2,Q8MJ14">GPX1</protein-id>) is a ubiquitously expressed selenium-dependent enzyme that protects cells against oxidative damage by reducing <compound-id="784">hydrogen peroxide</compound-id> and a wide range of organic peroxides.	hydrogen peroxide__Glutathione peroxidase 1__interaction	hydrogen peroxide__GPX1__interaction
18563708-512	<compound-id="145068">Nitric oxide</compound-id> (NO), which is produced by <protein-id="O61309,O61608,Q27571,Q9I9M2">nitric oxide synthase</protein-id> (<protein-id="O54705,O61309,O61608,Q26240,Q28969,Q9I9M2">NOS</protein-id>), may play a role in the development of ASD.	Nitric oxide__NOS__interaction	Nitric oxide__nitric oxide synthase__interaction
18563803-210	In conclusion, <compound-id="124886,128225">TAD</compound-id>-A has sufficient bonding strength and comparatively low toxicity in clinical use of 0.3 mmol or less of <compound-id="124886,128225">TAD</compound-id> and 0.8 mL of 44 w/w % <protein-id="P24807,Q07490">HSA</protein-id> solution.	TAD__HSA__interaction
18563826-616	Long intercalated defects in canine ribs can be repaired successfully using porous <compound-id="24456">beta-tricalcium phosphate</compound-id> (beta-TCP) cylinders, infused with a biodegradable polymer (poly D,L-lactic acid-polyethylene block copolymer) containing recombinant human bone <protein-id="P07580">morphogenetic protein</protein-id>-2 (rhBMP-2).	beta-tricalcium phosphate__morphogenetic protein__no_interaction
18564056-810	In the present study we explored the possibility of using genetic engineering to increase the <compound-id="2240,68827,452191,641602,5458876,9838675,11836791,23757058,44266427,49796325">artemisinin</compound-id> content of A. annua by suppressing the expression of <protein-id="O74165,P29704,P36596,P37268,P53798,P53799,P53800,P78589,Q02769,Q752X9,Q7S4Z6,Q92459,Q9HGZ6,Q9Y753">SQS</protein-id> (squalene synthase), a key enzyme of sterol pathway (a pathway competitive with that of <compound-id="2240,68827,452191,641602,5458876,9838675,11836791,23757058,44266427,49796325">artemisinin</compound-id> biosynthesis) by means of a hairpin-RNA-mediated RNAi (RNA interference) technique.	artemisinin__SQS__interaction
18564176-915	<compound-id="3476">Glimepiride</compound-id> upregulates <protein-id="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600">eNOS</protein-id> activity and inhibits cytokine-induced NF-kappaB activation through a phosphoinoside 3-kinase-<protein-id="P31750,Q8INB9">Akt</protein-id>-dependent pathway.	Glimepiride__Akt__interaction	Glimepiride__eNOS__interaction
18564211-943	It has been reported that <compound-id="2733526">tamoxifen</compound-id> may affect hepatoma cell growth in vitro by suppressing transforming growth factor beta-1 (<protein-id="O19011,O93449,P01137,P04202,P07200,P09531,P09533,P16176,P17246,P18341,P50414,P54831,Q38HS2,Q9PTQ2,Q9Z1Y6">TGF-beta1</protein-id>) expression, suggesting that <compound-id="2733526">tamoxifen</compound-id> might also retard fibrogenesis.	tamoxifen__TGF-beta1__interaction
18564211-944	Thus, we examined whether <compound-id="2733526">tamoxifen</compound-id> might suppress <protein-id="O19011,O93449,P01137,P04202,P07200,P09531,P09533,P16176,P17246,P18341,P50414,P54831,Q38HS2,Q9PTQ2,Q9Z1Y6">TGF-beta1</protein-id> expression and consequently inhibit the process of hepatic fibrosis in vivo.	tamoxifen__TGF-beta1__interaction
18564281-1010	We also explored the effect of <protein-id="P01289,P06767,P19850,P20366,P28498,P28499,P41333,P41539,P41540,P67932,P67933,Q60541">substance P</protein-id> released by <compound-id="1548943">capsaicin</compound-id> because this <protein-id="P21259">neuropeptide</protein-id> is known to affect the microvasculature environment.	capsaicin__substance P__interaction	capsaicin__neuropeptide__no_interaction
18565553-422	<compound-id="3907,5280493,5283121,5353716">Leukotriene C4</compound-id> release and gene expressions of <protein-id="O62812,P08317,P10145,P19874,P26894,P36925,P41324,P46653,P49113,P67813,P67814,P79255,Q102R3,Q7YRB5,Q9XSX5">IL-8</protein-id> and <protein-id="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3">MCP-1</protein-id> in porcine alveolar epithelial type II cells.	Leukotriene C4__IL-8__no_interaction	Leukotriene C4__MCP-1__no_interaction
18565553-424	These findings suggest that AEC IIs play an important role in initial inflammatory reactions of the lung by releasing <compound-id="5280493">LTC4</compound-id>, and that they also modulate later inflammatory reactions, evidenced by consistent elevation of <protein-id="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3">MCP-1</protein-id> gene expression after and during exogenous challenge in pigs.	LTC4__MCP-1__no_interaction
18565581-347	Whereas their toxicity is due to <protein-id="Q867X2,Q867X3,Q86GC9,Q92081">acetylcholinesterase</protein-id> inhibition, their secondary toxic effects have been related to free <compound-id="977">oxygen</compound-id> radicals.	oxygen__acetylcholinesterase__no_interaction
18565581-348	<compound-id="3017">Diazinon</compound-id> diminished the plasma <protein-id="Q867X2,Q867X3,Q86GC9,Q92081">acetylcholinesterase</protein-id> activity on day 1 post-treatment, although <compound-id="6013">testosterone</compound-id> levels remained unaffected.	Diazinon__acetylcholinesterase__interaction	testosterone__acetylcholinesterase__no_interaction
18565581-349	<compound-id="896">Melatonin</compound-id> pretreatment prevented every alteration induced by <compound-id="3017">diazinon</compound-id>, except the diminution of <protein-id="Q867X2,Q867X3,Q86GC9,Q92081">acetylcholinesterase</protein-id> plasmatic activity.	diazinon__acetylcholinesterase__interaction	Melatonin__acetylcholinesterase__no_interaction
18566887-1426	Sialic acid-specific O-<protein-id="P16966">acetyltransferases</protein-id> and O-<protein-id="P23553,P23872,Q325C0,Q3Z4S3,Q57S73,Q5PFJ2,Q83M39,Q8FK82,Q8XD38,Q8Z8T1,Q8ZRA1">acetylesterases</protein-id> are responsible for the metabolism of esterified <compound-id="349960">sialic acids</compound-id>.	sialic acids__acetyltransferases__interaction	sialic acids__acetylesterases__interaction
18567517-267	<compound-id="5311081">Endomorphin-2</compound-id> vector injection also reduced spontaneous pain-related behaviors in the delayed phase of the formalin test and in both <protein-id="O04350,O75347,P48427,P48428,P48606,P80584,P80585,Q9Y703">CFA</protein-id> and formalin models suppressed spinal c-<protein-id="P01101,P12841,Q56415">fos</protein-id> expression.	Endomorphin-2__fos__interaction	Endomorphin-2__CFA__interaction
18568363-1000	Furthermore, <compound-id="104767">8-bromo-cGMP</compound-id> and <compound-id="104806">peroxynitrite</compound-id> failed to reproduce the inhibitory effect of NO, indicating that NO acts directly on <protein-id="O94916">TonEBP</protein-id> rather than through classical NO signaling pathways.	peroxynitrite__TonEBP__no_interaction	8-bromo-cGMP__TonEBP__no_interaction
18568363-998	<compound-id="145068">Nitric oxide</compound-id> decreases expression of osmoprotective genes via direct inhibition of <protein-id="O94916">TonEBP</protein-id> transcriptional activity.	Nitric oxide__TonEBP__interaction
18568363-999	Because <compound-id="145068">nitric oxide</compound-id> (NO) is abundantly produced in the renal medulla, the present studies addressed the effect of NO on expression of osmoprotective genes and <protein-id="O94916">TonEBP</protein-id> activation in MDCK cells.	nitric oxide__TonEBP__interaction
18568422-1042	Ran GTPase guanine nucleotide exchange factor <protein-id="P18754,P23800,P52499">RCC1</protein-id> is phosphorylated on <compound-id="5951">serine</compound-id> 11 by <protein-id="P04551,P11440,P23572,P39951">cdc2</protein-id> kinase in vitro.	serine__RCC1__interaction	serine__cdc2__interaction
18568422-1043	An RCC1 mutant in which all N-terminal <compound-id="5951">serine</compound-id> and <compound-id="6288">threonine</compound-id> residues were substituted with <compound-id="611,23327,33032">glutamate</compound-id> residues to mimic phosphorylation at these residues showed decreased binding to the karyopherin, <protein-id="O00629">KPNA4</protein-id>, compared with wild type RCC1.	threonine__KPNA4__interaction	serine__KPNA4__interaction	glutamate__KPNA4__interaction
18568426-1046	<compound-id="5957">ATP</compound-id>, acting on <protein-id="P13900,P16604">P2X</protein-id> (7) receptors, stimulates changes in intracellular calcium concentrations, maturation, and release of interleukin-1beta (<protein-id="P01584,P09428,P10749,P14628,P21621,P26889,P41687,P46648,P48090,P51493,P51745,P79162,P79182,Q28292,Q28386,Q2HZH0,Q2MH07,Q63264,Q6PUD2,Q6R2X3,Q865X8,Q8WNR2,Q9WVG1,Q9XS77">IL-1beta</protein-id>), and following prolonged agonist exposure, cell death.	ATP__IL-1beta__interaction	ATP__P2X__interaction
18570309-903	The enantioselective interaction between penicillium expansum alkaline <protein-id="Q7M4U7">lipase</protein-id> and chiral <compound-id="13658">phenoxypropionic acid</compound-id> herbicide <compound-id="8427,119435">dichlorprop</compound-id> was studied by using UV differential spectrophotometry and fluorescence spectrophotometry in the presence of a pH 8, <compound-id="1061,167704,644102">phosphate</compound-id> buffer solution.	dichlorprop__lipase__interaction	phenoxypropionic acid__lipase__no_interaction	phosphate__lipase__no_interaction
18570315-909	While the total <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> released during a 1 h <compound-id="206,5793,64689,79025">glucose</compound-id> stimulation period was the same from islets in each sample, increasing hydrogel crosslinking density contributed to delays in <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> release from hydrogel samples within the 1 h stimulation period.	glucose__insulin__no_interaction
18570630-1172	Ischaemia and <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>, but not ischaemia and contraction, act synergistically in stimulating muscle <compound-id="206,5793,64689,79025">glucose</compound-id> uptake in vivo in humans.	glucose__insulin__interaction
18570630-1173	In summary, ischaemia and <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> independently stimulate skeletal muscle <compound-id="206,5793,64689,79025">glucose</compound-id> uptake in vivo in humans, whereas ischaemia and contraction do not.	glucose__insulin__interaction
18570631-224	A comparison of the inhibitory effect of <compound-id="9395">paraoxon</compound-id> on soluble and immobilized <protein-id="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3">AChE</protein-id> showed that immobilization increased the linearity of the inhibition plot particularly in the range 0.1 nM-0.1 microM.	paraoxon__AChE__interaction
18570695-1236	7,12-Dimethyl-benz[a] <compound-id="8418">anthracene</compound-id> (<compound-id="6001">DMBA</compound-id>) can induce expressions of <protein-id="O42231,O42430,O42457,P00185,P04798,P05176,P33616,P56590,P56591,P79716,P98181,Q00557,Q06367,Q3LFU0,Q5KQT7,Q6GUR1,Q6JZS3,Q92039,Q92095,Q92100,Q92109,Q92110,Q92116,Q92148,Q9W683,Q9YH64">CYP1A1</protein-id> and <protein-id="Q16678">CYP1B1</protein-id> which are known to be responsive to PAH.	DMBA__CYP1B1__interaction	anthracene__CYP1B1__interaction	DMBA__CYP1A1__interaction	anthracene__CYP1A1__interaction
18571801-413	Extracellular <protein-id="Q7M4U7">lipase</protein-id> <protein-id="O59952,P21764,P49081,Q06383,Q96Q15">LIP</protein-id> prepared in our lab from the yeast Yarrowia lipolytica was used for the resolution of racemic <compound-id="3672,39912">ibuprofen</compound-id>.	ibuprofen__LIP__interaction	ibuprofen__lipase__interaction
18571801-414	The high purity (<compound-id="39912">S)-ibuprofen</compound-id> (ee = 0.98) was obtained using <protein-id="Q7M4U7">lipase</protein-id> <protein-id="O59952,P21764,P49081,Q06383,Q96Q15">LIP</protein-id> to catalyze hydrolysis of (S)-ester in 0.1 M <compound-id="1061,167704,644102">phosphate</compound-id> buffer (pH = 8).	S)-ibuprofen__LIP__interaction	phosphate__LIP__no_interaction	S)-ibuprofen__lipase__interaction	phosphate__lipase__no_interaction
18571950-552	The potential action of <compound-id="6036,439353,439357">galactose</compound-id> as a "chemical chaperone": increase of <protein-id="O33815,O52629,O52847,P00722,P00723,P06219,P0C1Y0,P14288,P22498,P23989,P24131,P26257,P30812,P50388,P70753,P77989,P81650,Q1G9Z4,Q47077,Q48727,Q56307,Q59140,Q59750,Q9K9C6">beta galactosidase</protein-id> activity in fibroblasts from an adult GM1-gangliosidosis patient.	galactose__beta galactosidase__no_interaction
18571954-554	<compound-id="311">Citric acid</compound-id> perfusion marginally increased <protein-id="P21617,P34129,Q6YBR5,Q90W38">NGF</protein-id> levels to 7.3 fg/microg/ml on average in the upper arm and control axilla.	Citric acid__NGF__interaction
18571954-555	In contrast, perfusion of the inflamed axilla with <compound-id="311">citric acid</compound-id> significantly enhanced the release of both <protein-id="P21617,P34129,Q6YBR5,Q90W38">NGF</protein-id> and <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id>.	citric acid__NGF__interaction	citric acid__BDNF__interaction
18572174-747	<compound-id="5282452">Pitavastatin</compound-id> induces <protein-id="P27169,P27170">PON1</protein-id> expression through <protein-id="P16342,P19751,Q66198,Q8TCB0,Q8V439,Q8V6W7,Q91A29,Q93V93,Q9PYA3">p44</protein-id>/42 mitogen-activated <protein-id="P00513,P25848">protein kinase</protein-id> signaling cascade in Huh7 cells.	Pitavastatin__protein kinase__interaction	Pitavastatin__p44__interaction	Pitavastatin__PON1__interaction
18572174-748	Both <protein-id="P27169,P27170">PON1</protein-id> gene promoter activity and <protein-id="P27169,P27170">PON1</protein-id> protein expression were elevated by <compound-id="5282452">pitavastatin</compound-id> stimulation.	pitavastatin__PON1__interaction
18572174-749	<compound-id="5282452">Pitavastatin</compound-id> phosphorylated <protein-id="P16342,P19751,Q66198,Q8TCB0,Q8V439,Q8V6W7,Q91A29,Q93V93,Q9PYA3">p44</protein-id>/42 MAP kinase.	Pitavastatin__p44__interaction
18572174-751	<compound-id="5282452">Pitavastatin</compound-id> increased the <protein-id="O14300,O89090,P17379,Q01714,Q85439,Q85449,Q85451">Sp1</protein-id>-<protein-id="P27169,P27170">PON1</protein-id> DNA complex and this effect was attenuated by <compound-id="4713">PD98059</compound-id>.	Pitavastatin__Sp1__interaction	PD98059__PON1__interaction	PD98059__Sp1__interaction	Pitavastatin__PON1__interaction
18572174-752	These observations suggest that <compound-id="5282452">pitavastatin</compound-id> phosphorylates <protein-id="P16342,P19751,Q66198,Q8TCB0,Q8V439,Q8V6W7,Q91A29,Q93V93,Q9PYA3">p44</protein-id>/42 MAP kinase and then activates the transcription of <protein-id="P27169,P27170">PON1</protein-id> gene and increases the <protein-id="P27169,P27170">PON1</protein-id> protein expression in Huh7 cells.	pitavastatin__p44__interaction	pitavastatin__PON1__interaction
18572174-753	Furthermore, we speculate that <compound-id="5282452">pitavastatin</compound-id> affects both the phosphorylation of <protein-id="Q12772,Q60429">SREBP-2</protein-id> and the <protein-id="O14300,O89090,P17379,Q01714,Q85439,Q85449,Q85451">Sp1</protein-id> binding to <protein-id="P27169,P27170">PON1</protein-id> DNA through the activation of <protein-id="P16342,P19751,Q66198,Q8TCB0,Q8V439,Q8V6W7,Q91A29,Q93V93,Q9PYA3">p44</protein-id>/42 MAP kinase signaling cascade.	pitavastatin__p44__interaction	pitavastatin__SREBP-2__interaction	pitavastatin__Sp1__interaction	pitavastatin__PON1__interaction
18573668-277	Inhibition of <protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">cyclooxygenase 2</protein-id> expression by <compound-id="11617">diallyl sulfide</compound-id> on joint inflammation induced by urate crystal and <protein-id="P01584,P09428,P10749,P14628,P21621,P26889,P41687,P46648,P48090,P51493,P51745,P79162,P79182,Q28292,Q28386,Q2HZH0,Q2MH07,Q63264,Q6PUD2,Q6R2X3,Q865X8,Q8WNR2,Q9WVG1,Q9XS77">IL-1beta</protein-id>.	diallyl sulfide__IL-1beta__no_interaction	diallyl sulfide__cyclooxygenase 2__interaction
18573668-278	Investigation of the effects of <compound-id="11617">diallyl sulfide</compound-id> (DAS), a garlic <compound-id="402">sulfur</compound-id> compound, on joint tissue inflammatory responses induced by <compound-id="1175">monosodium urate</compound-id> (MSU) crystals and interleukin-1beta (<protein-id="P01584,P09428,P10749,P14628,P21621,P26889,P41687,P46648,P48090,P51493,P51745,P79162,P79182,Q28292,Q28386,Q2HZH0,Q2MH07,Q63264,Q6PUD2,Q6R2X3,Q865X8,Q8WNR2,Q9WVG1,Q9XS77">IL-1beta</protein-id>).	sulfur__IL-1beta__no_interaction	diallyl sulfide__IL-1beta__no_interaction	monosodium urate__IL-1beta__no_interaction
18574025-577	Genetic variants of <protein-id="P11712">cytochrome P450 2C9</protein-id> (<protein-id="P11712">CYP2C9</protein-id>) and vitamin K epoxide reductase (<protein-id="Q6B4J2,Q9BQB6">VKORC1</protein-id>) are known to influence <compound-id="54678486">warfarin</compound-id> dose, but the effect of other genes has not been fully elucidated.	warfarin__cytochrome P450 2C9__interaction	warfarin__VKORC1__interaction	warfarin__CYP2C9__interaction
18574025-578	In conclusion, <protein-id="P11712">CYP2C9</protein-id> and <protein-id="Q6B4J2,Q9BQB6">VKORC1</protein-id> significantly influenced <compound-id="54678486">warfarin</compound-id> dose and predicted individuals predisposed to unstable anticoagulation.	warfarin__VKORC1__interaction	warfarin__CYP2C9__interaction
18574490-986	BMI and <compound-id="6013">testosterone</compound-id> levels were evaluated for their ability to predict overall survival (OS) and prostate-specific antigen (<protein-id="P07288,P10658,P33619,P55786,Q11011,Q6DT45,Q9Y617">PSA</protein-id>) declines in the TAX327 clinical trial, an international phase III randomized trial of one of the two schedules of <compound-id="148124">docetaxel</compound-id> and <compound-id="5865">prednisone</compound-id> compared with <compound-id="4212">mitoxantrone</compound-id> and <compound-id="5865">prednisone</compound-id>.	docetaxel__PSA__no_interaction	testosterone__PSA__interaction	mitoxantrone__PSA__no_interaction	prednisone__PSA__no_interaction
18574490-987	In multivariate analysis, neither BMI, presence of obesity, nor baseline <compound-id="6013">testosterone</compound-id> was significantly associated with OS or <protein-id="P07288,P10658,P33619,P55786,Q11011,Q6DT45,Q9Y617">PSA</protein-id> declines.	testosterone__PSA__no_interaction
18574670-1109	The interaction between PAF and the platelet agonists ADP, <protein-id="P84122">thrombin</protein-id> and convulxin was analyzed in vitro in whole blood with the use of flow cytometry and was further characterized with the use of receptor antagonists to PAF (ABT-491), P2Y1 (<compound-id="5311303">MRS-2179</compound-id>), and P2Y12 (<compound-id="9854012">cangrelor</compound-id>) as well as a monoclonal anti-PSGL-1 antibody (anti-CD162).	cangrelor__thrombin__no_interaction	MRS-2179__thrombin__no_interaction
18575957-472	Aim The present study sought insight into the effects of <compound-id="60815">remifentanyl</compound-id> and <compound-id="3345">fentanyl</compound-id> on LPS-induced release of <protein-id="P41693">interleukin-6</protein-id> (<protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id>), <protein-id="Q8JFG3">tumor necrosis factor</protein-id>-alpha (<protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id>) and <protein-id="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5">IL-10</protein-id> in human whole blood.	remifentanyl__TNF-alpha__interaction	fentanyl__IL-6__interaction	fentanyl__tumor necrosis factor__interaction	remifentanyl__IL-6__interaction	remifentanyl__tumor necrosis factor__interaction	fentanyl__IL-10__interaction	remifentanyl__interleukin-6__interaction	fentanyl__interleukin-6__interaction	fentanyl__TNF-alpha__interaction	remifentanyl__IL-10__interaction
18575957-473	Effects of <compound-id="60815">remifentanyl</compound-id> and <compound-id="3345">fentanyl</compound-id> on spontaneous and <compound-id="53481793">endotoxin (lipopolysaccharide</compound-id> ; 100 ng ml(-1))-stimulated cytokine release were studied in whole blood from volunteers (n = 10) cultured for 6 h. Results <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id>, <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id> and <protein-id="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5">IL-10</protein-id> 0.01).	fentanyl__IL-10__no_interaction	remifentanyl__IL-10__no_interaction	fentanyl__TNF-alpha__no_interaction	remifentanyl__TNF-alpha__no_interaction	endotoxin (lipopolysaccharide__TNF-alpha__no_interaction	endotoxin (lipopolysaccharide__IL-6__no_interaction	endotoxin (lipopolysaccharide__IL-10__no_interaction	fentanyl__IL-6__no_interaction	remifentanyl__IL-6__no_interaction
18575957-475	<compound-id="60815">Remifentanyl</compound-id> and <compound-id="3345">fentanyl</compound-id> could inhibit the expressions of <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id>, <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id> and <protein-id="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5">IL-10</protein-id> induced by LPS.	Remifentanyl__TNF-alpha__interaction	fentanyl__IL-6__interaction	Remifentanyl__IL-6__interaction	fentanyl__IL-10__interaction	fentanyl__TNF-alpha__interaction	Remifentanyl__IL-10__interaction
18577298-1601	This reduction was associated with the storage of decreased TAG and increased <compound-id="439177">glycogen</compound-id>, which was a result of enhanced <compound-id="1153,6057,5460803">tyrosine</compound-id> phosphorylation of anti-insulin receptor substrate-2 and serine473 phosphporylation of <protein-id="P31749,P31750,P47196,Q01314,Q8INB9">protein kinase B</protein-id> (<protein-id="P31749,P31750,P47196,Q01314,Q8INB9">PKB</protein-id>, <protein-id="P31750,Q8INB9">Akt</protein-id>).	tyrosine__PKB__no_interaction	glycogen__Akt__interaction	glycogen__protein kinase B__interaction	glycogen__PKB__interaction	tyrosine__Akt__no_interaction	tyrosine__protein kinase B__no_interaction
18577298-1602	Improved hepatic <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> signalling led to decreased phosphoenolpyruvate carboxykinase expression and reduced hepatic <compound-id="206,5793,64689,79025">glucose</compound-id> output accordingly.	glucose__insulin__interaction
18577871-351	These data provide evidence that CMEC express <protein-id="O62714,P35384,P41180,P48442,Q9QY96">CaSR</protein-id>, which is able to respond to physiological agonists by mobilizing <compound-id="271">Ca(2</compound-id>+) from intracellular InsP(3)-sensitive stores.	Ca(2__CaSR__interaction
18579232-1493	Inhibition of these enzymes shows that chagasic autoantibodies up-regulation of <protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">COX-2</protein-id>/<protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id> mRNA level is under the control of endogenous <compound-id="804">iNO</compound-id>/<compound-id="24316">cGMP</compound-id> signaling system.	iNO__iNOS__interaction	cGMP__COX-2__interaction	cGMP__iNOS__interaction	iNO__COX-2__interaction
18580872-1175	Pre-synaptic <protein-id="P52451">CB1Rs</protein-id> inhibit neurotransmitter release, suggesting that <protein-id="P52451">CB1R</protein-id> activation during extinction may decrease <protein-id="O57312,O93464,P01355,P01356,P06307,P09240,P0C229,P23362,P41520,P50144,P50145,P68125,P68126,P80344,P80345,Q9PU29,Q9PU41">CCK</protein-id> peptide release as well as <compound-id="119">GABA</compound-id> release.	GABA__CB1R__interaction	GABA__CCK__no_interaction	GABA__CB1Rs__interaction
18580876-1179	Acute <compound-id="2826,5760,439497,446220,644017,54613779">cocaine</compound-id>, through <protein-id="O73810,P14416,P20288,P52702,P60026,P61168,P61169,Q6TLI9,Q9GJU1">D(2) dopamine receptors</protein-id>, induced a dose-response increase in <protein-id="Q13158,Q61160">FADD protein</protein-id> in the cortex, with opposite effects over pFADD (Ser191/194), and no induction of apoptotic cell death (poly-(ADP-ribose) polymerase cleavage).	cocaine__FADD protein__interaction	cocaine__D(2) dopamine receptors__interaction
18580876-1180	<protein-id="P46310,Q13158">FADD</protein-id> was increased by <compound-id="2826,5760,439497,446220,644017,54613779">cocaine</compound-id> in cytosol (approximately 142%), membranes (approximately 23%) and nucleus (approximately 54%).	cocaine__FADD__interaction
18580876-1181	In a second experiment, possible <protein-id="P46310,Q13158">FADD</protein-id> differences were investigated in rats selectively bred for differential responsiveness to novelty, propensity for drug-seeking and <compound-id="2826,5760,439497,446220,644017,54613779">cocaine</compound-id> sensitization.	cocaine__FADD__no_interaction
18581264-1465	<protein-id="P06181,P11542,P11543,P20010,P20011,P20012,P20013,P21764,P31837,P31838,P49012,P50622">Lignin peroxidases</protein-id> have the unique ability to catalyze oxidative cleavage of C-C bonds and <compound-id="3283,5382654">ether</compound-id> (C-O-C) bonds in non-phenolic aromatic substrates of high redox potential.	ether__Lignin peroxidases__interaction
18581264-1466	Manganese <protein-id="P15984,P16147,P84714">peroxidases</protein-id> oxidize <compound-id="27854">Mn(II</compound-id>) to <compound-id="105130">Mn(III</compound-id>), which facilitates the degradation of phenolic compounds or, in turn, oxidizes a second mediator for the breakdown of non-phenolic compounds.	Mn(III__peroxidases__interaction	Mn(II__peroxidases__interaction
18581264-1467	<protein-id="Q12570">Laccases</protein-id> are multi-<compound-id="23978">copper</compound-id>-containing proteins that catalyze the oxidation of phenolic substrates with concomitant reduction of molecular <compound-id="977">oxygen</compound-id> to water.	copper__Laccases__interaction	oxygen__Laccases__interaction
18581270-1477	The co-expression of <protein-id="P31645,Q9XT49">SERT</protein-id> with <protein-id="Q13491,Q5R603">M6B</protein-id> results in a significant decrease in <protein-id="P31645,Q9XT49">SERT</protein-id>-mediated <compound-id="5202">serotonin</compound-id> uptake caused by a down-regulation of <protein-id="P31645,Q9XT49">SERT</protein-id> surface expression.	serotonin__SERT__interaction	serotonin__M6B__interaction
18582556-870	Hence, resistance to cancer in old Snell dwarf mice may be mediated by neuroendocrine factors that reduce <compound-id="206,5793,64689,79025">glucose</compound-id> utilization besides elevated adiponectin, reduced <protein-id="P05017,P07455,P08025,P10763,P16545,P17085,P17647,P18254,P33712,P51457,P51458,P51462,Q02815,Q28933,Q68LC0,Q6GUL6,Q6IVA5,Q6JLX1,Q95222">IGF-I</protein-id> and a lack of GH, <protein-id="O62781,O62819,O93337,P01236,P01237,P01238,P01239,P01240,P06879,P09585,P10765,P12420,P14676,P17572,P21993,P22393,P29234,P29235,P33089,P33090,P33091,P33096,P34181,P35395,P37884,P40424,P43001,P43299,P46403,P48096,P48249,P51904,P55151,P87495,Q28318,Q28632,Q3Y4G6,Q6UC74,Q7ZZV3,Q8HXS1,Q9QZL1,Q9YGV6">PRL</protein-id> and TSH, seen in both Snell and Ames dwarf mice.	glucose__PRL__no_interaction	glucose__IGF-I__no_interaction
18582992-1242	Therefore, <compound-id="156419">cinacalcet</compound-id>, which inhibit the production of <protein-id="P01270">parathormone</protein-id> by negative feedback, was considered a treatment option to control the evolution of calciphylaxis in a dialysed patient suffering from cholangiocarcinoma.	cinacalcet__parathormone__interaction
18583434-1596	<compound-id="206,5793,64689,79025">Glucose</compound-id> levels and hormones [<protein-id="P10082,P68004,Q9TR93">Peptide YY(3-36)</protein-id>, <protein-id="O12956,P01272,P01273,P01274,P01275,P01278,P05110,P06883,P15438,P22890,P29794,P55095,P68259,Q8MJ25">glucagon-like peptide-1</protein-id> (<protein-id="O12956,P01272,P01273,P01274,P01275,P05110,P06883,P22890,P29794,P55095,P68259,Q06605,Q8MJ25">GLP-1</protein-id>), <protein-id="O02750,O93416,Q28603,Q95189,Q95234">leptin</protein-id>, <protein-id="Q6BEG6,Q6BEG7,Q9BDJ6,Q9BEF8,Q9EQX0,Q9GKY5,Q9QYH7,Q9UBU3">ghrelin</protein-id>, <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>] that regulate EI were measured.	Glucose__glucagon-like peptide-1__no_interaction	Glucose__insulin__no_interaction	Glucose__ghrelin__no_interaction	Glucose__leptin__no_interaction	Glucose__GLP-1__no_interaction	Glucose__Peptide YY(3-36)__no_interaction
18584284-591	<protein-id="P08587,P21980,P21981,P51176,P52181,Q01841">Transglutaminase 2</protein-id> (TG2) is an inducible transamidating <protein-id="P05521,P19197,P21309,P23148,P41302,Q06878,Q7N576,Q9AJA7,Q9S3Z2">acyltransferase</protein-id> that catalyzes <compound-id="271">Ca(2</compound-id>+)-dependent protein modifications.	Ca(2__acyltransferase__interaction	Ca(2__Transglutaminase 2__interaction
18584285-592	<protein-id="P40746,P52183,P81453,Q819L3,Q81MS1,Q8GR90,Q9K5W7">Transglutaminases</protein-id> catalyze a calcium-dependent transamidation reaction that produces covalent cross-linking of available substrate <compound-id="738,5961">glutamine</compound-id> residues and modifies the extracellular matrix.	glutamine__Transglutaminases__interaction
18584286-593	We fed rats <compound-id="866,5962">lysine</compound-id> or <compound-id="6287">valine</compound-id> deficient diet for 4 weeks and examined the mRNA expressions of serine synthesising (3-phosphoglycerate dehydrogenase, <protein-id="O43175,Q5EAD2,Q5R7M2,Q60HD7">PHGDH</protein-id>) and serine/threonine degrading enzymes (serine dehydratase, <protein-id="P20132">SDS</protein-id>) in the liver.	lysine__PHGDH__no_interaction	valine__PHGDH__no_interaction	valine__SDS__no_interaction	lysine__SDS__no_interaction
18584286-594	Dietary deficiency induced marked elevation of hepatic <compound-id="5951">serine</compound-id> and <compound-id="6288">threonine</compound-id> levels associated with enhancement of <protein-id="O43175,Q5EAD2,Q5R7M2,Q60HD7">PHGDH</protein-id> mRNA expression and repression of <protein-id="P20132">SDS</protein-id> mRNA expression.	threonine__PHGDH__no_interaction	serine__PHGDH__no_interaction	threonine__SDS__no_interaction	serine__SDS__no_interaction
18584306-333	Site-directed mutation test and <compound-id="29051,163659,230076,6326719">mithramycin A</compound-id> treatment demonstrated that the <protein-id="Q8WVD5,Q9UIE0">ZNF230</protein-id> promoter contained a functional <protein-id="O14300,O89090,P17379,Q01714,Q85439,Q85449,Q85451">Sp1</protein-id> site.	mithramycin A__Sp1__interaction	mithramycin A__ZNF230__interaction
18584320-630	<compound-id="5994">Progesterone</compound-id> effects on neuronal ultrastructure and expression of <protein-id="P11137,P15146,P20357">microtubule-associated protein 2</protein-id> (<protein-id="P11137,P38174,Q5Z859,Q6XMH6,Q6XMH7,Q8SR45">MAP2</protein-id>) in rats with acute spinal cord injury.	Progesterone__microtubule-associated protein 2__interaction	Progesterone__MAP2__interaction
18584320-631	(4) Our data indicated that <compound-id="5994">progesterone</compound-id> maintained in part neuronal ultrastructure, attenuated chromatolysis, and preclude the loss of <protein-id="P11137,P38174,Q5Z859,Q6XMH6,Q6XMH7,Q8SR45">MAP2</protein-id>, suggesting a protective effect during the early phases of spinal cord injury.	progesterone__MAP2__interaction
18584336-637	In conclusion, our results indicate that chronic <compound-id="16078,134740">THC</compound-id> modulates the expression and subcellular localization of proteins implicated in <protein-id="P03967,P22126,Q07152">Ras</protein-id> signaling, calcium-buffering potential, and trafficking.	THC__Ras__no_interaction
18584896-1102	For this purpose, on day 0, male Wistar rats received NTG (120 microg/kg, iv) with or without pre-administration of PKC inhibitor <compound-id="2703,411938">chelerythrine</compound-id> (CHE), <compound-id="1548943">capsaicin</compound-id> (CAP) to deplete <protein-id="P10286,P30880,P30881,P31888,P80511">CGRP</protein-id> from sensory nerves or mK(ATP) channel blocker 5-hydroxydecaonic acid (<compound-id="25058136">5HD</compound-id>).	chelerythrine__CGRP__no_interaction	5HD__CGRP__no_interaction	capsaicin__CGRP__interaction
18585399-1508	The anti-convulsant <compound-id="5311454">stiripentol</compound-id> acts directly on the <protein-id="P26714,Q08832,Q9BLY8">GABA(A) receptor</protein-id> as a positive allosteric modulator.	stiripentol__GABA(A) receptor__interaction
18585720-96	Di-<compound-id="5885531">oleoyl</compound-id> phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (<protein-id="P27169,P27170">PON1</protein-id>) enzymatic and biological activities: in vitro and in vivo studies.	oleoyl__PON1__interaction
18585721-97	With the exception of specific genetic defects in <compound-id="1044">purine</compound-id> metabolism, increased <compound-id="1175">uric acid</compound-id> is generally associated with important risk factors for atherosclerosis like hypertension, abdominal obesity, <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> resistance, the metabolic syndrome and renal failure.	uric acid__insulin__interaction	purine__insulin__interaction
18585744-108	The distribution of sugar moieties within the epididymal region of the Sudani duck was investigated using ten different <compound-id="18730">fluorescein isothiocyanate</compound-id> (<compound-id="18730">FITC</compound-id>) conjugated <protein-id="P02871,P02873,P02874,P02875,P07386,P16108,P16349,P16351,P16352,P33888,P38662,P42088,P83410,P83511,P84987,Q41114">lectins</protein-id>.	fluorescein isothiocyanate__lectins__interaction	FITC__lectins__interaction
18586252-521	High <compound-id="206,5793,64689,79025">glucose</compound-id> and <protein-id="Q9TTB0">interferon gamma</protein-id> synergistically stimulate <protein-id="P03956,P13943,P21692,P28053,P81563,Q11133,Q9XSZ5">MMP-1</protein-id> expression in U937 macrophages by increasing transcription factor <protein-id="P42224,Q764M5">STAT1</protein-id> activity.	glucose__interferon gamma__no_interaction	glucose__STAT1__interaction	glucose__MMP-1__interaction
18586252-522	To test our hypothesis that hyperglycemia interplays with <protein-id="Q9TTB0">interferon gamma</protein-id> (<protein-id="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9">IFN gamma</protein-id>), a key factor involved in atherosclerosis, to up-regulate the expression of genes such as matrix metalloproteinases (MMPs) and cytokines that are involved in plaque destabilization, U937 macrophages cultured in medium containing either normal or high <compound-id="206,5793,64689,79025">glucose</compound-id> were challenged with <protein-id="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9">IFN gamma</protein-id> and the expression of MMPs and cytokines were then quantified by real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA).	glucose__interferon gamma__no_interaction	glucose__IFN gamma__no_interaction
18586252-523	Results showed that high <compound-id="206,5793,64689,79025">glucose</compound-id> and <protein-id="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9">IFN gamma</protein-id> had a synergistic effect on the expression of <protein-id="P03956,P13943,P21692,P28053,P81563,Q11133,Q9XSZ5">MMP-1</protein-id>, <protein-id="O18733,P14780,P41245,P41246,P50282,P52176">MMP-9</protein-id> and <protein-id="P01584,P09428,P10749,P14628,P21621,P26889,P41687,P46648,P48090,P51493,P51745,P79162,P79182,Q28292,Q28386,Q2HZH0,Q2MH07,Q63264,Q6PUD2,Q6R2X3,Q865X8,Q8WNR2,Q9WVG1,Q9XS77">IL-1 beta</protein-id>.	glucose__IL-1 beta__interaction	glucose__MMP-1__interaction	glucose__IFN gamma__no_interaction	glucose__MMP-9__interaction
18586252-525	Furthermore, high <compound-id="206,5793,64689,79025">glucose</compound-id> and <protein-id="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9">IFN gamma</protein-id> exert the synergistic effect on <protein-id="P03956,P13943,P21692,P28053,P81563,Q11133,Q9XSZ5">MMP-1</protein-id> expression by enhancing <protein-id="P42224,Q764M5">STAT1</protein-id> phosphorylation and <protein-id="P42224,Q764M5">STAT1</protein-id> transcriptional activity.	glucose__STAT1__interaction	glucose__IFN gamma__no_interaction	glucose__MMP-1__interaction
18586420-663	In Experiment 2, <protein-id="O77698,O77811,P02788,P08071,P14632,P24627,Q29477,Q9TUM0">lactoferrin</protein-id> (10 mg/mL) combined with <compound-id="60613">cidofovir</compound-id> (62.5 microg/mL) inhibited up to 100,200 PFU/mL of virus in cell culture.	cidofovir__lactoferrin__no_interaction
18586549-790	We systematically investigated whether PD-related stresses including <compound-id="462382">MG132</compound-id> and epoxomicin (proteasomal impairment), tunicamycin (unfolded protein stress), and <compound-id="6758">rotenone</compound-id> (mitochondrial dysfunction) resulted in expressional changes of parkin and other E3 <protein-id="O46543,P08565,P08618,P0C014,P0C072,P13117,P14624,P14792,P15174,P19848,P20685,P22589,P23324,P23398,P42739,P42740,P46574,P49634,P49635,P59263,P59669,P61862,P61863,P61864,P62972,P62973,P62974,P62975,P62976,P62977,P62988,P62989,P62990,P62991,P63049,P63051,P68195,P68196,P68197,P68198,P68199,P68201,P68204,P69308,P69309,P69310,P69311,P69312,P69313,P69314,P69315,P69316,P69317,P69318,P69319,P69320,P69321,P69322,P69323,P69324,P69325,P69326,P84589,Q05550,Q865C5,Q867C2,Q867C3,Q867C4,Q8MKD1,Q9Y848">ubiquitin</protein-id> ligases (<protein-id="Q9NV58">dorfin</protein-id>, SIAH-1).	rotenone__ubiquitin__interaction	rotenone__dorfin__interaction	MG132__dorfin__interaction	MG132__ubiquitin__interaction
18587580-1638	<compound-id="400769">CDDO-Me</compound-id>, a synthetic triterpenoid, inhibits expression of <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> and <protein-id="P42227,P52631">Stat3</protein-id> phosphorylation in multi-drug resistant ovarian cancer cells.	CDDO-Me__Stat3__interaction	CDDO-Me__IL-6__interaction
18587580-1639	To explore potential therapeutic strategies for interrupting signaling through this pathway, we assessed the ability of <compound-id="400769">CDDO-Me</compound-id>, a synthetic triterpenoid, to inhibit <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> secretion, <protein-id="P42227,P52631">Stat3</protein-id> phosphorylation, <protein-id="P42227,P52631">Stat3</protein-id> nuclear translocation and <compound-id="4666,36314,441276,5352019,6713921,6915727,44155032,53313247">paclitaxel</compound-id> sensitivity in several cell line model systems.	paclitaxel__Stat3__no_interaction	CDDO-Me__IL-6__interaction	paclitaxel__IL-6__no_interaction	CDDO-Me__Stat3__interaction
18587580-1640	These studies demonstrated that <compound-id="400769">CDDO-Me</compound-id> significantly inhibits <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> secretion in paclitaxel-resistant ovarian cancer cells and specifically suppresses <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id>-or oncostatin M-induced <protein-id="P42227,P52631">Stat3</protein-id> nuclear translocation.	CDDO-Me__Stat3__interaction	CDDO-Me__IL-6__interaction
18587580-1641	Treatment with <compound-id="400769">CDDO-Me</compound-id> significantly decreases the levels of Stat3, <protein-id="Q62120,Q62689">Jak2</protein-id>, and <protein-id="P05480,Q9WUD9">Src</protein-id> phosphorylation in ovarian and breast cancer cell lines with constitutively activated Stat3.	CDDO-Me__Jak2__interaction	CDDO-Me__Src__interaction
18587580-1642	Our data confirm that <compound-id="400769">CDDO-Me</compound-id> interrupts the signaling of multiple kinases involved in the <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id>-<protein-id="P42227,P52631">Stat3</protein-id> and <protein-id="P05480,Q9WUD9">Src</protein-id> signaling pathways.	CDDO-Me__Stat3__interaction	CDDO-Me__Src__interaction	CDDO-Me__IL-6__interaction
18587601-1586	The anti-hyperlipemia effect of EPS and intracellular polysaccharide (IPS) extracted from mycelia were observed that both EPS and IPS can obviously reduce the serum triglyceride (TG), the blood <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> (TC) and serum low density lipoprotein (LDL) level, and increase the <protein-id="P81182">high density lipoprotein</protein-id> (HDL) level of the hyperlipemia mice.	cholesterol__high density lipoprotein__no_interaction
18587610-1674	On a molar basis, <compound-id="5999,19649,6426892,6602485">streptomycin</compound-id> yields a signal that is approximately 0.67 times that of <protein-id="O32849,O32857,O32858,O33159,O33160,O51428,O54312,O67315,O84461,P0A5L2,P0A5L3,P0A749,P0A750,P0A751,P19670,P33038,P33986,P45025,P45821,P56189,P57466,P57821,P65452,P65453,P65454,P65455,P65458,P65459,P70965,P84058,P84059,Q2RQ67,Q2YAN2,Q2YPB6,Q30T46,Q315P9,Q319I9,Q31GZ1,Q31W66,Q32BE4,Q39K93,Q39YP9,Q3A131,Q3A949,Q3AR32,Q3B5D7,Q3BQX2,Q3IG20,Q3J077,Q3J7G9,Q3JMZ4,Q3KHZ4,Q3KLP3,Q3MD78,Q3SHP2,Q3SW27,Q3YX52,Q46JH1,Q46WL0,Q47AK9,Q47KH3,Q47VJ4,Q48EC7,Q48UD0,Q493Y9,Q4FNE4,Q4FQF6,Q4JXA4,Q4KI75,Q4L7Y1,Q4QLK7,Q4UKX7,Q4UX36,Q4ZNV7,Q55673,Q57F97,Q57JG1,Q59561,Q5E7V0,Q5F5K6,Q5FME5,Q5FSM2,Q5GRP6,Q5H3C7,Q5HEA0,Q5HMC2,Q5HUT8,Q5L6U5,Q5L9P3,Q5LL90,Q5LZI4,Q5M439,Q5NLR2,Q5P787,Q5PBP4,Q5PLD1,Q5R0J5,Q5SM03,Q5WB82,Q5WY61,Q5X6Q6,Q5XCX7,Q5Z0X7,Q5ZX85,Q606Q0,Q62GD7,Q630W1,Q63Q84,Q64PY6,Q65RU6,Q661E8,Q665K4,Q68WF7,Q6AJM7,Q6DAF2,Q6FED0,Q6FYT1,Q6G226,Q6G7L0,Q6GEX5,Q6HAZ8,Q6LMC9,Q6MEP6,Q6MRK7,Q6N176,Q6NFK1,Q71WQ2,Q726D3,Q72GJ4,Q73FX6,Q73Q03,Q73X63,Q748B3,Q74LG1,Q7MAC1,Q7MPA3,Q7MUW1,Q7N068,Q7NGP3,Q7P0X5,Q7U5R6,Q7V0G1,Q7V8L0,Q7VAC5,Q7VAT0,Q7VIM8,Q7VP51,Q7VQS0,Q7VSZ3,Q7W2Y6,Q7WDY6,Q82TN2,Q83DI0,Q87DN8,Q87LF4,Q87WV2,Q88P88,Q89AE9,Q89W71,Q8A681,Q8CRN6,Q8D2M5,Q8DEB6,Q8DKS7,Q8DNE8,Q8E5U6,Q8EAF7,Q8EM86,Q8FMR0,Q8K825,Q8K9G4,Q8KEX7,Q8NML5,Q8P719,Q8PID3,Q8RIQ1,Q8UHW9,Q8X9J9,Q8XID7,Q8XV78,Q8Y4C4,Q8Z0C4,Q8ZB56,Q927W7,Q92H88,Q92S27,Q931H5,Q97F79,Q97NQ4,Q9A5U7,Q9CI17,Q9HVW7,Q9JWS7,Q9K1Q9,Q9K6I0,Q9KP62,Q9PDG4,Q9PJT7,Q9PP65,Q9RVA6,Q9WXW3,Q9Z3Z6,Q9Z7Y2,Q9ZCX3,Q9ZH21,Q9ZLI6">MurA</protein-id>.	streptomycin__MurA__no_interaction
18587665-16	<compound-id="5281807,5385074,5486172,44257207,53384442">Puerarin</compound-id> regulates expressions of <protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id> and <protein-id="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9">HIF-1alpha</protein-id> stimulated by STZ.	Puerarin__HIF-1alpha__interaction	Puerarin__VEGF__interaction
18588512-710	In patients with hypertension and diabetes, <compound-id="439764">ARB</compound-id>, ACEi and diuretic treatment increased <protein-id="P03967,P22126,Q07152">Ras</protein-id> activation only during the first week.	ARB__Ras__interaction
18590515-661	Although the co-expression of <protein-id="P54751,P61130,P61131,P72074,P72097,Q02745,Q11200,Q11201,Q11204,Q11205,Q11206,Q16842,Q48211,Q6KB58,Q6KB59,Q91Y74,Q9CNC4,Q9JUV5">alpha2,3-ST</protein-id> and CMP-SAS did not further increase sialylation, an increase in the intracellular pool of CMP-<compound-id="906,444885,445063">sialic acid</compound-id> was noted.	sialic acid__alpha2,3-ST__no_interaction
18590587-733	NOPE-<compound-id="65064">EGCG</compound-id> treatment improved <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> 0.0001).	EGCG__insulin__interaction
18590597-739	A 23.5-fold increase in <compound-id="130779">7-ethoxy-4-trifluoromethylcoumarin</compound-id> O-deethylation activity suggested that metabolic resistance through elevated levels of <protein-id="O08469">cytochrome P450</protein-id> dependent monooxygenase-activity is a possible resistance mechanism.However, synergism studies with different metabolic inhibitors revealed some contrasting resistance mechanisms between the METI-acaricides.	7-ethoxy-4-trifluoromethylcoumarin__cytochrome P450__interaction
18592271-409	The activities of <protein-id="O51891,O67031,O83281,P03304,P0A295,P0A296,P0AG30,P0AG31,P0AG32,P0AG33,P15409,P17593,P17594,P20350,P29403,P33561,P35359,P38527,P44619,P45835,P51489,P52152,P52153,P52154,P52155,P52156,P52157,P52158,P56466,P57652,P66028,P66029,Q03222,Q06447,Q89A22,Q9ZD24,Q9ZLS9">Rho</protein-id> GTPases are predominantly controlled by guanine nucleotide exchange factors (<protein-id="Q9NR83">GEFs</protein-id>), which activate GTPases by catalyzing the exchange of bound <compound-id="8977">GDP</compound-id> for <compound-id="6830">GTP</compound-id>.	GTP__Rho__no_interaction	GDP__Rho__no_interaction	GTP__GEFs__interaction	GDP__GEFs__interaction
18592327-379	11beta-Hydroxysteroid dehydrogenase type 1 (<protein-id="P16232,P28845,P50172,P51975,Q29608,Q6QLL4,Q6R0J2,Q7M3I4">11beta-HSD1</protein-id>) enzyme catalyzes interconversion of inactive <compound-id="222786">cortisone</compound-id> to active <compound-id="5754">cortisol</compound-id>.	cortisol__11beta-HSD1__interaction	cortisone__11beta-HSD1__interaction
18592344-477	Rebinding experiments with Lys-<compound-id="750,5460845">Gly</compound-id>-Asp, an analogue of Arg-<compound-id="750,5460845">Gly</compound-id>-Asp, and other different peptides, such as <protein-id="P0C229,P50144,P50145,P68125,P68126">cholecystokinin</protein-id> C-terminal tri- and <compound-id="25201604">pentapeptide</compound-id> and <compound-id="16130140">gramicidin</compound-id>, further indicated the selectivity of <compound-id="4093">methacrylic acid</compound-id>-trimethylpropane trimethacrylate copolymer for Arg-<compound-id="750,5460845">Gly</compound-id>-Asp giving specific selectivity factor values 1.27, 1.98, 1.31 and 1.67, respectively.	gramicidin__cholecystokinin__no_interaction	pentapeptide__cholecystokinin__no_interaction	Gly__cholecystokinin__no_interaction	methacrylic acid__cholecystokinin__no_interaction
18592367-499	Parents (N = 19) of children with autism spectrum disorders (ASD) and adult controls (N = 17) underwent positron emission tomography (PET) using [(18)F] <compound-id="68604">setoperone</compound-id> to image cortical serotonin type-2 (<protein-id="O46635,P14842,P18599,P28223,P35363,P35382,P50128,P50129,Q5R4Q6,Q75Z89">5-HT2</protein-id>) receptors.	setoperone__5-HT2__interaction
18592408-535	Natural <compound-id="167551">anacardic acid</compound-id> was enzymatically polymerized using soybean <protein-id="P15984,P16147,P84714">peroxidase</protein-id>.	anacardic acid__peroxidase__interaction
18592416-542	Vesicle mobilization requires <compound-id="271">Ca(2</compound-id>+)-induced Ca2+ release by presynaptic endoplasmic reticulum (ER) ryanodine receptors (<protein-id="Q24498">RyRs</protein-id>) that in turn stimulates Ca2+/<protein-id="O02367,O16305,O60041,O82018,O94739,O96102,O97341,P02594,P02595,P02598,P02599,P04352,P04353,P04464,P05933,P05934,P05935,P06787,P07463,P11118,P11120,P11121,P15094,P17928,P18061,P21251,P23286,P24044,P27161,P27165,P27166,P41040,P41041,P48976,P60204,P60205,P60206,P61859,P61860,P61861,P62144,P62145,P62149,P62151,P62152,P62154,P62155,P62156,P62157,P62158,P62160,P62161,P62162,P62184,P62201,P62202,P62203,P62204,P69097,P69098,P84339,P93087,P93171,Q05055,Q39752,Q40302,Q5EHV7,Q5RAD2,Q6IT78,Q6PI52,Q6R520,Q6YNX6,Q71UH5,Q71UH6,Q7T3T2,Q7Y052,Q8STF0,Q8X187,Q95NI4,Q95NR9,Q9GRJ1,Q9HFY6,Q9U6D3,Q9UWF0">calmodulin</protein-id>-dependent kinase II (CamKII).	Ca(2__calmodulin__interaction	Ca(2__RyRs__interaction
18593507-1421	These results highlight both the interactions between <protein-id="P31424,P41594">mGluR5</protein-id> and NMDA receptors in the determination of schizophreniform behaviours and the potential for the effects of <compound-id="2818">clozapine</compound-id> to be mediated by NMDA receptor regulation.	clozapine__mGluR5__no_interaction
18594129-259	Expression of <protein-id="P0AG38,P0AG39,Q8Z3B3,Q9L6N7">rhtC</protein-id> reduced the intracellular <compound-id="6288">L-threonine</compound-id> concentration from 140 to 11 mM and resulted in maximal excretion rates of 11.2 nmol min(-1) mg(-1) as compared to 2.3 nmol min(-1) mg(-1) obtained without <protein-id="P0AG38,P0AG39,Q8Z3B3,Q9L6N7">rhtC</protein-id> expression.	L-threonine__rhtC__interaction
18594129-260	In combination with an <protein-id="P04968,P20506,P37946,P46493,P53607,P66897,P66898,Q02145,Q04513,Q2FF63,Q2YUE8,Q3V7T4,Q3V7T5,Q49Z16,Q4L7U4,Q5HEE0,Q5HMF5,Q7A4H2,Q8CNK9,Q8NVI8,Q99SJ1,Q9CKJ2,Q9KC63,Q9X7F1">ilvA</protein-id> mutation generated and introduced into the chromosome, an accumulation of up to 54 mM <compound-id="6288">L-threonine</compound-id> was achieved as compared to 21 mM obtained with the ancestor strain.	L-threonine__ilvA__interaction
18594817-847	This additive effect was not observed when glioma cells were pre-treated with <compound-id="5394">temozolomide</compound-id>, which was unable to increase <protein-id="P25446,Q63199">Fas</protein-id> expression in tumor.	temozolomide__Fas__no_interaction
18594817-848	Furthermore, the CD3(+) T cells co-cultured with <compound-id="60700">topotecan</compound-id> treated U-87 and autologous GBM tumor cells showed a significant increase in expression in <protein-id="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9">IFN-gamma</protein-id>, a key cytokine produced by activated T cells, and accordingly enhanced tumor cytotoxicity.	topotecan__IFN-gamma__interaction
18594856-883	Hypergravity also induced a transient reorganization of <protein-id="O00937,O13419,O16808,O17320,O65314,O65315,O65316,O74258,O81221,P02577,P10365,P10989,P11426,P13363,P14235,P17128,P20904,P24902,P26182,P26183,P30161,P45520,P45521,P48465,P50138,P51775,P53455,P53476,P53477,P53491,P53498,P53499,P53500,P53502,P53689,P60009,P60010,P60011,P68555,P78711,P80709,P81085,P90689,P91754,Q05214,Q11212,Q24733,Q2U7A3,Q39596,Q39758,Q6TCF2,Q75D00,Q8SWN8,Q8X119,Q92192,Q92193,Q99023,Q9P4D1,Q9UVF3,Q9UVX4,Q9UVZ8">actin</protein-id> fibers in 3 min, which was inhibited by Rho-kinase inhibitor (<compound-id="448042">Y27632</compound-id>) and tyrosine kinase inhibitors (<compound-id="3591,5311102,6436247">herbimycin A</compound-id> and <compound-id="5328768">tyrphostin 46</compound-id>).	Y27632__actin__interaction	herbimycin A__actin__interaction	tyrphostin 46__actin__interaction
18594856-886	Collectively, these results indicate that hypergravity induces <compound-id="5957">ATP</compound-id> release and <protein-id="O00937,O13419,O16808,O17320,O65314,O65315,O65316,O74258,O81221,P02577,P10365,P10989,P11426,P13363,P14235,P17128,P20904,P24902,P26182,P26183,P30161,P45520,P45521,P48465,P50138,P51775,P53455,P53476,P53477,P53491,P53498,P53499,P53500,P53502,P53689,P60009,P60010,P60011,P68555,P78711,P80709,P81085,P90689,P91754,Q05214,Q11212,Q24733,Q2U7A3,Q39596,Q39758,Q6TCF2,Q75D00,Q8SWN8,Q8X119,Q92192,Q92193,Q99023,Q9P4D1,Q9UVF3,Q9UVX4,Q9UVZ8">actin</protein-id> reorganization via <protein-id="Q9C3Y4">RhoA</protein-id> activation and <protein-id="Q00944,Q05397">FAK</protein-id> phosphorylation, thereby activating cell proliferation and migration in BAECs.	ATP__FAK__interaction	ATP__RhoA__interaction	ATP__actin__interaction
18594946-953	Cell exposure to 250 microM <compound-id="778">homocysteine</compound-id> was able to induce <protein-id="P08587,P21980,P21981,P51176,P52181,Q01841">transglutaminase 2</protein-id> up-regulation and increased in situ <protein-id="P40746,P52183,P81453,Q819L3,Q81MS1,Q8GR90,Q9K5W7">transglutaminase</protein-id> activity.	homocysteine__transglutaminase__interaction	homocysteine__transglutaminase 2__interaction
18594946-954	<compound-id="778">Homocysteine</compound-id> also induced NF-kappaB activation that seemed associated with <protein-id="P08587,P21980,P21981,P51176,P52181,Q01841">transglutaminase 2</protein-id> up-regulation since the specific NF-kappaB inhibition by SN50 was able to reduce <protein-id="P40746,P52183,P81453,Q819L3,Q81MS1,Q8GR90,Q9K5W7">transglutaminase</protein-id> expression and activity levels.	Homocysteine__transglutaminase__no_interaction	Homocysteine__transglutaminase 2__interaction
18594965-980	<compound-id="3988,5311263,5497152">Lysophosphatidic acid</compound-id> can support the formation of membranous structures and an increase in <protein-id="P02686,P02687,P04370,P06906,P13727,P15720,P20939,P25188,P25274,P25336,P81558,P83487,P87346,P98190,Q61878,Q63189,Q91325,Q91439,Q9SAV1">MBP</protein-id> mRNA levels in differentiating oligodendrocytes.	Lysophosphatidic acid__MBP__interaction
18594989-1002	There was no correlation between the presence of significant heart-valve regurgitation and <compound-id="54746">cabergoline</compound-id> cumulative dose, duration of <compound-id="54746">cabergoline</compound-id> treatment, prior use of <compound-id="31101">bromocriptine</compound-id>, age, adenoma size, or <protein-id="P10765,P22393,P33089,P33090,P33091,P43001">prolactin</protein-id> levels.	cabergoline__prolactin__no_interaction	bromocriptine__prolactin__no_interaction
18595002-930	<protein-id="O77220,P14944,P30814,P55845,P56687,P59685,P81032,P83800,Q25588,Q25589,Q25683,Q26181">CHH</protein-id> elevates <compound-id="206,5793,64689,79025">glucose</compound-id> levels in the hemolymph by stimulating glycogenolysis in target tissues.	glucose__CHH__interaction
18596195-276	Here, we assessed the regulation of pancreatic <protein-id="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3">cytochrome c</protein-id> release by <compound-id="271">Ca(2</compound-id>+), mitochondrial membrane potential (Delta Psi m), and reactive <compound-id="977">oxygen</compound-id> species (ROS), the signals involved in acute pancreatitis.	oxygen__cytochrome c__interaction	Ca(2__cytochrome c__interaction
18596687-690	Here, we report the efficacy of <compound-id="2369,60657">betaxolol</compound-id> in reducing increases in gene expression of amygdalar <protein-id="P01142,P01143,P06296,P06850,P49188,P49926,Q8CIT0,Q95MI6,Q9PTS1">corticotropin-releasing factor</protein-id> (<protein-id="O75973,P01142,P01143,P06296,P06850,P49188,P49926,Q8CIT0,Q95MI6,Q9PTS1">CRF</protein-id>), a peptide known to be involved in mediating 'anxiety-like' behaviors during initial phases of <compound-id="2826,5760,439497,446220,644017,54613779">cocaine</compound-id> abstinence.	cocaine__CRF__interaction	betaxolol__corticotropin-releasing factor__interaction	betaxolol__CRF__interaction	cocaine__corticotropin-releasing factor__interaction
18596687-691	Results showed that <compound-id="2369,60657">betaxolol</compound-id> treatment during early <compound-id="2826,5760,439497,446220,644017,54613779">cocaine</compound-id> withdrawal attenuated increases in amygdalar <protein-id="O75973,P01142,P01143,P06296,P06850,P49188,P49926,Q8CIT0,Q95MI6,Q9PTS1">CRF</protein-id> gene expression and cyclic adenosine monophosphate-dependent <protein-id="P00513,P25848">protein kinase</protein-id> regulatory and catalytic subunit (nuclear fraction) protein expression.	betaxolol__protein kinase__interaction	cocaine__CRF__no_interaction	betaxolol__CRF__interaction	cocaine__protein kinase__no_interaction
18596687-692	The present findings suggest that the efficacy of <compound-id="2369,60657">betaxolol</compound-id> treatment on <compound-id="2826,5760,439497,446220,644017,54613779">cocaine</compound-id> withdrawal-induced anxiety may be related, in part, to its effect on amygdalar beta(1)-adrenergic receptor, modulation of its downstream cell-signaling elements and <protein-id="O75973,P01142,P01143,P06296,P06850,P49188,P49926,Q8CIT0,Q95MI6,Q9PTS1">CRF</protein-id> gene expression.	cocaine__CRF__no_interaction	betaxolol__CRF__interaction
18597051-1012	Furthermore, it is demonstrated that this strain has <protein-id="O43097,O59859,O60206,P07529,P09850,P17137,P23360,P23557,P29417,P40943,P45703,P48793,P56588,P81536,Q53317">xylanase</protein-id> activity, and the activity can be optimized under suitable growing conditions where wheat bran and <compound-id="1176,265993">urea</compound-id> are the primary sources of carbon and <compound-id="947,123329">nitrogen</compound-id>.	urea__xylanase__no_interaction	nitrogen__xylanase__no_interaction
18597073-1033	<protein-id="O04437,O18598,P0A9D2,P0A9D3,P30116,P44521,P46088,P46419,P46423,P46426,P46428,P46437,P48438,P80894,P81065,P82996,P82997,P82998,P82999,P83000,P83001,P83246,Q04522,Q08392,Q08393,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52,Q96324">Glutathione S-transferase</protein-id> (<protein-id="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52">GST</protein-id>) isozymes catalyze nucleophilic attack by <compound-id="124886">reduced Glutathione</compound-id> (<compound-id="124886">GSH</compound-id>) on a variety of electrophilic compounds and play a central role in biotransformation of xenobiotics (Hayes et al., Annu Rev Pharmacol Toxicol 45:51-88, 2005).	GSH__GST__interaction	reduced Glutathione__Glutathione S-transferase__interaction	reduced Glutathione__GST__interaction	GSH__Glutathione S-transferase__interaction
18597869-1683	<compound-id="4091">Metformin</compound-id> inhibits <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id>-induced <protein-id="O15111,Q60680">IkappaB kinase</protein-id> phosphorylation, <protein-id="P25963,Q08353,Q63746,Q91974,Q9Z1E3">IkappaB-alpha</protein-id> degradation and <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> production in endothelial cells through <protein-id="O00329,O02697,O35904,P23727,P26450,P27986,P32871,P42336,P42337,P42338,P42347,P42348,P48736,P54673,P54674,P54675,P54676,Q63787,Q8BTI9,Q8UUU2,Q9JHG7,Q9Z1L0">PI3K</protein-id>-dependent <protein-id="P54646,Q09136,Q9Y478">AMPK</protein-id> phosphorylation.	Metformin__AMPK__interaction	Metformin__TNF-alpha__interaction	Metformin__PI3K__interaction	Metformin__IkappaB-alpha__interaction	Metformin__IL-6__interaction	Metformin__IkappaB kinase__interaction
18599066-769	<compound-id="985">Palmitate</compound-id> phosphorylated <protein-id="O24473,O75791,O95433,O97628,P46108,P80350,P82869,Q01552,Q04929,Q63768,Q64010,Q9LDA4,Q9Y2S7">p38</protein-id> and <protein-id="P92208,Q966Y3">JNK</protein-id> kinases, and blocking of these kinases with specific inhibitors diminished the <compound-id="985">palmitate</compound-id>-induced cytokine secretion.	Palmitate__JNK__interaction	palmitate__p38__interaction	Palmitate__p38__interaction	palmitate__JNK__interaction
18599066-770	<compound-id="985">Palmitate</compound-id> also activated the <protein-id="P21525">AP-1</protein-id> (c-<protein-id="P05627,P17325,P18289">Jun</protein-id>) transcription factor.	Palmitate__AP-1__interaction	Palmitate__Jun__interaction
18599093-1004	Characterisation of <compound-id="5957">ATP</compound-id> analogues to cross-link and label <protein-id="P13900,P16604">P2X</protein-id> receptors.	ATP__P2X__interaction
18599093-1005	In this study we determined whether the UV light-reactive <compound-id="5957">ATP</compound-id> analogues <compound-id="123645,189791">2-azido ATP</compound-id>, <compound-id="5957">ATP</compound-id> azidoanilide (<compound-id="5957">ATP</compound-id>-AA) and 2', <compound-id="115205">3'-O-(4-benzoylbenzoyl)-ATP</compound-id> (<compound-id="115205">BzATP</compound-id>) can be used to label the ATP binding site of <protein-id="P47824,P51575,P51576">P2X1</protein-id> receptors.	ATP__P2X1__interaction	2-azido ATP__P2X1__interaction	BzATP__P2X1__interaction	3'-O-(4-benzoylbenzoyl)-ATP__P2X1__interaction
18599093-1006	cross-linked to <protein-id="P47824,P51575,P51576">P2X1</protein-id> receptors and this binding was reduced by co-incubation with <compound-id="5957">ATP</compound-id>.	ATP__P2X1__interaction
18599093-1007	These studies demonstrate that photo-reactive <compound-id="5957">ATP</compound-id> analogues can be used to label <protein-id="P13900,P16604">P2X</protein-id> receptor and may prove useful in elucidating the ATP binding site at this novel class of ATP binding proteins.	ATP__P2X__interaction
18599154-1053	<protein-id="O19011,O93449,P01137,P04202,P07200,P09531,P09533,P16176,P17246,P18341,P50414,P54831,Q38HS2,Q9PTQ2,Q9Z1Y6">TGF-beta1</protein-id> treatment for 72 h also induced EMT in the A549 cells and this transition led to resistance to <compound-id="123631">gefitinib</compound-id>.	gefitinib__TGF-beta1__interaction
18599191-1078	<protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">Insulin</protein-id>-antagonistic effects of hormones, cytokines and excess metabolic substrates such as <compound-id="206,5793,64689,79025">glucose</compound-id> and fatty acids may be exerted via common mechanisms involving for example reactive <compound-id="977">oxygen</compound-id> species (ROS) accumulation and associated inflammatory responses.	oxygen__Insulin__interaction	glucose__Insulin__interaction
18599210-1087	Optimization of decolorization of <compound-id="4139">methylene blue</compound-id> (MB) dye by <protein-id="P06181,P11542,P11543,P20010,P20011,P20012,P20013,P21764,P31837,P31838,P49012,P50622">lignin peroxidase</protein-id> (LiP) enzyme produced by white-rot fungus Phanerochaete chrysosporium using sewage treatment plant (STP) sludge as a major substrate was carried out in the laboratory.	methylene blue__lignin peroxidase__interaction
18600448-401	<compound-id="750">Glycine</compound-id> release was potentiated by the activation of <protein-id="P13678,Q25378">protein kinase C</protein-id> and diminished by increasing <compound-id="24316">cyclic guanosine monophosphate</compound-id> levels with a phosphodiesterase inhibitor, <compound-id="5722">zaprinast</compound-id>.	zaprinast__protein kinase C__no_interaction	cyclic guanosine monophosphate__protein kinase C__no_interaction	Glycine__protein kinase C__interaction
18600455-406	Our study demonstrates that <compound-id="6675">taurocholate</compound-id> causes evident damage to acinar cells, impairing both calcium homeostasis and secretory response to <protein-id="O57312,O93464,P01355,P01356,P06307,P09240,P0C229,P23362,P41520,P50144,P50145,P68125,P68126,P80344,P80345,Q9PU29,Q9PU41">CCK</protein-id>.	taurocholate__CCK__interaction
18600456-407	Enteric neuronal dopamine (DA) inhibits <compound-id="187">acetylcholine</compound-id> release and gastric motility; this has been thought to be mediated via neuronal dopamine-2 receptor (<protein-id="Q8IS44">D2R</protein-id>).	acetylcholine__D2R__interaction
18600473-984	As compared with parental B16 cells, the inhibitory effects of <protein-id="O19011,O93449,P01137,P04202,P07200,P09531,P09533,P16176,P17246,P18341,P50414,P54831,Q38HS2,Q9PTQ2,Q9Z1Y6">TGF-beta1</protein-id> and activin A on <compound-id="6325610">melanin</compound-id> content were relative smaller in B16 F10 cells, a subline of B16 cells that contain more pigment.	melanin__TGF-beta1__interaction
18601937-1660	ATP-gated <protein-id="P13900,P16604">P2X</protein-id> receptors on excitatory nerve terminals onto interneurons initiate a form of asynchronous <compound-id="611,23327,33032">glutamate</compound-id> release.	glutamate__P2X__interaction
18601937-1662	However asynchronous EPSCs were increased following synaptic depression and a component of these appeared to be initiated by endogenously released <compound-id="5957">ATP</compound-id> acting on presynaptic <protein-id="P13900,P16604">P2X</protein-id> receptors.	ATP__P2X__interaction
18601937-1663	Unexpectedly, the data suggest <protein-id="P13900,P16604">P2X</protein-id> receptor activation initiates a form of asynchronous <compound-id="611,23327,33032">glutamate</compound-id> release, rather than detectably affecting the vesicles underlying action potential evoked release.	glutamate__P2X__interaction
18601945-1673	The second enzyme of <compound-id="124886">GSH</compound-id> synthesis, <compound-id="124886">GSH</compound-id> synthase (GS) is also regulated in a coordinated manner as <protein-id="P28676,Q8NEA9,Q96IK5">GCL</protein-id> subunits and its up-regulation can further enhance the capacity of the cell to synthesize <compound-id="124886">GSH</compound-id>.	GSH__GCL__no_interaction
18602447-1075	The rise in [<compound-id="271">Ca(2</compound-id>+)](i) elicited by hGH is associated with an enhanced <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> secretion, effects that are mediated mainly through the <protein-id="P10765,P22393,P33089,P33090,P33091,P43001">prolactin</protein-id> receptor.	Ca(2__prolactin__interaction	Ca(2__insulin__interaction
18602447-1076	These mechanisms indicate that a rise in [<compound-id="271">Ca(2</compound-id>+)](i) elicited by activation of <protein-id="O46561,P14787,P16471,Q04594,Q28172,Q28235,Q6JTA8,Q90374,Q91094,Q91513">PRLR</protein-id> is <protein-id="O60674">JAK2</protein-id>-dependent and is associated with enhanced <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> secretion.	Ca(2__JAK2__no_interaction	Ca(2__insulin__no_interaction	Ca(2__PRLR__interaction
18602447-1077	In contrast, <protein-id="O46600,P10912,P16310,P16882,P19756,P19941,P79108,P79194,Q02092,Q28575,Q90375,Q95JF2,Q95ML5,Q9JI97,Q9TU69,Q9XSZ1">GH receptor</protein-id>-mediated increase in [<compound-id="271">Ca(2</compound-id>+)](i) is <protein-id="O60674">JAK2</protein-id>-independent and is dissociated from <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> secretion.	Ca(2__JAK2__interaction	Ca(2__insulin__interaction	Ca(2__GH receptor__interaction
18602691-569	<protein-id="P04279">SEMG</protein-id> I expression is upregulated by <protein-id="O77762,P05112,P07750,P20096,P30367,P30368,P42202,P46652,P47966,P51492,P51744,P55030,P79155,P79339,Q04745,Q2PE74,Q3S4V6,Q58M18,Q60440,Q7YS71,Q865X5,Q865Y0,Q8HYB1,Q9MZR8,Q9XS58">IL-4</protein-id>, <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> and <compound-id="9444">5-azacytidine</compound-id>.	5-azacytidine__IL-4__no_interaction	5-azacytidine__SEMG__interaction	5-azacytidine__IL-6__no_interaction
18602794-652	<compound-id="444732">Trichostatin A</compound-id> down-regulates <protein-id="O46512,P11511,P19098,P46194,P70091,P79690,P79699,Q29605,Q29624,Q5QQX7,Q69FB6,Q6QHT9,Q6YI21,Q92087,Q92111,Q92112,Q95M61,Q9XS28">CYP19</protein-id> transcript and protein levels in MCF-7 breast cancer cells.	Trichostatin A__CYP19__interaction
18602807-667	Consumption of the <compound-id="104763">trichothecene</compound-id> mycotoxin <compound-id="40024,430147,442408,6321385,6432495,49868109">deoxynivalenol</compound-id> (DON) induces <protein-id="P41693">interleukin-6</protein-id> (<protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id>)-dependent IgA nephropathy (IgAN) in mice.	deoxynivalenol__interleukin-6__interaction	trichothecene__IL-6__interaction	deoxynivalenol__IL-6__interaction	trichothecene__interleukin-6__interaction
18602807-668	The purpose of this study was to identify the signal transduction pathways by which DON up-regulates <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> in the peritoneal macrophage and how consumption of fish oil enriched with the n-3 PUFA <compound-id="445580">docosahexaenoic acid</compound-id> (DHA) suppresses these processes.	docosahexaenoic acid__IL-6__interaction
18602811-670	<compound-id="5282349,53394606">gamma-Tocotrienol</compound-id> induced activation of caspase-3 and increased the cleavage of the downstream substrate poly(<protein-id="P02783">ADP</protein-id>-ribose) polymerase.	gamma-Tocotrienol__ADP__interaction
18602814-672	The aim of the present study was to determine the effects of <compound-id="938">niacin</compound-id> and <compound-id="23976">chromium</compound-id> on HDL formation by investigating the changes in <protein-id="O95477">ABCA1</protein-id> and ApoA-1 transcription in the human hepatoblastoma cell line (HepG2 cells).	chromium__ABCA1__interaction	niacin__ABCA1__interaction
18602814-674	<compound-id="938">Niacin</compound-id> and <compound-id="23976">chromium</compound-id> cotreatment significantly induced the expression of <protein-id="O35507,P23204,P37230,P37232,Q07869,Q8HYL6,Q95N78">peroxisome proliferator-activated receptor-alpha</protein-id> (<protein-id="O35507,P23204,P37230,P37232,Q07869,Q8HYL6,Q95N78">PPARalpha</protein-id>) mRNA by approximately 1.3-1.8-fold.	chromium__peroxisome proliferator-activated receptor-alpha__interaction	chromium__PPARalpha__interaction	Niacin__peroxisome proliferator-activated receptor-alpha__interaction	Niacin__PPARalpha__interaction
18602814-675	A combination of <compound-id="938">niacin</compound-id> and <compound-id="24808,24871">chromium chloride</compound-id> did not significantly increase (3+1 mM) but instead reduced (1+3 mM) <protein-id="O95477">ABCA1</protein-id> gene expression.	niacin__ABCA1__interaction	chromium chloride__ABCA1__interaction
18602814-676	We hypothesize that the stimulation of <protein-id="O95477">ABCA1</protein-id> gene expression causes an enhanced <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> efflux, perhaps mediated by <protein-id="O35507,P23204,P37230,P37232,Q07869,Q8HYL6,Q95N78">PPARalpha</protein-id> pathway(s).	cholesterol__ABCA1__interaction	cholesterol__PPARalpha__interaction
18602822-681	<compound-id="104815">Cu</compound-id> deficiency disrupts the architecture of mitochondria, impairs respiration, and inhibits the activity of <protein-id="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3">cytochrome c</protein-id> oxidase-the terminal, <compound-id="104815">Cu</compound-id>-dependent respiratory complex (Complex IV) of the electron transport chain.	Cu__cytochrome c__interaction
18602823-684	<compound-id="5350">Sulforaphane</compound-id> inhibited cell proliferation with IC(50) values at 24 and 48 h of 12.5 and 7.5 muM doses, respectively, and decreased <protein-id="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7">ERalpha</protein-id> protein expression at concentrations between 2.5 and 30 muM.	Sulforaphane__ERalpha__interaction
18602823-685	30 muM, the SUL-induced suppression of <protein-id="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7">ERalpha</protein-id> protein was reversed by preincubation with the proteasome inhibitor <compound-id="462382">MG132</compound-id> and was accompanied by an increase in protein levels of the 20S catalytic core subunit <protein-id="P28074,P34065">PSMB5</protein-id>.	MG132__ERalpha__interaction	MG132__PSMB5__no_interaction
18602931-788	A-804598 was tritiated ([<compound-id="45481830">3H]A-804598</compound-id> ; 8.1Ci/mmol) and utilized to study recombinant rat <protein-id="Q64663,Q99572,Q9Z1M0">P2X7</protein-id> receptors expressed in 1321N1 cells.	3H]A-804598__P2X7__interaction
18602931-789	The pharmacological profile for P2X antagonists to inhibit [<compound-id="45481830">3H]A-804598</compound-id> binding correlated with their ability to block functional activation of <protein-id="Q64663,Q99572,Q9Z1M0">P2X7</protein-id> 0.05).	3H]A-804598__P2X7__no_interaction
18603252-1055	Of importance, treatment with <compound-id="150311">ezetimibe</compound-id> significantly improved endothelial dysfunction as assessed by the vasodilator response to <compound-id="187">acetylcholine</compound-id>, accompanied by inhibition of <protein-id="P41693">interleukin-6</protein-id> mRNA and an increase in endothelial <protein-id="O61309,O61608,Q27571,Q9I9M2">nitric oxide synthase</protein-id> (<protein-id="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600">eNOS</protein-id>) mRNA in the aorta.	ezetimibe__eNOS__interaction	acetylcholine__interleukin-6__no_interaction	acetylcholine__nitric oxide synthase__no_interaction	ezetimibe__interleukin-6__interaction	acetylcholine__eNOS__no_interaction	ezetimibe__nitric oxide synthase__interaction
18603252-1056	Furthermore, <compound-id="150311">ezetimibe</compound-id> increased the mRNA expression of 3-hydroxy-3-methylglutaryl co-enzyme A (<protein-id="O74164,P40625,Q05153,Q39601">HMG</protein-id>-CoA) synthase as a counteraction in the liver, but not in the aorta.	ezetimibe__HMG__interaction
18603333-1106	A series of <compound-id="9238">adamantane</compound-id> derivatives of thiazolyl-N-substituted amides were synthesized in a three-step reaction and tested for anti-inflammatory activity as well as <protein-id="P27481,P38414">lipoxygenase</protein-id> and cycloxygenase inhibitory actions.	adamantane__lipoxygenase__interaction
18604600-443	<protein-id="P21917,P30729,P51436,Q6TLJ0">Dopamine D4 receptor</protein-id> involvement in the discriminative stimulus effects in rats of <compound-id="5761">LSD</compound-id>, but not the <compound-id="1001,31016">phenethylamine</compound-id> <compound-id="31374">hallucinogen</compound-id> <compound-id="1229,6603801,9840090">DOI</compound-id>.	phenethylamine__Dopamine D4 receptor__no_interaction	LSD__Dopamine D4 receptor__interaction	DOI__Dopamine D4 receptor__no_interaction	hallucinogen__Dopamine D4 receptor__no_interaction
18606045-1675	Plasma levels of <compound-id="5462224">magnesium</compound-id>, zinc and carotenoids did not vary across quintiles, but weak negative correlations were observed with serum <protein-id="Q26061">ferritin</protein-id> and <protein-id="P02787,P09571,P12346,P19134,P27425,Q29443,Q921I1">transferrin</protein-id> saturation.	magnesium__transferrin__interaction	magnesium__ferritin__interaction
18606396-239	Two major groups of ligand-activated nuclear receptors/xenosensors evolved: the <protein-id="O02747,P30561,P35869,P41738,Q8R4S2,Q8R4S4,Q8R4S5,Q8R4S6,Q8R4S7,Q95LD9">Ah receptor</protein-id> (activated by aryl hydrocarbons and drugs such as <compound-id="4594,9579578">omeprazole</compound-id>) and type 2 steroid receptors such as <protein-id="O75469,Q8SQ01">PXR</protein-id> and CAR, activated by drugs such as <compound-id="5381226,5388984,5458213,6243627,6842115,6913622,16043998,17753751,25141428,45356263,56947149">rifampicin</compound-id>, carbamazepin and <compound-id="1775">phenytoin</compound-id>.	phenytoin__PXR__interaction	rifampicin__Ah receptor__interaction	rifampicin__PXR__interaction	omeprazole__PXR__interaction	phenytoin__Ah receptor__interaction	omeprazole__Ah receptor__interaction
18607531-1203	The structure-activity relationship between <compound-id="5281426">oxycoumarin</compound-id> derivatives showing inhibitory effects on <protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id> in mouse macrophage RAW264.7 cells.	oxycoumarin__iNOS__interaction
18607531-1204	We have investigated the structure-activity relationship between 63 natural <compound-id="5281426">oxycoumarin</compound-id> derivatives and their effects on the expression of inducible-<protein-id="O61309,O61608,Q27571,Q9I9M2">nitric oxide synthase</protein-id> (<protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id>) induced by <compound-id="11970143">lipopolysaccharide</compound-id>.	oxycoumarin__iNOS__interaction	lipopolysaccharide__iNOS__interaction	lipopolysaccharide__nitric oxide synthase__interaction	oxycoumarin__nitric oxide synthase__interaction
18607542-1212	Inhibition of protein synthesis by <compound-id="68791">imexon</compound-id> reduces <protein-id="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9">HIF-1alpha</protein-id> expression in normoxic and hypoxic pancreatic cancer cells.	imexon__HIF-1alpha__interaction
18607542-1213	Western blot analyses of <compound-id="68791">imexon</compound-id>-treated cells demonstrated that <compound-id="68791">imexon</compound-id> reduces <protein-id="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9">HIF-1alpha</protein-id> protein levels in both normoxic and hypoxic conditions in a time- and concentration-dependant fashion.	imexon__HIF-1alpha__interaction
18607542-1214	<compound-id="60750">Gemcitabine</compound-id> did not similarly affect <protein-id="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9">HIF-1alpha</protein-id> levels.	Gemcitabine__HIF-1alpha__no_interaction
18607542-1216	Concurrently, the half-life of existing <protein-id="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9">HIF-1alpha</protein-id> protein was increased by <compound-id="68791">imexon</compound-id>, in association with a marked inhibition of chymotryptic activity in the 20S proteasome.	imexon__HIF-1alpha__interaction
18607542-1217	The inhibition of <protein-id="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9">HIF-1alpha</protein-id> translation was not specific, rather it was part of a general decrease in protein translation caused by <compound-id="68791">imexon</compound-id>.	imexon__HIF-1alpha__interaction
18607689-1312	To determine whether a regimen of <compound-id="2244">aspirin</compound-id> pretreatment, <compound-id="16129704">bivalirudin</compound-id> during the procedure and <compound-id="2806,60606">clopidogrel</compound-id> (600 mg) immediately after percutaneous coronary intervention (PCI) was associated with platelet activation during and shortly after (1 and 2 h) PCI, we characterized platelet function in 10 patients with the use of flow cytometry in the absence of agonist and in response to <protein-id="P84122">thrombin</protein-id> (10 nM), ADP (1 microM), the collagen-mimetic convulxin (5 ng/ml), and <compound-id="108157">platelet activating factor</compound-id> (10 nM).	aspirin__thrombin__no_interaction	platelet activating factor__thrombin__no_interaction	clopidogrel__thrombin__no_interaction	bivalirudin__thrombin__no_interaction
18607722-1326	Brainstem concentrations of <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> are not influenced by genetic ablation of the <protein-id="P01131,P20063,Q28832">low-density lipoprotein receptor</protein-id>.	cholesterol__low-density lipoprotein receptor__no_interaction
18607722-1327	The <protein-id="P01131,P20063,Q28832">low-density lipoprotein receptor</protein-id> (LDLr) mediates the uptake of LDL particles enriched with <compound-id="304,5997,6432564,11025495">cholesterol</compound-id>, into several tissues.	cholesterol__low-density lipoprotein receptor__interaction
18607918-1505	Under the condition of delayed intervention (30 days after deafening) following <compound-id="3467">gentamicin</compound-id>+ <compound-id="3440">furosemide</compound-id> deafening in rats, we conclude that chronic intracochlear electrical stimulation (ES) and continuous intracochlear administration of <protein-id="P25430,P25431,P25432,Q06225">brain-derived neurotrophic factor</protein-id> (<protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id>) enhance spiral ganglion cell (SGC) body and peripheral process survival and improve auditory sensitivity.	gentamicin__brain-derived neurotrophic factor__no_interaction	gentamicin__BDNF__no_interaction	furosemide__brain-derived neurotrophic factor__no_interaction	furosemide__BDNF__no_interaction
18608743-488	Design and synthesis of substituted <compound-id="795">imidazole</compound-id> and <compound-id="67516">triazole</compound-id> N-phenylbenzo[d]oxazolamine inhibitors of retinoic acid metabolizing enzyme <protein-id="O43174,Q9PUB4">CYP26</protein-id>.	triazole__CYP26__interaction	imidazole__CYP26__interaction
18608753-1365	For this purpose, human erythrocyte <protein-id="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655">glutathione reductase</protein-id> was initially purified 2139-fold in a yield of 29% by using 2', 5'-ADP <compound-id="11966311">Sepharose</compound-id> 4B affinity gel and Sephadex G-200 gel filtration chromatography.	Sepharose__glutathione reductase__no_interaction
18608754-503	The enzyme <protein-id="O25536,O30931,O41033,O48500,O52597,O54134,O66592,O68992,O83855,O84294,P03195,P03370,P06968,P09254,P0A552,P0A553,P10234,P14597,P16088,P16824,P16901,P17374,P19028,P23426,P23427,P28892,P28893,P30007,P31625,P31822,P32208,P32518,P33317,P33826,P35956,P43058,P43792,P52341,P52541,P57623,P57914,P59408,P61906,P61907,P61908,P61909,P61910,P61911,P61912,P61913,P64004,P64005,P64006,P64007,P64008,P64009,P68634,P68635,P70583,P87630,Q00030,Q01034,Q06095,Q07275,Q2Y742,Q2YRG4,Q31EC7,Q31UY6,Q329L7,Q39DM5,Q39V99,Q3A499,Q3AQ75,Q3B304,Q3BNA6,Q3J0B2,Q3J6W1,Q3JV72,Q3K4M6,Q3KM70,Q3SFR7,Q3SWM9,Q3YRU2,Q3YW02,Q45920,Q47BB1,Q47NK1,Q48Q06,Q491W8,Q49992,Q4FU67,Q4JVB1,Q4K3S2,Q4QLV3,Q4ULV2,Q4UPP2,Q4ZZX9,Q57BK5,Q57IA2,Q58502,Q5F9E0,Q5FN20,Q5GST1,Q5H5L9,Q5L6D8,Q5LIH9,Q5LWD3,Q5NHX4,Q5P7Z9,Q5PAE6,Q5PC28,Q5QZB6,Q5WTW6,Q5X242,Q5YT90,Q5ZSN0,Q603M1,Q62HL1,Q63WI6,Q64ZK3,Q65R66,Q66GD8,Q68WX8,Q69151,Q6A8W1,Q6AFE0,Q6AJZ0,Q6BRN7,Q6C141,Q6CQN7,Q6DAV9,Q6E4Q0,Q6FDR0,Q6FKQ6,Q6FYR2,Q6G202,Q6MEK7,Q6MVL2,Q6RZR1,Q6TUZ4,Q74ZF0,Q76RE7,Q775Z7,Q7M9N1,Q7MAX3,Q7MBE8,Q7MVT6,Q7NKL2,Q7VJU0,Q7VN49,Q7VRK0,Q7VVR1,Q7W8Z8,Q7WKE3,Q823Q9,Q82KK4,Q82UM1,Q83G43,Q83I22,Q83PN3,Q87F19,Q88BD3,Q88C95,Q895R1,Q89662,Q8A245,Q8D2F3,Q8E9M0,Q8F729,Q8FPH9,Q8G4E8,Q8K921,Q8NPA9,Q8P458,Q8PFR5,Q8RA46,Q8RER7,Q8SRS0,Q8UII1,Q8V2Y0,Q8XWL1,Q8ZJP5,Q90030,Q92I74,Q92SM6,Q97J61,Q98C10,Q9A253,Q9CJ30,Q9F7S4,Q9HTN3,Q9J5G5,Q9JUW1,Q9JZU7,Q9PGZ6,Q9PKA2,Q9X3X5,Q9YYS0,Q9Z9C2,Q9ZDD2,Q9ZKY3">deoxyuridine 5'-triphosphate nucleotidohydrolase</protein-id> (<protein-id="O25536,O27642,O29157,O30931,O41033,O48500,O52597,O54134,O66592,O68992,O83855,O84294,P03195,P03370,P06968,P09254,P0A552,P0A553,P10234,P14597,P16088,P16824,P16901,P17374,P19028,P23426,P23427,P28892,P28893,P30007,P31625,P31822,P32208,P32518,P33316,P33317,P33826,P35956,P43058,P43792,P52341,P52541,P57623,P57914,P59408,P61906,P61907,P61908,P61909,P61910,P61911,P61912,P61913,P64004,P64005,P64006,P64007,P64008,P64009,P68634,P68635,P70583,P87630,Q00030,Q01034,Q06095,Q07275,Q2Y742,Q2YRG4,Q31EC7,Q31UY6,Q329L7,Q39DM5,Q39V99,Q3A499,Q3AQ75,Q3B304,Q3BNA6,Q3J0B2,Q3J6W1,Q3JV72,Q3K4M6,Q3KM70,Q3SFR7,Q3SWM9,Q3YRU2,Q3YW02,Q45920,Q47BB1,Q47NK1,Q48Q06,Q491W8,Q49992,Q4FU67,Q4JVB1,Q4K3S2,Q4QLV3,Q4ULV2,Q4UPP2,Q4ZZX9,Q57BK5,Q57IA2,Q58502,Q5F9E0,Q5FN20,Q5GST1,Q5H5L9,Q5L6D8,Q5LIH9,Q5LWD3,Q5NHX4,Q5P7Z9,Q5PAE6,Q5PC28,Q5QZB6,Q5WTW6,Q5X242,Q5YT90,Q5ZSN0,Q603M1,Q62HL1,Q63WI6,Q64ZK3,Q65R66,Q66GD8,Q68WX8,Q69151,Q6A8W1,Q6AFE0,Q6AJZ0,Q6BRN7,Q6C141,Q6CQN7,Q6DAV9,Q6E4Q0,Q6FDR0,Q6FKQ6,Q6FYR2,Q6G202,Q6MEK7,Q6MVL2,Q6RZR1,Q6TUZ4,Q74ZF0,Q76RE7,Q775Z7,Q7M9N1,Q7MAX3,Q7MBE8,Q7MVT6,Q7NKL2,Q7VJU0,Q7VN49,Q7VRK0,Q7VVR1,Q7W8Z8,Q7WKE3,Q823Q9,Q82KK4,Q82UM1,Q83G43,Q83I22,Q83PN3,Q87F19,Q88BD3,Q88C95,Q895R1,Q89662,Q8A245,Q8D2F3,Q8E9M0,Q8F729,Q8FPH9,Q8G4E8,Q8K921,Q8NPA9,Q8P458,Q8PFR5,Q8PWG1,Q8RA46,Q8RER7,Q8SRS0,Q8TGX9,Q8TV34,Q8UII1,Q8V2Y0,Q8XWL1,Q8ZJP5,Q90030,Q92I74,Q92SM6,Q97J61,Q98C10,Q9A253,Q9CJ30,Q9F7S4,Q9HMF3,Q9HTN3,Q9J5G5,Q9JUW1,Q9JZU7,Q9P6Q5,Q9PGZ6,Q9PKA2,Q9X3X5,Q9YG32,Q9YYS0,Q9Z9C2,Q9ZDD2,Q9ZKY3">dUTPase</protein-id>) catalyses the hydrolysis of <compound-id="65070">dUTP</compound-id> to dUMP and PPi thus controlling the incorporation of <compound-id="1174">uracil</compound-id> into DNA genomes.	uracil__dUTPase__interaction	uracil__deoxyuridine 5'-triphosphate nucleotidohydrolase__interaction	dUTP__deoxyuridine 5'-triphosphate nucleotidohydrolase__interaction	dUTP__dUTPase__interaction
18608754-504	In the present study we perform a kinetic analysis of Campylobacter <protein-id="O25536,O27642,O29157,O30931,O41033,O48500,O52597,O54134,O66592,O68992,O83855,O84294,P03195,P03370,P06968,P09254,P0A552,P0A553,P10234,P14597,P16088,P16824,P16901,P17374,P19028,P23426,P23427,P28892,P28893,P30007,P31625,P31822,P32208,P32518,P33316,P33317,P33826,P35956,P43058,P43792,P52341,P52541,P57623,P57914,P59408,P61906,P61907,P61908,P61909,P61910,P61911,P61912,P61913,P64004,P64005,P64006,P64007,P64008,P64009,P68634,P68635,P70583,P87630,Q00030,Q01034,Q06095,Q07275,Q2Y742,Q2YRG4,Q31EC7,Q31UY6,Q329L7,Q39DM5,Q39V99,Q3A499,Q3AQ75,Q3B304,Q3BNA6,Q3J0B2,Q3J6W1,Q3JV72,Q3K4M6,Q3KM70,Q3SFR7,Q3SWM9,Q3YRU2,Q3YW02,Q45920,Q47BB1,Q47NK1,Q48Q06,Q491W8,Q49992,Q4FU67,Q4JVB1,Q4K3S2,Q4QLV3,Q4ULV2,Q4UPP2,Q4ZZX9,Q57BK5,Q57IA2,Q58502,Q5F9E0,Q5FN20,Q5GST1,Q5H5L9,Q5L6D8,Q5LIH9,Q5LWD3,Q5NHX4,Q5P7Z9,Q5PAE6,Q5PC28,Q5QZB6,Q5WTW6,Q5X242,Q5YT90,Q5ZSN0,Q603M1,Q62HL1,Q63WI6,Q64ZK3,Q65R66,Q66GD8,Q68WX8,Q69151,Q6A8W1,Q6AFE0,Q6AJZ0,Q6BRN7,Q6C141,Q6CQN7,Q6DAV9,Q6E4Q0,Q6FDR0,Q6FKQ6,Q6FYR2,Q6G202,Q6MEK7,Q6MVL2,Q6RZR1,Q6TUZ4,Q74ZF0,Q76RE7,Q775Z7,Q7M9N1,Q7MAX3,Q7MBE8,Q7MVT6,Q7NKL2,Q7VJU0,Q7VN49,Q7VRK0,Q7VVR1,Q7W8Z8,Q7WKE3,Q823Q9,Q82KK4,Q82UM1,Q83G43,Q83I22,Q83PN3,Q87F19,Q88BD3,Q88C95,Q895R1,Q89662,Q8A245,Q8D2F3,Q8E9M0,Q8F729,Q8FPH9,Q8G4E8,Q8K921,Q8NPA9,Q8P458,Q8PFR5,Q8PWG1,Q8RA46,Q8RER7,Q8SRS0,Q8TGX9,Q8TV34,Q8UII1,Q8V2Y0,Q8XWL1,Q8ZJP5,Q90030,Q92I74,Q92SM6,Q97J61,Q98C10,Q9A253,Q9CJ30,Q9F7S4,Q9HMF3,Q9HTN3,Q9J5G5,Q9JUW1,Q9JZU7,Q9P6Q5,Q9PGZ6,Q9PKA2,Q9X3X5,Q9YG32,Q9YYS0,Q9Z9C2,Q9ZDD2,Q9ZKY3">dUTPase</protein-id> using the continuous spectrophotometric method and show that the enzyme is highly specific for <compound-id="13712">deoxyuridine</compound-id> nucleotides.	deoxyuridine__dUTPase__interaction
18608755-505	<protein-id="O07674,O30971,P0A853,P0A854,P21643,P28796,P48775,P48776,Q09474,Q2KIQ5,Q59342,Q5EBG2,Q5U4U6,Q7MCR1,Q7N8C9,Q7NYV9,Q7SY53,Q87JQ6,Q894M8,Q8D5Q4,Q8FBV2,Q8R9K5,Q8XB34,Q9CL27,Q9KN05,Q9ZNA8">Tryptophanase</protein-id> (tryptophan indole-lyase, Tnase, EC 4.1.99.1), a bacterial enzyme with no counterpart in eukaryotic cells, produces from <compound-id="4802,6305,5460850">L-tryptophan</compound-id> <compound-id="1060">pyruvate</compound-id>, <compound-id="222">ammonia</compound-id> and indole.	ammonia__Tryptophanase__interaction	L-tryptophan__Tryptophanase__interaction	pyruvate__Tryptophanase__interaction
18608764-1428	The structure-activity models of the <protein-id="O08775,P35918,P35968,P52583,Q8AXB3">VEGFR2</protein-id> kinase inhibitory activity of the derivatives of 2-<compound-id="137550">anilino</compound-id>-5-aryloxazole have been investigated using Combinatorial Protocol in Multiple Linear Regression (CP-MLR) with nearly 500 topological descriptors which were calculated from DRAGON software.	anilino__VEGFR2__interaction
18608765-513	Activity assays with <protein-id="P12614,P15885,P27034,P29091,P40740,Q03506,Q46684">beta-glucosidase</protein-id> indicated that <compound-id="5858639">compound 3</compound-id> was much more stable than the corresponding pentasaccharide.	compound 3__beta-glucosidase__interaction
18608766-514	<protein-id="O00084,O13465,P07374,P08298,Q5KCQ6,Q6A3P9">Urease</protein-id> allows soil microorganisms to use <compound-id="1176,265993">urea</compound-id> as a source of <compound-id="947,123329">nitrogen</compound-id> and aid in the rapid break down of <compound-id="1176,265993">urea</compound-id>-based fertilizers resulting in phytopathicity.	urea__Urease__interaction	nitrogen__Urease__no_interaction
18608782-527	<protein-id="O83085,P00813,P03958,P22333,P53909,P53984,P56658,P63907,P63908,P63909,P63910,Q2TZN9,Q4IMJ1,Q4X1Q4,Q59ZB1,Q5ZKP6,Q63ZU0,Q6CM42,Q6DG22,Q6FP78,Q6GP70,Q7M9R5,Q7MDL6,Q7N4H5,Q7VNV1,Q7WBG5,Q7WMY6,Q839J4,Q83RC0,Q889J2,Q88QA3,Q8D6Q8,Q8DTN8,Q8E8D4,Q8FH99,Q8UJ05,Q8X1T6,Q8X661,Q8XHH8,Q8XXL5,Q8Z6R2,Q8ZPL9,Q920P6,Q92T48,Q97EV1,Q98GV2,Q9A3M3,Q9CCL9,Q9CIR9,Q9I6Y4,Q9KNI7,Q9P6I7">Adenosine deaminase</protein-id> (<protein-id="P00813,P56658,Q5ZKP6">ADA</protein-id>), an enzyme involved in purine metabolism, catalyzes the hydrolytic breakdown of <compound-id="60961">adenosine</compound-id> into <compound-id="6021">inosine</compound-id> and free <compound-id="222">ammonia</compound-id>.	adenosine__ADA__interaction	inosine__ADA__interaction	ammonia__ADA__interaction	adenosine__Adenosine deaminase__interaction	ammonia__Adenosine deaminase__interaction	inosine__Adenosine deaminase__interaction
18609042-761	Diastolic function and <protein-id="P40753,P83965,Q805D7,Q805E8,Q9GLK4">BNP</protein-id> changes during exercise predict <compound-id="977">oxygen</compound-id> consumption in chronic heart failure patients.	oxygen__BNP__interaction
18609294-966	Although incubation with <protein-id="P10765,P22393,P33089,P33090,P33091,P43001">prolactin</protein-id> (<protein-id="O62781,O62819,O93337,P01236,P01237,P01238,P01239,P01240,P06879,P09585,P10765,P12420,P14676,P17572,P21993,P22393,P29234,P29235,P33089,P33090,P33091,P33096,P34181,P35395,P37884,P40424,P43001,P43299,P46403,P48096,P48249,P51904,P55151,P87495,Q28318,Q28632,Q3Y4G6,Q6UC74,Q7ZZV3,Q8HXS1,Q9QZL1,Q9YGV6">PRL</protein-id>) and/or adrenocorticotrophic hormone (<protein-id="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5">ACTH</protein-id>) resulted in a dose-dependent increase of <compound-id="5753">corticosterone</compound-id> and <compound-id="5994">progesterone</compound-id> release by adrenal cells from both HAA and LAA male rats, the responses were markedly increased for adrenal cells from LAA rats as compared with HAA rats.	corticosterone__ACTH__interaction	corticosterone__prolactin__interaction	progesterone__ACTH__interaction	corticosterone__PRL__interaction	progesterone__PRL__interaction	progesterone__prolactin__interaction
18609433-1079	<compound-id="5324346">Fluvoxamine</compound-id>, a SSRI, is mainly metabolized by <protein-id="O08469">cytochrome P450</protein-id> (<protein-id="P21568,P21569,P24525,P34887,Q26551">CYP</protein-id>) 2D6 and 1A2.	Fluvoxamine__CYP__interaction	Fluvoxamine__cytochrome P450__interaction
18611940-1422	Ki-67 <compound-id="28486">LI</compound-id> in clear cell adenoma components was lower than in common adenoma components of the same dysplasia grades (while <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id> and <protein-id="P26233,P35222,P35223,P35224,Q02248,Q9WU82">beta-catenin</protein-id> were similarly expressed).	LI__beta-catenin__no_interaction	LI__p53__no_interaction
18612599-292	<protein-id="P35557,Q12851,Q61161">GCK</protein-id> is expressed in the rat DVC, where mRNA is localized to neurons that exhibit electrophysiological sensitivity to <compound-id="206,5793,64689,79025">glucose</compound-id> imbalance.	glucose__GCK__no_interaction
18612687-586	However, <compound-id="23976">CR</compound-id>-ME had a little effect on the levels of reactive <compound-id="977">oxygen</compound-id> species, interleukin-1 and <protein-id="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9">IFN-gamma</protein-id> in <compound-id="23976">CR</compound-id>-ME-treated macrophages.	oxygen__IFN-gamma__no_interaction	CR__IFN-gamma__interaction
18612687-587	Thus, the tumoricidal effect of <compound-id="23976">CR</compound-id>-ME appeared to be mainly mediated by NO and <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id> production from macrophages.	CR__TNF-alpha__interaction
18612687-589	These results suggest that <compound-id="23976">CR</compound-id>-ME induces the tumoricidal activity via the <protein-id="O62618">p38 MAPK</protein-id>-dependent pathway.	CR__p38 MAPK__interaction
18612775-1047	<protein-id="P14902,P28776">Indoleamine 2,3-dioxygenase</protein-id> (<protein-id="P14902,P28776">IDO</protein-id>) catalyzes the first and rate-limiting step of <compound-id="846">Kynurenine</compound-id> pathway along the major route of Tryptophan catabolism.	Kynurenine__IDO__interaction	Kynurenine__Indoleamine 2,3-dioxygenase__interaction
18612777-425	Type I <protein-id="P40746,P52183,P81453,Q819L3,Q81MS1,Q8GR90,Q9K5W7">transglutaminase</protein-id> (TG1), an enzyme that catalyzes the formation of epsilon-(gamma-glutamyl) <compound-id="866,5962">lysine</compound-id> bonds, is the key protein responsible for generation of the crosslinks.	lysine__transglutaminase__interaction
18612811-461	<protein-id="P01108,P09416,P52160">Myc</protein-id>-oncogene inactivating effect by <compound-id="614,8988,145742">proline</compound-id> rich polypeptide (PRP-1) in chondrosarcoma JJ012 cells.	proline__Myc__interaction
18612819-471	Like PSC, DSL6A cells secrete less <protein-id="P05305,P09558,P13206,P17322,P22387,P22388,P29560,P97740,Q28469,Q5NRP9,Q5NRQ1,Q9BG76">ET-1</protein-id> when cultured with <compound-id="104865">bosentan</compound-id>.	bosentan__ET-1__interaction
18612824-1284	Caspase inhibition with z-<compound-id="5289545">VAD</compound-id> was unable to prevent <protein-id="O95831">AIF</protein-id> localization to the nucleus and subsequently unable to prevent cell death.	VAD__AIF__no_interaction
18614168-1607	Purinergic receptor agonists <compound-id="5957">ATP</compound-id> and <compound-id="6133">UTP</compound-id> selectively activate certain <protein-id="P05480,Q9WUD9">Src</protein-id> family tyrosine kinases and stimulate Na,K-ATPase activity.	ATP__Src__interaction	UTP__Src__interaction
18615010-596	Early deprivation led to decreases in hippocampal <protein-id="P06836,P06837,P07936,P17677,P17691,P35001,P55860,Q5IS67,Q5NVP7,Q6S9D9,Q95K78,Q98987">growth-associated protein-43</protein-id> (<protein-id="P09851,P20936,P50904,P74851,P74873,Q5PEA9,Q92211,Q92263">GAP</protein-id>-43) mRNA, serotonin 1A receptor (5-HT(1A)R) mRNA and binding ([<compound-id="5684">3H]WAY100635</compound-id>), and to increased <protein-id="O35458,O35633,P34579,Q95KE2,Q9H598">vesicular GABA transporter</protein-id> mRNA.	3H]WAY100635__GAP__no_interaction	3H]WAY100635__growth-associated protein-43__no_interaction	3H]WAY100635__vesicular GABA transporter__no_interaction
18615011-597	We measured the ability to increase GABA in eight healthy subjects by comparing the binding of [(11)C] <compound-id="3373">flumazenil</compound-id>, a positron emission tomography (PET) radiotracer specific for the benzodiazepine (BDZ) site, at baseline and in the presence of an acute elevation in GABA levels through the blockade of the GABA membrane transporter (<protein-id="P30531,P36148,P43574">GAT1</protein-id>).	flumazenil__GAT1__no_interaction
18615011-598	<protein-id="P30531,P36148,P43574">GAT1</protein-id> blockade resulted in significant increases in mean (+/-SD) [(11)C] <compound-id="3373">flumazenil</compound-id>-binding potential (BP(ND)) over baseline in brain regions representing the major functional domains of the cerebral cortex: association cortex+15.2+/-20.2% (p=0.05), sensory cortex+13.5+/-15.5% (p=0.03) and limbic (medial temporal lobe, MTL)+16.4+/-20.2% (p=0.03).	flumazenil__GAT1__interaction
18615280-830	<protein-id="O33830,O43451,O59645,P21517,P43473,Q02751">alpha-Glucosidase</protein-id> inhibitory activity of <compound-id="44256700">cyanidin-3-galactoside</compound-id> and synergistic effect with <compound-id="41774,441184,444254,445421,4432690">acarbose</compound-id>.	cyanidin-3-galactoside__alpha-Glucosidase__interaction	acarbose__alpha-Glucosidase__interaction
18615280-831	<compound-id="44256700">Cyanidin-3-galactoside</compound-id>, a natural <compound-id="145858">anthocyanin</compound-id>, was investigated for its <protein-id="O33830,O43451,O59645,P21517,P43473,Q02751">alpha-glucosidase</protein-id> inhibitory activity.	anthocyanin__alpha-glucosidase__no_interaction	Cyanidin-3-galactoside__alpha-glucosidase__interaction
18615288-840	A series of systematically modified vanadyl-beta-<compound-id="167775">diketone</compound-id> complexes, VO(beta-<compound-id="167775">diketone</compound-id>)(2), bearing substituent groups with different electron inductive properties were synthesized and evaluated as inhibitors against calf-intestine <protein-id="O60109,P81800,P83456">alkaline phosphatase</protein-id> (<protein-id="P00634,P19147,P21948">APase</protein-id>).	diketone__APase__interaction	diketone__alkaline phosphatase__interaction
18615705-81	The susceptibilities to three organophosphate (OP) insecticides (<compound-id="4004">malathion</compound-id>, <compound-id="2730">chlorpyrifos</compound-id>, and <compound-id="9570290">phoxim</compound-id>), responses to three metabolic synergists [<compound-id="8289">triphenyl phosphate</compound-id> (TPP), <compound-id="5794">piperonyl butoxide</compound-id> (PBO), and <compound-id="5271566">diethyl maleate</compound-id> (DEM)], activities of major detoxification enzymes [general <protein-id="P16397,P18773">esterases</protein-id> (ESTs), <protein-id="O04437,O18598,P0A9D2,P0A9D3,P30116,P44521,P46088,P46419,P46423,P46426,P46428,P46437,P48438,P80894,P81065,P82996,P82997,P82998,P82999,P83000,P83001,P83246,Q04522,Q08392,Q08393,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52,Q96324">glutathione S-transferases</protein-id> (<protein-id="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52">GSTs</protein-id>), and <protein-id="O08469">cytochrome P450</protein-id> monooxygenases (P450s)], and sensitivity of the target enzyme <protein-id="Q867X2,Q867X3,Q86GC9,Q92081">acetylcholinesterase</protein-id> (<protein-id="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3">AChE</protein-id>) were compared between a laboratory-susceptible strain (LS) and a field-resistant population (FR) of the oriental migratory locust, Locusta migratoria manilensis (Meyen).	triphenyl phosphate__acetylcholinesterase__no_interaction	phoxim__acetylcholinesterase__no_interaction	phoxim__AChE__no_interaction	triphenyl phosphate__GSTs__no_interaction	phoxim__esterases__no_interaction	piperonyl butoxide__GSTs__no_interaction	triphenyl phosphate__glutathione S-transferases__no_interaction	phoxim__GSTs__no_interaction	chlorpyrifos__GSTs__no_interaction	piperonyl butoxide__glutathione S-transferases__no_interaction	piperonyl butoxide__esterases__no_interaction	diethyl maleate__cytochrome P450__no_interaction	diethyl maleate__acetylcholinesterase__no_interaction	malathion__acetylcholinesterase__no_interaction	malathion__GSTs__no_interaction	chlorpyrifos__cytochrome P450__no_interaction	chlorpyrifos__esterases__no_interaction	malathion__cytochrome P450__no_interaction	piperonyl butoxide__acetylcholinesterase__no_interaction	triphenyl phosphate__esterases__no_interaction	piperonyl butoxide__cytochrome P450__no_interaction	diethyl maleate__AChE__no_interaction	diethyl maleate__GSTs__no_interaction	piperonyl butoxide__AChE__no_interaction	chlorpyrifos__AChE__no_interaction	malathion__esterases__no_interaction	triphenyl phosphate__AChE__no_interaction	malathion__AChE__no_interaction	phoxim__cytochrome P450__no_interaction	chlorpyrifos__acetylcholinesterase__no_interaction	diethyl maleate__glutathione S-transferases__no_interaction	diethyl maleate__esterases__no_interaction	phoxim__glutathione S-transferases__no_interaction	malathion__glutathione S-transferases__no_interaction	chlorpyrifos__glutathione S-transferases__no_interaction	triphenyl phosphate__cytochrome P450__no_interaction
18615705-83	All these results clearly indicated that the observed <compound-id="4004">malathion</compound-id> resistance in the FR was conferred by multiple mechanisms, including increased detoxification by ESTs and <protein-id="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52">GSTs</protein-id>, and increased activity and reduced sensitivity of <protein-id="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3">AChE</protein-id> to OP inhibition.	malathion__GSTs__interaction	malathion__AChE__interaction
18615707-1194	<protein-id="O64362,O80288,O80292,P00720,P03706,P07540,P09963,P10439,P11187,P13656,P15057,P19385,P19386,P21270,P23472,P23473,P27359,P33486,P37715,P39046,P51771,P62692,P62693,P68920,P68921,P81241,P82174,P82175,P83673,Q27650,Q37875,Q37896,Q48603,Q7SID7,Q9CIT4,Q9T1X2,Q9ZXB7">Lysozymes</protein-id> act as crucial bacteriolytic enzymes in insect immune system by hydrolyzing the beta (1--&gt;4) bonds between <compound-id="24139">N-acetylglucosamine</compound-id> and <compound-id="440822,542212,5462244,6323218">N-acetylmuramic acid</compound-id> in the <compound-id="9816401">peptidoglycan</compound-id> of prokaryotic cell walls.	N-acetylglucosamine__Lysozymes__interaction	N-acetylmuramic acid__Lysozymes__interaction	peptidoglycan__Lysozymes__no_interaction
18615734-449	These mRNAs no longer encode the <protein-id="P08567,Q4KM33,Q6Q308,Q9JHK5">pleckstrin</protein-id> homology (PH) domain of <protein-id="O43307,Q3UTH8,Q58DL7,Q5RDK0,Q9QX73">collybistin</protein-id>, which we now show binds <compound-id="6857403,9776841">phosphatidylinositol-3-phosphate</compound-id> (PI3P/<compound-id="643964,24755494">PtdIns-3-P</compound-id>), a <compound-id="16738692">phosphoinositide</compound-id> with an emerging role in membrane trafficking and signal transduction, rather than <compound-id="643963">phosphatidylinositol 3,4,5-trisphosphate</compound-id> (PIP3/<compound-id="643963">PtdIns-3,4,5-P</compound-id>) as previously suggested in the " membrane activation model" of <protein-id="Q03555,Q9NQX3">gephyrin</protein-id> clustering.	phosphatidylinositol-3-phosphate__pleckstrin__no_interaction	phosphoinositide__collybistin__no_interaction	PtdIns-3-P__collybistin__interaction	phosphatidylinositol 3,4,5-trisphosphate__collybistin__no_interaction	phosphatidylinositol 3,4,5-trisphosphate__pleckstrin__no_interaction	PtdIns-3,4,5-P__collybistin__interaction	PtdIns-3-P__pleckstrin__no_interaction	PtdIns-3,4,5-P__pleckstrin__no_interaction	PtdIns-3,4,5-P__gephyrin__no_interaction	phosphatidylinositol-3-phosphate__collybistin__interaction	phosphoinositide__pleckstrin__no_interaction	PtdIns-3-P__gephyrin__no_interaction	phosphatidylinositol-3-phosphate__gephyrin__no_interaction	phosphoinositide__gephyrin__no_interaction	phosphatidylinositol 3,4,5-trisphosphate__gephyrin__no_interaction
18616717-310	We investigated whether several different inflammatory markers including C-reactive protein (<protein-id="O19062,P02741,P02742,P08462,P18151,P21291,P41964,P47875,P49254,P49262,P52753,P67966,P67967,P97315,Q07203">CRP</protein-id>) and <protein-id="P22775,P81070">fibrinogen</protein-id> and white blood cells (WBCs) count, are associated with maximal <compound-id="977">oxygen</compound-id> consumption (VO(2 max)) in women with polycystic ovary syndrome (PCOS).	oxygen__CRP__interaction	oxygen__fibrinogen__interaction
18616988-540	Microelectrode array recordings revealed that <compound-id="977">oxygen</compound-id>-<compound-id="206,5793,64689,79025">glucose</compound-id> deprivation enhances hippocampal network firing rates, which induces c-<protein-id="P01101,P12841,Q56415">fos</protein-id> transcription through a signaling pathway that, in contrast to Clca1, is activated by synaptic but not extrasynaptic NMDA receptors.	oxygen__fos__interaction	glucose__fos__interaction
18617682-1119	CSE activated the <protein-id="P03956,P13943,P21692,P28053,P81563,Q11133,Q9XSZ5">MMP-1</protein-id> promoter, and this induction was prevented by <compound-id="4713">PD98059</compound-id> blockade of <protein-id="P27361,P28869,P42525,Q07176">ERK1</protein-id>/2 phosphorylation.	PD98059__ERK1__interaction	PD98059__MMP-1__interaction
18617682-1120	Cotransfection, <compound-id="29051,163659,230076,457831,6326719">mithramycin</compound-id>, and electrophoretic mobility shift assay studies identified activating and repressive roles for <protein-id="O14300,O89090,P17379,Q01714,Q85439,Q85449,Q85451">Sp1</protein-id> and PEA3 transcription factors, respectively.	mithramycin__Sp1__no_interaction
18617751-1188	We have previously demonstrated that <compound-id="5311181,6435378,6443959,53394043,53486260">iloprost</compound-id>, a stable <compound-id="5280427,5282411,6434194">prostacyclin</compound-id> (PGI (2)) analogue, induces angiogenesis in vivo, through a vascular endothelial growth factor (<protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id>)-dependent mechanism.	iloprost__VEGF__interaction	prostacyclin__VEGF__no_interaction
18617751-1189	In this study, we demonstrate that <compound-id="5311181,6435378,6443959,53394043,53486260">iloprost</compound-id>-induced angiogenesis and <protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id> upregulation are modulated by <protein-id="O35507,P23204,P37230,P37232,Q07869,Q8HYL6,Q95N78">peroxisome proliferator-activated receptor-alpha</protein-id> (<protein-id="O35507,P23204,P37230,P37232,Q07869,Q8HYL6,Q95N78">PPARalpha</protein-id>), a ligand-inducible transcription factor that belongs to the nuclear hormone receptor superfamily and plays multiple biological activities in the vascular system.	iloprost__VEGF__interaction	iloprost__PPARalpha__interaction	iloprost__peroxisome proliferator-activated receptor-alpha__interaction
18617751-1191	In contrast, <compound-id="5311181,6435378,6443959,53394043,53486260">iloprost</compound-id> induces a robust angiogenic response in wild-type mice, along with local upregulation of <protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id>.	iloprost__VEGF__interaction
18617751-1192	Importantly, mice lacking the PPARalpha gene exhibit a normal angiogenic response to <protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id>, indicating that the absence of PPARalpha does not result in a general impairment of angiogenesis, but specifically affects the ability of <compound-id="5311181,6435378,6443959,53394043,53486260">iloprost</compound-id> to induce angiogenesis.	iloprost__VEGF__no_interaction
18618086-1424	Inhibition of acyl-<compound-id="317,6816,87642,444624,445126,447444,448506,44216777,44246472">coenzyme A</compound-id> : cholesterol <protein-id="P05521,P19197,P21309,P23148,P41302,Q06878,Q7N576,Q9AJA7,Q9S3Z2">acyltransferase</protein-id> (<protein-id="O77761,P23141,P24752,P35610,Q60457">ACAT</protein-id>), which generates intracellular cholesteryl esters from free cholesterol and fatty acids, reduces the biogenesis of the Abeta from the amyloid precursor protein (<protein-id="O73683,O93279,P05067,P08592,P0A3Z1,P0A3Z2,P0A3Z3,P0A3Z4,P12023,P29216,P47566,P53601,P75313,P79307,Q11207,Q28053,Q28280,Q28748,Q28757,Q29149,Q5IS80,Q60495,Q95241">APP</protein-id>).	coenzyme A__ACAT__interaction	coenzyme A__acyltransferase__interaction	coenzyme A__APP__interaction
18618086-1425	The proportion of <protein-id="O73683,O93279,P05067,P08592,P0A3Z1,P0A3Z2,P0A3Z3,P0A3Z4,P12023,P29216,P47566,P53601,P75313,P79307,Q11207,Q28053,Q28280,Q28748,Q28757,Q29149,Q5IS80,Q60495,Q95241">APP</protein-id> molecules that are directed to the novel cleavage pathway is regulated by the ratio of free <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> and cholesteryl esters in cells.	cholesterol__APP__interaction
18618240-1582	In the hormone receptor-positive breast cancer cell line T47-D expression of <protein-id="P78310">hCAR</protein-id> and its soluble isoforms was increased by treatment with <compound-id="5757">estradiol</compound-id> and <compound-id="2733526">tamoxifen</compound-id>.	tamoxifen__hCAR__interaction	estradiol__hCAR__interaction
18618241-1584	In contrast to the behavior in aqueous solution, lactose binding in <compound-id="679">DMSO</compound-id> resulted in an increase of the <protein-id="P02871,P02873,P02874,P02875,P07386,P16108,P16349,P16351,P16352,P33888,P38662,P42088,P83410,P83511,P84987,Q41114">lectin</protein-id>'s radius of gyration from 49+/-1 to 55.5+/-1 A.	DMSO__lectin__interaction
18618243-1587	<protein-id="Q8JFG3">Tumor necrosis factor</protein-id>-alpha (<protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id>) levels were also investigated in rat serum, but there was no statistically significant difference between the <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id> levels of the <compound-id="2519">caffeine</compound-id>-treated rats groups and the control rats.	caffeine__Tumor necrosis factor__no_interaction	caffeine__TNF-alpha__no_interaction
18618243-1588	Our study indicates that brain <protein-id="O49046,P00812,P0A2X9,P0A2Y0,P0A2Y1,P14012,P33280,P37818,P39138,P40906,P46637,P53608,P60086,P60087,P60088,Q10066,Q12611,Q1E180,Q6G7E9,Q6GER3,Q74ZW4,Q7M0Z3,Q8NVE3">arginase</protein-id> activity decreases after <compound-id="2519">caffeine</compound-id> administration at doses of 30 mg/kg and 100 mg/kg.	caffeine__arginase__interaction
18618245-1590	Comparison of the PTM's of <protein-id="P02686,P02687,P04370,P06906,P13727,P15720,P20939,P25188,P25274,P25336,P81558,P83487,P87346,P98190,Q61878,Q63189,Q91325,Q91439,Q9SAV1">MBP</protein-id>'s isolated from several vertebrate species reveals marked differences in their <compound-id="1061,167704,644102">phosphate</compound-id> content.	phosphate__MBP__interaction
18618245-1591	Chicken <protein-id="P02686,P02687,P04370,P06906,P13727,P15720,P20939,P25188,P25274,P25336,P81558,P83487,P87346,P98190,Q61878,Q63189,Q91325,Q91439,Q9SAV1">MBP</protein-id> does not share any phosphorylated sites with dogfish <protein-id="P02686,P02687,P04370,P06906,P13727,P15720,P20939,P25188,P25274,P25336,P81558,P83487,P87346,P98190,Q61878,Q63189,Q91325,Q91439,Q9SAV1">MBP</protein-id> ; However, it does contain phosphorylated <compound-id="5951">serine</compound-id> and <compound-id="6288">threonine</compound-id> residues in common with mammalian <protein-id="P02686,P02687,P04370,P06906,P13727,P15720,P20939,P25188,P25274,P25336,P81558,P83487,P87346,P98190,Q61878,Q63189,Q91325,Q91439,Q9SAV1">MBP</protein-id>.	threonine__MBP__interaction	serine__MBP__interaction
18618304-1646	<compound-id="5070">Riluzole</compound-id>/<compound-id="4775">NaPB</compound-id> administration increased acetylation at H4 and increased NF-kappaB <protein-id="P23061,P38644,P83939,Q05894,Q28618,Q43731">p50</protein-id> translocation to the nucleus in G93A mice, consistent with a therapeutic effect.	Riluzole__p50__interaction	NaPB__p50__interaction
18618472-1060	Due to the absence of hydrophobic solute-material interactions, which limit the scope of microstructures fabricated from poly(dimethylsiloxane) for biocatalytic applications, the new microreactor was fully compatible with the alternate enzyme substrate 2-nitro-<compound-id="16218547">phenyl-beta-D-galactoside</compound-id> and the <compound-id="6947">2-nitro-phenol</compound-id> product resulting from its hydrolysis catalyzed by <protein-id="P04956,P06565,P06963,P10474,P17334,P18126,P22698,P23550,P23661,P26222,P37701,P38569,P46317,Q45400">CelB</protein-id>.	2-nitro-phenol__CelB__interaction	phenyl-beta-D-galactoside__CelB__interaction
18618621-1255	These findings suggest that multiple variations in the <protein-id="O35899,P31645,Q9MYX0,Q9XT49">SLC6A4</protein-id> gene are associated with remission in white non-Hispanic depressed adults treated with <compound-id="2771,146570">citalopram</compound-id>.	citalopram__SLC6A4__interaction
18618694-248	The planar angle between the <compound-id="278">carbamoyl phosphate</compound-id> and <compound-id="5960">aspartate</compound-id> domains of the catalytic chain is more open at pH 8.5 than in <protein-id="O25716,O27464,O30130,O58451,O66726,P05654,P0A1Z4,P0A1Z5,P0A786,P0A787,P0A788,P0A789,P19910,P41008,P49077,P56585,P57450,P65611,P65612,P65613,P65614,P65615,P65616,P65617,P65618,P65619,P65620,P65621,P74163,P77883,P77918,P96079,P96111,P96174,Q04595,Q2W156,Q55338,Q58976,Q59653,Q59711,Q5E7U5,Q5FGW9,Q5FJB7,Q5FRG8,Q5H2Z0,Q5HBA3,Q5HGN2,Q5HPZ1,Q5HU06,Q5JHM9,Q5L0U6,Q5LX75,Q5M0X1,Q5M5F8,Q5N3S1,Q5NPE5,Q5P6I4,Q5PAN5,Q5PJB2,Q5SK66,Q5V2T3,Q5WFI9,Q5WYW3,Q5X7G7,Q5XCR9,Q5YTM0,Q5ZXZ2,Q60252,Q605F1,Q62I89,Q636D7,Q63RI2,Q64U74,Q65JV0,Q665I6,Q67Q01,Q6A917,Q6AF88,Q6AS40,Q6DA73,Q6FCR5,Q6FZS5,Q6G3F3,Q6GA13,Q6GHN5,Q6HES5,Q6L0F2,Q6LUX0,Q6LWQ0,Q6N565,Q6NH13,Q71YH8,Q727F4,Q72KU0,Q72NJ5,Q732I0,Q73GP1,Q741H5,Q74DP5,Q74J31,Q7M9Y9,Q7MHF1,Q7MX58,Q7MZ16,Q7NCV1,Q7P145,Q7U9G2,Q7UNR3,Q7V355,Q7V4X7,Q7VDV6,Q7VIT3,Q7W044,Q7W3U7,Q7WF77,Q819S0,Q81WE9,Q827R1,Q82U44,Q83A16,Q87C22,Q87LF8,Q87V99,Q88D30,Q89K19,Q8A9S3,Q8CPJ7,Q8D293,Q8DCF6,Q8DIM4,Q8DPH9,Q8DUP5,Q8DZQ5,Q8E5F3,Q8ER38,Q8EUX9,Q8F812,Q8FT39,Q8G655,Q8K9H9,Q8KBI7,Q8NQ38,Q8P1G1,Q8P767,Q8PII1,Q8PXK5,Q8R9R5,Q8RG89,Q8THL2,Q8TVB2,Q8U373,Q8UFT9,Q8XL59,Q8Y1L2,Q8Y662,Q8YWD2,Q8ZB39,Q8ZYH7,Q92AH0,Q92QL5,Q934T0,Q970X2,Q97B29,Q97FS3,Q97QE2,Q98M86,Q9A5K4,Q9CCR5,Q9CF79,Q9HHN4,Q9HKM2,Q9K9V6,Q9KP66,Q9KXR2,Q9L4N6,Q9L4T8,Q9PBB8,Q9PNJ6,Q9RVC0,Q9UX08,Q9YBD4,Q9ZM81">ATCase</protein-id> structures determined at lower pH values.	aspartate__ATCase__interaction	carbamoyl phosphate__ATCase__interaction
18618700-254	At 0.15 microM <compound-id="271">Ca(2</compound-id>+), [(35)S] <protein-id="O02367,O16305,O60041,O82018,O94739,O96102,O97341,P02594,P02595,P02598,P02599,P04352,P04353,P04464,P05933,P05934,P05935,P06787,P07463,P11118,P11120,P11121,P15094,P17928,P18061,P21251,P23286,P24044,P27161,P27165,P27166,P41040,P41041,P48976,P60204,P60205,P60206,P61859,P61860,P61861,P62144,P62145,P62149,P62151,P62152,P62154,P62155,P62156,P62157,P62158,P62160,P62161,P62162,P62184,P62201,P62202,P62203,P62204,P69097,P69098,P84339,P93087,P93171,Q00168,Q05055,Q39752,Q40302,Q5EHV7,Q5RAD2,Q6IT78,Q6PI52,Q6R520,Q6YNX6,Q71UH5,Q71UH6,Q7T3T2,Q7Y052,Q8STF0,Q8X187,Q95NI4,Q95NR9,Q9GRJ1,Q9HFY6,Q9U6D3,Q9UWF0">CaM</protein-id> bound to <protein-id="P30957,Q92736">RyR2</protein-id> with decreased affinity and binding enthalpy compared with <protein-id="P11716,P16960,P21817">RyR1</protein-id>.	Ca(2__RyR2__interaction	Ca(2__CaM__interaction	Ca(2__RyR1__interaction
18618700-255	The rates of [(35)S] <protein-id="O02367,O16305,O60041,O82018,O94739,O96102,O97341,P02594,P02595,P02598,P02599,P04352,P04353,P04464,P05933,P05934,P05935,P06787,P07463,P11118,P11120,P11121,P15094,P17928,P18061,P21251,P23286,P24044,P27161,P27165,P27166,P41040,P41041,P48976,P60204,P60205,P60206,P61859,P61860,P61861,P62144,P62145,P62149,P62151,P62152,P62154,P62155,P62156,P62157,P62158,P62160,P62161,P62162,P62184,P62201,P62202,P62203,P62204,P69097,P69098,P84339,P93087,P93171,Q00168,Q05055,Q39752,Q40302,Q5EHV7,Q5RAD2,Q6IT78,Q6PI52,Q6R520,Q6YNX6,Q71UH5,Q71UH6,Q7T3T2,Q7Y052,Q8STF0,Q8X187,Q95NI4,Q95NR9,Q9GRJ1,Q9HFY6,Q9U6D3,Q9UWF0">CaM</protein-id> dissociation from <protein-id="P11716,P16960,P21817">RyR1</protein-id> increased as the temperature was raised, whereas at 0.15 microM <compound-id="271">Ca(2</compound-id>+) the rate from <protein-id="P30957,Q92736">RyR2</protein-id> was little affected.	Ca(2__RyR2__interaction	Ca(2__RyR1__no_interaction	Ca(2__CaM__no_interaction
18619522-636	In rats, infusion of angiotensin II increases <protein-id="Q26061">ferritin</protein-id> levels and arterial thickness which are reversed by treatment with the iron chelator <compound-id="2973">deferoxamine</compound-id>.	deferoxamine__ferritin__interaction
18619705-1094	Furthermore, <compound-id="3213">ellipticine</compound-id> regulated endogenous survival signaling by up-regulating phosphorylated <protein-id="P31750,Q8INB9">Akt</protein-id> that returned to its basal level later.	ellipticine__Akt__interaction
18619705-1095	Furthermore, <compound-id="3213">ellipticine</compound-id> induced nucleus translocalization of <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id> and <protein-id="P31750,Q8INB9">Akt</protein-id> and recruitment of autophagosomes.	ellipticine__Akt__interaction	ellipticine__p53__interaction
18619713-1104	The ubiquitous enzyme dUTP nucleotidohydrolase (<protein-id="O25536,O27642,O29157,O30931,O41033,O48500,O52597,O54134,O66592,O68992,O83855,O84294,P03195,P03370,P06968,P09254,P0A552,P0A553,P10234,P14597,P16088,P16824,P16901,P17374,P19028,P23426,P23427,P28892,P28893,P30007,P31625,P31822,P32208,P32518,P33316,P33317,P33826,P35956,P43058,P43792,P52341,P52541,P57623,P57914,P59408,P61906,P61907,P61908,P61909,P61910,P61911,P61912,P61913,P64004,P64005,P64006,P64007,P64008,P64009,P68634,P68635,P70583,P87630,Q00030,Q01034,Q06095,Q07275,Q2Y742,Q2YRG4,Q31EC7,Q31UY6,Q329L7,Q39DM5,Q39V99,Q3A499,Q3AQ75,Q3B304,Q3BNA6,Q3J0B2,Q3J6W1,Q3JV72,Q3K4M6,Q3KM70,Q3SFR7,Q3SWM9,Q3YRU2,Q3YW02,Q45920,Q47BB1,Q47NK1,Q48Q06,Q491W8,Q49992,Q4FU67,Q4JVB1,Q4K3S2,Q4QLV3,Q4ULV2,Q4UPP2,Q4ZZX9,Q57BK5,Q57IA2,Q58502,Q5F9E0,Q5FN20,Q5GST1,Q5H5L9,Q5L6D8,Q5LIH9,Q5LWD3,Q5NHX4,Q5P7Z9,Q5PAE6,Q5PC28,Q5QZB6,Q5WTW6,Q5X242,Q5YT90,Q5ZSN0,Q603M1,Q62HL1,Q63WI6,Q64ZK3,Q65R66,Q66GD8,Q68WX8,Q69151,Q6A8W1,Q6AFE0,Q6AJZ0,Q6BRN7,Q6C141,Q6CQN7,Q6DAV9,Q6E4Q0,Q6FDR0,Q6FKQ6,Q6FYR2,Q6G202,Q6MEK7,Q6MVL2,Q6RZR1,Q6TUZ4,Q74ZF0,Q76RE7,Q775Z7,Q7M9N1,Q7MAX3,Q7MBE8,Q7MVT6,Q7NKL2,Q7VJU0,Q7VN49,Q7VRK0,Q7VVR1,Q7W8Z8,Q7WKE3,Q823Q9,Q82KK4,Q82UM1,Q83G43,Q83I22,Q83PN3,Q87F19,Q88BD3,Q88C95,Q895R1,Q89662,Q8A245,Q8D2F3,Q8E9M0,Q8F729,Q8FPH9,Q8G4E8,Q8K921,Q8NPA9,Q8P458,Q8PFR5,Q8PWG1,Q8RA46,Q8RER7,Q8SRS0,Q8TGX9,Q8TV34,Q8UII1,Q8V2Y0,Q8XWL1,Q8ZJP5,Q90030,Q92I74,Q92SM6,Q97J61,Q98C10,Q9A253,Q9CJ30,Q9F7S4,Q9HMF3,Q9HTN3,Q9J5G5,Q9JUW1,Q9JZU7,Q9P6Q5,Q9PGZ6,Q9PKA2,Q9X3X5,Q9YG32,Q9YYS0,Q9Z9C2,Q9ZDD2,Q9ZKY3">dUTPase</protein-id>) catalyses the hydrolysis of dUTP to dUMP and can be considered as the first line of defence against incorporation of <compound-id="1174">uracil</compound-id> into DNA.	uracil__dUTPase__interaction
18621093-545	Recent findings indicate that the polypyrimidine tract-binding protein (<protein-id="P17225,P26599,Q00438,Q29099,Q8WN55,Q9MAC5,Q9UKA9">PTB</protein-id>), also named <protein-id="P17225,P26599,Q00438,Q29099">hnRNP I</protein-id>, by binding to the 3'-UTR (untranslated region) of the preproinsulin mRNA molecule, stabilizes the messenger, thereby participating in the <compound-id="206,5793,64689,79025">glucose</compound-id>-induced increase in preproinsulin mRNA.	glucose__PTB__interaction	glucose__hnRNP I__interaction
18621373-794	Pretreatment with extracellular signal-regulated kinase (ERK) and Jun N-terminal kinase (JNK) inhibitors, but not p38 mitogen-activated protein kinase (<protein-id="O62618">p38MAPK</protein-id>) significantly decreased <protein-id="O19062,P02741,P02742,P08462,P18151,P21291,P41964,P47875,P49254,P49262,P52753,P67966,P67967,P97315,Q07203">CRP</protein-id>-induced <compound-id="5359597">superoxide</compound-id> anion release from macrophages in vivo.	superoxide__CRP__interaction	superoxide__p38MAPK__no_interaction
18621413-823	The free radicals produced are thought to be generated during the production of <compound-id="1175">uric acid</compound-id>, a reaction catalyzed by <protein-id="P22985,P47989,P47990,P80457,Q00519,Q9MYW6">xanthine oxidase</protein-id>.	uric acid__xanthine oxidase__interaction
18621448-855	In the diabetic group, a decrease in the pancreatic <compound-id="124886">glutathione</compound-id> levels, <protein-id="O32770,O59858,Q00277,Q9CFV1">glutathione peroxidase</protein-id> and <protein-id="O50258">superoxide dismutase</protein-id> activities and an increase in the pancreatic lipid peroxidation level and <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id> activities were observed.	glutathione__catalase__no_interaction	glutathione__superoxide dismutase__no_interaction	glutathione__glutathione peroxidase__no_interaction
18621563-947	The immunomodulatory effects of <compound-id="5426,75792,92142">thalidomide</compound-id> are at least partially mediated through its ability to down-regulate the pathogenic over-production of <protein-id="Q8JFG3">tumor necrosis factor</protein-id>-alpha (<protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id>).	thalidomide__TNF-alpha__interaction	thalidomide__tumor necrosis factor__interaction
18621563-948	In the central nervous system, <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id> is involved in induction of a fever response and triggers the release of other cytokines, and may also influence transport of compounds into the brain, leading to cerebrospinal fluid leukocytosis, increased protein influx, and <compound-id="612">lactate</compound-id> accumulation.	lactate__TNF-alpha__interaction
18621563-949	<compound-id="5426,75792,92142">Thalidomide</compound-id> has been shown to down-regulate the production of <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id>.	Thalidomide__TNF-alpha__interaction
18622696-162	Both cell types expressed estrogen and <protein-id="P06186,P06401,P07812,P79373,Q00175,Q28590,Q63449,Q8AYI2,Q9GLW0">progesterone receptors</protein-id>, although only the epithelial LM05-E cells were stimulated by <compound-id="5757">estradiol</compound-id> and inhibited by <compound-id="2733526">tamoxifen</compound-id>.	estradiol__progesterone receptors__no_interaction	tamoxifen__progesterone receptors__no_interaction
18622720-185	This study was performed to investigate the effect of combined treatment with <compound-id="938">niacin</compound-id> and <compound-id="23976">chromium</compound-id> on vascular endothelial dysfunction, with the aim of gaining insight to the mechanisms by detecting the expression levels of ox-LDL and <protein-id="O70156,P78380,P79391,Q9EQ09,Q9TTK7,Q9XTA8">LOX-1</protein-id>.	niacin__LOX-1__no_interaction	chromium__LOX-1__no_interaction
18622720-186	In HF group, the serum levels of total <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> (TC), low-density lipoprotein (LDL), oxidized low-density lipoprotein (ox-LDL) and endothelin (ET) were higher, whereas the levels of <protein-id="P81182">high-density lipoprotein</protein-id> (HDL), serum NO were lower than those in CG group.	cholesterol__high-density lipoprotein__no_interaction
18622720-187	These findings indicated that combined treatment with <compound-id="938">niacin</compound-id> and <compound-id="23976">chromium</compound-id> has potential therapeutic protection of endothelial function by down-regulating ox-LDL/<protein-id="O70156,P78380,P79391,Q9EQ09,Q9TTK7,Q9XTA8">LOX-1</protein-id> signaling pathway.	chromium__LOX-1__interaction	niacin__LOX-1__interaction
18622759-218	The deduced amino acid sequence of Ai Lec was highly similar to those of the C-type <protein-id="P02871,P02873,P02874,P02875,P07386,P16108,P16349,P16351,P16352,P33888,P38662,P42088,P83410,P83511,P84987,Q41114">lectins</protein-id> from other animals and contained a typical carbohydrate-recognition domain (CRD) of 131 residues, which has four conserved disulfide-bonded <compound-id="594,5862,5360637">cysteine</compound-id> residues that define the CRD and two additional <compound-id="594,5862,5360637">cysteine</compound-id> residues at the amino terminus.	cysteine__lectins__interaction
18623061-1275	<protein-id="P05480,Q9WUD9">Src</protein-id> kinases can be activated by trans-phosphorylation of a <compound-id="1153,6057,5460803">tyrosine</compound-id> located in the central activation loop of the catalytic domain.	tyrosine__Src__interaction
18623061-1276	However, because the required exposure of this <compound-id="1153,6057,5460803">tyrosine</compound-id> is not observed in the down-regulated X-ray structures of <protein-id="P05480,Q9WUD9">Src</protein-id> kinases, transient partial opening of the activation loop appears to be necessary for such processes.	tyrosine__Src__no_interaction
18623078-486	The growth of L. minor (as fresh weight) and <compound-id="5351507,5459387,6326752,6433193,6914133,9600410">chlorophyll a</compound-id> content were significantly reduced and <protein-id="O50258">superoxide dismutase</protein-id> (<protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id>) activity was significantly decreased at microcystins concentration up to 0.5 mg/L.	chlorophyll a__superoxide dismutase__no_interaction	chlorophyll a__SOD__no_interaction
18623078-487	The experiment also indicated that <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id> (<protein-id="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7">CAT</protein-id>) activity was not significantly influenced by <compound-id="56841897">microcystin</compound-id> for both the two tested aquatic plants.	microcystin__CAT__no_interaction	microcystin__catalase__no_interaction
18623211-610	The purpose of this study was to investigate the solid-state properties of lyophilized formulations of protein (<protein-id="P27043">ribonuclease A</protein-id>) containing <compound-id="5988">sucrose</compound-id> or <compound-id="7427">trehalose</compound-id> across a wide range of compositions, both in the presence or absence of hydroxyethylstarch (HES).	sucrose__ribonuclease A__interaction	trehalose__ribonuclease A__interaction
18624726-1067	The stimulatory effects of stearic, palmitic and palmitoleic acids on resistin secretion and the stimulatory effect of <compound-id="5281">stearic acid</compound-id> on <protein-id="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3">MCP-1</protein-id> secretion are mediated via <protein-id="P23799">TLR</protein-id>-4.	stearic acid__MCP-1__interaction	stearic acid__TLR__interaction
18624760-178	<compound-id="5284513">Acitretin</compound-id> increased the levels of CD95 (<protein-id="P25446,Q63199">Fas</protein-id>), CD95-ligand and <protein-id="P25446,Q63199">Fas</protein-id>-associated death domain.	Acitretin__Fas__interaction
18624766-181	Since <compound-id="28486,3028194">lithium</compound-id> and <compound-id="4210951">SB-415286</compound-id>-induced G(2)/M arrest we studied changes in the expression of proteins involved in this phase, specifically <protein-id="O01377,O16852,P04961,P12004,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P61074,Q00265,Q00268">cyclin</protein-id> B, <protein-id="P04551,P11440,P23572,P39951">cdc2</protein-id> and the phosphorylated form of this protein (tyr15-<protein-id="P04551,P11440,P23572,P39951">cdc2</protein-id>).	SB-415286__cyclin__interaction	lithium__cdc2__interaction	SB-415286__cdc2__interaction	lithium__cyclin__interaction
18624766-182	On the other hand, <compound-id="4210951">SB-415286</compound-id> increased the expression of <protein-id="Q4R834,Q5RBF1,Q8IXJ6">SIRT2</protein-id>, involved in the regulation of proliferation.	SB-415286__SIRT2__interaction
18624766-184	We conclude that inhibitors of GSK-3 induced cell-cycle arrest, mediated by the phosphorylation of <protein-id="P04551,P11440,P23572,P39951">cdc2</protein-id> and, in the case of <compound-id="4210951">SB-415286</compound-id>, <protein-id="Q4R834,Q5RBF1,Q8IXJ6">SIRT2</protein-id> expression, which induced apoptosis in a caspase-independent manner.	SB-415286__SIRT2__interaction	SB-415286__cdc2__no_interaction
18624772-191	Reduced <protein-id="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600">eNOS</protein-id> protein levels were accompanied by an increase in intracellular Ca(2+), augmented production of reactive <compound-id="977">oxygen</compound-id> species (ROS) and induction of Ca(2+)-dependent <protein-id="P27730">calpain</protein-id> activity.	oxygen__eNOS__interaction	oxygen__calpain__no_interaction
18624772-192	Reduction of intracellular <compound-id="271">Ca(2</compound-id>+) levels abolished <protein-id="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600">eNOS</protein-id> reduction by HOG-LDL, as did pharmacological or genetic through calcium channel blockers or calcium chelator <compound-id="104751">BAPTA</compound-id> or inhibition of NAD(P)H oxidase (with <compound-id="2214">apocynin</compound-id>) or inhibition of calpain (calpain 1-specific siRNA).	Ca(2__eNOS__interaction	BAPTA__eNOS__interaction	apocynin__eNOS__interaction
18624794-206	In addition to transporting <compound-id="611,23327,33032">glutamate</compound-id>, <protein-id="P31597,P43005,Q95135">EAAC1</protein-id> plays other roles in regulating <compound-id="119">GABA</compound-id> synthesis, reducing oxidative stress in neurons, and is important in supporting neuron viability.	glutamate__EAAC1__interaction	GABA__EAAC1__interaction
18625283-633	Whereas both peptides <compound-id="44567785">lactoferricin</compound-id> (17-30) and lactoferrampin (265-284) did not have bactericidal activity, 40 microM of <protein-id="O77698,O77811,P02788,P08071,P14632,P24627,Q29477,Q9TUM0">lactoferrin</protein-id> chimera (a fusion of the two peptides) inhibited the growth of all Vibrio tested to the same extent as the antibiotic <compound-id="3467">gentamicin</compound-id>.	lactoferricin__lactoferrin__no_interaction	gentamicin__lactoferrin__no_interaction
18625298-638	We have recently shown that the antidepressant <compound-id="3386">fluoxetine</compound-id> enhances T cell proliferation and T(H)1 cytokine production in vivo, without changes on <protein-id="P01730,P05542,P16003,P16004,P33705,P46630,P79184,P79185,Q08336,Q08338,Q08339,Q08340,Q29037,Q9XS78">CD4</protein-id>/CD8 subsets.	fluoxetine__CD4__no_interaction
18625298-639	We found that <compound-id="3386">fluoxetine</compound-id> restored T cell proliferation and interleukin-2, <protein-id="Q9TTB0">interferon-gamma</protein-id> and <protein-id="Q8JFG3">tumor necrosis factor</protein-id>-alpha production by compensatory mechanisms.	fluoxetine__interferon-gamma__interaction	fluoxetine__tumor necrosis factor__interaction
18625569-874	Here we report a case of intragenic <protein-id="P00533,P13387,P55245">EGFR</protein-id> microdeletion in renal cell carcinoma (RCC) associated with the effect of treatment by <compound-id="123631">gefitinib</compound-id>.	gefitinib__EGFR__no_interaction
18626508-1659	Taking advantage of this prostate cancer-specific property of PSMA (E/P), we successfully introduced bacterial <protein-id="Q26998">UPRT</protein-id> into LNCaP cells where the tumoricidal effect of <compound-id="3385">5-fluorouracil</compound-id> (<compound-id="3385">5-FU</compound-id>) was significantly increased when compared with the cells without the exogenous <protein-id="Q26998">UPRT</protein-id>.	5-FU__UPRT__interaction	5-fluorouracil__UPRT__interaction
18626658-281	<protein-id="O97562,P55851,Q9N2J1,Q9W725">UCP2</protein-id> is expressed in pancreatic beta cells where its postulated uncoupling activity will modulate <compound-id="206,5793,64689,79025">glucose</compound-id>-induced changes in <compound-id="5957">ATP</compound-id>/ADP ratio and <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> secretion.	glucose__UCP2__interaction	glucose__insulin__interaction	ATP__UCP2__interaction	ATP__insulin__interaction
18626658-282	The consequences of <protein-id="O97562,P55851,Q9N2J1,Q9W725">UCP2</protein-id> over/underexpression on beta-cell function has mainly been studied in the basal state; however, a <protein-id="P04575,P10861,P14271,P25874">UCP</protein-id> has no uncoupling activity unless stimulated by fatty acids and/or reactive <compound-id="977">oxygen</compound-id> species.	oxygen__UCP__interaction	oxygen__UCP2__interaction
18626658-283	Neither <protein-id="P04575,P10861,P14271,P25874,Q18P97,Q8K404,Q9ER18,Q9GMZ1">UCP1</protein-id> expression nor <protein-id="O97562,P55851,Q9N2J1,Q9W725">UCP2</protein-id> overexpression modified basal or <compound-id="206,5793,64689,79025">glucose</compound-id>-stimulated metabolic changes.	glucose__UCP1__no_interaction	glucose__UCP2__no_interaction
18626709-112	The <protein-id="P13656,P14529,P23472,P23473,P81241,P84754">chitinase</protein-id> activity was increased by <compound-id="27854">Mn(2</compound-id>+), <compound-id="27099">Cu(2</compound-id>+), and Mg(2+), while strongly inhibited by <compound-id="27284">Fe(2</compound-id>+) and <compound-id="104810">Ba(2</compound-id>+).	Cu(2__chitinase__interaction	Mn(2__chitinase__interaction	Ba(2__chitinase__interaction	Fe(2__chitinase__interaction
18626709-113	Meanwhile, SDS, ethyleneglycoltetraacetic acid, <compound-id="1176,265993">urea</compound-id>, and <compound-id="6049">ethylenediaminetetraacetic acid</compound-id> were found to have significantly inhibitory effect on <protein-id="P13656,P14529,P23472,P23473,P81241,P84754">chitinase</protein-id> activity.	ethylenediaminetetraacetic acid__chitinase__interaction	urea__chitinase__interaction
18626726-122	In the present study, we screened the inhibitory effect of the extract from 50 Thai medicinal plants on an inducible-<protein-id="O61309,O61608,Q27571,Q9I9M2">nitric oxide synthase</protein-id> (<protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id>) expression induced by <compound-id="11970143">lipopolysaccharide</compound-id> (LPS) in mouse macrophages RAW 264.7.	lipopolysaccharide__iNOS__interaction	lipopolysaccharide__nitric oxide synthase__interaction
18626791-1140	Following thermal denaturation, rabbit reticulocyte lysate and <compound-id="5957">ATP</compound-id> were added and <protein-id="P08659,P13129,Q01158,Q26304,Q27757">luciferase</protein-id> activity measured.	ATP__luciferase__interaction
18626794-227	These results are in contrast to postmortem findings in schizophrenia and suggest that reduced <protein-id="P07825,P08247,P20488,Q5YJC1,Q62277">synaptophysin</protein-id> protein levels in schizophrenia patients' postmortem brain do not result from perinatal <compound-id="977">oxygen</compound-id> deprivation.	oxygen__synaptophysin__no_interaction
18627006-344	We found that the acetylated <protein-id="P02299,P07041,P08437,P08898,P22843,P23753,P40285,P50564,P61830,P61831,P61832,P61833,P61834,P61835,P61836,P80553,P83864,P84235,P84236,P84237,P84238,P84239,P90543,Q06196,Q2UCQ0,Q5DWI3,Q757N1,Q7XYZ0,Q98RY4,Q9HDN1,Q9P427,Q9U7D1">histone H3</protein-id> at <compound-id="866,5962">lysine</compound-id> 9 and <compound-id="866,5962">lysine</compound-id> 14 (H3K9/K14ac) is reduced in both the <protein-id="P02686,P02687,P04370,P06906,P15720,P20939,P25188,P25274,P81558,P83487,P87346,P98190,Q91325,Q91439">myelin basic protein</protein-id> (<protein-id="P02686,P02687,P04370,P06906,P13727,P15720,P20939,P25188,P25274,P25336,P81558,P83487,P87346,P98190,Q61878,Q63189,Q91325,Q91439,Q9SAV1">MBP</protein-id>) and proteolipid protein (<protein-id="P04116,P13085,P22858,P23289,P23294,P30044,P47789,P47790,P60201,P60202,P60203,P79826,P80145,P99029,Q8HXW7,Q96GD0,Q9R063">PLP</protein-id>) genes of maturing oligodendroglial OL-1 cells, and furthermore, this temporally correlates with increases in <protein-id="P02686,P02687,P04370,P06906,P13727,P15720,P20939,P25188,P25274,P25336,P81558,P83487,P87346,P98190,Q61878,Q63189,Q91325,Q91439,Q9SAV1">MBP</protein-id>, <protein-id="P04116,P13085,P22858,P23289,P23294,P30044,P47789,P47790,P60201,P60202,P60203,P79826,P80145,P99029,Q8HXW7,Q96GD0,Q9R063">PLP</protein-id>, and <protein-id="O22446">histone deacetylase</protein-id> (HDAC) 11 expression.	lysine__histone H3__interaction	lysine__MBP__interaction	lysine__histone deacetylase__interaction	lysine__myelin basic protein__interaction	lysine__PLP__interaction
18627414-696	Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, <protein-id="P01889,P03989,P10319,P18463,P18464,P18465,P30460,P30461,P30462,P30464,P30466,P30475,P30479,P30480,P30481,P30483,P30484,P30485,P30486,P30487,P30488,P30490,P30491,P30492,P30493,P30495,P30498,P30685,Q04826,Q29718,Q29836,Q29940,Q31610,Q31612,Q95365">HLA-B</protein-id> *1502, are at a higher risk for Stevens-Johnson syndrome when using <compound-id="2554">carbamazepine</compound-id>, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy.	carbamazepine__HLA-B__no_interaction
18627421-707	However, <protein-id="P10451,P14287,P31096,Q9XSY9">OPN</protein-id>-(/-) mice showed increased serum levels of tumour necrosis factor (<protein-id="O35734,O77510,O77764,P01375,P04924,P13296,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF</protein-id>)-alpha, which could be due to systemically present <compound-id="11970143">lipopolysaccharide</compound-id> translocated to the gut.	lipopolysaccharide__TNF__interaction	lipopolysaccharide__OPN__interaction
18627475-762	The expression of the <protein-id="O08703,O08962,O13306,O35219,P32476,Q12809,Q14534,Q75F69,Q7GC09,Q86QT3,Q86QU1,Q86QU6,Q86QV0,Q86QV3,Q86QV6,Q8WNY2,Q92206,Q9PT84,Q9TSZ3,Q9TUI4">ERG1</protein-id>, <protein-id="O13597,O93875,P32353,P50860,P78575,Q754B9,Q7F9X0,Q86QT9,Q86QU4,Q86QU8,Q86QV1,Q86QV4,Q86QV9,Q8J207,Q8NJ57,Q9NS40">ERG3</protein-id>, <protein-id="P38604,Q04782,Q96WJ0">ERG7</protein-id>, <protein-id="O74165,P29704,P78589,Q752X9,Q92459,Q9HGZ6">ERG9</protein-id>, <protein-id="P10613,P10614,P14263,P49602,P50859,Q759W0">ERG11</protein-id> and <protein-id="O59933,P53045,Q15800">ERG25</protein-id> genes in response to incubation with <compound-id="3365">fluconazole</compound-id> and biofilm formation was investigated using reverse-transcription PCR and real-time PCR in Candida albicans and Candida dubliniensis clinical isolates.	fluconazole__ERG9__interaction	fluconazole__ERG11__interaction	fluconazole__ERG25__interaction	fluconazole__ERG3__interaction	fluconazole__ERG1__interaction	fluconazole__ERG7__interaction
18627475-763	Expression of the <protein-id="P10613,P10614,P14263,P49602,P50859,Q759W0">ERG11</protein-id> gene was found to be low or moderate and it was regulated by <compound-id="3365">fluconazole</compound-id> addition more so than by biofilm formation.	fluconazole__ERG11__interaction
18627475-764	The expression of the <protein-id="O74165,P29704,P78589,Q752X9,Q92459,Q9HGZ6">ERG9</protein-id> increased in the presence of <compound-id="3365">fluconazole</compound-id> in some isolates.	fluconazole__ERG9__interaction
18629545-780	Concentrations of <compound-id="174">polyethylene glycol</compound-id> 1000 and <compound-id="24436">Na2SO4</compound-id> were selected as independent variables to evaluate their impact on parameters of partitioning in aqueous two-phase system--the partition coefficient of <protein-id="O42824,O59925,O93883,P05117,P20041,P24548,P26215,P26216,P27644,P35335,P35336,P35337,P35338,P35339,P41749,P41750,P43212,P47180,P48978,P48979,P49062,P49063,P49575,P58598,Q00446,Q02096,Q05967,Q07181,Q12708,Q39766,Q39786,Q40312,Q7M1E7,Q9FY19,Q9LW07,Q9Y718">pectinase</protein-id>, purification factor and <protein-id="O42824,O59925,O93883,P05117,P20041,P24548,P26215,P26216,P27644,P35335,P35336,P35337,P35338,P35339,P41749,P41750,P43212,P47180,P48978,P48979,P49062,P49063,P49575,P58598,Q00446,Q02096,Q05967,Q07181,Q12708,Q39766,Q39786,Q40312,Q7M1E7,Q9FY19,Q9LW07,Q9Y718">pectinase</protein-id> yield.	polyethylene glycol__pectinase__no_interaction	Na2SO4__pectinase__no_interaction
18629605-1551	In aged animals, administration of <compound-id="10918">L-carnitine</compound-id> for 21 days significantly decreased the levels of lipid peroxides and improved the activities of antioxidant enzymes like <protein-id="O50258">superoxide dismutase</protein-id>, <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id>, <protein-id="O32770,O59858,Q00277,Q9CFV1">glutathione peroxidase</protein-id> and <protein-id="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655">glutathione reductase</protein-id>.	L-carnitine__catalase__interaction	L-carnitine__glutathione reductase__interaction	L-carnitine__glutathione peroxidase__interaction	L-carnitine__superoxide dismutase__interaction
18629605-1552	<compound-id="10918">L-Carnitine</compound-id> enhanced T-cell proliferative responses as evaluated by T-cell proliferation assay using [3H] <compound-id="5789">thymidine</compound-id> incorporation and also significantly reduced DNA damage, apoptosis and <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id> level in lymphocytes of aged animals.	thymidine__TNF-alpha__no_interaction	L-Carnitine__TNF-alpha__interaction
18629630-845	In our microarray analysis we observed that <protein-id="O43255,Q06986,Q8R4T2,Q9I8X5,Q9M2P4">Seven-in-Absentia Homolog 2</protein-id> (<protein-id="O43255">SIAH2</protein-id>) levels were low in <protein-id="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7">estrogen receptor</protein-id> (ER) positive breast tumors of patients resistant to first-line <compound-id="2733526">tamoxifen</compound-id> therapy.	tamoxifen__estrogen receptor__no_interaction	tamoxifen__Seven-in-Absentia Homolog 2__no_interaction	tamoxifen__SIAH2__no_interaction
18629637-851	<compound-id="107647">Fluorocitrate</compound-id>, an inhibitor of glial metabolism, inhibits the up-regulation of <protein-id="O54705,O61309,O61608,Q26240,Q28969,Q9I9M2">NOS</protein-id> expression, activity and NO production in the spinal cord induced by formalin test in rats.	Fluorocitrate__NOS__interaction
18629637-852	In order to explore the involvement of glia in the NO-mediated nociceptive transmission, the present study was undertaken to investigate the effect of <compound-id="107647">fluorocitrate</compound-id> (FC), an inhibitor of glial metabolism, on <protein-id="O54705,O61309,O61608,Q26240,Q28969,Q9I9M2">NOS</protein-id> expression and activity and NO production in the spinal cord during the process of peripheral inflammatory pain and hyperalgesia induced by formalin test in rats.	fluorocitrate__NOS__interaction
18629640-41	Oral administration of <compound-id="5281670">morin</compound-id> remarkably prevented weight loss in the body and liver from DMN and inhibited the elevation of serum alanine transaminase (ALT), aspartate transaminase (<protein-id="P0AE37,P0AE38,P80357,P80358,Q0TH83,Q1C8B0,Q1RB46,Q321N9,Q32G89,Q3Z294,Q5PHB9,Q66B20,Q7N2G8,Q83L52,Q8FH00,Q8Z6G0,Q8ZPV1,Q9NRA2,Q9ZC67">AST</protein-id>), and total <compound-id="5280352">bilirubin</compound-id> levels.	morin__AST__interaction	bilirubin__AST__no_interaction
18631247-468	<compound-id="65064">Green tea extract</compound-id> reduces induction of <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id> and apoptosis in UVB-irradiated human skin independent of transcriptional controls.	Green tea extract__p53__interaction
18631247-469	We found that while OM24 treatment did not significantly affect UV-induced erythema and <compound-id="5789">thymidine</compound-id> dimer formation, OM24 treatment significantly reduced UV-induced <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id> expression in keratinocytes.	thymidine__p53__no_interaction
18632226-1291	Genetic characterization of the <protein-id="P46084">HA1</protein-id> portion of the haemagglutinin (HA) gene of virus isolated from the outbreak indicated that the isolate (A/equine/<compound-id="4033">Zagreb</compound-id>/04) was an H3N8 strain closely related to recent representative viruses of the American lineage Florida sub-lineage.	Zagreb__HA1__no_interaction
18632226-1292	In comparison with both H3N8 vaccine strains used in horses at the <compound-id="4033">Zagreb</compound-id> hippodrome, A/equine/<compound-id="4033">Zagreb</compound-id>/04 displayed amino acids changes localised to 4 of the 5 described antigenic sites (A-D) of subunit protein <protein-id="P46084">HA1</protein-id>.	Zagreb__HA1__no_interaction
18632742-27	Here we show that <protein-id="Q99988,Q9JKM5">NRG-1</protein-id> selectively increases the power of <compound-id="10255">kainate</compound-id>-induced, but not <compound-id="2551">carbachol</compound-id>-induced, gamma oscillations in acute hippocampal slices.	kainate__NRG-1__interaction	carbachol__NRG-1__no_interaction
18632742-28	These effects of NRG-1beta are blocked by <compound-id="4707">PD158780</compound-id>, a pan-specific antagonist of ErbB receptors, and are mediated specifically via ErbB4 receptors, because mice harboring a targeted mutation of ErbB4 do not respond to <protein-id="Q99988,Q9JKM5">NRG-1</protein-id>.	PD158780__NRG-1__no_interaction
18633436-86	Of various agents tested in HaCaT cell cultures, only <compound-id="444795">retinoic acid</compound-id> (10(-6) M) and <compound-id="5279,44259,451705,5311103,5459111,6419748,6711321,9956178,44299148">staurosporine</compound-id> (2.5 x 10(-8) M) upregulated <protein-id="O75900,O93470,Q8K3F2,Q8N119,Q90YC2,Q9R0S2">MMP-21</protein-id> mRNA and protein expression, whereas tumor promoters, hormones, or <compound-id="5743">dexamethasone</compound-id> were without effect.	retinoic acid__MMP-21__interaction	staurosporine__MMP-21__interaction	dexamethasone__MMP-21__no_interaction
18633446-279	We have generated two novel chimeric <protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id>-binding molecules, sFLT01 and sFLT02, which consist of the second immunoglobulin (IgG)-like domain of <protein-id="P17948,P53767">Flt-1</protein-id> fused either to a human IgG1 Fc or solely to the <compound-id="297">CH3</compound-id> domain of IgG1 Fc through a <compound-id="750">polyglycine</compound-id> linker 9Gly.	CH3__VEGF__no_interaction	polyglycine__VEGF__no_interaction	CH3__Flt-1__no_interaction	polyglycine__Flt-1__no_interaction
18633600-1063	By contrast, treatment of N2a cells with 1-10 microM <compound-id="6419789">DZO</compound-id> resulted in marked reductions in the expression of the axon growth-associated protein <protein-id="P09851,P20936,P50904,P74851,P74873,Q5PEA9,Q92211,Q92263">GAP</protein-id>-43.	DZO__GAP__interaction
18633600-1064	<compound-id="6419789">DZO</compound-id>-treated cells also showed an increased expression of the heat shock protein <protein-id="P27894">HSP-70</protein-id> compared to controls.	DZO__HSP-70__interaction
18633619-1153	Resistance of neoplastic cells to the alkylating drug <compound-id="2578">BCNU</compound-id> [1,3-bis (2-chloroethyl)-1-nitrosourea] has been correlated with expression of O (6)-methylguanine-DNA <protein-id="O40976,P03588,P03589,P06011,P17769,P20122,P27752,P28726,P28931,Q00020,Q66121,Q83264,Q83270">methyltransferase</protein-id>, which repairs the O (6)-<compound-id="161383">chloroethylguanine</compound-id> produced by the drug.	chloroethylguanine__methyltransferase__interaction	BCNU__methyltransferase__interaction
18633701-1577	We showed that in comparison to stage VI, stages I-V oocytes expressed higher levels of <protein-id="O18158">O-GlcNAc</protein-id> correlating changes in <protein-id="O15294,O18158,P81436">OGT</protein-id> expression, but not in <compound-id="445675,643981,9547196">UDP-GlcNAc</compound-id> pools.	UDP-GlcNAc__OGT__no_interaction	UDP-GlcNAc__O-GlcNAc__no_interaction
18633701-1578	Upon <compound-id="5994">progesterone</compound-id> stimulation, an <protein-id="O18158">O-GlcNAc</protein-id> level burst occurred during meiotic resumption long before <protein-id="Q13421,Q61468,Q9ERA7">MPF</protein-id> and <protein-id="P00536,P00539,P12965">Mos</protein-id>-<protein-id="P63085,P63086">Erk2</protein-id> pathways activations.	progesterone__MPF__interaction	progesterone__Mos__interaction	progesterone__Erk2__interaction	progesterone__O-GlcNAc__interaction
18633707-828	Mean plasma levels of <compound-id="6037">folic acid</compound-id>, <compound-id="778">homocysteine</compound-id>, and vitamin B12 did not change, but there was a significant decrease of <protein-id="O19062,P02741,P02742,P08462,P18151,P21291,P41964,P47875,P49254,P49262,P52753,P67966,P67967,P97315,Q07203">CRP</protein-id> at T1, 0.36 mg dl(-1) on average (P = 0.01), which was maintained at T2.	homocysteine__CRP__no_interaction	folic acid__CRP__no_interaction
18634065-1113	Chondrocytes grown in monolayer were treated with interleukin-1alpha (<protein-id="O46612,O46613,P01582,P01583,P04822,P08831,P16598,P18430,P46647,P48089,P79161,P79340,Q28385,Q28579,Q3HWU1,Q60480,Q865X7">IL-1alpha</protein-id>), <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>-like growth factor-I (<protein-id="P05017,P07455,P08025,P10763,P16545,P17085,P17647,P18254,P33712,P51457,P51458,P51462,Q02815,Q28933,Q68LC0,Q6GUL6,Q6IVA5,Q6JLX1,Q95222">IGF-I</protein-id>), C3 Transferase, <compound-id="448042">Y27632</compound-id>, or transfected with Rho wild type or two constitutively active mutants of Rho (Q63L and G14V).	Y27632__IL-1alpha__no_interaction	Y27632__insulin__no_interaction	Y27632__IGF-I__no_interaction
18634065-1115	Affinity assays were performed to measure endogenous <compound-id="6830">GTP</compound-id>-bound <protein-id="O51891,O67031,O83281,P03304,P0A295,P0A296,P0AG30,P0AG31,P0AG32,P0AG33,P15409,P17593,P17594,P20350,P29403,P33561,P35359,P38527,P44619,P45835,P51489,P52152,P52153,P52154,P52155,P52156,P52157,P52158,P56466,P57652,P66028,P66029,Q03222,Q06447,Q89A22,Q9ZD24,Q9ZLS9">Rho</protein-id>, and confocal microscopy was used to assess changes in organization of the <protein-id="O00937,O13419,O16808,O17320,O65314,O65315,O65316,O74258,O81221,P02577,P10365,P10989,P11426,P13363,P14235,P17128,P20904,P24902,P26182,P26183,P30161,P45520,P45521,P48465,P50138,P51775,P53455,P53476,P53477,P53491,P53498,P53499,P53500,P53502,P53689,P60009,P60010,P60011,P68555,P78711,P80709,P81085,P90689,P91754,Q05214,Q11212,Q24733,Q2U7A3,Q39596,Q39758,Q6TCF2,Q75D00,Q8SWN8,Q8X119,Q92192,Q92193,Q99023,Q9P4D1,Q9UVF3,Q9UVX4,Q9UVZ8">actin</protein-id> cytoskeleton.	GTP__Rho__interaction	GTP__actin__no_interaction
18634065-1116	<protein-id="O46612,O46613,P01582,P01583,P04822,P08831,P16598,P18430,P46647,P48089,P79161,P79340,Q28385,Q28579,Q3HWU1,Q60480,Q865X7">IL-1alpha</protein-id> and RhoG14V increased cytoplasmic <protein-id="O00937,O13419,O16808,O17320,O65314,O65315,O65316,O74258,O81221,P02577,P10365,P10989,P11426,P13363,P14235,P17128,P20904,P24902,P26182,P26183,P30161,P45520,P45521,P48465,P50138,P51775,P53455,P53476,P53477,P53491,P53498,P53499,P53500,P53502,P53689,P60009,P60010,P60011,P68555,P78711,P80709,P81085,P90689,P91754,Q05214,Q11212,Q24733,Q2U7A3,Q39596,Q39758,Q6TCF2,Q75D00,Q8SWN8,Q8X119,Q92192,Q92193,Q99023,Q9P4D1,Q9UVF3,Q9UVX4,Q9UVZ8">actin</protein-id> stress fiber formation, which was blocked by C3 Transferase, and <compound-id="448042">Y27632</compound-id>.	Y27632__actin__interaction	Y27632__IL-1alpha__interaction
18634065-1118	Expression of RhoQ63L or RhoG14V resulted in increased <protein-id="O18927,O62806,O77656,P23097,P33435,P45452,Q10835">MMP-13</protein-id> expression; however, inhibition of <protein-id="O51891,O67031,O83281,P03304,P0A295,P0A296,P0AG30,P0AG31,P0AG32,P0AG33,P15409,P17593,P17594,P20350,P29403,P33561,P35359,P38527,P44619,P45835,P51489,P52152,P52153,P52154,P52155,P52156,P52157,P52158,P56466,P57652,P66028,P66029,Q03222,Q06447,Q89A22,Q9ZD24,Q9ZLS9">Rho</protein-id> with <compound-id="448042">Y27632</compound-id> was unable to inhibit <protein-id="O46612,O46613,P01582,P01583,P04822,P08831,P16598,P18430,P46647,P48089,P79161,P79340,Q28385,Q28579,Q3HWU1,Q60480,Q865X7">IL-1alpha</protein-id>-induced <protein-id="O18927,O62806,O77656,P23097,P33435,P45452,Q10835">MMP-13</protein-id> expression.	Y27632__IL-1alpha__no_interaction	Y27632__Rho__interaction	Y27632__MMP-13__no_interaction
18634706-392	Plasma total <compound-id="304,5997,6432564,11025495">cholesterol</compound-id>, <protein-id="P44321">TAG</protein-id>, HDL, HDL2, HDL3, LDL, C-reactive protein, <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id>, <protein-id="O19073,P70380,P97636,Q14116,Q3ZT29,Q5I931,Q8QFQ8,Q95M33,Q9TU73,Q9XSQ7,Q9XSR0">IL-18</protein-id>, intercellular adhesion molecule-1, oxidised LDL, <compound-id="977">oxygen</compound-id> radical absorbance capacity using <compound-id="24247">perchloric acid</compound-id> (ORACPCA), whole-blood fatty acids, bleeding time and blood pressure were measured at the beginning and end of each dietary period.	cholesterol__IL-6__no_interaction	cholesterol__IL-18__no_interaction	perchloric acid__TAG__no_interaction	oxygen__IL-18__no_interaction	perchloric acid__IL-18__no_interaction	cholesterol__TAG__no_interaction	perchloric acid__IL-6__no_interaction	oxygen__IL-6__no_interaction	oxygen__TAG__no_interaction
18634843-1147	The increase of mature <protein-id="O19073,P70380,P97636,Q14116,Q3ZT29,Q5I931,Q8QFQ8,Q95M33,Q9TU73,Q9XSQ7,Q9XSR0">IL-18</protein-id> by macrophages was inhibited by <compound-id="44134608">caspase-1 inhibitor</compound-id> : caspase-1 is known to cleave the proform of <protein-id="O19073,P70380,P97636,Q14116,Q3ZT29,Q5I931,Q8QFQ8,Q95M33,Q9TU73,Q9XSQ7,Q9XSR0">IL-18</protein-id> to produce active mature <protein-id="O19073,P70380,P97636,Q14116,Q3ZT29,Q5I931,Q8QFQ8,Q95M33,Q9TU73,Q9XSQ7,Q9XSR0">IL-18</protein-id>.	caspase-1 inhibitor__IL-18__interaction
18635261-398	In absence of stretch, we could activate <protein-id="P64267,P64268">Gns</protein-id> and deactivate <protein-id="Q9GTW9">GK1</protein-id> by <compound-id="1394,5353264,6437055">1-oleoyl-2-acetyl-sn-glycerol</compound-id> (<compound-id="5353264">OAG</compound-id>) and other amphipaths.	OAG__Gns__interaction	1-oleoyl-2-acetyl-sn-glycerol__Gns__interaction	1-oleoyl-2-acetyl-sn-glycerol__GK1__interaction	OAG__GK1__interaction
18635336-453	Using enzyme-linked immunosorbent assays, we showed <compound-id="9881652">DHMEQ</compound-id> to inhibit LPS-induced secretion of <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> and <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id>.	DHMEQ__IL-6__interaction	DHMEQ__TNF-alpha__interaction
18635390-1443	The inhibition of DMBA-carcinogenesis by GLN application was associated with increased arterial GLN and <compound-id="124886">GSH</compound-id>, elevated buccal mucosa <compound-id="124886">GSH</compound-id> as well as induction of <protein-id="P27297,Q07813,Q63690">bax</protein-id> and <protein-id="O50017,P08469,P14043,P31669,P35875,P55057,Q08824,Q11208">PARP</protein-id>, and inhibition of <protein-id="P10417,P49950">bcl-2</protein-id>.	GSH__bax__interaction	GSH__bcl-2__interaction	GSH__PARP__interaction
18635693-781	Dopamine release and direct stimulation of dopamine D2 and serotonin <protein-id="P50129">5-HT2A</protein-id> receptors also contributes to the overall action of <compound-id="1615">MDMA</compound-id>.	MDMA__5-HT2A__interaction
18635693-783	Our findings suggest that <compound-id="1615">MDMA</compound-id> differentially affects higher cognitive functions, but does not support the hypothesis from animal studies, that some of the <compound-id="1615">MDMA</compound-id> effects are causally mediated through action at the <protein-id="P08908,P19327,P28285,Q64264,Q6XXX9,Q6XXY0,Q98998,Q9N296,Q9N297,Q9N298">5-HT1A</protein-id> receptor system.	MDMA__5-HT1A__no_interaction
18635704-791	These results suggest that <protein-id="P31749,Q01314,Q38998,Q8VYX2">AKT1</protein-id> does not play a significant role in clinical and functional manifestations in patients with schizophrenia who receive <compound-id="5073">risperidone</compound-id> treatment.	risperidone__AKT1__no_interaction
18635814-879	<compound-id="5641">Urethane</compound-id> is a chemical carcinogen found in tobacco smoke that causes activating mutations in <protein-id="P08644,P32883,Q05147">Kras</protein-id> and induces lung tumors in mice.	Urethane__Kras__interaction
18636040-1068	In the present study, we measured plasma <protein-id="P08263,Q08863">GSTA1-1</protein-id> levels by enzyme-linked immunosorbent assay in seven healthy volunteers after repeated experimental endotoxemia induced by 2 ng kg Escherichia coli <compound-id="44268108">endotoxin</compound-id> per day (to investigate inflammation-induced hepatic injury) and in 21 patients within 12 h after the occurrence of severe sepsis/septic shock (to investigate its ability to predict an increase of transaminases on day 7).	endotoxin__GSTA1-1__no_interaction
18636040-1069	Furthermore, <protein-id="P08263,Q08863">GSTA1-1</protein-id> levels did not correlate with <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> levels but did with <compound-id="36811">dobutamine</compound-id> infusion rate (Spearman r = 0.94; P = 0.02), suggesting that the extent of hemodynamic instability and not the degree of inflammation could be of importance for the occurrence of liver damage.	dobutamine__GSTA1-1__interaction	dobutamine__IL-6__no_interaction
18636042-1310	Heparin (H), <compound-id="2232,92722,152951,440542,445156">argatroban</compound-id> (A), <protein-id="P81050">antithrombin III</protein-id> (<protein-id="P01008,P32261,P32262,P41361,P81050,Q03352,Q5R5A3">ATIII</protein-id>), and recombinant human activated <protein-id="O55527,O55779,P02810,P03314,P03424,P04861,P04862,P06022,P06164,P06165,P06941,P07602,P08097,P10030,P14253,P14254,P14340,P26035,P26779,P27384,P28055,P29165,P32533,P32534,P32535,P35940,P35948,P35977,P69738,Q00794,Q03339,Q074N0,Q1X880,Q1X881,Q6DV88,Q6J3P1,Q89277,Q98803,Q997F1,Q9DUE0,Q9WS38,Q9YRV3">protein C</protein-id> (rhAPC) with and without <protein-id="P84122">thrombin</protein-id> were added to cells suspended in septic plasma and normal plasma.	argatroban__thrombin__no_interaction	argatroban__protein C__no_interaction	argatroban__ATIII__no_interaction	argatroban__antithrombin III__no_interaction
18636044-1070	<compound-id="402,108196">Hydrogen sulfide</compound-id> (<compound-id="6857678">H2S</compound-id>) is a novel gaseous mediator produced by <protein-id="P32232,P32582,P35520,P46794,Q58H57,Q91WT9,Q9N0V7,Q9YBL2">cystathionine-beta-synthase</protein-id> and <protein-id="P18757,P31373,P32929,Q58DW2,Q60HG7,Q8VCN5">cystathionine-gamma-lyase</protein-id> in the cardiovascular system, including the heart.	Hydrogen sulfide__cystathionine-beta-synthase__interaction	H2S__cystathionine-beta-synthase__interaction	Hydrogen sulfide__cystathionine-gamma-lyase__interaction	H2S__cystathionine-gamma-lyase__interaction
18636221-1488	Chemotaxis, <protein-id="O64362,O80288,O80292,P00720,P03706,P07540,P09963,P10439,P11187,P13656,P15057,P19385,P19386,P21270,P23472,P23473,P27359,P33486,P37715,P39046,P51771,P62692,P62693,P68920,P68921,P81241,P82174,P82175,P83673,Q27650,Q37875,Q37896,Q48603,Q7SID7,Q9CIT4,Q9T1X2,Q9ZXB7">lysozyme</protein-id> release and <compound-id="5359597">superoxide</compound-id> anion production have been measured.	superoxide__lysozyme__no_interaction
18636241-1243	According to <protein-id="P08758,P14668,P17153,P48036,P70075,P81287,Q4R4H7,Q5R1W0">annexin V</protein-id>-binding, arsenic trioxide (7 microM) within 48 h significantly increased <compound-id="445141,6323481,44147587">phosphatidylserine</compound-id> exposure of human erythrocytes without inducing hemolysis.	phosphatidylserine__annexin V__no_interaction
18636241-1244	Removal of extracellular Ca2+ or inhibition of the Ca2+-permeable cation channels with <compound-id="16231">amiloride</compound-id> blunted the effects of arsenic on <protein-id="P08758,P14668,P17153,P48036,P70075,P81287,Q4R4H7,Q5R1W0">annexin V</protein-id>-binding and cell shrinkage.	amiloride__annexin V__interaction
18636311-1287	In the present study, we investigated the inhibitory effect of the known oxycoumarins poncitrin (3), <compound-id="10228">osthol</compound-id> (4), and <compound-id="66548">xanthoxyletin</compound-id> (5), newly isolated from Clausena guillauminii (Rutaceae), together with the known carbazoles <compound-id="5318015">heptaphylline</compound-id> (1) and 7-methoxyheptaphylline (2) on inducible-<protein-id="O61309,O61608,Q27571,Q9I9M2">nitric oxide synthase</protein-id> (<protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id>) expression induced by <compound-id="11970143">lipopolysaccharide</compound-id> (LPS) and the NO generation in RAW 264.7 mouse macrophages.	osthol__iNOS__interaction	xanthoxyletin__iNOS__interaction	heptaphylline__iNOS__interaction	osthol__nitric oxide synthase__interaction	lipopolysaccharide__nitric oxide synthase__interaction	lipopolysaccharide__iNOS__interaction	heptaphylline__nitric oxide synthase__interaction	xanthoxyletin__nitric oxide synthase__interaction
18636399-1328	Cell viability and reactive <compound-id="977">oxygen</compound-id> species concentration were determined, and the effects of pre-treatment with LA on these parameters were investigated together with the <protein-id="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52">GST</protein-id> and GPx activity as well as the concentration of <compound-id="124886">reduced glutathione</compound-id>.	reduced glutathione__GST__no_interaction	oxygen__GST__no_interaction
18636508-1410	Fibril growth was a second-order process with an enthalpy of activation (27+/-5 kcal mol(-1)), which is indistinguishable from that of tetramer formation by <protein-id="P08935,P25973,P81061,P81714,Q06445">cystatins</protein-id>, which involves limited conformational changes including <compound-id="614,8988,145742">proline</compound-id> trans to cis isomerization.	proline__cystatins__interaction
18636565-515	Mutations in <protein-id="P36021">MCT8</protein-id> are associated with severe psychomotor retardation, high serum T3 and low <compound-id="5920,644280">3,3',5'-triiodothyronine</compound-id> (<compound-id="644280">rT3</compound-id>) levels.	3,3',5'-triiodothyronine__MCT8__interaction	rT3__MCT8__interaction
18637152-268	Results showed that <compound-id="19582,9838899">MENT</compound-id> treatments increased <protein-id="P07288,P10658,P33619,P55786,Q11011,Q6DT45,Q9Y617">PSA</protein-id> secretion and proliferation rate with a potency ranged between T and <compound-id="10635">DHT</compound-id>.	DHT__PSA__interaction	MENT__PSA__interaction
18637152-269	The studies with <compound-id="57363">finasteride</compound-id> showed that in BPH and CaP cells, the conversion of T into <compound-id="10635">DHT</compound-id> significantly contributes to its effect on the proliferation and <protein-id="P07288,P10658,P33619,P55786,Q11011,Q6DT45,Q9Y617">PSA</protein-id> secretion, and corroborated the resistance of <compound-id="19582,9838899">MENT</compound-id> to the 5-AR.	finasteride__PSA__interaction	MENT__PSA__no_interaction	DHT__PSA__interaction
18637154-273	Pregnant Sprague-Dawley female rats were treated once with <compound-id="15625">TCDD</compound-id> (0, 0.3 or 1 microg/kg) by gavage on embryonic day (ED) 11 and the expression levels of androgen (AR) and <protein-id="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7">estrogen receptors</protein-id> (ER), steroidogenic enzymes (P450scc and <protein-id="O46516,O57245,P14893,P21097,P26670,P27365,Q5IFP1,Q67477,Q9N119">3beta-HSD</protein-id>) and four regulatory factors (<protein-id="O46689,P49675,P51557,P58864,P70114,P79245,P97826,Q28918,Q28996,Q9DE06,Q9DEB4,Q9DG08,Q9DG09,Q9DG10">StAR</protein-id>, <protein-id="P33242,P50569,P79387,Q04752,Q13285,Q95L87,Q9GKL2">SF-1</protein-id>, <protein-id="P49604">GATA</protein-id>-4 and Insl-3) involved in foetal Leydig cell and adrenal function were analysed on ED 19.5.	TCDD__estrogen receptors__interaction	TCDD__SF-1__interaction	TCDD__3beta-HSD__interaction	TCDD__GATA__interaction	TCDD__StAR__interaction
18637154-274	In utero exposure to <compound-id="15625">TCDD</compound-id> reduced intratesticular T of foetal males (significant at 0.3 microg/kg <compound-id="15625">TCDD</compound-id>) and tended to reduce the protein expression of <protein-id="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7">ERalpha</protein-id> and AR of foetal male rat testis.	TCDD__ERalpha__interaction
18637154-275	mRNA expression of developmental regulatory factors was not influenced by foetal <compound-id="15625">TCDD</compound-id> exposure, except for significantly reduced adrenal <protein-id="P33242,P50569,P79387,Q04752,Q13285,Q95L87,Q9GKL2">SF-1</protein-id>.	TCDD__SF-1__interaction
18637708-746	<compound-id="947,123329">Nitrogen</compound-id>-containing bisphosphonates were found to inhibit <protein-id="O66126,O66952,P22939,P45204,P54383,P55539,P57537,Q08291,Q45220,Q8K9A0">farnesyl diphosphate synthase</protein-id>-an essential enzyme in the cholesterol biosynthesis pathway, but their effect on <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> synthesis per se in the central nervous system (CNS) remains unknown.	Nitrogen__farnesyl diphosphate synthase__interaction	cholesterol__farnesyl diphosphate synthase__no_interaction
18637712-756	hsBAFF-upregulated intracellular free <compound-id="271">Ca(2</compound-id>+) homeostasis regulates <protein-id="P27361,P28869,P42525,Q07176">ERK1</protein-id>/2 activity and cell proliferation in B cells in vitro.	Ca(2__ERK1__interaction
18637712-757	Using immunocytochemistry and Western blot analysis, we found that the activation of <protein-id="P27361,P28869,P42525,Q07176">ERK1</protein-id>/2 due to hsBAFF was triggered by a [<compound-id="271">Ca(2</compound-id>+)](i)-dependent pathway, leading to elevation of B cell proliferation.	Ca(2__ERK1__interaction
18637712-758	This is supported by the findings that intracellular Ca(2+) chelator <compound-id="2293">BAPTA/AM</compound-id> attenuated phosphorylated <protein-id="P27361,P28869,P42525,Q07176">ERK1</protein-id>/2 expression and cell proliferation in hsBAFF-stimulated B cells.	BAPTA/AM__ERK1__interaction
18637712-759	Taken together, the main finding of this study is that hsBAFF elicits higher but homeostatic [<compound-id="271">Ca(2</compound-id>+)](i) levels, which regulates <protein-id="P27361,P28869,P42525,Q07176">ERK1</protein-id>/2 activity and cell proliferation in in vitro B cells.	Ca(2__ERK1__interaction
18637714-1311	Surgical removal of pheochromocytoma significantly increased body weight, decreased both systolic and diastolic blood pressure, fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> and glycated <protein-id="P15160,P17724,P73925,Q03459">hemoglobin</protein-id> levels.	glucose__hemoglobin__no_interaction
18637715-1322	In this study we have investigated a long-term pattern of expression and production of spinal <protein-id="O62664,O97554,P05979,P22437,P23219,Q63921,Q9T0N8">COX-1</protein-id> and <protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">COX-2</protein-id> in the model of osteoarthritis induced in rats by injection of <compound-id="5240">monoiodoacetate</compound-id> (MIA) into the knee joint.	monoiodoacetate__COX-2__no_interaction	monoiodoacetate__COX-1__no_interaction
18639339-380	The enzyme <protein-id="P14902,P28776">indoleamine 2,3-dioxygenase</protein-id> (<protein-id="P14902,P28776">IDO</protein-id>) converts <compound-id="1148,6305,9060,5460840">tryptophan</compound-id> to <compound-id="846">kynurenine</compound-id>, blocking T-cell activation and inducing immunosuppression.	tryptophan__indoleamine 2,3-dioxygenase__interaction	kynurenine__IDO__interaction	tryptophan__IDO__interaction	kynurenine__indoleamine 2,3-dioxygenase__interaction
18639341-381	Serum l-<compound-id="846">kynurenine</compound-id> (l-<compound-id="161166">KYN</compound-id>) concentrations, l-<compound-id="161166">KYN</compound-id>/l-<protein-id="P07147,P17643">TRP</protein-id> ratio, and the level of <protein-id="P14902,P28776">IDO</protein-id> mRNA expression in ATLL cells were significantly increased in ATLL patients compared to those in healthy and HTLV-positive carrier subjects.	kynurenine__TRP__no_interaction	KYN__TRP__no_interaction	KYN__IDO__no_interaction	kynurenine__IDO__no_interaction
18639629-311	Peripheral administration of the acetylcholinesterase inhibitor <compound-id="9651">galantamine</compound-id> significantly reduced serum <protein-id="O35734,O77510,O77764,P01375,P04924,P13296,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF</protein-id> levels through vagus nerve signaling, and protected against lethality during murine endotoxemia.	galantamine__TNF__interaction
18639629-312	Administration of a centrally-acting muscarinic receptor antagonist abolished the suppression of <protein-id="O35734,O77510,O77764,P01375,P04924,P13296,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF</protein-id> by <compound-id="9651">galantamine</compound-id>, indicating that suppressing <protein-id="Q867X2,Q867X3,Q86GC9,Q92081">acetylcholinesterase</protein-id> activity, coupled with central muscarinic receptors, controls peripheral cytokine responses.	galantamine__acetylcholinesterase__interaction	galantamine__TNF__interaction
18639629-313	Administration of <compound-id="9651">galantamine</compound-id> to alpha7nAChR knockout mice failed to suppress <protein-id="O35734,O77510,O77764,P01375,P04924,P13296,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF</protein-id> levels, indicating that the alpha7nAChR-mediated cholinergic anti-inflammatory pathway is required for the anti-inflammatory effect of <compound-id="9651">galantamine</compound-id>.	galantamine__TNF__no_interaction
18639930-897	The involvement of <compound-id="5359597">superoxide</compound-id> and <compound-id="145068">nitric oxide</compound-id> was verified by the block of <protein-id="O60682">MSC</protein-id> using specific scavengers (<compound-id="9002">tiron</compound-id> and PTIO, respectively).	superoxide__MSC__interaction	tiron__MSC__no_interaction	nitric oxide__MSC__interaction
18639930-898	Accordingly, <protein-id="O60682">MSC</protein-id> were blocked by the <compound-id="104806">peroxynitrite</compound-id> scavenger <compound-id="1175">uric acid</compound-id> and could be mimicked by application of exogenous <compound-id="104806">peroxynitrite</compound-id>.	peroxynitrite__MSC__no_interaction	uric acid__MSC__interaction
18639930-899	This conclusion is supported by our findings that <protein-id="O60682">MSC</protein-id> were suppressed by inhibitors of phospholipases but could be mimicked by exogenous phospholipases or by amphipaths (<compound-id="445639">oleic acid</compound-id>, <compound-id="5590">Triton X-100</compound-id>).	Triton X-100__MSC__interaction	oleic acid__MSC__interaction
18640003-956	In the present study, therefore, the effect of FA/AD in presence or absence of p38MAPK inhibitor SB203580 on the proliferation, apoptosis, p38MAPK, caspase-3, location of p38MAPK and caspase-3, and interaction between p38MAPK and caspase-3 in Bel-7402 cell was investigated by <compound-id="64966">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide</compound-id> (MTT), <protein-id="P08758,P14668,P17153,P48036,P70075,P81287,Q4R4H7,Q5R1W0">annexin V</protein-id>-<compound-id="18730">FITC</compound-id>/<compound-id="4939">propidium iodide</compound-id> (PI) double staining, electron microscopy, immunoblot, immunofluorescence and immunoprecipitation/immunoblot assay, respectively.	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide__annexin V__no_interaction	propidium iodide__annexin V__no_interaction	FITC__annexin V__no_interaction
18640059-934	To investigate the role of <compound-id="60961">adenosine</compound-id> analogs and electromagnetic field (EMF) stimulation on prostaglandin E(2) (<protein-id="Q29458">PGE</protein-id> (2)) release and <protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">cyclooxygenase-2</protein-id> (<protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">COX-2</protein-id>) expression in bovine synovial fibroblasts (SFs).	adenosine__PGE__interaction	adenosine__COX-2__interaction	adenosine__cyclooxygenase-2__interaction
18640663-1479	In this study, we compared the effects of <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>-like growth factor-I (<protein-id="P05017,P07455,P08025,P10763,P16545,P17085,P17647,P18254,P33712,P51457,P51458,P51462,Q02815,Q28933,Q68LC0,Q6GUL6,Q6IVA5,Q6JLX1,Q95222">IGF-I</protein-id>), <protein-id="P03969,P09038,P12226,P13109,P15655,P20003,P48798,P48799,P48800,Q60487">basic fibroblast growth factor</protein-id> (bFGF), transforming growth factor beta1 (<protein-id="O19011,O93449,P01137,P04202,P07200,P09531,P09533,P16176,P17246,P18341,P50414,P54831,Q38HS2,Q9PTQ2,Q9Z1Y6">TGF-beta1</protein-id>), and <compound-id="3034366">glucosamine sulphate</compound-id> on porcine TMJ condylar cartilage and ankle cartilage cells in monolayer culture.	glucosamine sulphate__insulin__no_interaction	glucosamine sulphate__TGF-beta1__no_interaction	glucosamine sulphate__IGF-I__no_interaction	glucosamine sulphate__basic fibroblast growth factor__no_interaction
18640679-288	Meanwhile, both the enhanced expression of <protein-id="P19320,P29533,P29534,Q28260">VCAM-1</protein-id> and increased activation of NF-kappaB induced by <protein-id="P01142,P06296,P06850,P49926,Q95MI6,Q9PTS1">CRH</protein-id> in aortas of LDLr-/-mice were also largely suppressed by <compound-id="176157">NBI27914</compound-id>, whereas these inhibitory effects were not observed in anti-Svg-30 group.	NBI27914__VCAM-1__interaction	NBI27914__CRH__interaction
18640717-1523	<protein-id="O00329,O02697,O35904,P23727,P26450,P27986,P32871,P42336,P42337,P42338,P42347,P42348,P48736,P54673,P54674,P54675,P54676,Q63787,Q8BTI9,Q8UUU2,Q9JHG7,Q9Z1L0">PI3K</protein-id>/Akt activity, analyzed by <compound-id="53477912">phosphatidylinositol</compound-id> trisphosphate production and phosphorylated Akt (p-Akt) expression, was higher in the resistant cell lines than in the sensitive one and inhibition with <compound-id="312145">wortmannin</compound-id> or <compound-id="3973">LY294002</compound-id> improved apoptosis in the resistant cell lines.	wortmannin__PI3K__no_interaction	LY294002__PI3K__no_interaction	phosphatidylinositol__PI3K__interaction
18640717-1524	<compound-id="5978">Vincristine</compound-id> but not <compound-id="31703">doxorubicin</compound-id> increased p-<protein-id="P31750,Q8INB9">Akt</protein-id> expression whereas co-treatment with PI3K inhibitors and <compound-id="5978">vincristine</compound-id> increased apoptosis in the three cell lines.	doxorubicin__Akt__no_interaction	Vincristine__Akt__no_interaction	vincristine__Akt__no_interaction
18640717-1525	<compound-id="312145">Wortmannin</compound-id> and <compound-id="3973">LY294002</compound-id> inhibited P-<protein-id="P08163">glycoprotein</protein-id> (Pgp) function and also increased NF-kappaB activity.	LY294002__glycoprotein__interaction	Wortmannin__glycoprotein__interaction
18640746-1557	Namely, the results obtained for the most active compounds, 5-(chloroacetylamino) <compound-id="23648490">uracil (2</compound-id>) and its acyclic sugar analogue 18, suggest that formation of a covalent bond between reactive substituent and several possible targets within the <protein-id="O02604,O26868,O33380,O66108,O76511,O81395,O96650,P00469,P00471,P04818,P06785,P06854,P07382,P07606,P07607,P09249,P0A0M5,P0A884,P0A885,P0A886,P0C0M4,P0C0M5,P12461,P12462,P13100,P13922,P16126,P19368,P20712,P44420,P45350,P45351,P45352,P46103,P47469,P48464,P51820,P57515,P57808,P59427,P67042,P67043,P67044,P67045,P67046,P67047,P67048,P67049,P67050,P67051,P67052,P78029,P80305,P90463,Q05762,Q05763,Q07422,Q23695,Q27713,Q27783,Q27793,Q27828,Q2QRX6,Q4QM04,Q57931,Q5D189,Q5E7P1,Q5FKL6,Q5GWB5,Q5HFZ6,Q5HMP6,Q5KZ25,Q5M0S7,Q5M5B3,Q5NFK5,Q5P233,Q5PEN6,Q5R064,Q5UQG3,Q5WDS1,Q5WSU5,Q5X119,Q5XCM3,Q5YPL7,Q5ZRL3,Q603S2,Q63BV5,Q64PV5,Q65J44,Q65VJ8,Q667F9,Q67JQ1,Q6A761,Q6AFI0,Q6D8I6,Q6F145,Q6FER7,Q6FZ91,Q6G2S8,Q6G9D4,Q6GGY0,Q6HJC7,Q6KIQ6,Q6LUM1,Q6MID2,Q6N447,Q6NIF2,Q6REU8,Q6YQT0,Q71YE1,Q738X7,Q73VZ2,Q74IU3,Q7MNN6,Q7MTB5,Q7N8U4,Q7NZ95,Q7UID0,Q7VMH2,Q7VUE3,Q7W1A9,Q7WP13,Q81E05,Q81R23,Q82WU3,Q834R3,Q83BG2,Q87BT4,Q87SA0,Q87UL4,Q88CN9,Q88W05,Q89940,Q89G35,Q8A639,Q8D2N4,Q8DER9,Q8DUI4,Q8DZ07,Q8E4L6,Q8EH94,Q8EQG0,Q8EV81,Q8FR47,Q8G3T9,Q8K9C3,Q8NS38,Q8P1D1,Q8PCE7,Q8PP46,Q8PXI1,Q8RGP6,Q8THH4,Q8TVL9,Q8UDS3,Q8Y0U6,Q8Y626,Q8Z412,Q8ZHV1,Q8ZMA9,Q92AD4,Q92NQ5,Q97EV3,Q98KH9,Q98Q31,Q9A6H0,Q9CBW0,Q9I6F1,Q9JT57,Q9JY72,Q9K7B5,Q9P4T7,Q9PB13,Q9RAM7,Q9XC19,Q9Z671">thymidylate synthase</protein-id> mechanism (sulphur of the <compound-id="594,5862,5360637">cysteine</compound-id> residue, basic part of the enzyme, N,N-methylene tetrahydrofolate or its reactive iminium forms) is the most probable mode of action.	cysteine__thymidylate synthase__interaction	uracil (2__thymidylate synthase__interaction
18641920-846	<compound-id="151194">PTK787/ZK222584</compound-id>, a potent orally active angiogenesis inhibitor capable of inhibiting all known isoforms of Vascular Endothelial Growth Factor (<protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id>) receptor, belongs to the class of aminophthalazines.	PTK787/ZK222584__VEGF__interaction
18642040-946	Recent evidence for toxic <compound-id="5359597">superoxide</compound-id> (O(2)(-)) production by marine microalgae is afforded particular attention given that release of O(2)(-) anions can be exacerbated by the binding of <protein-id="P82953">mannose-specific lectins</protein-id> to the microalgal cell wall ; a novel model for grazing-activated chemical defence is proposed.	superoxide__mannose-specific lectins__no_interaction
18642088-995	Activation of these receptors can inhibit <protein-id="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5">ACTH</protein-id>-release in primary cultured corticotroph adenomas and compounds that target either sst (5) (<compound-id="56603683">pasireotide</compound-id>, or <compound-id="56841596">SOM230</compound-id>) or D(2) (<compound-id="54746">cabergoline</compound-id>) have shown significant efficacy in subsets of patients in recent clinical studies.	pasireotide__ACTH__no_interaction	cabergoline__ACTH__no_interaction	SOM230__ACTH__no_interaction
18642106-1330	The <compound-id="611,23327,33032">glutamate</compound-id> induced chemotaxis was accompanied by polarization of the <protein-id="O00937,O13419,O16808,O17320,O65314,O65315,O65316,O74258,O81221,P02577,P10365,P10989,P11426,P13363,P14235,P17128,P20904,P24902,P26182,P26183,P30161,P45520,P45521,P48465,P50138,P51775,P53455,P53476,P53477,P53491,P53498,P53499,P53500,P53502,P53689,P60009,P60010,P60011,P68555,P78711,P80709,P81085,P90689,P91754,Q05214,Q11212,Q24733,Q2U7A3,Q39596,Q39758,Q6TCF2,Q75D00,Q8SWN8,Q8X119,Q92192,Q92193,Q99023,Q9P4D1,Q9UVF3,Q9UVX4,Q9UVZ8">actin</protein-id> cytoskeleton, and by polymerization of F-<protein-id="O00937,O13419,O16808,O17320,O65314,O65315,O65316,O74258,O81221,P02577,P10365,P10989,P11426,P13363,P14235,P17128,P20904,P24902,P26182,P26183,P30161,P45520,P45521,P48465,P50138,P51775,P53455,P53476,P53477,P53491,P53498,P53499,P53500,P53502,P53689,P60009,P60010,P60011,P68555,P78711,P80709,P81085,P90689,P91754,Q05214,Q11212,Q24733,Q2U7A3,Q39596,Q39758,Q6TCF2,Q75D00,Q8SWN8,Q8X119,Q92192,Q92193,Q99023,Q9P4D1,Q9UVF3,Q9UVX4,Q9UVZ8">actin</protein-id>.	glutamate__actin__interaction
18642386-611	<compound-id="97663">SD4</compound-id> in anionic DSPG liposomes stimulated murine <protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id> production in RAW 264 cells at concentrations 25-to 30-fold lower than free drug.	SD4__IL-6__interaction
18643838-993	To elucidate the mechanism by which <compound-id="77999">rosiglitazone</compound-id> regulates adipose triglyceride <protein-id="Q7M4U7">lipase</protein-id> (ATGL).	rosiglitazone__lipase__interaction
18643908-800	<protein-id="O16005,O16017,O16018,O16019,O16020,O18312,O18315,O18481,O18485,O18486,O18766,O42268,O42294,O42300,O42301,O42307,O42327,O42328,O42330,O42427,O42431,O42451,O42452,O42466,O42604,O62791,O62792,O62793,O62794,O62795,O62796,O62798,O93441,O93459,P02699,P02700,P08100,P09241,P15409,P22328,P22671,P24603,P28681,P29403,P31355,P31356,P32308,P32309,P35356,P35359,P35362,P35403,P41590,P41591,P49912,P51470,P51488,P51489,P52202,P56514,P56515,P56516,P79756,P79798,P79807,P79808,P79809,P79812,P79848,P79863,P79898,P79901,P79902,P79903,P79911,P79914,P87369,Q17094,Q17292,Q17296,Q28886,Q68J47,Q6W3E1,Q769E8,Q8HY69,Q90245,Q90305,Q90373,Q95KU1,Q98980,Q9DGG4,Q9YGY9,Q9YGZ0,Q9YGZ1,Q9YGZ2,Q9YGZ3,Q9YGZ4,Q9YGZ5,Q9YGZ6,Q9YGZ7,Q9YGZ8,Q9YGZ9,Q9YH00,Q9YH01,Q9YH02,Q9YH03,Q9YH04,Q9YH05">Rhodopsin</protein-id> is one of the members of the G protein-coupled receptor family that can catalyze a <compound-id="8977">GDP</compound-id>-<compound-id="6830">GTP</compound-id> exchange reaction on the retinal G protein <protein-id="P49177">transducin</protein-id> (Gt) upon photon absorption.	GTP__Rhodopsin__interaction	GDP__transducin__interaction	GTP__transducin__interaction	GDP__Rhodopsin__interaction
18644606-1339	<compound-id="4585">Olanzapine</compound-id> was associated with a lower frequency of extrapyramidal symptoms than other antipsychotics, fewer <protein-id="P10765,P22393,P33089,P33090,P33091,P43001">prolactin</protein-id>-related adverse events than risperidone and other atypical antipsychotics, but greater weight gain than typicals and risperidone.	Olanzapine__prolactin__interaction
18646192-1003	In our earlier method, <compound-id="65359">glutathione disulfide</compound-id> (<compound-id="65359">GSSG</compound-id>) was measured by first reducing it to <compound-id="124886">GSH</compound-id> with <protein-id="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655">glutathione reductase</protein-id> (GR) in the presence of <compound-id="5884">NADPH</compound-id>.	GSSG__glutathione reductase__interaction	glutathione disulfide__glutathione reductase__interaction	NADPH__glutathione reductase__interaction	GSH__glutathione reductase__interaction
18647134-77	<protein-id="P01180,P01181,P01183,P01185,P01186,P10769,P35455">Copeptin</protein-id>, derived from the C-terminal portion of the precursor to AVP (<compound-id="8230,644077,44285245">arginine vasopressin</compound-id>), is secreted stoichiometrically with vasopressin, hence it can be used as a surrogate marker of the AVP system.	arginine vasopressin__Copeptin__interaction
18647135-78	The <protein-id="Q10751">angiotensin-converting enzyme</protein-id> insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent <compound-id="5359597">superoxide</compound-id> generation: potential implication in hypertension.	superoxide__angiotensin-converting enzyme__interaction
18648748-1370	Administration of <compound-id="72281">hesperetin</compound-id> to DMH treated rats significantly decreased the tumor incidence, the number of aberrant crypt foci with simultaneous enhancement of tissue lipid peroxidation, <protein-id="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52">GST</protein-id>, GPx, <protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id>, and <protein-id="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7">CAT</protein-id> activities.	hesperetin__SOD__interaction	hesperetin__GST__interaction	hesperetin__CAT__interaction
18648826-1446	Culture of mid-segments of hair follicles in low calcium culture medium kept on <compound-id="11966311">agarose</compound-id> increased expression of <protein-id="P11088,P20930">filaggrin</protein-id> and <protein-id="O09043">Kdap</protein-id>, but downregulated expression of <protein-id="P07476,P14590,P14591,P14708,P17941,P18174,P18175,P24708,P24709,P24710,P24711,P24712,P48997,P48998,Q95337">involucrin</protein-id>.	agarose__involucrin__interaction	agarose__filaggrin__interaction	agarose__Kdap__interaction
18648877-1504	The <compound-id="979">p-hydroxyphenylpyruvate</compound-id> produced by the Escherichia coli host was converted to <compound-id="449178">HGA</compound-id> through the oxidation reaction of introduced <protein-id="O42764">HPPD</protein-id>.	HGA__HPPD__interaction	p-hydroxyphenylpyruvate__HPPD__interaction
18649000-1622	The results showed that the intakes of dry matter (DM), organic matter (OM), <compound-id="947,123329">nitrogen</compound-id> (N), the N-balance, urinary <compound-id="1044">purine</compound-id> derivatives (PD) excretion, the ratios of <compound-id="204">allantoin</compound-id> to <compound-id="588">creatinine</compound-id> (<compound-id="23976">CR</compound-id>), PD to <compound-id="23976">CR</compound-id>, the plasma <compound-id="1176,265993">urea</compound-id>-N (PUN) and <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> increased in the animals, but the intake of neutral detergent fiber (NDF), the coefficient of whole tract, apparent digestibility of NDF, the transit time (TT) and the mean retention time (TMRT) decreased, when the proportion of concentrate in the diet increased.	urea__insulin__no_interaction	nitrogen__insulin__no_interaction	purine__insulin__no_interaction	CR__insulin__no_interaction	creatinine__insulin__no_interaction	allantoin__insulin__no_interaction
18649135-39	Activation of <protein-id="P41693">interleukin-6</protein-id>/<protein-id="P40763,P61635">STAT3</protein-id> in rat cholangiocyte proliferation induced by <compound-id="11970143">lipopolysaccharide</compound-id>.	lipopolysaccharide__STAT3__interaction	lipopolysaccharide__interleukin-6__interaction
18650080-815	Determination of reactive <compound-id="977">oxygen</compound-id> species generated in <protein-id="Q12570">laccase</protein-id> catalyzed oxidation of wood fibers from Chinese fir (Cunninghamia lanceolata) by electron spin resonance spectrometry.	oxygen__laccase__interaction
18650080-816	To investigate the activation pathways triggered by <protein-id="Q12570">laccase</protein-id>, ESR spin-trapping techniques using N-tert-butyl-alpha-phenylnitrone (PBN) as spin trap followed by <compound-id="8857">ethyl acetate</compound-id> extraction were employed to identify and quantify the free radical intermediates.	ethyl acetate__laccase__no_interaction
18650805-1377	Methylation of these <compound-id="6804">CpG</compound-id> sites may lead to reduced <protein-id="P35372,P79350,P97266,Q5IS39,Q5IS84,Q95247,Q95M54,Q9MYW9">OPRM1</protein-id> expression in the lymphocytes of these former heroin addicts.	CpG__OPRM1__interaction
18651093-1447	Two infants with elevated serum <protein-id="Q05902">gamma-GT</protein-id> had a decreased serum <compound-id="738,5961">glutamine</compound-id>.	glutamine__gamma-GT__interaction
18651113-1681	Human bone marrow-derived mesenchymal stem cells and osteoblast differentiation on <compound-id="23963">titanium</compound-id> with surface-grafted chitosan and immobilized bone <protein-id="P07580">morphogenetic protein</protein-id>-2.	titanium__morphogenetic protein__no_interaction
18651133-1703	None of the compounds altered <protein-id="P15393">Cyp11b1</protein-id> gene expression, indicating that 3-<compound-id="119115">MeSO2-DDE</compound-id> inhibits <protein-id="P15150,P15538,P51663,P97720,Q29527,Q29552,Q64408">CYP11B1</protein-id> activity on the protein level.	MeSO2-DDE__Cyp11b1__interaction	MeSO2-DDE__CYP11B1__interaction
18651191-669	Functional analysis demonstrated that elkj encoded a <protein-id="Q9SDN0">C20</protein-id>-elongase that mediated the elongation of EPA into <compound-id="3145,5497182,6441454">docosapentaenoic acid</compound-id> (22:5n-3), confirming the two-step conversion from EPA to DHA in marine microalga.	docosapentaenoic acid__C20__interaction
18651838-564	<protein-id="O46540,P01160,P01161,P05125,P07499,P07500,P07501,P09196,P18144,P18908,P18909,P24259,P27104,P27596,P83964,Q805D8,Q805E9,Q9GLD0">ANP</protein-id> (<protein-id="O46540,P01160,P01161,P05125,P07499,P07500,P07501,P09196,P18144,P18908,P18909,P24259,P27104,P27596,P83964,Q805D8,Q805E9,Q9GLD0">atrial natriuretic peptide</protein-id>) exerts its biological effects by binding to GC (guanylate <protein-id="O94303,P33734,Q9P4P9,Q9SZ30">cyclase</protein-id>)-A/<protein-id="P20910,Q41249">NPR</protein-id> (<protein-id="P28374">natriuretic peptide</protein-id> receptor)-A, which generates the second messenger <compound-id="24316">cGMP</compound-id>.	cGMP__cyclase__interaction	cGMP__ANP__no_interaction	cGMP__NPR__interaction	cGMP__natriuretic peptide__no_interaction	cGMP__atrial natriuretic peptide__no_interaction
18651838-565	Overexpression of <protein-id="P27577,P41156">Ets-1</protein-id> enhanced significantly <protein-id="P18293,P18910">Npr1</protein-id> mRNA levels, protein expression, GC activity and <protein-id="O46540,P01160,P01161,P05125,P07499,P07500,P07501,P09196,P18144,P18908,P18909,P24259,P27104,P27596,P83964,Q805D8,Q805E9,Q9GLD0">ANP</protein-id>-stimulated intracellular accumulation of <compound-id="24316">cGMP</compound-id> in transfected cells.	cGMP__Npr1__no_interaction	cGMP__ANP__interaction	cGMP__Ets-1__interaction
18652538-1158	In the current study, these cells were cultured with three different media: " <protein-id="P35855">BMP</protein-id>-plus" medium containing <compound-id="5743">dexamethasone</compound-id> and 100 ng/mL of rhBMP-2, "odontogenic" medium containing <compound-id="5743">dexamethasone</compound-id>, and "control" medium without supplements.	dexamethasone__BMP__no_interaction
18652864-1389	The <protein-id="P42559">allatostatins</protein-id> (<protein-id="P0AE37,P0AE38,P80357,P80358,Q0TH83,Q1C8B0,Q1RB46,Q321N9,Q32G89,Q3Z294,Q5PHB9,Q66B20,Q7N2G8,Q83L52,Q8FH00,Q8Z6G0,Q8ZPV1,Q9NRA2,Q9ZC67">ASTs</protein-id>), with a Tyr/Phe-Xaa-Phe-Gly-Leu/Ile-amide C-terminus, are <protein-id="P21259">neuropeptides</protein-id> that occur in many orders of insects, but are known to inhibit <compound-id="6439662">juvenile hormone</compound-id> (JH) synthesis by corpora allata (CA) only in cockroaches, crickets, and termites.	juvenile hormone__ASTs__interaction	juvenile hormone__allatostatins__interaction	juvenile hormone__neuropeptides__no_interaction
18652909-1018	Lecithin:retinol <protein-id="P05521,P19197,P21309,P23148,P41302,Q06878,Q7N576,Q9AJA7,Q9S3Z2">acyltransferase</protein-id> (<protein-id="O95237,Q9BGL2">LRAT</protein-id>) catalyzes the esterification of retinol (<compound-id="445354">vitamin A</compound-id>).	vitamin A__LRAT__interaction	vitamin A__acyltransferase__interaction
18652909-1019	<compound-id="444795">Retinoic acid</compound-id> (RA) treatment increased this <protein-id="O95237,Q9BGL2">LRAT</protein-id> promoter-<protein-id="P08659,P13129,Q01158,Q26304,Q27757">luciferase</protein-id> activity in PrEC cells, but not in PC-3 cells.	Retinoic acid__LRAT__interaction	Retinoic acid__luciferase__interaction
18654608-1184	As multidrug resistance (MDR) is a major problem in the chemotherapy of progressive breast cancer, the in vitro effects of Ad-<protein-id="Q9UBP4">REIC</protein-id> treatment were investigated in terms of the sensitivity of multidrug-resistant MCF7/ADR cells to <compound-id="31703">doxorubicin</compound-id> and of the P-<protein-id="P08163">glycoprotein</protein-id> expression.	doxorubicin__glycoprotein__no_interaction	doxorubicin__REIC__interaction
18654608-1185	Ad-<protein-id="Q9UBP4">REIC</protein-id> treatment in MCF7/ADR cells also downregulated P-<protein-id="P08163">glycoprotein</protein-id> expresssion through <protein-id="P92208,Q966Y3">JNK</protein-id> activation, and sensitized its drug resistance against <compound-id="31703">doxorubicin</compound-id>.	doxorubicin__JNK__no_interaction	doxorubicin__glycoprotein__no_interaction	doxorubicin__REIC__interaction
18654747-1289	<compound-id="219023">Diflomotecan</compound-id>, a homocamptothecin, targets <protein-id="O27661,O28469,O34204,O51768,O58356,O66893,O69548,O73954,O83409,P04786,P06612,P07799,P0A2I1,P0A2I2,P0A620,P0A621,P11387,P16472,P30181,P30189,P32989,P34184,P34185,P39814,P40114,P41511,P41512,P43012,P46155,P46799,P47368,P55991,P57371,P68697,P68698,P73810,P78032,P93119,Q00313,Q04750,Q07050,Q59046,Q76ZS7,Q7YR26,Q87AQ6,Q8K9P7,Q92IH1,Q9CG80,Q9CN30,Q9HM08,Q9HZJ5,Q9JN65,Q9KA23,Q9KRB2,Q9PEV8,Q9PLZ2,Q9UYS8,Q9WUL0,Q9X3X7,Q9X909,Q9YB01,Q9ZDK2,Q9ZMV7">DNA topoisomerase I</protein-id>.	Diflomotecan__DNA topoisomerase I__interaction
18654835-1331	Both MudPIT and cDNA microarray analyses indicate that <compound-id="784">H2O2</compound-id> treatment caused elevated levels of <protein-id="P29509,Q17745,Q39243">thioredoxin reductase 1</protein-id>.	H2O2__thioredoxin reductase 1__interaction
18655070-1550	Altogether these changes offer a straightforward explanation for how following the addition of <compound-id="271">Ca(2</compound-id>+), the <compound-id="2830">coelenterazine</compound-id> could escape and become available for bioluminescence on Renilla <protein-id="P08659,P13129,Q01158,Q26304,Q27757">luciferase</protein-id>.	coelenterazine__luciferase__interaction	Ca(2__luciferase__no_interaction
18655138-1615	The <compound-id="4346576">APTS</compound-id> functionalization was then used to immobilize bone <protein-id="P07580">morphogenetic protein</protein-id> on the bioactive glasses.	APTS__morphogenetic protein__interaction
18655158-1630	L-<compound-id="846">Kynurenine</compound-id> (<compound-id="161166">KYN</compound-id>), a <compound-id="1148,6305,9060,5460840">tryptophan</compound-id> metabolite, is metabolized to <compound-id="3845">kynurenic acid</compound-id> (<compound-id="3845">KYNA</compound-id>), which is an antagonist of N-methyl-D-aspartate and alpha7 nicotinic acetylcholine receptors, by <compound-id="846">kynurenine</compound-id> aminotransferase (<protein-id="Q8NFU3">KAT</protein-id>) I and <protein-id="Q8NFU3">KAT</protein-id> II.	KYNA__KAT__interaction	KYN__KAT__interaction	Kynurenine__KAT__interaction	kynurenic acid__KAT__interaction	tryptophan__KAT__no_interaction	kynurenine__KAT__interaction
18655176-1654	Exposure to <compound-id="2336">benzo(a)pyrene</compound-id> (BaP) by intraperitoneal injection increased biliary BaP metabolites and liver <protein-id="Q6JZS3,Q92039,Q9YH64">CYP1A</protein-id> gene expression.	benzo(a)pyrene__CYP1A__interaction
18655177-1378	We examined the effect of several different doses of <compound-id="4004">malathion</compound-id> (25, 75, 200 microM), or <compound-id="4004">malathion</compound-id> in combination with <compound-id="54670067">vitamin C</compound-id> (VC; 10 microM) or <compound-id="2116,14985,1548900,1742129">vitamin E</compound-id> (VE; 30 microM), on the levels of <compound-id="10964">malondialdehyde</compound-id> (MDA), and <protein-id="O50258">superoxide dismutase</protein-id> (<protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id>), <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id> (<protein-id="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7">CAT</protein-id>), and <protein-id="O32770,O59858,Q00277,Q9CFV1">glutathione peroxidase</protein-id> (GPx) activities in human erythrocytes in vitro.	vitamin E__CAT__interaction	malondialdehyde__catalase__no_interaction	vitamin C__CAT__interaction	malathion__glutathione peroxidase__interaction	vitamin E__superoxide dismutase__interaction	vitamin E__catalase__interaction	vitamin C__SOD__interaction	vitamin E__SOD__interaction	malathion__superoxide dismutase__interaction	malondialdehyde__SOD__no_interaction	malondialdehyde__glutathione peroxidase__no_interaction	vitamin C__catalase__interaction	malathion__CAT__interaction	malathion__SOD__interaction	malondialdehyde__CAT__no_interaction	malathion__catalase__interaction	malondialdehyde__superoxide dismutase__no_interaction	vitamin C__glutathione peroxidase__interaction	vitamin E__glutathione peroxidase__interaction	vitamin C__superoxide dismutase__interaction
18655177-1379	Erythrocytes were incubated under various treatment conditions (<compound-id="4004">malathion</compound-id> alone, vitamins alone, or <compound-id="4004">malathion</compound-id> plus vitamin) at 37 degrees C for 60 min, and the levels of MDA, and <protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id>, <protein-id="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7">CAT</protein-id> and GPx activities, were determined.	malathion__CAT__interaction	malathion__SOD__interaction
18655177-1380	Treatment with <compound-id="4004">malathion</compound-id> alone increased the levels of MDA and decreased <protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id>, <protein-id="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7">CAT</protein-id> 0.05).	malathion__CAT__interaction	malathion__SOD__interaction
18655190-1668	<protein-id="O62827,O77559,P35318,P43145,P53366,P97297">Adrenomedullin</protein-id> reduces antioxidant defense system and enhances kidney tissue damage in <compound-id="23973">cadmium</compound-id> and lead exposed rats.	cadmium__Adrenomedullin__interaction
18655190-1669	In the present study, we investigated the effect of AdM, Pb+ AdM, and Cd+ AdM treatments on <protein-id="O50258">superoxide dismutase</protein-id> (<protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id>), <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id> (<protein-id="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7">CAT</protein-id>), and <protein-id="O32770,O59858,Q00277,Q9CFV1">glutathione peroxidase</protein-id> (<compound-id="124886">GSH</compound-id>-Px) activities as well as the level of <compound-id="10964">malondialdehyde</compound-id> (MDA) in the kidney.	GSH__SOD__no_interaction	GSH__glutathione peroxidase__no_interaction	GSH__superoxide dismutase__no_interaction	malondialdehyde__SOD__no_interaction	malondialdehyde__glutathione peroxidase__no_interaction	GSH__CAT__no_interaction	malondialdehyde__CAT__no_interaction	GSH__catalase__no_interaction	malondialdehyde__superoxide dismutase__no_interaction	malondialdehyde__catalase__no_interaction
18655797-440	We found that <protein-id="P01101,P12841,Q56415">Fos</protein-id> expression in LH orexin neurons varied in proportion to preference for <compound-id="5288826,5479215">morphine</compound-id>, <compound-id="2826,5760,439497,446220,644017,54613779">cocaine</compound-id> or food.	cocaine__Fos__interaction	morphine__Fos__interaction
18655797-441	Recent studies showed that LH orexin neurons that project to ventral tegmental area (VTA) have greater <protein-id="P01101,P12841,Q56415">Fos</protein-id> induction in association with elevated <compound-id="5288826,5479215">morphine</compound-id> preference during protracted withdrawal than non-VTA-projecting orexin neurons, indicating that the VTA is an important site of action for orexin's role in reward processing.	morphine__Fos__interaction
18655808-447	<protein-id="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3">Cytochromes c</protein-id> are metalloproteins that function in electron transfer reactions and contain a <compound-id="4971">heme</compound-id> moiety covalently attached via thioether linkages between the co-factor and a CXXCH motif in the protein.	heme__Cytochromes c__interaction
18655848-489	The antioxidant roles of <compound-id="6326970">selenium</compound-id> (Se) were evaluated in Brycon cephalus exposed to 2 mg L(-1) of Folisuper 600 BR (MP commercial formulation-MPc, 600 g L(-1)) for 96 h. <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">Catalase</protein-id> (<protein-id="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7">CAT</protein-id>), <protein-id="O32770,O59858,Q00277,Q9CFV1">glutathione peroxidase</protein-id> (GPx), <protein-id="O50258">superoxide dismutase</protein-id> (<protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id>), <protein-id="O04437,O18598,P0A9D2,P0A9D3,P30116,P44521,P46088,P46419,P46423,P46426,P46428,P46437,P48438,P80894,P81065,P82996,P82997,P82998,P82999,P83000,P83001,P83246,Q04522,Q08392,Q08393,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52,Q96324">glutathione S-transferase</protein-id> (<protein-id="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52">GST</protein-id>), <compound-id="124886">reduced glutathione</compound-id> (<compound-id="124886">GSH</compound-id>) and lipid peroxidation (LPO) levels in the gills, white muscle and liver were evaluated in fish fed on diets containing 0 or 1.5 mg Se kg(-1) for 8 weeks.	selenium__glutathione S-transferase__no_interaction	GSH__glutathione S-transferase__no_interaction	reduced glutathione__Catalase__no_interaction	GSH__SOD__no_interaction	GSH__glutathione peroxidase__no_interaction	selenium__Catalase__no_interaction	reduced glutathione__glutathione peroxidase__no_interaction	reduced glutathione__GST__no_interaction	selenium__CAT__no_interaction	GSH__superoxide dismutase__no_interaction	selenium__GST__no_interaction	reduced glutathione__SOD__no_interaction	GSH__CAT__no_interaction	selenium__glutathione peroxidase__no_interaction	reduced glutathione__CAT__no_interaction	GSH__Catalase__no_interaction	GSH__GST__no_interaction	selenium__superoxide dismutase__no_interaction	selenium__SOD__no_interaction	reduced glutathione__glutathione S-transferase__no_interaction	reduced glutathione__superoxide dismutase__no_interaction
18655848-490	MPc also increased <protein-id="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52">GST</protein-id> activity in all tissues with a concurrent decrease in <compound-id="124886">GSH</compound-id> levels.	GSH__GST__no_interaction
18656273-863	<compound-id="445154">Resveratrol</compound-id> reverses <protein-id="P05305,P09558,P13206,P17322,P22387,P22388,P29560,P97740,Q28469,Q5NRP9,Q5NRQ1,Q9BG76">ET-1</protein-id>-evoked mitogenic effects in human coronary arterial cells by activating the kinase-G to inhibit <protein-id="P29323">ERK</protein-id>-enzymes.	Resveratrol__ERK__interaction	Resveratrol__ET-1__interaction
18656273-864	Pretreatment with the MEK-ERK inhibitor (<compound-id="4713">PD98059</compound-id>) appreciably reversed the mitogenic effects of <protein-id="P05305,P09558,P13206,P17322,P22387,P22388,P29560,P97740,Q28469,Q5NRP9,Q5NRQ1,Q9BG76">ET-1</protein-id>.	PD98059__ET-1__interaction
18656273-865	On the other hand, pretreatment with the polyphenolic <compound-id="638088">stilbene</compound-id> <compound-id="445154">resveratrol</compound-id> (RSVL, 1-100 microM) triggered more prominent inhibition of ET-1-evoked cell proliferation and <protein-id="P27361,P28869,P42525,Q07176">ERK1</protein-id>/2 activation.	stilbene__ERK1__no_interaction	resveratrol__ERK1__interaction
18656273-866	Further, pretreatment with the specific cGMP-phosphodiesterase inhibitor, <compound-id="5722">zaprinast</compound-id> (10 microM) appreciably augmented RSVL-evoked cGMP formation, <protein-id="P29323">ERK</protein-id> inhibition, and cytostatic response.	zaprinast__ERK__interaction
18656273-867	Moreover, the RSVL-induced <protein-id="P29323">ERK</protein-id>-inhibitory effects were significantly reversed by the kinase-G inhibitor, <compound-id="108152">KT-5823</compound-id> (10 microM; 69%), but not by the kinase-A inhibitor (<compound-id="3844,454202,16219545">KT-5720</compound-id>).	KT-5720__ERK__no_interaction	KT-5823__ERK__interaction
18656335-913	Adding <compound-id="5280489">beta-carotene</compound-id> to the diet of the mice during the period of irradiation suppressed the activity and expression of <protein-id="O18733,P14780,P41245,P41246,P50282,P52176">MMP-9</protein-id> as well as the wrinkling and sagging formation.	beta-carotene__MMP-9__interaction
18656335-914	Dietary <compound-id="5280489">beta-carotene</compound-id> prevents the expression of <protein-id="O18733,P14780,P41245,P41246,P50282,P52176">MMP-9</protein-id>, at least partly, by inhibiting photodynamic action involved in the formation of Chol-OOHs.	beta-carotene__MMP-9__interaction
18656337-916	Exposure to <compound-id="5280450">linoleic acid</compound-id> for 6 h induced expression of both <protein-id="P33724,P35431,P41350,P49817,P79132,Q03135,Q07DV9,Q07DX1,Q07DY2,Q07DZ2,Q07E02,Q07E25,Q07E38,Q07E49,Q09YH8,Q09YK1,Q09YN6,Q108U7,Q2IBA5,Q2IBC1,Q2IBD7,Q2IBF0,Q2IBG8,Q2QL79,Q2QL90,Q2QLB0,Q2QLC1,Q2QLF2,Q2QLG6,Q2QLH7,Q6B3Y2,Q6RVA9,Q94051,Q9YGM8">caveolin-1</protein-id> and cyclooxygenase (<protein-id="P11353,P36551,P36552,Q9UTE2,Q9V3D2">COX</protein-id>)-2.	linoleic acid__COX__interaction	linoleic acid__caveolin-1__interaction
18656337-917	Pretreatment with <compound-id="65064">EGCG</compound-id> blocked fatty-acid-induced <protein-id="P33724,P35431,P41350,P49817,P79132,Q03135,Q07DV9,Q07DX1,Q07DY2,Q07DZ2,Q07E02,Q07E25,Q07E38,Q07E49,Q09YH8,Q09YK1,Q09YN6,Q108U7,Q2IBA5,Q2IBC1,Q2IBD7,Q2IBF0,Q2IBG8,Q2QL79,Q2QL90,Q2QLB0,Q2QLC1,Q2QLF2,Q2QLG6,Q2QLH7,Q6B3Y2,Q6RVA9,Q94051,Q9YGM8">caveolin-1</protein-id> and <protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">COX-2</protein-id> expression in a time- and concentration-dependent manner.	EGCG__caveolin-1__interaction	EGCG__COX-2__interaction
18656337-918	Exposure to <compound-id="5280450">linoleic acid</compound-id> rapidly increased phosphorylation of several kinases, including <protein-id="O62618">p38 MAPK</protein-id>, <protein-id="P21708,P27361,P28869,P42525,Q63844">extracellular signal regulated kinase 1</protein-id>/2 (<protein-id="P27361,P28869,P42525,Q07176">ERK1</protein-id>/2) and amino kinase terminal (<protein-id="P31750,Q8INB9">Akt</protein-id>), with maximal induction at about 10 min.	linoleic acid__p38 MAPK__interaction	linoleic acid__Akt__interaction	linoleic acid__extracellular signal regulated kinase 1__interaction	linoleic acid__ERK1__interaction
18656337-919	Inhibitors of ERK1/2 and Akt down-regulated the <compound-id="5280450">linoleic-acid</compound-id>-induced increase in <protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">COX-2</protein-id> protein, which also occurred after pretreatment with <compound-id="65064">EGCG</compound-id>.	linoleic-acid__COX-2__interaction	EGCG__COX-2__interaction
18656337-920	<protein-id="P33724,P35431,P41350,P49817,P79132,Q03135,Q07DV9,Q07DX1,Q07DY2,Q07DZ2,Q07E02,Q07E25,Q07E38,Q07E49,Q09YH8,Q09YK1,Q09YN6,Q108U7,Q2IBA5,Q2IBC1,Q2IBD7,Q2IBF0,Q2IBG8,Q2QL79,Q2QL90,Q2QLB0,Q2QLC1,Q2QLF2,Q2QLG6,Q2QLH7,Q6B3Y2,Q6RVA9,Q94051,Q9YGM8">Caveolin-1</protein-id> silencing blocked <compound-id="5280450">linoleic-acid</compound-id>-induced phosphorylation of <protein-id="P27361,P28869,P42525,Q07176">ERK1</protein-id>/2 and protein expression of <protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">COX-2</protein-id>, suggesting that specific <protein-id="O42781,P27638,Q00859">MAPK</protein-id> signaling is caveolae dependent.	linoleic-acid__ERK1__interaction	linoleic-acid__Caveolin-1__interaction	linoleic-acid__MAPK__no_interaction	linoleic-acid__COX-2__no_interaction
18656338-921	<compound-id="5280443">Apigenin</compound-id> causes G(2)/M arrest associated with the modulation of <protein-id="O19002,O39927,O39928,O39929,O91936,O92529,O92530,O92531,O92532,P26660,P26661,P26662,P26663,P26664,P27954,P27955,P27956,P27957,P27958,P27959,P27960,P27961,P29846,P38936,P39689,P61585,P63028,Q00269,Q01403,Q01404,Q07828,Q11118,Q42580,Q5EG65,Q5I2N3,Q62092,Q68749,Q68798,Q68801,Q81258,Q81487,Q81495,Q81754,Q913D4,Q99IB8,Q9DHD6,Q9QAX1,Q9WMX2">p21</protein-id> (<protein-id="O42923,P39689">Cip1</protein-id>) and <protein-id="P04551,P11440,P23572,P39951">Cdc2</protein-id> and activates <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id>-dependent apoptosis pathway in human breast cancer SK-BR-3 cells.	Apigenin__Cdc2__interaction	Apigenin__p53__interaction	Apigenin__p21__interaction	Apigenin__Cip1__interaction
18656338-922	To investigate the regulatory proteins of cell cycle arrest affected by <compound-id="5280443">apigenin</compound-id>, we treated cells with 50 and 100 microM <compound-id="5280443">apigenin</compound-id> for 72 h. <compound-id="5280443">Apigenin</compound-id> caused a slight decrease in <protein-id="Q5SCB5">cyclin D</protein-id> and <protein-id="O01377,O16852,P04961,P12004,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P61074,Q00265,Q00268">cyclin</protein-id> E expression, with no change in <protein-id="O55076,P24941,P43450,P48963,Q5E9Y0">CDK2</protein-id> and <protein-id="P11802,P79432">CDK4</protein-id>.	apigenin__cyclin D__interaction	Apigenin__cyclin__interaction	Apigenin__CDK2__no_interaction	apigenin__cyclin__interaction	apigenin__CDK4__no_interaction	Apigenin__cyclin D__interaction	apigenin__CDK2__no_interaction	Apigenin__CDK4__no_interaction
18656338-923	In addition, the <compound-id="5280443">apigenin</compound-id>-induced accumulation of the cell population in the G(2)/M phase resulted in a decrease in <protein-id="P00546,P06493,P11440,P13863,P39951,P43063,P48734,P51958,Q5RCH1,Q9DG98,Q9DGA2,Q9DGA5,Q9DGD3">CDK1</protein-id> together with <protein-id="P20248,P30274,P37881,P43449,P51943,Q92161">cyclin A</protein-id> and <protein-id="O01377,O16852,P04961,P12004,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P61074,Q00265,Q00268">cyclin</protein-id> B.	apigenin__cyclin__interaction	apigenin__cyclin A__interaction	apigenin__CDK1__interaction
18656338-924	In an additional study, <compound-id="5280443">apigenin</compound-id> also increased the accumulation of <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id> and further enhanced the level of <protein-id="O19002,O39927,O39928,O39929,O91936,O92529,O92530,O92531,O92532,P26660,P26661,P26662,P26663,P26664,P27954,P27955,P27956,P27957,P27958,P27959,P27960,P27961,P29846,P38936,P39689,P61585,P63028,Q00269,Q01403,Q01404,Q07828,Q11118,Q42580,Q5EG65,Q5I2N3,Q62092,Q68749,Q68798,Q68801,Q81258,Q81487,Q81495,Q81754,Q913D4,Q99IB8,Q9DHD6,Q9QAX1,Q9WMX2">p21</protein-id> (<protein-id="O42923,P39689">Cip1</protein-id>), with no change in <protein-id="O11451,O11452,O11453,O39927,O39928,O39929,O91936,O92529,O92530,O92531,O92532,P06934,P16342,P19751,P25880,P25881,P25882,P25884,P25989,P26660,P26661,P26662,P26663,P26664,P27958,P29833,P29846,P29996,P29997,P40305,P68763,P68764,P68765,P69180,P69181,P69182,P69183,P69184,P69618,P69619,Q00269,Q43735,Q5I2N3,Q66198,Q68749,Q68798,Q68801,Q81258,Q81487,Q81495,Q81754,Q81835,Q81842,Q8V439,Q8V6W7,Q913D4,Q91A29,Q91DH7,Q91DH8,Q91DH9,Q99IB8,Q9DHD6,Q9E925,Q9PYA3,Q9QAX1,Q9WMX2">p27</protein-id> (Kip1).	apigenin__p21__interaction	apigenin__Cip1__interaction	apigenin__p27__no_interaction	apigenin__p53__interaction
18656338-925	The expression of <protein-id="P27297,Q07813,Q63690">Bax</protein-id> and <protein-id="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3">cytochrome c</protein-id> of <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id> downstream target was increased markedly at high concentration treatment over 50 microM <compound-id="5280443">apigenin</compound-id>.	apigenin__cytochrome c__interaction	apigenin__p53__interaction	apigenin__Bax__interaction
18656400-711	Therefore, we next examined whether <protein-id="P50129">5-HT2A</protein-id> and <protein-id="P08909,P28335,P34968,Q5IS66,Q60F97">5-HT2C</protein-id> receptors are involved, and from where <compound-id="5202">5-HT</compound-id> is released in the <compound-id="712">formalin</compound-id> test.	formalin__5-HT2A__no_interaction	5-HT__5-HT2C__no_interaction	5-HT__5-HT2A__no_interaction	formalin__5-HT2C__no_interaction
18656400-713	These results indicate that <compound-id="5202">5-HT</compound-id> released into peripheral tissue and its receptors, <protein-id="P50129">5-HT2A</protein-id> as well as <protein-id="P08909,P28335,P34968,Q5IS66,Q60F97">5-HT2C</protein-id>, at the periphery have an important role in pain-related behaviors during acute peripheral inflammation.	5-HT__5-HT2A__interaction	5-HT__5-HT2C__interaction
18656896-1449	<compound-id="3559">Haloperidol</compound-id> strongly decreased the expression of <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id> 0.01).	Haloperidol__BDNF__interaction
18656896-1450	In contrast, the administration of <compound-id="60854">ziprasidone</compound-id> significantly attenuated the immobilization stress-induced decrease in <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id> 0.01).	ziprasidone__BDNF__interaction
18656896-1451	<compound-id="60854">Ziprasidone</compound-id> exhibited differential effects on <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id> mRNA expression in the rat hippocampus and neocortex.	Ziprasidone__BDNF__interaction
18656896-1452	These results suggest that <compound-id="60854">ziprasidone</compound-id> might have a neuroprotective effect by recovering stress-induced decreases in <protein-id="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3">BDNF</protein-id> mRNA expression.	ziprasidone__BDNF__interaction
18657000-1427	In conclusion, <compound-id="5984">fructose</compound-id> overload in rats induced hypertriglyceridemia and <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> resistance associated with an enhanced oxidative stress.	fructose__insulin__interaction
18657005-297	Clinical and biochemical parameters including <compound-id="20484">fructosamine</compound-id> (FAM), glycated <protein-id="P15160,P17724,P73925,Q03459">hemoglobin</protein-id> (HbA1c) and serum <protein-id="O18921,P17560,P51606,P51607,P82343">AGEs</protein-id> were investigated in children and adolescents with 1 type diabetes with (+DC) and without (-DC) complications.	fructosamine__AGEs__no_interaction	fructosamine__hemoglobin__no_interaction
18657007-1437	<protein-id="O02750,O93416,Q28603,Q95189,Q95234">Leptin</protein-id> and soluble <protein-id="O02750,O93416,Q28603,Q95189,Q95234">leptin</protein-id> receptor changes after pulmonary endarterectomy: relations to <compound-id="5754">cortisol</compound-id> and cytokine network.	cortisol__leptin__interaction	cortisol__Leptin__interaction
18657007-1438	<protein-id="O02750,O93416,Q28603,Q95189,Q95234">Leptin</protein-id> and soluble <protein-id="O02750,O93416,Q28603,Q95189,Q95234">leptin</protein-id> receptor (SLR) were compared with evolution of <compound-id="5754">cortisol</compound-id> and inflammatory cytokines in twenty-two patients with chronic thromboembolic pulmonary hypertension treated with pulmonary endarterectomy using cardiopulmonary bypass (CBP) and deep hypothermic circulatory arrest (DHCA).	cortisol__leptin__interaction	cortisol__Leptin__interaction
18657009-1440	Using this method, we also determined whether streptozotocin-induced DM in rats (4-week duration) leads to changes in renal subcellular targeting of <protein-id="Q9YGM8">CAV-1</protein-id>, and evaluated the effects of tight metabolic control (<protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>, 12 IU/day) and angiotensin receptor blocker, <compound-id="3961">losartan</compound-id> (4 weeks, 20 mg/kg/day).	losartan__CAV-1__no_interaction	losartan__insulin__no_interaction
18657194-724	Androgenic action correlates inversely with a polymorphic CAG repeat region in the AR gene encoding for <compound-id="738,5961">glutamine</compound-id> residues the length of which appears to influence <protein-id="P81182">high density lipoprotein</protein-id> (HDL) <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> levels.	cholesterol__high density lipoprotein__interaction	glutamine__high density lipoprotein__interaction
18657228-1396	These vessels are formed by proliferating cells that incorporate <compound-id="6035">bromodeoxyuridine</compound-id> and express the endothelial cell markers vegfr2/<protein-id="O08775,P35918,Q8AXB3">kdr</protein-id> and <protein-id="P26323,P41157,Q9JJ28">fli1</protein-id>.	bromodeoxyuridine__kdr__no_interaction	bromodeoxyuridine__fli1__no_interaction
18657228-1398	Moreover, similar to rFGF2, injection of the zebrafish form of <protein-id="P26617">vascular endothelial growth factor-A</protein-id> (<protein-id="P15691,P15692,P16612,P26617,P49151,P50412,P67860,P67964,P67965,P83906,Q00731,Q99PS1,Q9GKR0,Q9MYV3">VEGF-A</protein-id>) induces a significant angiogenic response in the ZFYM assay that is suppressed by the VEGF receptor-2/KDR TK inhibitor <compound-id="5329098">SU5416</compound-id>.	SU5416__vascular endothelial growth factor-A__interaction	SU5416__VEGF-A__interaction
18657961-1695	In this study, we examined <compound-id="445858">ferulate</compound-id> for its ability to suppress redox-sensitive, proinflammatory NF-kappaB activation via NF-kappaB-inducing kinase (<protein-id="O95819,Q99558">NIK</protein-id>)/<protein-id="O15111,Q60680">IkappaB kinase</protein-id> (IKK) and <protein-id="Q00859">mitogen-activated protein kinases</protein-id> (<protein-id="O42781,P27638,Q00859">MAPKs</protein-id>) by reducing oxidative stress in aged rats.	ferulate__IkappaB kinase__interaction	ferulate__mitogen-activated protein kinases__interaction	ferulate__MAPKs__interaction	ferulate__NIK__interaction
18657961-1696	Data show that in aged kidney tissue, <compound-id="445858">ferulate</compound-id> exhibited its antioxidative action by maintaining redox regulation, suppressing NF-kappaB activation and modulating the expression of NF-kappaB-induced, proinflammatory <protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">COX-2</protein-id>, <protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id>, <protein-id="P19320,P29533,P29534,Q28260">VCAM-1</protein-id> and <protein-id="P05362,P13597,P33729,Q00238,Q28806,Q5NKV4,Q5NKV6,Q5NKV9,Q95132">ICAM-1</protein-id>.	ferulate__COX-2__interaction	ferulate__VCAM-1__interaction	ferulate__iNOS__interaction	ferulate__ICAM-1__interaction
18657961-1698	The molecular modulation of NF-kappaB by <compound-id="445858">ferulate</compound-id> was further revealed in endothelial YPEN-1 cells through <compound-id="445858">ferulate</compound-id>'s ability to suppress the activation of <protein-id="O95819,Q99558">NIK</protein-id>/IKK and <protein-id="O42781,P27638,Q00859">MAPKs</protein-id>.	ferulate__NIK__interaction	ferulate__MAPKs__interaction
18657961-1699	Based on these results, we conclude that <compound-id="445858">ferulate</compound-id>'s antioxidative capacity suppressed the age-related increase in NF-kappaB activity through inhibition of <protein-id="O95819,Q99558">NIK</protein-id>/IKK and <protein-id="O42781,P27638,Q00859">MAPKs</protein-id> in vivo.	ferulate__NIK__interaction	ferulate__MAPKs__interaction
18658095-656	Previous studies have shown that wounding of human corneal epithelial cells (HCECs) results in the release of G-protein-coupled receptor ligands such as <compound-id="5957">ATP</compound-id> and <compound-id="3988,5311263,5497152">lysophosphatidic acid</compound-id> (LPA), which in turn transactivate <protein-id="P01132,P01133,P07522,Q00968,Q95ND4,Q9BEA0">epidermal growth factor</protein-id> (<protein-id="P01132,P01133,P07522,P26224,Q00968,Q95ND4,Q9BEA0">EGF</protein-id>) receptor (<protein-id="P00533,P13387,P55245">EGFR</protein-id>) through ectodomain shedding of heparin-binding <protein-id="P01132,P01133,P07522,P26224,Q00968,Q95ND4,Q9BEA0">EGF</protein-id>-like growth factor (<protein-id="Q01580,Q06175,Q06186,Q09118,Q99075">HB-EGF</protein-id>).	ATP__EGFR__interaction	lysophosphatidic acid__HB-EGF__interaction	ATP__epidermal growth factor__interaction	lysophosphatidic acid__EGFR__interaction	lysophosphatidic acid__EGF__interaction	lysophosphatidic acid__epidermal growth factor__interaction	ATP__EGF__interaction	ATP__HB-EGF__interaction
18660796-396	<compound-id="145068">Nitric oxide</compound-id> is a free radical molecule synthesized from <compound-id="6322">L-arginine</compound-id> by <protein-id="O61309,O61608,Q27571,Q9I9M2">nitric oxide synthases</protein-id> that plays a critical role in various physiological and pathological processes, including tumor growth and angiogenesis.	Nitric oxide__nitric oxide synthases__interaction	L-arginine__nitric oxide synthases__interaction
18661133-1463	Furthermore, restoration of <protein-id="Q8IVT5">KSR1</protein-id> expression in KSR (-/-) MEFs following stable transduction of cells with a <protein-id="Q8IVT5">KSR1</protein-id> expression vector, enhanced sensitivity of cells to tunicamycin and <compound-id="5351303,6434468,13892272,17751001">cytochalasin H</compound-id> and decreased <protein-id="P27361,P28869,P42525,Q07176">ERK1</protein-id>/2 activation following exposure to these drugs.	cytochalasin H__ERK1__no_interaction	cytochalasin H__KSR1__interaction
18661183-1518	NH(4) <compound-id="312">Cl</compound-id> treatment causes an increase in intracellular [pH]i of sperm, suggesting that <protein-id="O02367,O16305,O60041,O82018,O94739,O96102,O97341,P02594,P02595,P02598,P02599,P04352,P04353,P04464,P05933,P05934,P05935,P06787,P07463,P11118,P11120,P11121,P15094,P17928,P18061,P21251,P23286,P24044,P27161,P27165,P27166,P41040,P41041,P48976,P60204,P60205,P60206,P61859,P61860,P61861,P62144,P62145,P62149,P62151,P62152,P62154,P62155,P62156,P62157,P62158,P62160,P62161,P62162,P62184,P62201,P62202,P62203,P62204,P69097,P69098,P84339,P93087,P93171,Q00168,Q05055,Q39752,Q40302,Q5EHV7,Q5RAD2,Q6IT78,Q6PI52,Q6R520,Q6YNX6,Q71UH5,Q71UH6,Q7T3T2,Q7Y052,Q8STF0,Q8X187,Q95NI4,Q95NR9,Q9GRJ1,Q9HFY6,Q9U6D3,Q9UWF0">CaM</protein-id> and CaMK are involved in sperm motility initiation caused by an increase in [pH]i.	Cl__CaM__interaction
18661233-1568	We demonstrated the increase in the levels of <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id>, <protein-id="P27297,Q07813,Q63690">Bax</protein-id>, and <protein-id="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3">cytochrome c</protein-id> and decrease in the level of <protein-id="P10417,P49950">Bcl-2</protein-id>, which are associated with the induction of apoptotic cell death after 24 h treatment with <compound-id="5281605">baicalein</compound-id> in N18 cells.	baicalein__cytochrome c__interaction	baicalein__Bcl-2__interaction	baicalein__Bax__interaction	baicalein__p53__interaction
18661547-124	GFP-fluorescent cells were slowly cycling, as shown by their long-term retention of <compound-id="6035">BrdU</compound-id>, and less than 10% expressed the proliferative markers Ki67 and <protein-id="P07759,P40377,P49735,P55861,P97310,Q6DIH3">Mcm2</protein-id>.	BrdU__Mcm2__no_interaction
18662278-741	<protein-id="P42898,Q5I598,Q60HE5">MTHFR</protein-id> gene polymorphisms and high levels of <compound-id="778">homocysteine</compound-id> are associated with a high degree of steatosis and fibrosis, conditions associated with a low sustained virological response (SVR) rate.	homocysteine__MTHFR__no_interaction
18662930-1285	<compound-id="24759">Hyaluronan</compound-id> inhibits expression of <protein-id="O75173,Q5RFQ8,Q9TT93">ADAMTS4</protein-id> (<protein-id="O75173,Q5RFQ8,Q8BNJ2,Q9ESP7,Q9TT93">aggrecanase-1</protein-id>) in human osteoarthritic chondrocytes.	Hyaluronan__aggrecanase-1__interaction	Hyaluronan__ADAMTS4__interaction
18663366-1650	The discovery that a common polymorphism (5-HTTLPR, short variant) in the human serotonin transporter gene (<protein-id="O35899,P31645,Q9MYX0,Q9XT49">SLC6A4</protein-id>) can influence personality traits and increase the risk for depression in adulthood has led to the hypothesis that a relative increase in the extracellular levels of serotonin (<compound-id="5202">5-HT</compound-id>) during development could be critical for the establishment of brain circuits.	5-HT__SLC6A4__no_interaction
18663367-1653	Besides the biogenesis of lysosome-related organelles complex 1 and <protein-id="O97592,P11530,P11531,P11532,P11533,Q5GN48">dystrophin</protein-id>-associated protein complex, several molecules in the <protein-id="Q96EV8">DTNBP1</protein-id> network likely provide insight into the role of <protein-id="Q96EV8">DTNBP1</protein-id> in biological systems: <compound-id="444795">retinoic acid</compound-id>, <compound-id="5757">beta-estradiol</compound-id>, <protein-id="O02367,O16305,O60041,O82018,O94739,O96102,O97341,P02594,P02595,P02598,P02599,P04352,P04353,P04464,P05933,P05934,P05935,P06787,P07463,P11118,P11120,P11121,P15094,P17928,P18061,P21251,P23286,P24044,P27161,P27165,P27166,P41040,P41041,P48976,P60204,P60205,P60206,P61859,P61860,P61861,P62144,P62145,P62149,P62151,P62152,P62154,P62155,P62156,P62157,P62158,P62160,P62161,P62162,P62184,P62201,P62202,P62203,P62204,P69097,P69098,P84339,P93087,P93171,Q05055,Q39752,Q40302,Q5EHV7,Q5RAD2,Q6IT78,Q6PI52,Q6R520,Q6YNX6,Q71UH5,Q71UH6,Q7T3T2,Q7Y052,Q8STF0,Q8X187,Q95NI4,Q95NR9,Q9GRJ1,Q9HFY6,Q9U6D3,Q9UWF0">calmodulin</protein-id> and tumour necrosis factor.	beta-estradiol__dystrophin__no_interaction	retinoic acid__calmodulin__no_interaction	retinoic acid__dystrophin__no_interaction	retinoic acid__DTNBP1__interaction	beta-estradiol__calmodulin__no_interaction	beta-estradiol__DTNBP1__interaction
18663553-101	Prior to the first dose of <compound-id="3899">leflunomide</compound-id>, serum concentrations of studied chemokines correlated with marker of RA activity such as the erythrocyte sedimentation rate and <protein-id="O62812,P08317,P10145,P19874,P26894,P36925,P41324,P46653,P49113,P67813,P67814,P79255,Q102R3,Q7YRB5,Q9XSX5">IL-8</protein-id> level with DAS.	leflunomide__IL-8__no_interaction
18663559-103	Hypothetically, <protein-id="P10635,Q2XNC8,Q2XNC9">cytochrome P450 2D6</protein-id> influences the transport of <compound-id="1123">taurine</compound-id> across the blood-brain barrier.	taurine__cytochrome P450 2D6__interaction
18663659-168	Most genes involved in lipid metabolism and especially in ergosterol biosynthesis were up-regulated in response to <compound-id="3793,55283,6917738,14179013">itraconazole</compound-id>, including <protein-id="O74198,P25087,Q5EN22,Q6BRB7,Q6C2D9,Q6CYB3,Q6FRZ7,Q759S7,Q875K1">ERG6</protein-id>, <protein-id="P38604,Q04782,Q96WJ0">ERG7</protein-id>, <protein-id="P10613,P10614,P14263,P49602,P50859,Q759W0">ERG11</protein-id>, <protein-id="P32462">ERG24</protein-id>, <protein-id="O59933,P53045,Q15800">ERG25</protein-id> and <protein-id="P53199">ERG26</protein-id>.	itraconazole__ERG7__interaction	itraconazole__ERG11__interaction	itraconazole__ERG6__interaction	itraconazole__ERG25__interaction	itraconazole__ERG26__interaction	itraconazole__ERG24__interaction
18665046-1318	In prolonged OJ with LPS administration, hepatocyte apoptosis depending on <protein-id="P36940,P41047,P48023,P63306,P63307,P63308,Q861W5,Q9BDN1,Q9BEA8">Fas ligand</protein-id> expression significantly increased in association with a decrease in <compound-id="5957">ATP</compound-id> contents, thus resulting in liver necrapoptosis.	ATP__Fas ligand__no_interaction
18665051-1321	Administration of <compound-id="12041">ethyl pyruvate</compound-id> to inhibit HMGB1 or anti-RAGE antibody could significantly decrease expression levels of <protein-id="P09793,P16410,P42072,Q9MYX7,Q9XSI1">CTLA-4</protein-id>, <protein-id="Q99JB6">Foxp3</protein-id> on Tregs, and <protein-id="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5">IL-10</protein-id> production after burns.	ethyl pyruvate__Foxp3__interaction	ethyl pyruvate__IL-10__interaction	ethyl pyruvate__CTLA-4__interaction
18665052-290	In contrast, the degree of (1) spinal cord inflammation and tissue injury (histological score), (2) nitrotyrosine and poly(<compound-id="6022">adenosine diphosphate</compound-id> [ADP] ribose) formation, (3) <protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id> expression, (4) nuclear factor-kappaB activation, and (5) apoptosis (<protein-id="O02789,O57486,P04053,P06526,P09838,P36195,P42118,Q92089">terminal deoxynucleotidyltransferase</protein-id>-mediated dUTP-biotin end labeling, <protein-id="P27297,Q07813,Q63690">Bax</protein-id>, and <protein-id="P10417,P49950">Bcl-2</protein-id>) was markedly reduced in spinal cord tissue obtained from mice treated with <compound-id="3495,14982,128229,44260118,45358130,46878350">glycyrrhizin</compound-id> extract (10 mg/kg, i.p., 30 min before and 1 and 6 h after SCI).	adenosine diphosphate__iNOS__no_interaction	glycyrrhizin__Bax__interaction	adenosine diphosphate__Bcl-2__no_interaction	glycyrrhizin__iNOS__interaction	adenosine diphosphate__Bax__no_interaction	adenosine diphosphate__terminal deoxynucleotidyltransferase__no_interaction	glycyrrhizin__terminal deoxynucleotidyltransferase__interaction	glycyrrhizin__Bcl-2__interaction
18665326-1562	<compound-id="5213,31553,1548994,3086637,24832061,44147684">Silymarin</compound-id> attenuated mast cell recruitment thereby decreased the expressions of <protein-id="P08253,P33434,P33436,P50757,Q90611,Q9GLE5">matrix metalloproteinases-2</protein-id> and 9 in rat liver carcinogenesis.	Silymarin__matrix metalloproteinases-2__interaction
18665326-1563	<compound-id="5921">NDEA</compound-id> administered rats showed increased MCD as revealed by toluidine blue staining along with upregulated expressions of <protein-id="P08253,P33434,P33436,P50757,Q90611,Q9GLE5">MMP-2</protein-id> and <protein-id="O18733,P14780,P41245,P41246,P50282,P52176">MMP-9</protein-id>.	NDEA__MMP-9__interaction	NDEA__MMP-2__interaction
18665326-1564	<compound-id="5213,31553,1548994,3086637,24832061,44147684">Silymarin</compound-id> treatment inhibited this increase in MCD and downregulated the expressions of <protein-id="P08253,P33434,P33436,P50757,Q90611,Q9GLE5">MMP-2</protein-id> and <protein-id="O18733,P14780,P41245,P41246,P50282,P52176">MMP-9</protein-id> as revealed by Western blotting and immunohistochemistry.	Silymarin__MMP-2__interaction	Silymarin__MMP-9__interaction
18665326-1565	In conclusion, <compound-id="5213,31553,1548994,3086637,24832061,44147684">silymarin</compound-id> exerted beneficial effects on liver carcinogenesis by attenuating the recruitment of mast cells and thereby decreased the expressions of <protein-id="P08253,P33434,P33436,P50757,Q90611,Q9GLE5">MMP-2</protein-id> and <protein-id="O18733,P14780,P41245,P41246,P50282,P52176">MMP-9</protein-id>.	silymarin__MMP-2__interaction	silymarin__MMP-9__interaction
18665390-1624	As a result, combined <compound-id="206,5793,64689,79025">glucose</compound-id> and <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> infusion significantly decreased plasma K+ concentration despite a significant decrease of urinary K+ excretion in sgk1+/+ but not in sgk1-/-mice.	glucose__insulin__no_interaction
18665391-1625	While it is clearly demonstrated that members of the <protein-id="Q13507">TRPC3</protein-id>/6/7 subfamily are activated by <compound-id="6026790">diacylglycerol</compound-id>, the mechanism by which phospholipase C activates members of the <protein-id="O18784,P48995,Q9TUN9">TRPC1</protein-id>/4/5 subfamily remains a mystery.	diacylglycerol__TRPC3__interaction	diacylglycerol__TRPC1__no_interaction
18665391-1626	Depletion of polyphosphatidylinositol 4-<compound-id="1061,167704,644102">phosphate</compound-id> and <compound-id="5311358">phosphatidylinositol 4,5-bisphosphate</compound-id> (PIP2) through inhibition of <protein-id="P54677">phosphatidylinositol 4-kinase</protein-id> activates calcium entry and membrane currents in <protein-id="O62852,Q9MYV9,Q9UL62">TRPC5</protein-id>-expressing but not in <protein-id="Q13507">TRPC3</protein-id>-or <protein-id="O94759,Q9HCX4">TRPC7</protein-id>-expressing cells.	phosphatidylinositol 4,5-bisphosphate__phosphatidylinositol 4-kinase__interaction	phosphatidylinositol 4,5-bisphosphate__TRPC3__no_interaction	phosphatidylinositol 4,5-bisphosphate__TRPC7__no_interaction	phosphatidylinositol 4,5-bisphosphate__TRPC5__interaction	phosphate__TRPC3__no_interaction	phosphate__TRPC7__no_interaction	phosphate__phosphatidylinositol 4-kinase__interaction	phosphate__TRPC5__interaction
18665391-1627	Inclusion of polyphosphatidylinositol 4-<compound-id="1061,167704,644102">phosphate</compound-id> or PIP2, but not <compound-id="643963">phosphatidylinositol 3,4,5-trisphosphate</compound-id>, in the patch pipette inhibited <protein-id="O62852,Q9MYV9,Q9UL62">TRPC5</protein-id> currents.	phosphate__TRPC5__no_interaction	phosphatidylinositol 3,4,5-trisphosphate__TRPC5__no_interaction
18665432-1672	Osteogenic differentiation was enhanced after treatment with <compound-id="2088">alendronate</compound-id> as confirmed by Alizarin Red S staining, elevated <protein-id="O60109,P81800,P83456">alkaline phosphatase</protein-id> activity and <protein-id="P02819,P02821,P02823,P0C225,P0C226,P15504,P28317,P39056,P81455,P83005,P83238,P83473,P83489,P84348,P84349,P84350,P84351,Q7LZI4,Q8HYY9">osteocalcin</protein-id> mRNA expression, a greater calcium peak by energy-dispersive xray spectrophotometry, and by immunofluorescence staining against <protein-id="P14745,P16070,P20944,Q05078,Q28284,Q29423,Q60522">CD44</protein-id> by flow cytometric analysis.	alendronate__osteocalcin__interaction	alendronate__alkaline phosphatase__interaction	alendronate__CD44__interaction
18667202-1391	<protein-id="Q6BEG6,Q6BEG7,Q9BDJ6,Q9BEF8,Q9EQX0,Q9GKY5,Q9QYH7,Q9UBU3">Ghrelin</protein-id> inhibits contraction and proliferation of human aortic smooth muscle cells by <compound-id="6076">cAMP</compound-id>/PKA pathway activation.	cAMP__Ghrelin__interaction
18667202-1393	<protein-id="Q6BEG6,Q6BEG7,Q9BDJ6,Q9BEF8,Q9EQX0,Q9GKY5,Q9QYH7,Q9UBU3">Ghrelin</protein-id> was able to inhibit angiotensin II-induced proliferation and contraction in a dose-response fashion via the <compound-id="6076">cAMP</compound-id>/PKA pathway.	cAMP__Ghrelin__interaction
18667302-1496	The results indicated that the backbone of <protein-id="Q9XF19">POP</protein-id> was composed of (1--&gt;6)-linked-alpha-<compound-id="439271">D-galactopyranosyl</compound-id> and (1--&gt;2,6)-linked-alpha-<compound-id="439271">D-galactopyranosyl</compound-id> residues, which were terminated with a single terminal (1--&gt;)-<compound-id="206,64689">beta-D-glucose</compound-id> residue at the O-2 position of galactosyl along the main chain in the ratio of 1:1:1.	beta-D-glucose__POP__interaction	D-galactopyranosyl__POP__interaction
18667302-1497	Preliminary tests in vitro showed <protein-id="Q9XF19">POP</protein-id> is capable of enhancing <protein-id="P81460,P81461">concanavalin A</protein-id> (<protein-id="P02866,P14894,P81460,P81461">ConA</protein-id>)-or <compound-id="11970143">lipopolysaccharide</compound-id> (LPS)-induced lymphocyte proliferation, which suggested that <protein-id="Q9XF19">POP</protein-id> could be a potential immunostimulating agent for use in functional foods or medicine against both pathogens and cancer.	lipopolysaccharide__ConA__no_interaction	lipopolysaccharide__POP__interaction	lipopolysaccharide__concanavalin A__no_interaction
18668138-492	Inhibition of the phosphatidyl-inositol-3 kinase/Akt pathway by <compound-id="312145">wortmannin</compound-id> and specific abrogation of <protein-id="P31750,P47196,Q8INB9,Q98TY9">Akt1</protein-id> protein using small-interfering RNA revealed a regulatory function of <protein-id="P31750,P47196,Q8INB9,Q98TY9">Akt1</protein-id> in <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>-mediated <protein-id="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3">VEGF</protein-id> biosynthesis in keratinocytes.	wortmannin__insulin__no_interaction	wortmannin__VEGF__no_interaction	wortmannin__Akt1__no_interaction
18668211-556	Cross-linked hydrogels showed increased resistance to digestion by testicular <protein-id="P15316,P26831,P49370,P49371,Q08169,Q53591,Q54699,Q54873,Q59634,Q59801,Q9U6V9">hyaluronidase</protein-id> and <protein-id="P15316,P26831,P49370,P49371,Q08169,Q53591,Q54699,Q54873,Q59634,Q59801,Q9U6V9">hyaluronidase</protein-id> SD with increasing <compound-id="24759">hyaluronan</compound-id> concentration.	hyaluronan__hyaluronidase__no_interaction
18668222-95	<compound-id="2730">Chlorpyrifos</compound-id> (CPF), a commonly used organophosphorus insecticide, induces <protein-id="Q867X2,Q867X3,Q86GC9,Q92081">acetylcholinesterase</protein-id> inhibition and cholinergic toxicity.	Chlorpyrifos__acetylcholinesterase__interaction
18668243-580	Role of <protein-id="Q05823,Q05921">RNase L</protein-id> in apoptosis induced by <compound-id="56841052">1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine</compound-id>.	1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine__RNase L__interaction
18668351-55	It was observed that administration of the PKC inhibitor <compound-id="2703">chelerythrine chloride</compound-id> (5 mg/kg) suppressed the activation of three exercise-induced PKC isoforms (<protein-id="P04409,P05696,P10102,P17252,P20444">PKCalpha</protein-id>, <protein-id="P10829">PKCdelta</protein-id>, and PKCepsilon) and attenuated the exercise-mediated reduction of myocardial infarct size during ischemia-reperfusion injury.	chelerythrine chloride__PKCdelta__interaction	chelerythrine chloride__PKCalpha__interaction
18668366-689	<compound-id="1548943">Capsaicin</compound-id> is known to have regulatory effects on gastrointestinal functions via the vanilloid receptor (<protein-id="Q8NER1">VR1</protein-id>).	Capsaicin__VR1__interaction
18670196-1382	<protein-id="P25914">Cholesteryl ester transfer protein</protein-id> (<protein-id="P11597,P22687,P25914,P47896">CETP</protein-id>) is a plasma <protein-id="P08163">glycoprotein</protein-id> that facilitates the transfer of neutral lipids and phospholipids between lipoproteins and contributes to the regulation of the plasma concentration of <protein-id="P81182">high density lipoprotein</protein-id> <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> (HDL-C).	cholesterol__CETP__interaction	cholesterol__high density lipoprotein__interaction	cholesterol__glycoprotein__no_interaction	cholesterol__Cholesteryl ester transfer protein__interaction
18670732-960	These studies frequently showed that erythropoietic stimulating agents (ESA) with oral or IV iron often resulted in improvement in left ventricular systolic and diastolic function, dilation, and hypertrophy, stabilization or improvement in renal function, reduced hospitalizations, diuretic dose, mitral regurgitation, pulmonary artery pressure, plasma volume, heart rate, serum <protein-id="P40753">brain natriuretic peptide</protein-id> levels, and the inflammatory markers C reactive protein and <protein-id="P41693">Interleukin 6</protein-id>, and an improvement in New York Heart Association class, exercise capacity, <compound-id="977">oxygen</compound-id> utilization during exercise, sleep apnea, caloric intake, depression, and quality of life.	oxygen__Interleukin 6__no_interaction	oxygen__brain natriuretic peptide__no_interaction
18670809-1037	DNA sequences of a <protein-id="O02367,O16305,O60041,O82018,O94739,O96102,O97341,P02594,P02595,P02598,P02599,P04352,P04353,P04464,P05933,P05934,P05935,P06787,P07463,P11118,P11120,P11121,P15094,P17928,P18061,P21251,P23286,P24044,P27161,P27165,P27166,P41040,P41041,P48976,P60204,P60205,P60206,P61859,P61860,P61861,P62144,P62145,P62149,P62151,P62152,P62154,P62155,P62156,P62157,P62158,P62160,P62161,P62162,P62184,P62201,P62202,P62203,P62204,P69097,P69098,P84339,P93087,P93171,Q05055,Q39752,Q40302,Q5EHV7,Q5RAD2,Q6IT78,Q6PI52,Q6R520,Q6YNX6,Q71UH5,Q71UH6,Q7T3T2,Q7Y052,Q8STF0,Q8X187,Q95NI4,Q95NR9,Q9GRJ1,Q9HFY6,Q9U6D3,Q9UWF0">calmodulin</protein-id> (<protein-id="O02367,O16305,O60041,O82018,O94739,O96102,O97341,P02594,P02595,P02598,P02599,P04352,P04353,P04464,P05933,P05934,P05935,P06787,P07463,P11118,P11120,P11121,P15094,P17928,P18061,P21251,P23286,P24044,P27161,P27165,P27166,P41040,P41041,P48976,P60204,P60205,P60206,P61859,P61860,P61861,P62144,P62145,P62149,P62151,P62152,P62154,P62155,P62156,P62157,P62158,P62160,P62161,P62162,P62184,P62201,P62202,P62203,P62204,P69097,P69098,P84339,P93087,P93171,Q00168,Q05055,Q39752,Q40302,Q5EHV7,Q5RAD2,Q6IT78,Q6PI52,Q6R520,Q6YNX6,Q71UH5,Q71UH6,Q7T3T2,Q7Y052,Q8STF0,Q8X187,Q95NI4,Q95NR9,Q9GRJ1,Q9HFY6,Q9U6D3,Q9UWF0">CaM</protein-id>)-encoding gene region containing three exons, two introns and a 411-bp mt intergenic spacer (IGS) spanning the <protein-id="O03176,O03207,O03363,O03473,O03474,O03478,O03503,O03520,O03522,O03523,O03538,O03543,O03545,O03548,O03553,O03713,O03810,O03811,O03812,O20433,O20434,O20435,O20539,O20540,O20544,O20546,O20547,O20549,O20603,O20604,O20611,O20612,O20613,O20644,O20645,O20672,O20964,O20965,O20968,O20998,O21159,O21163,O21166,O21167,O21175,O21205,O21217,O21220,O21223,O21224,O21298,O21337,O21366,O21411,O21414,O21416,O21424,O21425,O21764,O21789,O21795,O21804,O21807,O21816,O31215,O47414,O47415,O47419,O47420,O47421,O47431,O47477,O47488,O47499,O47554,O47555,O47556,O47557,O47558,O47560,O47561,O47583,O47584,O47714,O47716,O47718,O47721,O47723,O47885,O47890,O47892,O47893,O47922,O47923,O47924,O47926,O47930,O47976,O47993,O48001,O48009,O48010,O48012,O48014,O48017,O48023,O48025,O48027,O48039,O48041,O48043,O48047,O48049,O48052,O48053,O48055,O48057,O48060,O48062,O48063,O48065,O48066,O48067,O48073,O48076,O48079,O48080,O48085,O48087,O48089,O48090,O48092,O48093,O48094,O48096,O48098,O48100,O48101,O48102,O48106,O48109,O48111,O48114,O48277,O48285,O48309,O48321,O48334,O48336,O48350,O48372,O54070,O63534,O63535,O63536,O63537,O63696,O63699,O63848,O78690,O78742,O78761,O78773,O78774,O78775,O78776,O78777,O78778,O78779,O78780,O78781,O78782,O78783,O78784,O78785,O78786,O78787,O78788,O78789,O78790,O78858,O78927,O78928,O78929,O78930,O78931,O78932,O78933,O78934,O78935,O78936,O78937,O79122,O79195,O79196,O79197,O79198,O79199,O79200,O79201,O79202,O79203,O79204,O79205,O79206,O79207,O79208,O79209,O79210,O79211,O79212,O79213,O79215,O79216,O79217,O79218,O79219,O79220,O79221,O79222,O79223,O79224,O79225,O79226,O79227,O79228,O79229,O79230,O79274,O79311,O79327,O79360,O79386,O79413,O79426,O79440,O79445,O79446,O79447,O79448,O79450,O79451,O79452,O79453,O79454,O79455,O79460,O79461,O79462,O79463,O79464,O79465,O79468,O79512,O79520,O79524,O79558,O79648,O79652,O79657,O79659,O79660,O79680,O79785,O79925,O79927,O79936,O79967,O79969,O79980,O79993,O79996,O79997,O80005,O80019,O99240,O99253,O99256,O99257,O99258,O99338,O99342,O99343,O99345,O99468,O99655,O99795,O99797,O99798,O99799,O99800,O99828,P00156,P00157,P00158,P00159,P00160,P00161,P00162,P00163,P00164,P04165,P05418,P05501,P05718,P07704,P07747,P08502,P09843,P11669,P12778,P14548,P14833,P15547,P15585,P16357,P16358,P16359,P16360,P16362,P16363,P16364,P16366,P16367,P16674,P18935,P18946,P21713,P21714,P21715,P21716,P21717,P21718,P21719,P21720,P21721,P21722,P21723,P23134,P23662,P23663,P24878,P24890,P24950,P24951,P24952,P24953,P24954,P24955,P24956,P24957,P24958,P24959,P24960,P24962,P24964,P24965,P24966,P24992,P26852,P29630,P29631,P29632,P29633,P29634,P29635,P29636,P29637,P29638,P29639,P29640,P29641,P29642,P29663,P29664,P29665,P29666,P29667,P29668,P29669,P29670,P29671,P29672,P29757,P33501,P34197,P34844,P34845,P34860,P34861,P34862,P34863,P34864,P34865,P34866,P34867,P34868,P34869,P34870,P34871,P34872,P34873,P34874,P34875,P34876,P35075,P38593,P38594,P39480,P41280,P41281,P41282,P41283,P41284,P41285,P41286,P41287,P41288,P41289,P41290,P41303,P42792,P48173,P48517,P48518,P48519,P48520,P48521,P48665,P48875,P48876,P48877,P48884,P48885,P48886,P49341,P49390,P50663,P51131,P51941,P56629,P56630,P56631,P56697,P56731,P62513,P68090,P68091,P68092,P68093,P68094,P68095,P68533,P68534,P69219,P69220,P69221,P81376,P81378,P81381,P82045,P82046,P82047,P82048,P82049,P87410,P87416,P87419,P87421,P92472,P92487,P92493,P92509,P92583,P92584,P92592,P92599,P92600,P92605,P92651,P92657,P92658,P92671,P92701,P92717,P92723,P92845,P92846,P92847,P92848,P92849,P92850,P92852,P92853,P92857,P92870,Q00228,Q00530,Q02655,Q02761,Q02768,Q04910,Q04911,Q104Y0,Q104Y1,Q104Y3,Q1EG05,Q1H8Y8,Q1HUU1,Q1HUV6,Q1KTB0,Q1MWH4,Q1MWK0,Q1PG50,Q1PG51,Q1PG54,Q1PG55,Q1PG56,Q1PG57,Q1PG58,Q1X6J6,Q1X6K1,Q1XA12,Q1XA32,Q1XII1,Q1XII7,Q1XII9,Q1XIJ0,Q1XIJ4,Q1XIK7,Q1XIK9,Q1XIL4,Q1XIM0,Q1XIM1,Q1XIM5,Q1XIM8,Q1XIN0,Q1XIN1,Q1XIN6,Q1XIP1,Q1XIP3,Q1XIP4,Q1XIP7,Q1XIP8,Q1XIQ2,Q1XIQ3,Q1XIQ4,Q1ZYR2,Q20FQ1,Q20FQ2,Q20FQ7,Q20FR3,Q20FR8,Q20FS0,Q20K40,Q20K43,Q25CF7,Q288H1,Q288H2,Q288H4,Q288H5,Q2N2B5,Q2N2B8,Q2N2J6,Q2N2J7,Q2Q1V7,Q2TVN0,Q2TVN1,Q2Y060,Q2Y067,Q31652,Q31684,Q33377,Q33401,Q33452,Q33487,Q33500,Q33537,Q33568,Q33607,Q33629,Q33645,Q33688,Q33695,Q33697,Q33706,Q33723,Q33754,Q33772,Q33782,Q33784,Q33798,Q33800,Q33818,Q33842,Q33865,Q33887,Q33941,Q33950,Q33954,Q33976,Q33987,Q33989,Q34028,Q34045,Q34070,Q34101,Q34106,Q34107,Q34108,Q34161,Q34169,Q34172,Q34179,Q34235,Q34253,Q34254,Q34260,Q34261,Q34279,Q34289,Q34300,Q34301,Q34302,Q34306,Q34321,Q34340,Q34341,Q34376,Q34382,Q34399,Q34409,Q34459,Q34462,Q34471,Q34473,Q34501,Q34534,Q34607,Q34653,Q34677,Q34683,Q34717,Q34724,Q34732,Q34760,Q34814,Q34876,Q34889,Q34890,Q34891,Q34893,Q34900,Q34902,Q34916,Q34945,Q34952,Q34957,Q34972,Q34973,Q35000,Q35019,Q35020,Q35038,Q35054,Q35065,Q35066,Q35075,Q35076,Q35078,Q35083,Q35111,Q35113,Q35117,Q35118,Q35130,Q35131,Q35157,Q35160,Q35172,Q35196,Q35273,Q35350,Q35377,Q35380,Q35409,Q35425,Q35438,Q35457,Q35459,Q35467,Q35468,Q35485,Q35505,Q35506,Q35516,Q35518,Q35522,Q35532,Q35533,Q35534,Q35553,Q35558,Q35614,Q35618,Q35621,Q35630,Q35653,Q35673,Q35675,Q35677,Q35695,Q35727,Q35805,Q35810,Q35819,Q35861,Q35873,Q35877,Q35886,Q35895,Q35925,Q35930,Q35942,Q35966,Q35968,Q35994,Q36012,Q36035,Q36055,Q36058,Q36082,Q36089,Q36096,Q36099,Q36118,Q36128,Q36192,Q36194,Q36201,Q36209,Q36222,Q36227,Q36229,Q36262,Q36266,Q36291,Q36294,Q36311,Q36319,Q36324,Q36368,Q36427,Q36445,Q36461,Q36507,Q36548,Q36549,Q36551,Q36572,Q36590,Q36644,Q36654,Q36659,Q36922,Q36976,Q37006,Q37064,Q37078,Q37080,Q37311,Q37378,Q37395,Q37713,Q3L2T5,Q3L6X7,Q3L701,Q3LTW2,Q3LZS3,Q3T4C8,Q3T4F1,Q3YLA8,Q3YLC2,Q3ZEC1,Q3ZEC3,Q3ZEC9,Q3ZED1,Q3ZEG3,Q4FBI3,Q4JQH5,Q4QXK3,Q4UJ67,Q4VGP8,Q4VKI6,Q4VKI7,Q4VUT8,Q4VUU0,Q4VUU2,Q4VUU4,Q4VUV4,Q4VUV8,Q4VUV9,Q4VUY0,Q4VUY6,Q4VUY8,Q4VUY9,Q4VWH4,Q4VWH9,Q508J0,Q508J1,Q508J2,Q508J3,Q508J4,Q508J5,Q508J7,Q508J9,Q508K1,Q508K2,Q508K4,Q508K5,Q508K6,Q508K7,Q508K8,Q508K9,Q508L0,Q508L1,Q508L2,Q508L3,Q508L4,Q508L6,Q508L8,Q508M1,Q508M2,Q508M3,Q508M4,Q508M6,Q508M8,Q508M9,Q508N0,Q508N1,Q508N2,Q508N3,Q508N6,Q508P2,Q50DL8,Q539B4,Q539Z1,Q53AJ7,Q53AK6,Q53AK8,Q53AL7,Q53AM3,Q564N6,Q564N8,Q564P1,Q564P2,Q58F56,Q58F69,Q58F82,Q597C5,Q597C7,Q597E2,Q597E3,Q597E4,Q597E6,Q597E7,Q597E8,Q597E9,Q597F0,Q597F1,Q597F2,Q598T9,Q598V2,Q599A4,Q5BQG8,Q5BQG9,Q5BU73,Q5C9H5,Q5DWG5,Q5DX17,Q5F4E4,Q5F4E8,Q5F4F1,Q5F4F4,Q5F4F5,Q5F4G0,Q5F4G2,Q5F4G3,Q5F4G7,Q5F4G9,Q5I191,Q5J1T0,Q5J1T3,Q5J1T4,Q5J1T5,Q5NUR5,Q5NUR7,Q5QD74,Q5QD76,Q5QFW4,Q5QFW5,Q5QFW6,Q5QS02,Q5QS15,Q5QS28,Q5QS41,Q5QS67,Q5S1V3,Q5UVI3,Q5UVI4,Q5UVI5,Q5UVI6,Q5UVI8,Q5UVJ0,Q5VJ36,Q5VJ37,Q5VJ39,Q5VJ41,Q5VJ42,Q5VJ44,Q5VJ45,Q5VJ46,Q5VJ49,Q5VJ50,Q5VJ52,Q5VJ55,Q5VJ57,Q5VJ58,Q5VJ59,Q5VJ60,Q5VJ61,Q5VJ65,Q5VJ67,Q5Y4Q0,Q5YBK0,Q5YJ58,Q5YJ78,Q5YJ93,Q5YKK4,Q5ZN98,Q64GI8,Q64GJ1,Q64J97,Q64JA0,Q678S1,Q678S2,Q678S3,Q678S5,Q678S8,Q678S9,Q692W3,Q698P7,Q6DUL2,Q6ED58,Q6ELU6,Q6ELU7,Q6ELU8,Q6ELU9,Q6ELV2,Q6ELV4,Q6ELV5,Q6ELV7,Q6ELV8,Q6ELV9,Q6ELW1,Q6ELW2,Q6ELW3,Q6ELW6,Q6IYG6,Q6JDN5,Q6JDP8,Q6JDQ6,Q6JDS2,Q6JDS4,Q6JDS5,Q6JDS6,Q6JDS8,Q6JDT0,Q6JDT3,Q6JDT4,Q6JDT8,Q6JDU0,Q6JDU8,Q6JWX5,Q6KF39,Q6KF53,Q6RSH5,Q6RSH6,Q6SQI7,Q6U1P6,Q6V8Y0,Q6V8Y1,Q6V9D6,Q6W6K7,Q6W6L7,Q6WRG2,Q6WRG3,Q6WRG4,Q6WRG7,Q6WRH2,Q6WRH4,Q6WRH5,Q6X2M0,Q6X9S4,Q6XBV1,Q6XBV6,Q6XBW1,Q6XBW4,Q6XBW5,Q6XBW7,Q6XBW8,Q6XZH2,Q6XZH3,Q6XZN8,Q6XZN9,Q6XZP4,Q6Y8J2,Q6Y8J6,Q6Y8J7,Q6YDK5,Q6YDK7,Q6YDL2,Q6YDL6,Q6YDL7,Q6YLN1,Q70RT7,Q70RV0,Q70RW3,Q70XG0,Q70XI6,Q710S3,Q711L6,Q71E87,Q71E89,Q71E95,Q71E97,Q71E99,Q71EA6,Q71EB0,Q71FH1,Q71FH2,Q71FI6,Q71FI8,Q71FI9,Q71FJ0,Q71FJ2,Q71MR3,Q71MR6,Q71RU1,Q75R30,Q76LN6,Q76MX5,Q7GEV4,Q7GGQ9,Q7GI23,Q7HEI2,Q7HFF9,Q7HFG0,Q7HKW1,Q7IY93,Q7IY99,Q7IYN8,Q7IYZ1,Q7J370,Q7J6I1,Q7JE02,Q7Y5X9,Q7Y778,Q7Y779,Q7Y7B2,Q7Y8F6,Q7Y8I2,Q7Y8J5,Q7Y8K8,Q7Y8L0,Q7Y8L4,Q7Y8L5,Q7Y8L6,Q7Y8L9,Q7Y8M0,Q7YA49,Q7YBY4,Q7YBY6,Q7YC63,Q7YC71,Q7YC73,Q7YC74,Q7YC75,Q7YC76,Q7YD12,Q7YD13,Q7YD16,Q7YD72,Q7YD73,Q7YD75,Q7YEV2,Q7YGD4,Q85AG5,Q85AV3,Q85C06,Q85C43,Q85DD9,Q85DE4,Q85DF2,Q85DF5,Q85DF8,Q85IN3,Q85IN4,Q85IN5,Q85IN6,Q85IN7,Q85IN8,Q85IN9,Q85PK7,Q85PM6,Q85PN0,Q85PN4,Q85PN6,Q85PN7,Q85PN8,Q85PP0,Q85PP1,Q85Q58,Q85QA4,Q85RV3,Q8HCJ4,Q8HD57,Q8HD60,Q8HEC2,Q8HEM1,Q8HF67,Q8HG55,Q8HL81,Q8HL93,Q8HLB9,Q8HLD2,Q8HLR2,Q8HMZ7,Q8HQ92,Q8HQE6,Q8HQE7,Q8HQE8,Q8HQE9,Q8HQF0,Q8HQF1,Q8HQF2,Q8LW83,Q8LWM2,Q8LWM4,Q8LWN0,Q8LWP6,Q8LWU4,Q8LX87,Q8LZ88,Q8LZ94,Q8LZ97,Q8M0A6,Q8M0E7,Q8M0K7,Q8M0K9,Q8M354,Q8M3J6,Q8M4C6,Q8M4C7,Q8M4D6,Q8M4E2,Q8M4E6,Q8M5M3,Q8M6Z3,Q8M700,Q8M703,Q8M706,Q8M708,Q8SE00,Q8SE72,Q8SE77,Q8SE89,Q8SEH7,Q8SEJ1,Q8SEL4,Q8SEP4,Q8SET9,Q8SFK5,Q8SFK7,Q8SG72,Q8SGA0,Q8SGQ9,Q8SJB6,Q8SJK5,Q8SJK6,Q8SJK7,Q8SJK8,Q8SJK9,Q8SJL1,Q8SJL2,Q8SJL3,Q8SJX4,Q8SJX5,Q8SJZ1,Q8SJZ2,Q8SJZ3,Q8SJZ4,Q8W7G4,Q8W822,Q8W8Q1,Q8W8W1,Q8W8Y1,Q8W926,Q8W9E4,Q8W9F5,Q8W9F9,Q8W9J6,Q8W9L2,Q8W9N7,Q8WA39,Q8WA47,Q8WB03,Q8WB05,Q8WBP9,Q8WBV2,Q8WCJ7,Q8WCK9,Q8WCL1,Q8WDK6,Q8WDU1,Q8WDV0,Q8WDV2,Q8WDV6,Q8WE97,Q8WEK2,Q8WEK7,Q8WEW8,Q8WFX3,Q8WGF6,Q8WGF7,Q8WGF8,Q8WGG5,Q8WGG8,Q8WGL0,Q94ND7,Q94NF7,Q94NM3,Q94P21,Q94PA3,Q94PB4,Q94Q38,Q94Q45,Q94Q84,Q94QD3,Q94QP2,Q94QQ7,Q94S37,Q94S78,Q94SA4,Q94SD0,Q94SJ5,Q94SK8,Q94SZ7,Q94T21,Q94T42,Q94T68,Q94TE4,Q94TI3,Q94UZ9,Q94V00,Q94V01,Q94V02,Q94VK4,Q94WP7,Q94WQ8,Q94WW5,Q94WW7,Q94WW9,Q94WX2,Q94WX4,Q94WX5,Q94WY6,Q94WY7,Q94Y46,Q94Y47,Q94Y50,Q94Y51,Q94Y56,Q94Y62,Q94Y64,Q94Y66,Q94Y71,Q94Y72,Q94YE5,Q94YL4,Q94YL5,Q94YL9,Q94ZD1,Q94ZJ2,Q94ZK8,Q950B9,Q950C2,Q950C6,Q950C7,Q950S3,Q951T4,Q951T6,Q953G9,Q953J5,Q953K8,Q955G5,Q955G6,Q956S6,Q956Y7,Q956Y9,Q956Z1,Q956Z2,Q956Z3,Q956Z5,Q956Z6,Q956Z7,Q956Z8,Q956Z9,Q95711,Q95718,Q95719,Q95723,Q95726,Q95727,Q95728,Q95729,Q95730,Q95731,Q95734,Q95735,Q95736,Q95737,Q95738,Q95739,Q95741,Q95744,Q95745,Q95750,Q95776,Q957A1,Q957A2,Q957A4,Q957A7,Q957A8,Q957A9,Q957B0,Q957B1,Q957B2,Q957B3,Q957B4,Q957B5,Q957B6,Q957B7,Q957B8,Q957B9,Q957C1,Q957C3,Q957C6,Q957C7,Q957C8,Q957D1,Q95920,Q959V6,Q96071,Q9B0S2,Q9B0Y1,Q9B106,Q9B161,Q9B167,Q9B1D2,Q9B1N0,Q9B1X4,Q9B1Z4,Q9B203,Q9B205,Q9B2C4,Q9B2F7,Q9B365,Q9B506,Q9B5Q1,Q9B5Q3,Q9B5Q4,Q9B5Q5,Q9B5Q6,Q9B5Q7,Q9B5Q8,Q9B5Q9,Q9B5R0,Q9B5R1,Q9B5R2,Q9B5R3,Q9B5R7,Q9B5R8,Q9B5S0,Q9B5S1,Q9B6D0,Q9B6F0,Q9B7V7,Q9B7W1,Q9B7W3,Q9B9E4,Q9B9E8,Q9B9F5,Q9B9F6,Q9B9F9,Q9B9G0,Q9B9Z1,Q9BA02,Q9G0M4,Q9G0S9,Q9G0W6,Q9G156,Q9G1B9,Q9G1C4,Q9G1F7,Q9G1R4,Q9G1Z0,Q9G210,Q9G215,Q9G250,Q9G273,Q9G2R8,Q9G2S5,Q9G2U4,Q9G2U7,Q9G2W6,Q9G396,Q9G3M2,Q9G3M7,Q9G3M9,Q9G3N1,Q9G3N2,Q9G3N4,Q9G3R1,Q9G3S4,Q9G3T7,Q9G4Q1,Q9G6G2,Q9G6G3,Q9G6M3,Q9G7T9,Q9G7U1,Q9G946,Q9G964,Q9G9J4,Q9G9J6,Q9G9J7,Q9GA18,Q9GAM6,Q9GAM7,Q9GAM9,Q9GAN2,Q9GAN4,Q9GAP0,Q9GAR5,Q9GAR6,Q9GAW0,Q9GAW3,Q9GAW6,Q9GBG9,Q9GBY1,Q9GBY4,Q9GBY5,Q9GBY6,Q9GBY8,Q9GBZ0,Q9GBZ1,Q9GBZ2,Q9GBZ4,Q9GBZ5,Q9GBZ6,Q9GBZ7,Q9MDF2,Q9MDZ9,Q9MED6,Q9MFN3,Q9MFN9,Q9MG84,Q9MGL5,Q9MGM4,Q9MI31,Q9MI32,Q9MI35,Q9MI36,Q9MI37,Q9MI38,Q9MI39,Q9MI64,Q9MI97,Q9MIX8,Q9MIZ2,Q9MJ99,Q9MJA1,Q9MJA2,Q9MJV1,Q9MLD6,Q9MLD7,Q9MLI3,Q9MLI6,Q9MLI7,Q9MLI8,Q9MLI9,Q9MLJ0,Q9MLJ1,Q9MLJ2,Q9MLJ3,Q9MLJ4,Q9MLJ5,Q9MLJ6,Q9MLJ7,Q9MLJ8,Q9MLJ9,Q9MLK0,Q9MLK1,Q9MLK2,Q9MLK3,Q9MLK4,Q9MLK5,Q9MLK6,Q9MLK7,Q9MLK8,Q9MLK9,Q9MLL0,Q9MLL3,Q9MLL4,Q9MLL5,Q9MLL6,Q9MMZ2,Q9MQX1,Q9MQX8,Q9MQY0,Q9MQY1,Q9MQY3,Q9MQY5,Q9MQY6,Q9MR49,Q9T3H9,Q9T3Q2,Q9T3R3,Q9T3S9,Q9T3Y0,Q9T3Y2,Q9T3Y3,Q9T443,Q9T469,Q9T475,Q9T4A7,Q9T4B2,Q9T4N0,Q9T4P2,Q9T4R0,Q9T4U3,Q9T5N4,Q9T6I4,Q9T6J0,Q9T6R2,Q9T6R3,Q9T6R5,Q9T6R8,Q9T6R9,Q9T7L5,Q9T7L6,Q9T7L7,Q9T7L8,Q9T7L9,Q9T7M0,Q9T7M3,Q9T7N2,Q9T7N5,Q9T7P0,Q9T7P1,Q9T7Q0,Q9T7Q5,Q9T7Q6,Q9T7Q8,Q9T7Q9,Q9T7S2,Q9T7T7,Q9T7T8,Q9T7T9,Q9T9A5,Q9T9A6,Q9T9A7,Q9T9A8,Q9T9B2,Q9T9B6,Q9T9B7,Q9T9B9,Q9T9C0,Q9T9C1,Q9T9C8,Q9T9I2,Q9T9I7,Q9T9J2,Q9T9J5,Q9T9V5,Q9T9W4,Q9T9Y3,Q9TA00,Q9TAB1,Q9TAD3,Q9TDJ6,Q9TDJ9,Q9TDK1,Q9TDK2,Q9TDK4,Q9TDK6,Q9TDK7,Q9TDK9,Q9TDL0,Q9TDL1,Q9TDL2,Q9TDL3,Q9TDL4,Q9TDL5,Q9TDL6,Q9TDL7,Q9TDL8,Q9TDL9,Q9TDM0,Q9TDM1,Q9TDM3,Q9TDM5,Q9TDM6,Q9TDM7,Q9TDN0,Q9TDN1,Q9TDN2,Q9TDQ5,Q9TDQ7,Q9TDT5,Q9TEB4,Q9TEB5,Q9TEC1,Q9TEU7,Q9TEX8,Q9TEY4,Q9TEY5,Q9TEY6,Q9TEY7,Q9TEY8,Q9TEZ5,Q9TF10,Q9TF12,Q9TF14,Q9TF17,Q9TF20,Q9TF27,Q9TF30,Q9TF31,Q9TF32,Q9TF34,Q9TF37,Q9TF45,Q9TF46,Q9TF47,Q9TF49,Q9TF50,Q9TF51,Q9TF52,Q9TF55,Q9TF57,Q9TF61,Q9TF73,Q9TF74,Q9TF80,Q9TF86,Q9TF89,Q9TF91,Q9TF93,Q9TF95,Q9TFA0,Q9TFX4,Q9TFX5,Q9TFX6,Q9TG16,Q9TGH6,Q9TGH8,Q9TGL9,Q9TH43,Q9TH45,Q9TH46,Q9TH47,Q9TH52,Q9TH56,Q9THD6,Q9XK52,Q9XK70,Q9XKC0,Q9XKK0,Q9XKK2,Q9XKK5,Q9XLE0,Q9XLE1,Q9XLE2,Q9XM10,Q9XMC1,Q9XMC2,Q9XNM0,Q9XNM1,Q9XNM5,Q9XNN0,Q9XNN1,Q9XNN3,Q9XNN4,Q9XNT9,Q9XNU0,Q9XNU2,Q9XNU4,Q9XNU5,Q9XNU6,Q9XNU9,Q9XNV3,Q9XNV4,Q9XNV7,Q9XNW3,Q9XNW4,Q9XNW5,Q9XNW7,Q9XNW8,Q9XNW9,Q9XNX0,Q9XNX1,Q9XNX3,Q9XNX4,Q9XNX6,Q9XNX7,Q9XNX8,Q9XP34,Q9XP68,Q9XP73,Q9XP76,Q9XP77,Q9XP78,Q9XP81,Q9XP82,Q9XP83,Q9XP84,Q9XP86,Q9XP87,Q9XP88,Q9XP89,Q9ZY14,Q9ZY15,Q9ZY46,Q9ZY49,Q9ZZ40,Q9ZZ42,Q9ZZD2,Q9ZZD4,Q9ZZD8,Q9ZZE3,Q9ZZE4,Q9ZZF6,Q9ZZR4,Q9ZZT5,Q9ZZT6,Q9ZZT7,Q9ZZT8,Q9ZZU1">cytochrome b</protein-id> (<protein-id="P00158,P00159,P00160,P00162,P05501,P07704,P18935,P24890,P51941,Q8HEC2,Q8HMZ7,Q8HQ92,Q8WA47,Q9MDZ9,Q9MGL5,Q9MGM4,Q9MIX8">cytb</protein-id>) and <compound-id="439153">NADH</compound-id> 2 genes, were obtained from 49 Acropora species.	NADH__CaM__no_interaction	NADH__cytochrome b__no_interaction	NADH__cytb__no_interaction	NADH__calmodulin__no_interaction
18670810-1039	Both expression of tac and <protein-id="P06767,P08435,P41539,P55099">tac2</protein-id> were induced by 2% <compound-id="5988">sucrose</compound-id>.	sucrose__tac2__interaction
18670880-1082	Contaminants of current high use in the LRGV, such as <compound-id="2256">atrazine</compound-id>, and some of the highly persistent organochlorines, such as <compound-id="5284469">toxaphene</compound-id> and <compound-id="3035">DDE</compound-id>, could be potentially associated with modulation of <protein-id="O42145,O46512,P11511,P19098,P22443,P28649,P46194,P70091,P79304,P79430,P79699,Q29605,Q29624,Q5QQX7,Q69FB6,Q6QHT9,Q6YI21,Q92087,Q92111,Q92112,Q95M61,Q9XS28">aromatase</protein-id> activity in avian tissues.	toxaphene__aromatase__interaction	atrazine__aromatase__interaction	DDE__aromatase__interaction
18670892-1460	In this view, this study aimed at the investigating the use of a crude <protein-id="P15984,P16147,P84714">peroxidase</protein-id> preparation from onion solid by-products for oxidising <compound-id="689043">caffeic acid</compound-id>, a widespread o-diphenol, whose various derivatives may occur in food industry wastes, such as olive mill waste waters.	caffeic acid__peroxidase__interaction
18670896-1090	<compound-id="6599">Ziram</compound-id> exposures that caused a loss of binding function were examined for effects on expression of key NK cell-<protein-id="O12164,O41803,O42043,O56861,O70902,O71037,O89292,O91086,P03374,P03375,P03377,P03378,P03379,P03380,P03381,P03383,P03385,P03386,P03387,P03388,P03390,P03391,P03392,P03395,P03396,P03397,P03399,P04027,P04502,P04577,P04578,P04579,P04580,P04581,P04582,P04583,P04624,P05877,P05878,P05879,P05880,P05881,P05882,P05883,P05884,P05885,P05886,P06445,P06751,P06752,P07575,P08359,P08360,P08810,P0C212,P10259,P10267,P10269,P11261,P11267,P11268,P11306,P12449,P12487,P12488,P12489,P12492,P14075,P14351,P15073,P15831,P16082,P16090,P16899,P17281,P17755,P18040,P18094,P18799,P19030,P19503,P19549,P19550,P19551,P19556,P19557,P20871,P20872,P20888,P21412,P21415,P21436,P21443,P21444,P21445,P22380,P22427,P22428,P22429,P22430,P23064,P23073,P23422,P23423,P24105,P25057,P25504,P25505,P25506,P25507,P26803,P26804,P27399,P27757,P27977,P31621,P31626,P31627,P31789,P31791,P31794,P31796,P31819,P31872,P32536,P32541,P33498,P35954,P35961,P51515,P51519,P51520,P60507,P60508,P60608,P61549,P61550,P61552,P61553,P61554,P61555,P61556,P61557,P61558,P61559,P61561,P61562,P61563,P61564,P61565,P61566,P61567,P61570,Q02076,Q02077,Q02282,Q02837,Q03804,Q03816,Q03817,Q04993,Q04995,Q05312,Q09SZ7,Q0R5Q9,Q14264,Q1A243,Q1A261,Q69384,Q70626,Q73372,Q74126,Q75008,Q76638,Q77377,Q79670,Q85646,Q89607,Q8AIH5,Q8MIB6,Q902F8,Q902F9,Q96L62,Q9IDV2,Q9N2J8,Q9N2J9,Q9N2K0,Q9NX77,Q9Q714,Q9QBY2,Q9QBZ0,Q9QBZ4,Q9QBZ8,Q9QSQ7,Q9TTC0,Q9UKH3,Q9UQF0,Q9WC60,Q9WC69">surface proteins</protein-id> needed for binding to targets.	Ziram__surface proteins__interaction
18670905-814	Here, we have investigated how the post-synthetic acetylation of <protein-id="P07156,P09429,P10103,P12682,P36194,Q4R844,Q6YKA4">HMGB1</protein-id> affects its interaction with negatively supercoiled DNA by employing monoacetylated at Lys2 protein, isolated from <compound-id="264">butyrate</compound-id>-treated cells.	butyrate__HMGB1__no_interaction
18670906-1096	<protein-id="Q8IUC2">KAP8.1</protein-id> protein contains high <compound-id="750">glycine</compound-id> and <compound-id="1153,6057,5460803">tyrosine</compound-id>, which concerns regulation and function of the matrix structure fiber.	tyrosine__KAP8.1__interaction	glycine__KAP8.1__interaction
18671273-1368	<compound-id="6197">Cycloheximide</compound-id> inhibited <protein-id="O61389,O96605,P19806,P55321,P55846,P55847,P55848,P83220,P83636,Q10987,Q27225">MIH</protein-id> induced <protein-id="P00536,P00539,P12965">Mos</protein-id> expression and its phosphorylation, which in turn reduced <protein-id="P70047,Q8CFC2,Q91618,Q9ESG9,Q9NI63">Myt1</protein-id> phosphorylation and GVBD.	Cycloheximide__Myt1__interaction	Cycloheximide__Mos__interaction	Cycloheximide__MIH__interaction
18671672-48	<compound-id="11984615">CLNO2</compound-id> levels were found to increase approximately 20-fold 24 h after macrophage activation with Escherichia coli <compound-id="11970143">lipopolysaccharide</compound-id> plus <protein-id="Q9TTB0">interferon-gamma</protein-id> ; this response was concurrent with an increase in the expression of <protein-id="O19114,O46660,O54705,O62699,P35228,P60321,P79290,Q27995,Q28314,Q90703,Q92037,Q92091">NOS2</protein-id> (inducible <protein-id="O61309,O61608,Q27571,Q9I9M2">nitric oxide synthase</protein-id>) and was inhibited by the (*)NO (<compound-id="145068">nitric oxide</compound-id>) inhibitor L-NAME (<compound-id="39836">N(G)-nitro-L-arginine methyl ester</compound-id>).	CLNO2__interferon-gamma__interaction	N(G)-nitro-L-arginine methyl ester__interferon-gamma__no_interaction	CLNO2__nitric oxide synthase__interaction	nitric oxide__interferon-gamma__no_interaction	lipopolysaccharide__NOS2__no_interaction	N(G)-nitro-L-arginine methyl ester__NOS2__no_interaction	lipopolysaccharide__nitric oxide synthase__no_interaction	nitric oxide__nitric oxide synthase__no_interaction	CLNO2__NOS2__interaction	nitric oxide__NOS2__no_interaction	lipopolysaccharide__interferon-gamma__no_interaction	N(G)-nitro-L-arginine methyl ester__nitric oxide synthase__no_interaction
18671761-109	<compound-id="3290">Parkin</compound-id>-mediated ubiquitination regulates <protein-id="P08487,P10686,P19174,Q62077">phospholipase C-gamma1</protein-id>.	Parkin__phospholipase C-gamma1__interaction
18671795-129	Short-acting <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> analogues, in comparison with regular human <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> (<protein-id="P33279,Q9BQI3">HRI</protein-id>), provide a greater control of postprandial <compound-id="206,5793,64689,79025">glucose</compound-id>, while their superiority on haemoglobin A1c (HbA1c) is controversial.	glucose__insulin__interaction	glucose__HRI__interaction
18671897-205	Western blotting showed that <compound-id="21913,636403,5311038">carbenoxolone</compound-id> down-regulated <protein-id="O57474,P08050,P14154,P16863,P17302,P18246,P23242,Q29101,Q6S9C0">Cx43</protein-id> protein expression in the BA, which in the SAH-only group was significantly higher than that of the normal group.	carbenoxolone__Cx43__interaction
18672341-581	Hepatocytes exposed to resistin, but only in the presence of <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>, show a decrease in <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>-stimulated <compound-id="439177">glycogen</compound-id> content.	glycogen__insulin__interaction
18672928-1390	To further test this hypothesis, we have measured the fluorescence quantum yield in solvents of different polarity for the following systems: <compound-id="2003,94230">N-acetyl-L-tryptophanamide</compound-id> (NATA), an analogue for Trp in <protein-id="P03161,P03610,P03631,P03632,P07394,P15966,P25243,P25244,P35823,P98005">a protein</protein-id> ; <compound-id="304749,2724382">N-acetyl-L-tryptophan ethyl ester</compound-id> (NATE), wherein the Trp amide is replaced by an ester group, lowering the CT state energy; and <compound-id="6736">3-methylindole</compound-id> (<compound-id="11001318">3MI</compound-id>), a control wherein this quenching mechanism cannot take place.	3-methylindole__a protein__no_interaction	3MI__a protein__no_interaction	N-acetyl-L-tryptophanamide__a protein__interaction	N-acetyl-L-tryptophan ethyl ester__a protein__no_interaction
18673089-1229	Differentiated EBD cells in both monolayer and three-dimensional in vitro culture demonstrated fat granules by light microscopy, stained positive for lipids with <compound-id="6046885,6821284">oil red-O</compound-id>, and expressed adipocyte-specific genes (lipoprotein <protein-id="Q7M4U7">lipase</protein-id> [<protein-id="O46647,P06858,P11151,P11152,P11153,P11602,P49060,P49923,P55031,Q06000,Q29524">LPL</protein-id>], peroxisome proliferator activated receptor <protein-id="P02528">gamma2</protein-id>, and adipocyte-specific <protein-id="O42494,O45035,O76821,P80547,Q17284,Q8MUC1,Q9U5P1">fatty acid binding protein</protein-id> [alphaP2]).	oil red-O__lipase__no_interaction	oil red-O__fatty acid binding protein__no_interaction	oil red-O__LPL__no_interaction	oil red-O__gamma2__no_interaction
18673303-1358	In addition, AIT induced a more favourable regulation of blood <compound-id="206,5793,64689,79025">glucose</compound-id> and <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> compared with MTG.	glucose__insulin__no_interaction
18673333-52	Beta1,4-<protein-id="P14769,P23336,P50127">galactosyltransferase</protein-id>-I (<protein-id="P08037,P15291">B4GALT1</protein-id>), one of seven beta1,4-<protein-id="P14769,P23336,P50127">galactosyltransferases</protein-id>, is an enzyme commonly found in the trans-Golgi complex that adds <compound-id="6036,439353,439357">galactose</compound-id> to oligosaccharides.	galactose__galactosyltransferase__interaction	galactose__B4GALT1__interaction	galactose__galactosyltransferases__interaction
18673333-53	When compared to the other mammalian <protein-id="P08037,P15291">B4GALT1</protein-id> genes, the porcine coding sequence contained a single <compound-id="6288">threonine</compound-id> codon inserted into the region encoding the cytoplasmic domain.	threonine__B4GALT1__interaction
18674953-1307	<compound-id="64947">Gyp</compound-id> inhibited the levels of the anti-apoptotic proteins <protein-id="P10417,P49950">Bcl-2</protein-id> and Bcl-xl, but promoted the levels of the pro-apoptotic <protein-id="P27297">protein Bax</protein-id>.	Gyp__Bcl-2__interaction	Gyp__protein Bax__interaction
18674953-1308	In conclusion, <compound-id="64947">Gyp</compound-id> induced ER stress and production of reactive <compound-id="977">oxygen</compound-id> species and <compound-id="271">Ca(2</compound-id>+), change the ratio of <protein-id="P10417,P49950">Bcl-2</protein-id> and <protein-id="P27297,Q07813,Q63690">Bax</protein-id>, followed by the dysfunction of mitochondria, caused <protein-id="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3">cytochrome c</protein-id> release, activation of caspase-3 before leading to apoptosis.	oxygen__Bcl-2__no_interaction	Ca(2__Bax__no_interaction	Ca(2__Bcl-2__no_interaction	oxygen__cytochrome c__no_interaction	Gyp__Bcl-2__interaction	Ca(2__cytochrome c__no_interaction	Gyp__cytochrome c__interaction	oxygen__Bax__no_interaction	Gyp__Bax__interaction
18675966-641	To compare expression of endometrial estrogen (ER) and progesterone (PR) receptors, beta(3)-integrin subunit, leukemia inhibitory factor (<protein-id="O62728,P09056,P15018,P17777,Q27956">LIF</protein-id>), <protein-id="P41693">interleukin-6</protein-id> (<protein-id="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80">IL-6</protein-id>), and pinopodes in Indian women using <compound-id="35805,154413">ormeloxifene</compound-id> as a contraceptive with fertile and infertile subjects during the window of implantation.	ormeloxifene__IL-6__interaction	ormeloxifene__interleukin-6__interaction	ormeloxifene__LIF__interaction
18676014-229	We have also observed that the reduction of transition at 95+/-3 degrees C in thermal scans of nuclear preparations isolated from blood of B-CLL randomized patients who showed response to <compound-id="20279">cladribine</compound-id> or <compound-id="657237">fludarabine</compound-id> combined with <compound-id="2907,9554282">cyclophosphamide</compound-id>, i.e., CC and FC, respectively, corresponded with the decrease or disappearance of anti-apoptotic proteins <protein-id="P10417,P49950">Bcl-2</protein-id> and/or <protein-id="Q69FH1,Q9Z2H6">Mcl</protein-id> 1.	cladribine__Bcl-2__no_interaction	cyclophosphamide__Bcl-2__no_interaction	fludarabine__Mcl__no_interaction	cyclophosphamide__Mcl__no_interaction	fludarabine__Bcl-2__no_interaction	cladribine__Mcl__no_interaction
18676199-799	Exposure of erythrocytes to <protein-id="Q9UQ90">PGNs</protein-id> increased cytosolic <compound-id="271">Ca(2</compound-id>+) concentration, increased ceramide formation, enhanced the percentage of <protein-id="P08758,P14668,P17153,P48036,P70075,P81287,Q4R4H7,Q5R1W0">annexin V</protein-id>-binding erythrocytes, decreased erythrocyte forward scatter, and lowered the intracellular <compound-id="5957">ATP</compound-id> concentration.	ATP__annexin V__no_interaction	ATP__PGNs__interaction	Ca(2__annexin V__no_interaction	Ca(2__PGNs__interaction
18676776-233	Inhibition of <protein-id="Q00859">mitogen-activated protein kinase</protein-id> (<protein-id="O42781,P27638,Q00859">MAPK</protein-id>) and <protein-id="P31750,Q8INB9">Akt</protein-id> prevented the antiapoptotic effects of <compound-id="942,89594,157672">nicotine</compound-id> and decreased chemotherapy-induced apoptosis.	nicotine__Akt__interaction	nicotine__MAPK__interaction	nicotine__mitogen-activated protein kinase__interaction
18676776-235	<compound-id="942,89594,157672">Nicotine</compound-id> up-regulated <protein-id="P31750,Q8INB9">Akt</protein-id>-mediated antiapoptotic X-linked <protein-id="Q90660">inhibitor of apoptosis protein</protein-id> and phosphorylated proapoptotic <protein-id="O35147,Q61337,Q92934">Bcl2-antagonist of cell death</protein-id>.	Nicotine__Akt__interaction	Nicotine__Bcl2-antagonist of cell death__interaction	Nicotine__inhibitor of apoptosis protein__interaction
18677478-391	Induction of NY-ESO-1 expression on tumor targets using the demethylating agent <compound-id="451668">5-aza-2'-deoxycytidine</compound-id> (alone or in combination with the histone deacetylase inhibitor <compound-id="5352062">depsipeptide</compound-id>) resulted in enhanced <protein-id="Q9TTB0">interferon-gamma</protein-id> secretion by the TCR-transduced PBL on culture with treated targets.	depsipeptide__interferon-gamma__interaction	5-aza-2'-deoxycytidine__interferon-gamma__interaction
18677521-1468	In the absence of <protein-id="P18151,P21354,P23603,P23700,P23701,P26758,P94664,Q253E5,Q3KLQ7,Q548P6,Q933I7,Q9AIS7,Q9PJV0">OmcB</protein-id>, cells lost the ability to reduce soluble or insoluble <compound-id="29936">Fe(III</compound-id>).	Fe(III__OmcB__interaction
18677521-1470	DNA sequences of upstream regions of coregulated operons in the adapted mutant are divergent, suggesting the presence of recognition sites for different <protein-id="Q9CJ45">transcriptional regulators</protein-id> and indicating that adaptation of the omcB mutant to growth on soluble <compound-id="29936">Fe(III</compound-id>) has shifted the relevant expression networks involved to a more diverse molecular basis.	Fe(III__transcriptional regulators__no_interaction
18677561-697	Elevated beta1,4-<protein-id="P14769,P23336,P50127">galactosyltransferase</protein-id>-I induced by the intraspinal injection of <compound-id="11970143">lipopolysaccharide</compound-id>.	lipopolysaccharide__galactosyltransferase__interaction
18677561-698	E-selectin, which ligand was modified by beta1,4-<protein-id="O33836,O84904,P09148,P13212,P22714,P31764,P39575,P45981,P96994,Q00054,Q5LYY8,Q5M3K1,Q836N8,Q88SF0,Q8R8R6,Q8RHC9,Q8VS92,Q8XKP8,Q93MM1,Q97EZ4,Q9CE63,Q9KDV2,Q9RGR9,Q9S6S3,Q9ZB09">GalT</protein-id>-I, was correlated with <compound-id="6036,439353,439357">galactose</compound-id>-containing glycans following injecting LPS into spinal cord.	galactose__GalT__no_interaction
18677571-1520	Effects of <protein-id="O43439,P46655,P49846,Q14155">P85</protein-id> on amino acid transporters were examined using their substrates: (3)H-<compound-id="994,6140,71567">phenylalanine</compound-id>, (3)H-<compound-id="866,5962">lysine</compound-id>, and (3)H-methylaminoisobutyric acid, respectively.	phenylalanine__P85__no_interaction	lysine__P85__no_interaction
18677583-1526	<compound-id="3121">Valproate</compound-id>, an anticonvulsant and mood stabilizer, up-regulates <protein-id="P10417,P49950">Bcl-2</protein-id>, a neurotrophic/neuroprotective protein.	Valproate__Bcl-2__interaction
18677583-1527	In this study, we investigated the molecular mechanism through which <protein-id="P10417,P49950">Bcl-2</protein-id> is up-regulated by <compound-id="3121">valproate</compound-id> using cultured human neuron-like cells.	valproate__Bcl-2__interaction
18677583-1528	<compound-id="3121">Valproate</compound-id>, within therapeutically relevant ranges, induced time- and concentration-dependent up-regulations of both <protein-id="P10417,P49950">Bcl-2</protein-id> messenger RNA and protein implicating an underlying gene transcriptional-mediated mechanism.	Valproate__Bcl-2__interaction
18677583-1529	<compound-id="3121">Valproate</compound-id> increased transcriptional activity of a human <protein-id="P10417,P49950">bcl-2</protein-id> promoter-reporter gene construct.	Valproate__bcl-2__interaction
18677583-1530	ERK and/or PI3K pathway inhibitors and RSK1 small hairpin RNA knockdown reduced, but did not abolish, baseline and <compound-id="3121">valproate</compound-id>-induced promoter activities and lowered <protein-id="P10417,P49950">Bcl-2</protein-id> protein levels.	valproate__Bcl-2__no_interaction
18677583-1531	These data collectively suggest that <compound-id="3121">valproate</compound-id> induces <protein-id="P10417,P49950">Bcl-2</protein-id> regulation partially through activations of the <protein-id="P29323">ERK</protein-id> and <protein-id="O00329,O02697,O35904,P23727,P26450,P27986,P32871,P42336,P42337,P42338,P42347,P42348,P48736,P54673,P54674,P54675,P54676,Q63787,Q8BTI9,Q8UUU2,Q9JHG7,Q9Z1L0">PI3K</protein-id> cascades and their convergent kinase, <protein-id="P18652">RSK</protein-id>, although other unknown mechanism(s) are likely involved.	valproate__PI3K__interaction	valproate__RSK__interaction	valproate__Bcl-2__interaction	valproate__ERK__interaction
18677583-1532	Given the known roles of <protein-id="P10417,P49950">Bcl-2</protein-id> in the central nervous system, the current findings offer a partial yet complex molecular mechanistic explanation for the known neurobiological effects of <compound-id="3121">valproate</compound-id> including neurite growth, neuronal survival, and neurogenesis.	valproate__Bcl-2__no_interaction
18679593-620	With covalent method, <compound-id="3485">glutaraldehyde</compound-id> was introduced to immobilize <protein-id="O33843,P06835,P07337,P10482,P12614,P14002,P15885,P16084,P22073,P22505,P22506,P22507,P26208,P27034,P29090,P29091,P33363,P38645,P40740,P42403,P48825,P49235,Q03506,Q08638,Q46684,Q56078">cellobiase</protein-id>.	glutaraldehyde__cellobiase__interaction
18679731-726	As metabolic flux for the operation of the <compound-id="10251">flavonoid</compound-id> pathway is maintained through the activities of <protein-id="O03979,O04058,O93967,P10248,P10731,P11544,P14166,P14717,P14925,P19021,P26600,P35511,P35512,P45726,P45727,P45730,P45731,P45735,P52777,P83388,P91268,P97467,Q42609,Q43210,Q9P2V4,Q9PSN0">PAL</protein-id> and <protein-id="O24312,O81928,P37114,P37115,P48522,P92994,Q04468,Q42797,Q43033,Q43054,Q43067,Q43240,Q96423,Q9AR74">C4H</protein-id>, thus, catechins biosynthesis in tea is critically dependent on the products of these enzymes.	flavonoid__PAL__interaction	flavonoid__C4H__interaction
18679812-4	Activities of antioxidant enzymes (<protein-id="O50258">superoxide dismutase</protein-id>, <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id>, <protein-id="O32770,O59858,Q00277,Q9CFV1">glutathione peroxidase</protein-id>, <protein-id="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655">glutathione reductase</protein-id>, glutatione-S-transferase, and <compound-id="124886">reduced glutathione</compound-id>) in liver also decreased in carcinogen-administered rats, which were significantly elevated in bacoside A-pretreated rats.	reduced glutathione__superoxide dismutase__no_interaction	reduced glutathione__glutathione peroxidase__no_interaction	reduced glutathione__catalase__no_interaction	reduced glutathione__glutathione reductase__no_interaction
18679831-20	In this study, we report that AR-<compound-id="77681">M1896</compound-id>, a non-GalR1 agonist, inhibited plasma extravasation induced by <protein-id="P01289,P06767,P19850,P20366,P28498,P28499,P41333,P41539,P41540,P67932,P67933,Q60541">substance P</protein-id> and <protein-id="P30880,P30881,P31888">calcitonin gene-related peptide</protein-id> in a manner similar to <protein-id="P07480,P10683,P11242,P22466,P30802,P31234,P33710,P47212,P47213,P47214,P47215,P47216,Q9W6M9">galanin</protein-id>, confirming a non-GalR1-mediated effect.	M1896__calcitonin gene-related peptide__interaction	M1896__galanin__no_interaction	M1896__substance P__interaction
18680102-211	Inhibition of non-small cell lung cancer cell migration by grape seed <compound-id="108065">proanthocyanidins</compound-id> is mediated through the inhibition of nitric oxide, guanylate <protein-id="O94303,P33734,Q9P4P9,Q9SZ30">cyclase</protein-id>, and <protein-id="P27361,P28869,P42525,Q07176">ERK1</protein-id>/2.	proanthocyanidins__ERK1__interaction	proanthocyanidins__cyclase__interaction
18680102-215	Additionally, UO126 and <compound-id="1456">ODQ</compound-id> inhibited the migration restoring effects of <compound-id="6322">L-arginine</compound-id> in L-NAME-treated cells, suggesting the involvement of <compound-id="24316">cGMP</compound-id> and <protein-id="O42781,P27638,Q00859">MAPK</protein-id> pathways in NO-mediated migration.	ODQ__MAPK__no_interaction	L-arginine__MAPK__no_interaction	cGMP__MAPK__no_interaction
18680102-216	GSPs inhibited <compound-id="6322">L-arginine</compound-id> and <compound-id="104767">8-Br-cGMP</compound-id>-induced activation of <protein-id="P27361,P28869,P42525,Q07176">ERK1</protein-id>/2 in A549 cells.	L-arginine__ERK1__interaction	8-Br-cGMP__ERK1__interaction
18680106-970	Enhancement of <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id> expression in keratinocytes by the <compound-id="5280805">bioflavonoid</compound-id> <compound-id="5280443">apigenin</compound-id> is associated with <protein-id="P03526,P04487,P07940,P12002,P56958,P82866">RNA-binding protein</protein-id> <protein-id="P70372,Q15717">HuR</protein-id>.	bioflavonoid__HuR__interaction	bioflavonoid__p53__interaction	apigenin__RNA-binding protein__no_interaction	apigenin__HuR__interaction	apigenin__p53__interaction	bioflavonoid__RNA-binding protein__no_interaction
18680106-971	We have reported previously that <compound-id="5280443">apigenin</compound-id>, a naturally occurring nonmutagenic <compound-id="10251">flavonoid</compound-id>, increased wild-type <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id> protein expression in the mouse keratinocyte 308 cell line by a mechanism involving <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id> protein stabilization.	apigenin__p53__interaction	flavonoid__p53__no_interaction
18680106-973	Instead, biosynthetic labeling showed that <compound-id="5280443">apigenin</compound-id> increased nascent <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id> protein synthesis by enhancing <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id> translation.	apigenin__p53__interaction
18680106-975	Furthermore, <compound-id="5280443">apigenin</compound-id> treatment increased the level of association of the <protein-id="P03526,P04487,P07940,P12002,P56958,P82866">RNA binding protein</protein-id> <protein-id="P70372,Q15717">HuR</protein-id> with endogenous <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id> mRNA.	apigenin__p53__interaction	apigenin__HuR__interaction	apigenin__RNA binding protein__no_interaction
18680106-976	<compound-id="5280443">Apigenin</compound-id> treatment also augmented <protein-id="P70372,Q15717">HuR</protein-id> translocation into the cytoplasm.	Apigenin__HuR__interaction
18680106-979	Overall, these findings indicate that, in addition to modulating <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id> protein stability, one of the mechanisms by which <compound-id="5280443">apigenin</compound-id> induces <protein-id="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679">p53</protein-id> protein expression is enhancement of translation through the <protein-id="P03526,P04487,P07940,P12002,P56958,P82866">RNA binding protein</protein-id> <protein-id="P70372,Q15717">HuR</protein-id>.	apigenin__p53__interaction	apigenin__HuR__interaction	apigenin__RNA binding protein__no_interaction
18680156-264	Immunoblot analysis of signaling molecules, including cyclic-<protein-id="O24006">AMP</protein-id> response element binding protein (<protein-id="P15337,P16220,P27925,P51984,P51985,Q01147">CREB</protein-id>), <protein-id="Q00859">mitogen-activated protein kinases</protein-id> (MAPKp44/42; <protein-id="P27361,P28869,P42525,Q07176">ERK1</protein-id>/2), in area CA1 revealed that <compound-id="5819">thyroxin</compound-id> treatment reversed hypothyroidism-induced reduction of signaling molecules essential for learning and memory, and L-LTP.	thyroxin__CREB__interaction	thyroxin__ERK1__interaction	thyroxin__mitogen-activated protein kinases__interaction	thyroxin__AMP__interaction
18680550-1533	<protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">Insulin</protein-id> resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus <compound-id="37542">ribavirin</compound-id>.	ribavirin__Insulin__interaction
18680550-1535	Aim To investigate retrospectively the impact of <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> resistance on treatment response in Chinese genotype 1 CHC patients receiving a 24-week course therapy with peginterferon alpha-2b/<compound-id="37542">ribavirin</compound-id>.	ribavirin__insulin__interaction
18680626-658	We hypothesised that <protein-id="P04181,Q07805,Q4XWV5,Q6LFH8,Q7RT90">OAT</protein-id> could be a limiting step in <compound-id="738,5961">glutamine</compound-id>-<compound-id="232,4367,6322">arginine</compound-id> interconversion.	glutamine__OAT__interaction	arginine__OAT__interaction
18680626-659	<protein-id="P04181,Q07805,Q4XWV5,Q6LFH8,Q7RT90">OAT</protein-id> overexpression decreased plasma and liver <compound-id="389,6262,71082">ornithine</compound-id> concentrations but did not affect <compound-id="738,5961">glutamine</compound-id> or <compound-id="232,4367,6322">arginine</compound-id> homeostasis.	ornithine__OAT__interaction	glutamine__OAT__no_interaction	arginine__OAT__no_interaction
18680626-660	There was an inverse relationship between <compound-id="389,6262,71082">ornithine</compound-id> levels and <protein-id="P04181,Q07805,Q4XWV5,Q6LFH8,Q7RT90">OAT</protein-id> activity.	ornithine__OAT__interaction
18681858-1	In men there is a large interindividual variation of <protein-id="P04278,P08689,P15196,P97497,Q62588">SHBG</protein-id> levels and consequently of <compound-id="6013">testosterone</compound-id> (T) and E(2) levels.	testosterone__SHBG__interaction
18682334-364	Bone marrow cells were obtained from 5-day-old Muscovy ducks and cultured with (Group A) No added factors, (B) 30ng/mL soluble <protein-id="O14788,O35235,Q9ESE2">RANKL</protein-id> (sRANKL), (C) 30ng/mL sRANKL and 10ng/mL <protein-id="O00300">OPG</protein-id>, (D) 10ng/mL <protein-id="O00300">OPG</protein-id>, (E) 50ng/mL <protein-id="O00300">OPG</protein-id>, (F) 100ng/mL <protein-id="O00300">OPG</protein-id> and (G) 30ng/mL sRANKL, 6mmol/<compound-id="5281764">L Ca</compound-id> and 3mmol/L P. sRANKL promoted the survival of OCs on day 2, whereas the number of OCs decreased with addition of <protein-id="O00300">OPG</protein-id> in a dose-dependent manner.	L Ca__RANKL__no_interaction	L Ca__OPG__no_interaction
18682988-518	Over-expression of <protein-id="O52310,O59650,O74024,O95479,P00366,P00367,P00368,P0AES2,P0AES3,P10860,P13443,P26443,P28270,P36234,P42174,P42206,P42238,P49448,P52596,P54385,P56201,P80319,P82264,P93541,P94598,P96110,Q09115,Q43260,Q47950,Q47951,Q53199,Q56304,Q59516,Q64HZ8,Q64HZ9,Q64I00,Q64I01,Q9HFR6,Q9HGU3,Q9HGU4,Q9RDE9,Q9URS1,Q9YC65">GDH</protein-id> decreased the yield of <compound-id="702">ethanol</compound-id> and <compound-id="262,225936">2,3-butanediol</compound-id>, meanwhile it increased the concentration of <compound-id="176,286,291512">acetic acid</compound-id>.	acetic acid__GDH__interaction	ethanol__GDH__interaction	2,3-butanediol__GDH__interaction
18683011-1547	<compound-id="5282199">Geranylgeranylacetone</compound-id> prevents acute liver damage after massive hepatectomy in rats through suppression of a CXC chemokine <protein-id="P09341">GRO1</protein-id> and induction of heat shock proteins.	Geranylgeranylacetone__GRO1__interaction
18683188-1093	Furthermore, HA induced dose-dependent elevation of reactive <compound-id="977">oxygen</compound-id> species (ROS) level in SMCs, and antioxidant <compound-id="54670067">vitamin C</compound-id> and <compound-id="40634">Trolox</compound-id> effectively suppressed HA-induced DNA damage and dysregulation of <protein-id="P10417,P49950">Bcl-2</protein-id>/<protein-id="P27297,Q07813,Q63690">Bax</protein-id>.	oxygen__Bcl-2__no_interaction	Trolox__Bax__interaction	Trolox__Bcl-2__interaction	vitamin C__Bcl-2__interaction	vitamin C__Bax__interaction	oxygen__Bax__no_interaction
18683221-1122	The adsorption of ovine <protein-id="P22775,P81070">fibrinogen</protein-id> onto <compound-id="27924,122634,22833501">PMA</compound-id>-modified surfaces was reduced relative to unmodified surfaces, and in vitro ovine blood contact through a rocking test revealed marked reductions in platelet deposition and bulk phase platelet activation relative to unmodified TiAl6V4 and polystyrene controls.	PMA__fibrinogen__interaction
18683225-1127	When the <protein-id="P84122">thrombin</protein-id> concentration was higher than 15 U/mL, the gelation could be finished within 1 min and yielded a composite with evenly suspended and distributed <compound-id="36797">PLGA</compound-id> microspheres.	PLGA__thrombin__interaction
18683233-58	The culture tests using MSCs show that the level of <protein-id="O60109,P81800,P83456">alkaline phosphatase</protein-id> (<protein-id="P03973,P12547,P22298,P28296,P29118,P35211,P83610,P97430,Q03420,Q53GG5,Q9H0A0,Q9PU47,Q9Z1X0">ALP</protein-id>) activity in the cells cultured on SPV-H increased during the 21-day culture in a medium without Dex and <compound-id="2526">beta-GP</compound-id>.	beta-GP__ALP__interaction	beta-GP__alkaline phosphatase__interaction
18683233-59	The level was unchanged in MSCs cultured on PV-H. In the case of supplementing Dex and <compound-id="2526">beta-GP</compound-id> to the medium, the level of <protein-id="P03973,P12547,P22298,P28296,P29118,P35211,P83610,P97430,Q03420,Q53GG5,Q9H0A0,Q9PU47,Q9Z1X0">ALP</protein-id> activity in MSCs cultured on SPV-H was higher than that on PV-H at all time points during the 21-day culture.	beta-GP__ALP__interaction
18683244-106	The combined treatment strategy not only decreased <protein-id="O46543,P08565,P08618,P0C014,P0C072,P13117,P14624,P14792,P15174,P19848,P20685,P22589,P23324,P23398,P42739,P42740,P46574,P49634,P49635,P59263,P59669,P61862,P61863,P61864,P62972,P62973,P62974,P62975,P62976,P62977,P62988,P62989,P62990,P62991,P63049,P63051,P68195,P68196,P68197,P68198,P68199,P68201,P68204,P69308,P69309,P69310,P69311,P69312,P69313,P69314,P69315,P69316,P69317,P69318,P69319,P69320,P69321,P69322,P69323,P69324,P69325,P69326,P84589,Q05550,Q865C5,Q867C2,Q867C3,Q867C4,Q8MKD1,Q9Y848">ubiquitin</protein-id>-positive aggregation in striatum, alleviated <compound-id="5961">polyglutamine</compound-id> aggregation formation, and reduced striatal volume, but also extended life span in the R6/2 animal model.	polyglutamine__ubiquitin__no_interaction
18683246-1143	<protein-id="P01282,P01283,P01284,P04566,P09684,P09685,P32648,P32649,P39089,P45644,P48142,P48143,P63289,P63290,P63291,P81016,P81401,P84488,P84771,P84772">Vasoactive intestinal peptide</protein-id> inhibits toll-like receptor 3-induced <compound-id="145068">nitric oxide</compound-id> production in Schwann cells and subsequent sensory neuronal cell death in vitro.	nitric oxide__Vasoactive intestinal peptide__interaction
18683252-1154	The <protein-id="P05804">GUS</protein-id> and LUC genes were chosen because they can be used as markers for the easy detection of transgenic plants, while <compound-id="773,6274">histidine</compound-id> tail better enables the isolation of protein expressed in plant tissue.	histidine__GUS__no_interaction
18683262-1162	Expression was performed in fusion to <compound-id="294,6255,439186,439341,10991489,45109807">maltose</compound-id> binding protein using chemically defined minimal medium, followed by a single-step affinity capture and enzymatic cleavage using tobacco etch virus <protein-id="O41798,O89290,O89940,O91080,O93215,P03311,P03353,P03355,P03356,P03362,P03363,P03366,P03367,P03369,P03370,P04023,P04024,P04323,P04584,P04585,P04587,P04588,P04589,P05959,P05960,P05961,P05962,P07570,P0C210,P0C211,P10210,P10265,P10270,P10271,P10272,P10273,P10274,P10394,P10978,P11227,P11365,P12451,P12497,P12498,P12499,P14074,P14078,P15833,P16046,P16423,P16901,P17757,P18042,P18096,P18802,P19028,P19199,P19560,P19561,P20825,P20875,P20876,P20892,P21407,P21414,P24107,P24740,P26808,P26809,P26810,P27502,P28936,P31822,P35956,P35963,P51518,P63119,P63120,P63121,P63122,P63123,P63124,P63125,P63127,P63128,P63129,P63131,P84454,Q09SZ9,Q0R5R2,Q0R5R3,Q1A249,Q1A267,Q4U0X6,Q73368,Q74120,Q75002,Q76634,Q77373,Q79666,Q89928,Q8AII1,Q8I7P9,Q9IDV9,Q9Q720,Q9QBY3,Q9QBZ1,Q9QBZ5,Q9QSR3,Q9WC54,Q9WC63,Q9Y6I0">protease</protein-id>.	maltose__protease__no_interaction
18683263-1164	The amplification of <protein-id="O33915,O34002,O68883,P09948,P0ABH7,P0ABH8,P14165,P18789,P20902,P20903,P21553,P26491,P39812,P42457,P51031,P51032,P51033,P51034,P51035,P51036,P51039,P51040,P51041,P51042,P51043,P51045,P56062,P80148,P94325,Q10530,Q53554,Q59136,Q59198,Q59258,Q59730,Q59732,Q59734,Q59741,Q59742,Q59748,Q59759,Q59768,Q59776,Q59778,Q59977,Q9RWB2,Q9ZN37">gltA</protein-id> gene encoding <protein-id="O33915,O34002,O68883,P09948,P0ABH7,P0ABH8,P14165,P18789,P20901,P20902,P20903,P21553,P26491,P27660,P42457,P51031,P51032,P51033,P51034,P51035,P51036,P51039,P51040,P51041,P51042,P51043,P51045,P56062,P80148,P84543,P94325,Q53554,Q59136,Q59198,Q59258,Q59730,Q59732,Q59734,Q59741,Q59742,Q59748,Q59759,Q59768,Q59776,Q59778,Q59939,Q59977,Q9RWB2,Q9ZN37">citrate synthase</protein-id> of TCA cycle was required for the efficient conversion of acetyl-CoA, generated during <compound-id="1183">vanillin</compound-id> production from <compound-id="445858">ferulic acid</compound-id>, to CoA, which is essential for <compound-id="1183">vanillin</compound-id> production.	ferulic acid__citrate synthase__interaction	ferulic acid__gltA__interaction	vanillin__citrate synthase__interaction	vanillin__gltA__interaction
18683263-1167	The <protein-id="O33915,O34002,O68883,P09948,P0ABH7,P0ABH8,P14165,P18789,P20902,P20903,P21553,P26491,P39812,P42457,P51031,P51032,P51033,P51034,P51035,P51036,P51039,P51040,P51041,P51042,P51043,P51045,P56062,P80148,P94325,Q10530,Q53554,Q59136,Q59198,Q59258,Q59730,Q59732,Q59734,Q59741,Q59742,Q59748,Q59759,Q59768,Q59776,Q59778,Q59977,Q9RWB2,Q9ZN37">gltA</protein-id> amplification of the glyoxylate bypass in the icdA null mutant remarkably increased the production rate of <compound-id="1183">vanillin</compound-id> with a little increase in the amount of <compound-id="1183">vanillin</compound-id> production.	vanillin__gltA__interaction
18683263-1168	The real synergistic effect of <protein-id="O33915,O34002,O68883,P09948,P0ABH7,P0ABH8,P14165,P18789,P20902,P20903,P21553,P26491,P39812,P42457,P51031,P51032,P51033,P51034,P51035,P51036,P51039,P51040,P51041,P51042,P51043,P51045,P56062,P80148,P94325,Q10530,Q53554,Q59136,Q59198,Q59258,Q59730,Q59732,Q59734,Q59741,Q59742,Q59748,Q59759,Q59768,Q59776,Q59778,Q59977,Q9RWB2,Q9ZN37">gltA</protein-id> amplification and <protein-id="P08200,P79089">icdA</protein-id> deletion was observed with use of XAD-2 resin reducing the toxicity of <compound-id="1183">vanillin</compound-id> produced during culture.	vanillin__gltA__no_interaction	vanillin__icdA__no_interaction
18683889-1688	Treatment of dermal fibroblasts with <compound-id="5280795,5283711">vitamin D(3</compound-id>) induced expression of <protein-id="O46576,P12644,P21275,P30885,Q06826,Q29607,Q2KJH1,Q8MJV5,Q90752">BMP-4</protein-id> (1.2+/-0.2, 1.7+/-0.2, and 1.8+/-0.2 relative fold increase) and <protein-id="P20722,P22004,Q04906">BMP-6</protein-id> (9.1+/-0.3, 23.3+/-2.1, and 30.4+/-3.0 relative fold increase) at 3, 14, and 21 days, respectively.	vitamin D(3__BMP-4__interaction	vitamin D(3__BMP-6__interaction
18683889-1689	<compound-id="5280795,5283711">Vitamin D(3</compound-id>) was also shown to induce the expression of the osteoblast-specific markers, <protein-id="O60109,P81800,P83456">alkaline phosphatase</protein-id> and <protein-id="P02819,P02821,P02823,P0C225,P0C226,P15504,P28317,P39056,P81455,P83005,P83238,P83473,P83489,P84348,P84349,P84350,P84351,Q7LZI4,Q8HYY9">osteocalcin</protein-id>, in a dose-dependent manner in human dermal fibroblasts.	Vitamin D(3__alkaline phosphatase__interaction	Vitamin D(3__osteocalcin__interaction
18684212-1656	The aims of this study were: (i) to characterize the basal circadian rhythm of adrenocorticotropin hormone (<protein-id="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5">ACTH</protein-id>) and <compound-id="5754">cortisol</compound-id> in IBS vs healthy controls; (ii) to compare stimulated <protein-id="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5">ACTH</protein-id>, <compound-id="5754">cortisol</compound-id> and <compound-id="951,439260">noradrenaline</compound-id> responses to a pelvic visceral stressor (sigmoidoscopy) in IBS and controls; and (iii) to correlate neuroendocrine responses with colonic mucosal cytokine expression and symptoms in IBS.	noradrenaline__ACTH__no_interaction	cortisol__ACTH__no_interaction
18684212-1657	In Study 1, basal <compound-id="5754">cortisol</compound-id> levels were analysed in 41 IBS and 25 controls using 24-h collections of plasma <protein-id="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5">ACTH</protein-id> and <compound-id="5754">cortisol</compound-id> (q10 min sampling).	cortisol__ACTH__no_interaction
18684212-1658	Basal <protein-id="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5">ACTH</protein-id> 0.05), while basal and stimulated plasma <compound-id="5754">cortisol</compound-id> levels were higher in patients.	cortisol__ACTH__no_interaction
18684339-438	A 3-fold increase in the expression of the <protein-id="P00448,P66828,P66829,Q8Z2V9,Q9RUV2">MnSOD</protein-id> gene was associated with decreased <compound-id="6804">CpG</compound-id> methylation of the analysed promoter region in the vegetarian group compared with the age-matched omnivores group.	CpG__MnSOD__interaction
18684712-650	<protein-id="Q9Y758">ALK2</protein-id> (R206H) with <protein-id="P70340,P97588,Q9I8V2">Smad1</protein-id> or <protein-id="P97454,Q99717,Q9R1V3,Q9W7E7">Smad5</protein-id> induced osteoblastic differentiation that could be inhibited by <protein-id="O15105,O35253,O88406">Smad7</protein-id> or <compound-id="11524144">dorsomorphin</compound-id>.	dorsomorphin__Smad1__interaction	dorsomorphin__Smad7__no_interaction	dorsomorphin__Smad5__interaction	dorsomorphin__ALK2__interaction
18685817-1575	Combustion products of <compound-id="7845">1,3-butadiene</compound-id> inhibit <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id> activity and induce expression of oxidative DNA damage repair enzymes in human bronchial epithelial cells.	1,3-butadiene__catalase__interaction
18686014-49	The aim of the present study was to examine whether increased serum <protein-id="P30722,P47547,P49463,P75344,Q7YQC6,Q8TQR2,Q9UXR0,Q9WYK6">Hsp70</protein-id> levels are related to clinical characteristics and standard laboratory parameters of preeclamptic patients, as well as to markers of inflammation (C-reactive protein), endothelial activation (von Willebrand factor antigen) or endothelial injury (<protein-id="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400">fibronectin</protein-id>), trophoblast debris (cell-free fetal DNA) and oxidative stress (<compound-id="10964">malondialdehyde</compound-id>).	malondialdehyde__fibronectin__no_interaction	malondialdehyde__Hsp70__no_interaction
18686014-50	Furthermore, serum levels of blood <compound-id="1176,265993">urea</compound-id> <compound-id="947,123329">nitrogen</compound-id>, <compound-id="588">creatinine</compound-id>, <compound-id="5280352">bilirubin</compound-id> and <protein-id="O19062,P02741,P02742,P08462,P18151,P21291,P41964,P47875,P49254,P49262,P52753,P67966,P67967,P97315,Q07203">CRP</protein-id>, serum alanine aminotransferase and lactate dehydrogenase (<protein-id="P29038,P33571,P93052,Q27797,Q27888,Q95028,Q99289">LDH</protein-id>) activities, as well as plasma levels of <protein-id="P04275,P80012,Q28295,Q28833,Q8CIZ8">VWF</protein-id> :Ag, <protein-id="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400">fibronectin</protein-id>, cell-free fetal DNA and <compound-id="10964">malondialdehyde</compound-id> were also significantly higher in preeclamptic patients than in normotensive, healthy pregnant women.	creatinine__fibronectin__no_interaction	malondialdehyde__VWF__no_interaction	bilirubin__VWF__no_interaction	nitrogen__CRP__no_interaction	creatinine__CRP__no_interaction	nitrogen__LDH__no_interaction	urea__fibronectin__no_interaction	urea__CRP__no_interaction	bilirubin__LDH__no_interaction	malondialdehyde__CRP__no_interaction	urea__VWF__no_interaction	creatinine__VWF__no_interaction	bilirubin__fibronectin__no_interaction	nitrogen__VWF__no_interaction	nitrogen__fibronectin__no_interaction	bilirubin__CRP__no_interaction	urea__LDH__no_interaction	malondialdehyde__LDH__no_interaction	malondialdehyde__fibronectin__no_interaction	creatinine__LDH__no_interaction
18686014-51	In preeclamptic patients, serum <protein-id="P30722,P47547,P49463,P75344,Q7YQC6,Q8TQR2,Q9UXR0,Q9WYK6">Hsp70</protein-id> levels showed significant correlations with serum <protein-id="O19062,P02741,P02742,P08462,P18151,P21291,P41964,P47875,P49254,P49262,P52753,P67966,P67967,P97315,Q07203">CRP</protein-id> levels (Spearman R = 0.32, p = 0.010), serum <protein-id="O33822,O58489,O67781,O86459,O93744,P00509,P14909,P23034,P44425,P53001,P58661,P72173,Q4J8X2,Q55128,Q56114,Q56232,Q59228,Q60013,Q92JE7,Q972A2,Q9V0L2,Q9X0Y2,Q9ZE56">aspartate aminotransferase</protein-id> (R = 0.32, p = 0.008) and <protein-id="P29038,P33571,P93052,Q27797,Q27888,Q95028,Q99289">LDH</protein-id> (0.001), as well as with plasma <compound-id="10964">malondialdehyde</compound-id> levels (R = 0.25, p = 0.043).	malondialdehyde__CRP__interaction	malondialdehyde__Hsp70__interaction	malondialdehyde__aspartate aminotransferase__interaction	malondialdehyde__LDH__interaction
18686047-887	In an effort to identify agents which enhance the activity of oligos and which possess less toxicity than traditionally employed chemotherapeutics, <compound-id="5040,478951,5284616,5358081,5374464,5460439,5497196,6436030,16760631,17753749,44295234,53627520,54600319">Rapamycin</compound-id>, an immunosuppressive agent known to regulate tumor growth and signal transduction mediated by the <protein-id="P42345,P42346,Q9JLN9">mTOR</protein-id> receptor, is compared to <compound-id="4666,36314,441276,5352019,6713921,6915727,44155032,53313247">paclitaxel</compound-id> in combination therapy employing monospecific or bispecific oligos.	Rapamycin__mTOR__interaction	paclitaxel__mTOR__no_interaction
18686136-131	In this study we investigated the <compound-id="5359597">superoxide</compound-id> radicals scavenging effect and <protein-id="P22985,P47989,P47990,P80457,Q00519,Q9MYW6">xanthine oxidase</protein-id> inhibitory activity by <compound-id="6451084">magnesium lithospermate B</compound-id>, which was originally isolated from the roots of Salvia miltiorrhiza (also named Danshen or Dansham), an important herb in Oriental medicine.	magnesium lithospermate B__xanthine oxidase__interaction	superoxide__xanthine oxidase__no_interaction
18686136-132	<compound-id="5359597">Superoxide</compound-id> radicals were generated both in <compound-id="928,439153,11250888">beta-NADH</compound-id>/<compound-id="9286">PMS</compound-id> system and <compound-id="1188">xanthine</compound-id>/<protein-id="P22985,P47989,P47990,P80457,Q00519,Q9MYW6">xanthine oxidase</protein-id> system.	PMS__xanthine oxidase__no_interaction	beta-NADH__xanthine oxidase__no_interaction	xanthine__xanthine oxidase__interaction	Superoxide__xanthine oxidase__interaction
18686136-133	Further study suggested that <compound-id="6451084">magnesium lithospermate B</compound-id> can directly inhibit <protein-id="P22985,P47989,P47990,P80457,Q00519,Q9MYW6">xanthine oxidase</protein-id> and exhibits competitive inhibition.	magnesium lithospermate B__xanthine oxidase__interaction
18686136-134	In addition, <compound-id="6451084">magnesium lithospermate B</compound-id> significantly protected HL-60 cells from superoxide radicals-induced apoptosis in the <compound-id="1188">xanthine</compound-id>/<protein-id="P22985,P47989,P47990,P80457,Q00519,Q9MYW6">xanthine oxidase</protein-id> reactions.	magnesium lithospermate B__xanthine oxidase__interaction	xanthine__xanthine oxidase__interaction
18686165-403	Four different molecules contain galactofuranose in A. fumigatus: (i) the <compound-id="439336">galactomannan</compound-id> present in the alkali soluble and insoluble fraction of the cell wall (ii) N- and O <compound-id="871">glycan</compound-id> moieties of secreted <protein-id="P08163">glycoproteins</protein-id> (iii) a <protein-id="O25781,O51672,O59618,O66954,O82059,O83488,O84382,P06744,P06745,P08059,P0A0T0,P0A0T1,P0A6T1,P0A6T2,P12341,P12709,P13377,P18240,P28718,P29333,P34795,P34796,P34797,P42861,P44312,P46479,P47357,P49105,P50309,P52029,P52030,P52031,P52983,P54234,P54235,P54236,P54237,P54238,P54239,P54240,P54241,P54242,P54243,P57636,P64192,P64193,P64194,P64195,P64196,P77877,P78033,P78917,P80860,P81181,P83194,P83780,P84140,P99078,Q0TA36,Q0VR14,Q11MA0,Q13Z07,Q165T7,Q18FQ4,Q1ASN4,Q1BH79,Q1CSA0,Q1CX51,Q1GAY0,Q1GJQ5,Q1GTU1,Q1H1P4,Q1IYT4,Q1J8N2,Q1JDQ8,Q1JIS1,Q1JNM4,Q1LM68,Q1LU73,Q1MM06,Q1QEK1,Q1R3R3,Q1WUR2,Q21M11,Q21ZD5,Q24VW9,Q255I6,Q28QX4,Q2A2C5,Q2FIB3,Q2FZU0,Q2G7C4,Q2IE39,Q2JH03,Q2JHU0,Q2JX86,Q2KCY8,Q2KYE9,Q2LRD0,Q2NJ38,Q2NR04,Q2P380,Q2RQ51,Q2S8W1,Q2SS24,Q2SWP6,Q2VYV7,Q2YBU4,Q2YPF3,Q2YWS3,Q31AX5,Q31I19,Q31LL0,Q31TX1,Q328X7,Q38WF1,Q39FF4,Q39SU1,Q3A201,Q3AFH3,Q3AJU7,Q3ASZ0,Q3AXV8,Q3B3Q8,Q3BUL3,Q3IKH4,Q3IMS0,Q3J2U4,Q3JCN1,Q3JRE2,Q3K2Y2,Q3K6Q4,Q3KLX6,Q3M6S3,Q3YUW0,Q3ZBD7,Q44407,Q46L16,Q47IJ3,Q48N88,Q48VF9,Q491V0,Q49WA1,Q4A5S9,Q4A7J2,Q4A9F3,Q4FVH5,Q4JCA7,Q4JX51,Q4K5Y1,Q4L4X8,Q4QL07,Q4R591,Q4UTV8,Q4ZY88,Q57F73,Q57H06,Q59000,Q59088,Q5E847,Q5FL04,Q5H0A7,Q5HHC2,Q5HQJ9,Q5JE38,Q5KVS7,Q5L5E1,Q5L9E3,Q5LRS9,Q5M1N9,Q5N0B4,Q5NFC4,Q5P0T4,Q5PL07,Q5QWW0,Q5R4E3,Q5SLL6,Q5UXU0,Q5WDX0,Q5WYE0,Q5X6Y8,Q5XE09,Q5YPP1,Q5ZXH2,Q600A8,Q609I7,Q62JL8,Q632G4,Q63V31,Q64PM7,Q65FL6,Q65TC2,Q660E3,Q664W9,Q67QQ0,Q6A5X5,Q6AQ48,Q6D022,Q6F1L2,Q6FRW1,Q6G0T9,Q6GAW4,Q6GIC6,Q6HC08,Q6KH90,Q6LM51,Q6LXQ4,Q6MD44,Q6MTA3,Q6NIE5,Q6YQU0,Q711G1,Q71X61,Q72GY6,Q72MT7,Q72YI4,Q73K18,Q742E4,Q74DK5,Q74K31,Q758L0,Q7MH97,Q7MUV9,Q7MZB4,Q7NJY9,Q7S986,Q7U6T0,Q7V1I1,Q7V7M6,Q7VBZ6,Q7VNR9,Q7VRI4,Q7VUF4,Q7W197,Q7WP01,Q816G0,Q81K75,Q822E7,Q82SP4,Q835G1,Q83D91,Q83XM3,Q848I4,Q87EV7,Q87L81,Q888Q7,Q88UI4,Q891H2,Q89A35,Q8A5W2,Q8CT80,Q8D1V8,Q8DCK7,Q8DKY2,Q8DN74,Q8EBH1,Q8ENY8,Q8EVU1,Q8EZG6,Q8FB44,Q8FR39,Q8G2N3,Q8G7I6,Q8K8Q6,Q8K910,Q8KDQ7,Q8L1Z9,Q8NS31,Q8NXF1,Q8P2R3,Q8P9S7,Q8R924,Q8RHH5,Q8SRY1,Q8UI94,Q8VVB7,Q8XI54,Q8XYN9,Q8Y4R7,Q8YF86,Q8YY05,Q8Z1U7,Q8ZAS2,Q8ZKI4,Q8ZWV0,Q928R6,Q92SC4,Q96YC2,Q978F3,Q97FP8,Q97NG0,Q97WE5,Q98BV5,Q98R79,Q9A1L1,Q9ABK5,Q9CD75,Q9CNL2,Q9FXM4,Q9FXM5,Q9HGZ2,Q9HIC2,Q9HNQ6,Q9HV67,Q9K7L8,Q9KUY4,Q9KX58,Q9N1E2,Q9PGR6,Q9PK16,Q9PMD4,Q9RDY2,Q9RMC1,Q9RTL8,Q9UXW3,Q9X1A5,Q9X670,Q9YE01,Q9Z6N4,Q9ZK49">GPI</protein-id>-anchored lipophosphogalactomannan and (iv) several sphingolipids also anchored to the membrane by an <compound-id="57339182">inositol phosphoceramide</compound-id>.	galactomannan__glycoproteins__no_interaction	inositol phosphoceramide__glycoproteins__no_interaction	galactomannan__GPI__no_interaction	glycan__glycoproteins__interaction	inositol phosphoceramide__GPI__no_interaction	glycan__GPI__interaction
18687549-1315	The estimated <protein-id="O19062,P02741,P02742,P08462,P18151,P21291,P41964,P47875,P49254,P49262,P52753,P67966,P67967,P97315,Q07203">CRP</protein-id> level and the IMCL content in these patients were correlated with body mass index, percentage of body fat, other measures of abdominal obesity, serum lipoproteins, fasting and post-oral <compound-id="206,5793,64689,79025">glucose</compound-id> load serum <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> levels and other surrogate markers of <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> resistance.	glucose__CRP__no_interaction	glucose__insulin__no_interaction
18687985-1621	Studies suggest that <protein-id="O94907">DKK1</protein-id> activation in osteoblasts is the underlying cause of glucocorticoid- and estrogen deficiency-mediated osteoporosis, and at least partially underlies the teratogenic effects of <compound-id="5426,75792,92142">thalidomide</compound-id> on limb development.	thalidomide__DKK1__interaction
18688040-30	The <protein-id="P20109,P35225,P42203,P61126,Q5I6E4,Q864V6,Q865W5,Q865X3,Q95J68,Q9N0W9,Q9XSV9">IL-13</protein-id>-induced up-regulation of <protein-id="Q9C3Y4">RhoA</protein-id> was inhibited by <compound-id="3899">leflunomide</compound-id>, an inhibitor of signal transducer and activator of transcription 6 (<protein-id="P42226">STAT6</protein-id>).	leflunomide__IL-13__interaction	leflunomide__RhoA__interaction	leflunomide__STAT6__interaction
18688042-1313	The goal of this study was to determine the mechanisms by which <compound-id="5757">17beta-estradiol</compound-id> induces <protein-id="Q9HC84">MUC5B</protein-id> gene expression in airway epithelial cells.	17beta-estradiol__MUC5B__interaction
18688042-1314	Pretreatment with ER antagonist <compound-id="104741">ICI 182,780</compound-id> blocked both E2-induced <protein-id="P27361,P28869,P42525,Q07176">ERK1</protein-id>/2-<protein-id="O42781,P27638,Q00859">MAPK</protein-id> activation and <protein-id="Q9HC84">MUC5B</protein-id> gene expression.	ICI 182,780__ERK1__interaction	ICI 182,780__MAPK__interaction	ICI 182,780__MUC5B__interaction
18688696-558	We here show that calumenin in the presence of <compound-id="271">Ca(2</compound-id>+) binds to <protein-id="P07996,P54000,Q28178">TSP1</protein-id> with a dissociation constant K (d) around 0.4 muM.	Ca(2__TSP1__interaction
18688816-657	It represents transition in <compound-id="402">sulfur</compound-id>-deprived conditions, known to lead to H2 production in Chlamydomonas reinhardtii, and the two main processes then induced which are an over-accumulation of intracellular starch and a progressive reduction of <protein-id="O47040,O78462,O96813,P12185,P12186,P12187,P13165,P17227,P17228,P28251,P30980,P48116,P49159,P49484,P51387,P52768,P56768,P58214,P69396,P69397,P69398,Q31909,Q5QA78,Q5SCW1,Q68RZ6,Q6B8K8,Q6ENG4,Q6ENV4,Q6EW69,Q6L390,Q6L603,Q6QBN9,Q70XZ3,Q7FNS8,Q7YJW3,Q85CI4,Q85FL2,Q85X26,Q8M9X5,Q8WI10,Q9BBS0,Q9GDV2,Q9MTL2,Q9MUQ4,Q9TL12,Q9TM24">PSII</protein-id> activity for anoxia achievement.	sulfur__PSII__interaction
18689429-1187	We examined whether <compound-id="5839">aldosterone</compound-id> produced locally in the brain may contribute to the activation of <protein-id="P08235,P22199,P79404,Q29131,Q3YC04,Q4JM28,Q8QHI2,Q8VII8,Q91573,Q9BDJ7,Q9IAC6,Q9N0W8">mineralocorticoid receptors</protein-id> in the CNS.	aldosterone__mineralocorticoid receptors__interaction
18690415-286	Macrophages isolated from iron deficient rats, or pregnant rats at day 21 of gestation, either supplemented with a single dose of <compound-id="105075">iron dextran</compound-id>, 10 mg, at the commencement of pregnancy, or not, showed significant increases of macrophage ferroportin mRNA expression, which was paralleled by significant decreases in hepatic <protein-id="Q7T273,Q99MH3,Q9EQ21">Hamp</protein-id> mRNA expression.	iron dextran__Hamp__no_interaction
18690549-796	Rat dicarboxylate transporter (<protein-id="Q13183,Q28615">SDCT1</protein-id>), expressed in renal tubular epithelial cells, plays a key role in regulating blood and urinary <compound-id="311,2733526">citrate</compound-id> level by reabsorbing <compound-id="311,2733526">citrate</compound-id> from the lumen.	citrate__SDCT1__interaction
18690792-145	However, as opposed to exogenous <compound-id="5047209,46173182">HS</compound-id>, the continuous use of <protein-id="P03969,P20003,P48800,Q60487">FGF-2</protein-id> during in vitro differentiation completely blocked rMSC mineralization.	HS__FGF-2__no_interaction
18690792-146	We show that the effects of both <protein-id="P03969,P20003,P48800,Q60487">FGF-2</protein-id> and <compound-id="5047209,46173182">HS</compound-id> are mediated through <protein-id="O10284,P41444">FGF</protein-id> receptor 1 (<protein-id="P11362,P21804,Q8MY86,Q91285">FGFR1</protein-id>) and that inhibition of signaling through this receptor arrests cell growth, resulting in the cells being unable to reach the critical density necessary to induce differentiation.	HS__FGF__no_interaction	HS__FGF-2__no_interaction	HS__FGFR1__interaction
18690792-147	It also confirms the importance of <compound-id="5047209,46173182">HS</compound-id> as a coreceptor for the signaling of endogenous <protein-id="P03969,P20003,P48800,Q60487">FGF-2</protein-id> and suggests that purified glycosaminoglycans may be attractive alternatives to growth factors for improved ex vivo growth and differentiation of MSCs.	HS__FGF-2__interaction
18691156-926	Two related polytopic <protein-id="P16629,P24266,P28991,Q04565,Q07252">membrane proteins</protein-id> of the major facilitator family, <protein-id="P10903,P46907">NarK</protein-id> and <protein-id="P37593,P37758">NarU</protein-id>, catalyse <compound-id="943">nitrate</compound-id> uptake, nitrite export and nitrite uptake across the Escherichia coli cytoplasmic membrane by an unknown mechanism.	nitrate__membrane proteins__no_interaction	nitrate__NarU__interaction	nitrate__NarK__interaction
18691343-1073	Intracellular interleukin-4 (Th2 cytokine) and <protein-id="Q9TTB0">interferon-gamma</protein-id> (<protein-id="Q64279,Q922L6">Th1</protein-id> cytokine) production was assessed in CD4+ T lymphocytes activated by <compound-id="4792,27924,122634,22833501">phorbol 12-myristate 13-acetate</compound-id> and <compound-id="3733,6434517,6912226,25134244">ionomycin</compound-id> using flow cytometry.	ionomycin__interferon-gamma__interaction	phorbol 12-myristate 13-acetate__Th1__interaction	phorbol 12-myristate 13-acetate__interferon-gamma__interaction	ionomycin__Th1__interaction
18691603-1685	This signaling system is engaged by the active component of cannabis, <compound-id="16078">Delta9-tetrahydrocannabinol</compound-id> (<compound-id="16078">Delta9-THC</compound-id>), which exerts its pharmacological effects by activation of G protein-coupled type-1 (<protein-id="O02777,P20272,P21554,P47746,P56971,Q333S9,Q5IS73,Q71SP5,Q801M1,Q9PUI7">CB1</protein-id>) and type-2 (<protein-id="P34972,P47936,Q9QZN9">CB2</protein-id>) cannabinoid receptors.	Delta9-THC__CB2__interaction	Delta9-tetrahydrocannabinol__CB2__interaction	Delta9-tetrahydrocannabinol__CB1__interaction	Delta9-THC__CB1__interaction
18691715-1342	<compound-id="778">Homocysteine</compound-id> stimulates antioxidant response element-mediated expression of <protein-id="O68838,P0A6W9,P0A6X0,P32477,P57485,P58994,P61379,Q09768,Q20117,Q57KV3,Q5E7F8,Q5LYY5,Q5M3J8,Q5PF10,Q65RX0,Q66E64,Q6ANW2,Q6D1T4,Q6LMV1,Q71VZ1,Q72RD4,Q7MHS5,Q7N7A4,Q7W3F2,Q7WES2,Q82ZG8,Q87LS2,Q88AR1,Q88R90,Q88UW5,Q89AD8,Q8D2V5,Q8DC38,Q8DW15,Q8DXM9,Q8E399,Q8EBF9,Q8F4D5,Q8X0X0,Q8X900,Q8XK30,Q8Y3R3,Q8Z4D6,Q8ZBU2,Q926X7,Q97IV1,Q9CM00,Q9HF78,Q9HTY6,Q9KUG5,Q9NFN6,Q9W3K5">glutamate-cysteine ligase</protein-id> in mouse macrophages.	Homocysteine__glutamate-cysteine ligase__interaction
18691715-1343	The current study investigated whether <compound-id="778">homocysteine</compound-id> induces transcription of <protein-id="O68838,P0A6W9,P0A6X0,P32477,P57485,P58994,P61379,Q09768,Q20117,Q57KV3,Q5E7F8,Q5LYY5,Q5M3J8,Q5PF10,Q65RX0,Q66E64,Q6ANW2,Q6D1T4,Q6LMV1,Q71VZ1,Q72RD4,Q7MHS5,Q7N7A4,Q7W3F2,Q7WES2,Q82ZG8,Q87LS2,Q88AR1,Q88R90,Q88UW5,Q89AD8,Q8D2V5,Q8DC38,Q8DW15,Q8DXM9,Q8E399,Q8EBF9,Q8F4D5,Q8X0X0,Q8X900,Q8XK30,Q8Y3R3,Q8Z4D6,Q8ZBU2,Q926X7,Q97IV1,Q9CM00,Q9HF78,Q9HTY6,Q9KUG5,Q9NFN6,Q9W3K5">glutamate-cysteine ligase</protein-id> (<protein-id="P0AEP7,P0AEP8,Q01820,Q920G9">Gcl</protein-id>), via ARE driven gene expression in mouse macrophages.	homocysteine__glutamate-cysteine ligase__interaction	homocysteine__Gcl__interaction
18691715-1344	Treatment of mouse macrophages with d-/l-<compound-id="778">homocysteine</compound-id> (50microM) induced depletion of intracellular <compound-id="124886">glutathione</compound-id> and a compensatory increase in <protein-id="P0AEP7,P0AEP8,Q01820,Q920G9">Gcl</protein-id> activity.	homocysteine__Gcl__interaction	glutathione__Gcl__no_interaction
18691715-1345	Real-time RT-PCR revealed increased mRNA-expression of the catalytic subunit of Gcl (Gclc) after treatment with <compound-id="778">homocysteine</compound-id>, and this occurred via increased transcription as demonstrated with <protein-id="P08659,P13129,Q01158,Q26304,Q27757">luciferase</protein-id> promoter reporter constructs for Gclc.	homocysteine__luciferase__no_interaction
18691757-12	Ligand-induced <protein-id="Q00342">Flt3</protein-id>-downregulation modulates cell death associated proteins and enhances chemosensitivity to <compound-id="42890">idarubicin</compound-id> in THP-1 acute myeloid leukemia cells.	idarubicin__Flt3__interaction
18692155-570	Only <protein-id="P01132,P01133,P07522,P26224,Q00968,Q95ND4,Q9BEA0">EGF</protein-id> activated <protein-id="P29323">ERK</protein-id> signaling and up-regulated early gene expression, while <compound-id="10635">DHT</compound-id> triggered the expression of classical AR-responsive genes with the exception of the <protein-id="P01132,P01133,P07522,P26224,Q00968,Q95ND4,Q9BEA0">EGF</protein-id>-induced <protein-id="P07288,P10658,P33619,P55786,Q11011,Q6DT45,Q9Y617">PSA</protein-id> transcript in A549 cells.	DHT__ERK__no_interaction	DHT__PSA__no_interaction	DHT__EGF__no_interaction
18692155-571	<compound-id="10635">DHT</compound-id> and <protein-id="P01132,P01133,P07522,P26224,Q00968,Q95ND4,Q9BEA0">EGF</protein-id> up-regulated cyclinD1 (<protein-id="P23043">CD1</protein-id>) at both mRNA and protein levels in A549 cells, while in LNCaP cells each mitogen increased only <protein-id="P23043">CD1</protein-id> protein expression.	DHT__EGF__no_interaction	DHT__CD1__interaction
18692592-835	High <compound-id="206,5793,64689,79025">glucose</compound-id> induced endothelial cell growth inhibition is associated with an increase in <protein-id="O19011,O93449,P01137,P04202,P07200,P09531,P09533,P16176,P17246,P18341,P50414,P54831,Q38HS2,Q9PTQ2,Q9Z1Y6">TGFbeta1</protein-id> secretion and inhibition of <protein-id="P03967,P22126,Q07152">Ras</protein-id> prenylation via suppression of the mevalonate pathway.	glucose__TGFbeta1__interaction	glucose__Ras__interaction
18692592-836	The influence of the prenylation status of <protein-id="P03967,P22126,Q07152">Ras</protein-id> on the observed changes in endothelial cell growth under high <compound-id="206,5793,64689,79025">glucose</compound-id> conditions has not previously been examined.	glucose__Ras__interaction
18692599-393	<protein-id="O88480,Q9Y6J0">Calcineurin inhibitors</protein-id> (CsA, <compound-id="6436007">FK-506</compound-id> and <compound-id="6447131,6509979,17753757,24847863,53394893,53486290">pimecrolimus</compound-id>) inhibited NO production and <protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id> expression in a concentration-dependent manner, CsA being more potent than <compound-id="6436007">FK-506</compound-id> and <compound-id="6447131,6509979,17753757,24847863,53394893,53486290">pimecrolimus</compound-id>.	FK-506__Calcineurin inhibitors__interaction	FK-506__iNOS__interaction	pimecrolimus__Calcineurin inhibitors__interaction	pimecrolimus__iNOS__interaction
18692599-395	In conclusion, the results suggest that <protein-id="O88480,Q9Y6J0">calcineurin inhibitors</protein-id> <compound-id="2909,5280754,5284373,5458585,5497195,6435893,24883466,49867938">cyclosporin A</compound-id>, <compound-id="5372,445643,445647,6426916,6436007,6473866,6536850,9940643,23581796,54611630">tacrolimus</compound-id> (<compound-id="6436007">FK-506</compound-id>) and <compound-id="6447131,6509979,17753757,24847863,53394893,53486290">pimecrolimus</compound-id> inhibit <protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id> expression and NO production in response to inflammatory stimuli by enhancing the decay of <protein-id="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091">iNOS</protein-id> mRNA by a 3'UTR-dependent manner.	FK-506__calcineurin inhibitors__interaction	pimecrolimus__iNOS__interaction	pimecrolimus__calcineurin inhibitors__interaction	cyclosporin A__iNOS__interaction	tacrolimus__calcineurin inhibitors__interaction	tacrolimus__iNOS__interaction	cyclosporin A__calcineurin inhibitors__interaction	FK-506__iNOS__interaction
18692849-615	An increased activity of ATP-binding cassette transporter A1 (<protein-id="O95477">ABCA1</protein-id>) and <protein-id="Q9H222">ABCG5</protein-id>/G8 heterodimer has been proposed as a mechanism underlying the hypocholesterolaemic effect of <compound-id="12303662">phytosterols</compound-id>.	phytosterols__ABCA1__interaction	phytosterols__ABCG5__interaction
18692896-648	In sum, <compound-id="23978">copper</compound-id> exposure lowered TOSC, a result that at least in part can be related to lowering of antioxidant enzymes like <protein-id="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7">CAT</protein-id>.	copper__CAT__interaction
18693051-793	Accumulation of <compound-id="206,5793,64689,79025">glucose</compound-id> in PA was increased by <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> at 10nM and by <protein-id="P05017,P07455,P08025,P10763,P16545,P17085,P17647,P18254,P33712,P51457,P51458,P51462,Q02815,Q28933,Q68LC0,Q6GUL6,Q6IVA5,Q6JLX1,Q95222">IGF-I</protein-id> at 1 nM and 10nM.	glucose__insulin__interaction	glucose__IGF-I__interaction
18693094-1555	<protein-id="O12956,O42143,O42144,P01272,P01273,P01274,P01275,P04093,P05110,P06883,P07449,P09566,P09567,P09682,P09686,P0C235,P13189,P15438,P18108,P22890,P29794,P31297,P33528,P55095,P68259,P68260,P68273,P68274,P68275,P68952,P68953,P68954,P68955,P68956,P68957,P79695,P81880,Q8MJ25,Q9PRQ9">Glucagon</protein-id> is important to this response because it increases <compound-id="738,5961">glutamine</compound-id> uptake.	glutamine__Glucagon__interaction
18693095-825	It was shown that PAR significantly increased serum ALT, <protein-id="P0AE37,P0AE38,P80357,P80358,Q0TH83,Q1C8B0,Q1RB46,Q321N9,Q32G89,Q3Z294,Q5PHB9,Q66B20,Q7N2G8,Q83L52,Q8FH00,Q8Z6G0,Q8ZPV1,Q9NRA2,Q9ZC67">AST</protein-id>, <protein-id="P03973,P12547,P22298,P28296,P29118,P35211,P83610,P97430,Q03420,Q53GG5,Q9H0A0,Q9PU47,Q9Z1X0">ALP</protein-id>, liver MDA levels and significantly decreased liver <compound-id="124886">GSH</compound-id>-Px activity, when compared to the control group (Group 1).	GSH__AST__no_interaction	GSH__ALP__no_interaction
18693100-829	Biological testing of the compound demonstrated a significant antidiabetic activity by reducing the elevated blood <compound-id="206,5793,64689,79025">glucose</compound-id> levels and restoring the <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> levels in <compound-id="5300,29327,6420074,6713972,7067772,45357367">streptozotocin</compound-id>-induced diabetic rats.	streptozotocin__insulin__no_interaction	glucose__insulin__no_interaction
18693294-868	The activity of guanylyl <protein-id="O94303,P33734,Q9P4P9,Q9SZ30">cyclase</protein-id> was determined by the amount of <compound-id="24316">cGMP</compound-id> generated in responses to sodium nitroprusside (SNP) or ANP.	cGMP__cyclase__interaction
18694296-116	Both <compound-id="5311">SAHA</compound-id> and <compound-id="4261">MS-275</compound-id> induced an arrest in the cell cycle along with the induction of apoptotic pathways as evidenced by flow cytometry, annexin assay, detection of activated caspase 9, and molecular analysis of <protein-id="P27297,Q07813,Q63690">Bax</protein-id>/<protein-id="P10417,P49950">Bcl-2</protein-id> expression.	MS-275__Bax__interaction	SAHA__Bax__interaction	MS-275__Bcl-2__interaction	SAHA__Bcl-2__interaction
18694429-208	Immunolocalization of <protein-id="O97775,O97776,O97952,O97960,P10275,P15207,P19091,P49699,Q6QT55,Q7T1K4,Q8MIK0,Q9GKL7,Q9TT90">androgen receptor</protein-id> in the boar epididymis: the effect of GnRH agonist <compound-id="25074999,25077495,25078016">deslorelin</compound-id>.	deslorelin__androgen receptor__no_interaction
18694845-560	E(2) increased the expression of <protein-id="P33724,P35431,P41350,P49817,P79132,Q03135,Q07DV9,Q07DX1,Q07DY2,Q07DZ2,Q07E02,Q07E25,Q07E38,Q07E49,Q09YH8,Q09YK1,Q09YN6,Q108U7,Q2IBA5,Q2IBC1,Q2IBD7,Q2IBF0,Q2IBG8,Q2QL79,Q2QL90,Q2QLB0,Q2QLC1,Q2QLF2,Q2QLG6,Q2QLH7,Q6B3Y2,Q6RVA9,Q94051,Q9YGM8">caveolin-1</protein-id> and <protein-id="O46550,P51636,Q07DW0,Q07DX2,Q07DZ3,Q07E26,Q07E39,Q07E50,Q09YH9,Q09YJ1,Q09YK2,Q09YL4,Q09YN7,Q108U8,Q18879,Q2IBA4,Q2IBC2,Q2IBD6,Q2IBF3,Q2IBG9,Q2QL80,Q2QL91,Q2QLB1,Q2QLC2,Q2QLD3,Q2QLE2,Q2QLF3,Q2QLG7,Q2QLH8,Q66WT7,Q9WVC3,Q9YGM9">caveolin-2</protein-id> mRNA and proteins, but pre-treatment with <compound-id="104741">ICI 182,780</compound-id> [an estrogen receptor (ER) antagonist] inhibited E(2)-induced increase in <protein-id="P33724,P35431,P41350,P49817,P79132,Q03135,Q07DV9,Q07DX1,Q07DY2,Q07DZ2,Q07E02,Q07E25,Q07E38,Q07E49,Q09YH8,Q09YK1,Q09YN6,Q108U7,Q2IBA5,Q2IBC1,Q2IBD7,Q2IBF0,Q2IBG8,Q2QL79,Q2QL90,Q2QLB0,Q2QLC1,Q2QLF2,Q2QLG6,Q2QLH7,Q6B3Y2,Q6RVA9,Q94051,Q9YGM8">caveolin-1</protein-id> and <protein-id="O46550,P51636,Q07DW0,Q07DX2,Q07DZ3,Q07E26,Q07E39,Q07E50,Q09YH9,Q09YJ1,Q09YK2,Q09YL4,Q09YN7,Q108U8,Q18879,Q2IBA4,Q2IBC2,Q2IBD6,Q2IBF3,Q2IBG9,Q2QL80,Q2QL91,Q2QLB1,Q2QLC2,Q2QLD3,Q2QLE2,Q2QLF3,Q2QLG7,Q2QLH8,Q66WT7,Q9WVC3,Q9YGM9">caveolin-2</protein-id> proteins expression.	ICI 182,780__caveolin-1__interaction	ICI 182,780__caveolin-2__interaction
18694845-561	Phospho-<protein-id="P33724,P35431,P41350,P49817,P79132,Q03135,Q07DV9,Q07DX1,Q07DY2,Q07DZ2,Q07E02,Q07E25,Q07E38,Q07E49,Q09YH8,Q09YK1,Q09YN6,Q108U7,Q2IBA5,Q2IBC1,Q2IBD7,Q2IBF0,Q2IBG8,Q2QL79,Q2QL90,Q2QLB0,Q2QLC1,Q2QLF2,Q2QLG6,Q2QLH7,Q6B3Y2,Q6RVA9,Q94051,Q9YGM8">caveolin-1</protein-id> was significantly blocked by <compound-id="104741">ICI 182,780</compound-id> or <compound-id="15077741,21083976">pyrazolopyrimidine</compound-id> 2 (PP2 ; a Src-kinase inhibitor).	ICI 182,780__caveolin-1__interaction	pyrazolopyrimidine__caveolin-1__interaction
18694845-562	<compound-id="3973">LY 294002</compound-id> (a PI3K inhibitor) or <compound-id="4713">PD 98059</compound-id> (an ERK1/2 inhibitor) prevented E(2)-induced increase in <protein-id="P33724,P35431,P41350,P49817,P79132,Q03135,Q07DV9,Q07DX1,Q07DY2,Q07DZ2,Q07E02,Q07E25,Q07E38,Q07E49,Q09YH8,Q09YK1,Q09YN6,Q108U7,Q2IBA5,Q2IBC1,Q2IBD7,Q2IBF0,Q2IBG8,Q2QL79,Q2QL90,Q2QLB0,Q2QLC1,Q2QLF2,Q2QLG6,Q2QLH7,Q6B3Y2,Q6RVA9,Q94051,Q9YGM8">caveolin-1</protein-id> expression and the accompanying [(3)H]-<compound-id="5789">thymidine</compound-id> incorporation.	thymidine__caveolin-1__interaction	PD 98059__caveolin-1__interaction	LY 294002__caveolin-1__interaction
18694845-563	Furthermore, inhibition of caveolin-1 expression using a caveolin-1 siRNA significantly attenuated E(2)-induced up-regulation of proto-oncogenes, <protein-id="P18754,Q18211">cell cycle regulatory proteins</protein-id>, [(3)H]-<compound-id="5789">thymidine</compound-id> incorporation, overall cell number, and percent of the cell population in S phase, while mediating a concomitant increase in the G0/G1 population.	thymidine__cell cycle regulatory proteins__no_interaction
18694847-1230	Almost all <protein-id="P31750,Q8INB9">Akt</protein-id> kinase that translocates to the nucleus shows a marked phosphorylation on <compound-id="5951">serine</compound-id> 473.	serine__Akt__interaction
18695846-1364	During the early response in AR, <compound-id="774">histamine</compound-id> has been found to be the most abundant mediator and it is associated with many symptoms of this disease mediated through the <protein-id="P30546,P31389,P31390,P35367,P70174,Q9N2B0,Q9N2B1,Q9N2B2">histamine H1 receptor</protein-id>.	histamine__histamine H1 receptor__interaction
18695937-929	During the incubation of <compound-id="6140">L-phenylalanine</compound-id> with para-hydroquinones using <protein-id="Q12570">laccase</protein-id> as biocatalyst, one or two main products were formed.	L-phenylalanine__laccase__interaction
18696104-1256	The effect on activation voltage but not that on amplitude was absent when expressing a cAMP-insensitive mutant (HCN2R/E), while a C-terminal truncated form of <protein-id="Q9UL51">HCN2</protein-id> (HCN2DeltaCx) exhibited only the voltage dependent but not the amplitude effect of <compound-id="5328552">erbstatin</compound-id>.	erbstatin__HCN2__interaction
18696104-1257	Thus, the action of <compound-id="5328552">erbstatin</compound-id> on the activation relation and current amplitude are distinct and separable in newborn myocytes, and the effect on activation voltage depends on the <compound-id="6076">cAMP</compound-id> status of <protein-id="Q9UL51">HCN2</protein-id> channels.	cAMP__HCN2__interaction	erbstatin__HCN2__interaction
18696104-1258	In contrast to newborn myocytes, <compound-id="5328552">erbstatin</compound-id> had no effect on <protein-id="Q9UL51">HCN2</protein-id> under control conditions in adult myocytes but induced a negative shift with no change in amplitude when saturated <compound-id="6076">cAMP</compound-id> was added to the pipette solution.	erbstatin__HCN2__no_interaction	cAMP__HCN2__no_interaction
18696216-140	<compound-id="232,4367,6322">Arginine</compound-id>-specific <protein-id="P14299">ADP-ribosyltransferase</protein-id> (Art) catalyzes the mono-ADP-ribosylation, in which it transfers a single ADP-ribose moiety of <compound-id="5893">NAD</compound-id> to the <compound-id="232,4367,6322">arginine</compound-id> residue(s) of target proteins, and may regulate the function of the proteins or peptides in cellular processes.	arginine__ADP-ribosyltransferase__interaction	Arginine__ADP-ribosyltransferase__interaction	NAD__ADP-ribosyltransferase__interaction
18696256-54	Solute carrier family 27 (fatty acid transporter), member 4 (<protein-id="Q4R3Y4,Q5RDY4,Q6P1M0">SLC27A4</protein-id>) is a fatty <protein-id="P0A4X8,P0A4X9,P38135,P54200,P63523,P63524,P69451,P69452,Q02278,Q10776,Q10976,Q4L3Q0,Q50586,Q5HIA1,Q5HRH4,Q6GBR2,Q6GJ94,Q7A1Q0,Q7A769,Q8CQ67,Q8XDR6,Q99W34,Q9KWK5">acyl-CoA synthetase</protein-id> producing very <compound-id="284">long chain fatty acid</compound-id>-CoA for lipid metabolic pathways, suggesting that the <protein-id="Q4R3Y4,Q5RDY4,Q6P1M0">SLC27A4</protein-id> gene is a potential candidate gene for traits related to fat deposition in animals.	long chain fatty acid__SLC27A4__interaction	long chain fatty acid__acyl-CoA synthetase__interaction
18696261-327	A D-amino acid oxidase gene (<protein-id="O35078,P18894">dao</protein-id>) was ligated with the P(Hase) and cloned into pGEMKT to constitutively express protein of <protein-id="O01739,O35078,P00371,P14920,P18894,P22942,P24552,P80324,Q19564,Q99042,Q9Z1M5,Q9Z302">DAAO</protein-id> without the use of any inducer such as <compound-id="656894">isopropyl beta-D-1-thiogalactopyranoside</compound-id> which is poisonous to the cells and environment.	isopropyl beta-D-1-thiogalactopyranoside__DAAO__interaction	isopropyl beta-D-1-thiogalactopyranoside__dao__interaction
18698091-1558	In response to a <compound-id="304,5997,6432564,11025495">cholesterol</compound-id>-containing atherogenic diet, C57BL/6J mice significantly increased expression of <protein-id="O97562,P55851,Q9N2J1,Q9W725">UCP2</protein-id> in the aorta, while mice lacking <protein-id="O97562,P55851,Q9N2J1,Q9W725">UCP2</protein-id>, in the absence of any other genetic modification, displayed significant endothelial dysfunction following the atherogenic diet.	cholesterol__UCP2__interaction
18698091-1559	These data establish that in the vasculature <protein-id="O97562,P55851,Q9N2J1,Q9W725">UCP2</protein-id> functions as an adaptive antioxidant defense to protect against the development of atherosclerosis in response to a fat and <compound-id="304,5997,6432564,11025495">cholesterol</compound-id> diet.	cholesterol__UCP2__interaction
18698130-1197	To confirm that mouse <protein-id="Q13316,Q95120">DMP1</protein-id>-PG possesses a single GAG chain attached to Ser (89), we substituted Ser (89) by <compound-id="750,5460845">Gly</compound-id> (89).	Gly__DMP1__interaction
18698132-1603	PC-1 is the primary generator of <compound-id="644102">pyrophosphate</compound-id> in osteoblastic cells; therefore, regulated expression of PC-1 by <protein-id="O10284,P41444">FGFs</protein-id> may be a principal mechanism by which <protein-id="O10284,P41444">FGF</protein-id> signaling affects bone mineralization.	pyrophosphate__FGF__no_interaction	pyrophosphate__FGFs__no_interaction
18698333-75	In analogy to the reduction of <compound-id="271">Ca(2</compound-id>+) oscillation frequency, the blockers impaired HCEC contraction, NF-kappaB activation, and <protein-id="P19320,P29533,P29534,Q28260">VCAM-1</protein-id> expression.	Ca(2__VCAM-1__no_interaction
18698333-76	Cisternal SAH-CSF induces cytosolic <compound-id="271">Ca(2</compound-id>+) oscillations in HCEC that results in cellular constriction, NF-kappaB activation, and <protein-id="P19320,P29533,P29534,Q28260">VCAM-1</protein-id> expression.	Ca(2__VCAM-1__interaction
18698636-309	For proof of principle, we use <compound-id="107689">L-lactate</compound-id> and <compound-id="61503">D-lactate</compound-id> as representative pair of enantiomers, L-<protein-id="P21795">lactate oxidase</protein-id> as stereospecific signal generator, and cascade blue hydrazide as reactive signal amplifier to capture the produced <compound-id="1060">pyruvate</compound-id>.	D-lactate__lactate oxidase__no_interaction	L-lactate__lactate oxidase__no_interaction	pyruvate__lactate oxidase__no_interaction
18698648-318	Escherichia coli strain PC09 (DeltaxylB, cAMP-independent CRP (crp *) mutant) expressing an NADPH-dependent <protein-id="P38715">xylose reductase</protein-id> from Candida boidinii (CbXR) was previously reported to produce <compound-id="6912">xylitol</compound-id> from xylose while metabolizing <compound-id="206,5793,64689,79025">glucose</compound-id> [Cirino et al.	xylitol__xylose reductase__interaction	glucose__xylose reductase__interaction
18698648-319	Studies in which the expression of CbXR or a <protein-id="P96792">xylose transporter</protein-id> was increased suggest that enzyme activity and xylose transport are not limiting <compound-id="6912">xylitol</compound-id> production in PC09.	xylitol__xylose transporter__interaction
18698648-321	For the case of xylose-proton symport, omitting the <protein-id="O51581,O54537,O68282,O83491,O84188,P0A584,P0A585,P0A586,P0A587,P0AC53,P0AC54,P11411,P21907,P29686,P37986,P44311,P48848,P48992,P54547,P56110,P57405,P73411,P77809,Q89AI7,Q8K9M2,Q8XCJ6,Q9PKK8,Q9X0N9,Q9Z3S2,Q9Z8U6,Q9ZKB2">Zwf</protein-id> (glucose-6-phosphate dehydrogenase) or <protein-id="P0C187,P51995,Q2RSB3">PntAB</protein-id> (membrane-bound transhydrogenase) reactions or TCA cycle activity from the model reduces the theoretical maximum yield from 9.2 to 8.8, 3.6, and 8.0 mol <compound-id="6912">xylitol</compound-id> (mol glucose)(-1), respectively.	xylitol__Zwf__interaction	xylitol__PntAB__interaction
18698648-322	Experimentally, deleting <protein-id="O25781,O51672,O83488,O84382,O88015,P0A0T0,P0A0T1,P0A6T1,P0A6T2,P28718,P44312,P47357,P52029,P52030,P52031,P52983,P57636,P64192,P64193,P64194,P64195,P64196,P77877,P78033,P80860,P81181,P96803,P99078,Q0TA36,Q0VR14,Q11MA0,Q13Z07,Q165T7,Q18FQ4,Q1ASN4,Q1BH79,Q1CSA0,Q1CX51,Q1GAY0,Q1GJQ5,Q1GTU1,Q1H1P4,Q1IYT4,Q1J8N2,Q1JDQ8,Q1JIS1,Q1JNM4,Q1LM68,Q1LU73,Q1MM06,Q1QEK1,Q1R3R3,Q1WUR2,Q21M11,Q21ZD5,Q24VW9,Q255I6,Q28QX4,Q2A2C5,Q2FIB3,Q2FZU0,Q2G7C4,Q2IE39,Q2JH03,Q2JHU0,Q2JX86,Q2KCY8,Q2KYE9,Q2LRD0,Q2NJ38,Q2NR04,Q2P380,Q2RQ51,Q2S8W1,Q2SS24,Q2SWP6,Q2VYV7,Q2YBU4,Q2YPF3,Q2YWS3,Q31AX5,Q31I19,Q31LL0,Q31TX1,Q328X7,Q38WF1,Q39FF4,Q39SU1,Q3A201,Q3AFH3,Q3AJU7,Q3ASZ0,Q3AXV8,Q3B3Q8,Q3BUL3,Q3IKH4,Q3IMS0,Q3J2U4,Q3JCN1,Q3JRE2,Q3K2Y2,Q3K6Q4,Q3KLX6,Q3M6S3,Q3YUW0,Q46L16,Q47IJ3,Q48N88,Q48VF9,Q491V0,Q49WA1,Q4A5S9,Q4A7J2,Q4A9F3,Q4FVH5,Q4JX51,Q4K5Y1,Q4L4X8,Q4QL07,Q4UTV8,Q4ZY88,Q57F73,Q57H06,Q59000,Q59088,Q5E847,Q5FL04,Q5H0A7,Q5HHC2,Q5HQJ9,Q5KVS7,Q5L5E1,Q5L9E3,Q5LRS9,Q5M1N9,Q5N0B4,Q5NFC4,Q5P0T4,Q5PL07,Q5QWW0,Q5SLL6,Q5UXU0,Q5WDX0,Q5WYE0,Q5X6Y8,Q5XE09,Q5YPP1,Q5ZXH2,Q600A8,Q609I7,Q62JL8,Q632G4,Q63V31,Q64PM7,Q65FL6,Q65TC2,Q660E3,Q664W9,Q67QQ0,Q6A5X5,Q6AQ48,Q6D022,Q6F1L2,Q6G0T9,Q6GAW4,Q6GIC6,Q6HC08,Q6KH90,Q6LM51,Q6LXQ4,Q6MD44,Q6MTA3,Q6NIE5,Q6YQU0,Q71X61,Q72GY6,Q72MT7,Q72YI4,Q73K18,Q742E4,Q74DK5,Q74K31,Q7MH97,Q7MUV9,Q7MZB4,Q7NJY9,Q7U6T0,Q7V1I1,Q7V7M6,Q7VBZ6,Q7VNR9,Q7VRI4,Q7VUF4,Q7W197,Q7WP01,Q816G0,Q81K75,Q822E7,Q82SP4,Q835G1,Q83D91,Q83XM3,Q848I4,Q87EV7,Q87L81,Q888Q7,Q88UI4,Q891H2,Q89A35,Q8A5W2,Q8CT80,Q8D1V8,Q8DCK7,Q8DKY2,Q8DN74,Q8EBH1,Q8ENY8,Q8EVU1,Q8EZG6,Q8FB44,Q8FR39,Q8G2N3,Q8G7I6,Q8K8Q6,Q8K910,Q8KDQ7,Q8L1Z9,Q8NS31,Q8NXF1,Q8P2R3,Q8P9S7,Q8R924,Q8RHH5,Q8UI94,Q8VVB7,Q8XI54,Q8XYN9,Q8Y4R7,Q8YF86,Q8YY05,Q8Z1U7,Q8ZAS2,Q8ZKI4,Q928R6,Q92SC4,Q97FP8,Q97NG0,Q98BV5,Q98R79,Q9A1L1,Q9ABK5,Q9CD75,Q9CNL2,Q9HNQ6,Q9HV67,Q9K7L8,Q9KUY4,Q9KX58,Q9PGR6,Q9PK16,Q9PMD4,Q9RDY2,Q9RMC1,Q9RTL8,Q9X1A5,Q9X670,Q9Z6N4,Q9ZK49">pgi</protein-id> (encoding <protein-id="O25781,O51672,O59618,O66954,O82059,O83488,O84382,P06744,P06745,P08059,P0A0T0,P0A0T1,P0A6T1,P0A6T2,P12341,P12709,P13377,P18240,P28718,P29333,P34795,P34796,P34797,P42861,P44312,P46479,P47357,P49105,P50309,P52029,P52030,P52031,P52983,P54234,P54235,P54236,P54237,P54238,P54239,P54240,P54241,P54242,P54243,P57636,P64192,P64193,P64194,P64195,P64196,P77877,P78033,P78917,P80860,P81181,P83194,P83780,P84140,P96803,P99078,Q0TA36,Q0VR14,Q11MA0,Q13Z07,Q165T7,Q18FQ4,Q1ASN4,Q1BH79,Q1CSA0,Q1CX51,Q1GAY0,Q1GJQ5,Q1GTU1,Q1H1P4,Q1IYT4,Q1J8N2,Q1JDQ8,Q1JIS1,Q1JNM4,Q1LM68,Q1LU73,Q1MM06,Q1QEK1,Q1R3R3,Q1WUR2,Q21M11,Q21ZD5,Q24VW9,Q255I6,Q28QX4,Q2A2C5,Q2FIB3,Q2FZU0,Q2G7C4,Q2IE39,Q2JH03,Q2JHU0,Q2JX86,Q2KCY8,Q2KYE9,Q2LRD0,Q2NJ38,Q2NR04,Q2P380,Q2RQ51,Q2S8W1,Q2SS24,Q2SWP6,Q2VYV7,Q2YBU4,Q2YPF3,Q2YWS3,Q31AX5,Q31I19,Q31LL0,Q31TX1,Q328X7,Q38WF1,Q39FF4,Q39SU1,Q3A201,Q3AFH3,Q3AJU7,Q3ASZ0,Q3AXV8,Q3B3Q8,Q3BUL3,Q3IKH4,Q3IMS0,Q3J2U4,Q3JCN1,Q3JRE2,Q3K2Y2,Q3K6Q4,Q3KLX6,Q3M6S3,Q3YUW0,Q3ZBD7,Q44407,Q46L16,Q47IJ3,Q48N88,Q48VF9,Q491V0,Q49WA1,Q4A5S9,Q4A7J2,Q4A9F3,Q4FVH5,Q4JCA7,Q4JX51,Q4K5Y1,Q4L4X8,Q4QL07,Q4R591,Q4UTV8,Q4ZY88,Q57F73,Q57H06,Q59000,Q59088,Q5E847,Q5FL04,Q5H0A7,Q5HHC2,Q5HQJ9,Q5JE38,Q5KVS7,Q5L5E1,Q5L9E3,Q5LRS9,Q5M1N9,Q5N0B4,Q5NFC4,Q5P0T4,Q5PL07,Q5QWW0,Q5R4E3,Q5SLL6,Q5UXU0,Q5WDX0,Q5WYE0,Q5X6Y8,Q5XE09,Q5YPP1,Q5ZXH2,Q600A8,Q609I7,Q62JL8,Q632G4,Q63V31,Q64PM7,Q65FL6,Q65TC2,Q660E3,Q664W9,Q67QQ0,Q6A5X5,Q6AQ48,Q6D022,Q6F1L2,Q6FRW1,Q6G0T9,Q6GAW4,Q6GIC6,Q6HC08,Q6KH90,Q6LM51,Q6LXQ4,Q6MD44,Q6MTA3,Q6NIE5,Q6YQU0,Q711G1,Q71X61,Q72GY6,Q72MT7,Q72YI4,Q73K18,Q742E4,Q74DK5,Q74K31,Q758L0,Q7MH97,Q7MUV9,Q7MZB4,Q7NJY9,Q7S986,Q7U6T0,Q7V1I1,Q7V7M6,Q7VBZ6,Q7VNR9,Q7VRI4,Q7VUF4,Q7W197,Q7WP01,Q816G0,Q81K75,Q822E7,Q82SP4,Q835G1,Q83D91,Q83XM3,Q848I4,Q87EV7,Q87L81,Q888Q7,Q88UI4,Q891H2,Q89A35,Q8A5W2,Q8CT80,Q8D1V8,Q8DCK7,Q8DKY2,Q8DN74,Q8EBH1,Q8ENY8,Q8EVU1,Q8EZG6,Q8FB44,Q8FR39,Q8G2N3,Q8G7I6,Q8K8Q6,Q8K910,Q8KDQ7,Q8L1Z9,Q8NS31,Q8NXF1,Q8P2R3,Q8P9S7,Q8R924,Q8RHH5,Q8SRY1,Q8UI94,Q8VVB7,Q8XI54,Q8XYN9,Q8Y4R7,Q8YF86,Q8YY05,Q8Z1U7,Q8ZAS2,Q8ZKI4,Q8ZWV0,Q928R6,Q92SC4,Q96YC2,Q978F3,Q97FP8,Q97NG0,Q97WE5,Q98BV5,Q98R79,Q9A1L1,Q9ABK5,Q9CD75,Q9CNL2,Q9FXM4,Q9FXM5,Q9HGZ2,Q9HIC2,Q9HNQ6,Q9HV67,Q9K7L8,Q9KUY4,Q9KX58,Q9N1E2,Q9PGR6,Q9PK16,Q9PMD4,Q9RDY2,Q9RMC1,Q9RTL8,Q9UXW3,Q9X1A5,Q9X670,Q9YE01,Q9Z6N4,Q9ZK49">phosphoglucose isomerase</protein-id>) from strain PC09 improves the yield from 3.4 to 4.0 mol <compound-id="6912">xylitol</compound-id> (mol <compound-id="206,5793,64689,79025">glucose</compound-id>)(-1), while deleting either or both E. coli transhydrogenases (<protein-id="O05139,P27306,P50529,P57112,P66006,P66007,P66008,P66009,P71317,Q0TA96,Q1CBU5,Q1CNP4,Q1QX78,Q1R3U7,Q2NQZ3,Q2SIP2,Q3K9F5,Q48A14,Q48KI8,Q4KFA6,Q4ZV77,Q57H91,Q5E212,Q5PK71,Q66G61,Q6CZB1,Q6LLT9,Q7MBG9,Q7MQ83,Q83MI1,Q87KN5,Q884I6,Q88KY8,Q8DD46,Q8FB93,Q8X727,Q8ZA97,Q9XBQ9">sthA</protein-id> and <protein-id="P07001,P43842">pntA</protein-id>) has no significant effect on the measured yield.	glucose__pgi__interaction	xylitol__phosphoglucose isomerase__interaction	xylitol__pgi__interaction	xylitol__sthA__no_interaction	glucose__phosphoglucose isomerase__interaction	glucose__sthA__no_interaction	glucose__pntA__no_interaction	xylitol__pntA__no_interaction
18698648-323	Deleting either <protein-id="O51581,O54537,O68282,O83491,O84188,P0A584,P0A585,P0A586,P0A587,P0AC53,P0AC54,P11411,P21907,P29686,P37986,P44311,P48848,P48992,P54547,P56110,P57405,P73411,P77809,Q89AI7,Q8K9M2,Q8XCJ6,Q9PKK8,Q9X0N9,Q9Z3S2,Q9Z8U6,Q9ZKB2">zwf</protein-id> or <protein-id="O05966,O27115,O67546,O84828,O87840,P0A836,P0A837,P0A838,P0A839,P25126,P45101,P53592,P53593,P66867,P66868,P66869,P66870,P66871,P66872,P71559,P80886,P99071,Q49X32,Q4L5U8,Q4ULQ7,Q57663,Q57RL3,Q5HGI7,Q5HPU5,Q5PBI8,Q5PCM7,Q66DA0,Q68WU5,Q6F8L4,Q6G9W8,Q6GHJ0,Q72PA2,Q7MMN3,Q7U0Z1,Q7UKI3,Q822A1,Q87A98,Q87RE8,Q8CPH5,Q8DFQ1,Q8EFN8,Q8F746,Q8KFE7,Q8NMK7,Q8P676,Q8PHL5,Q8UC60,Q8Y1Y3,Q8ZH00,Q8ZVF3,Q92I21,Q98EC5,Q9AB94,Q9CNZ0,Q9EYG9,Q9HPP1,Q9JUT0,Q9JZP4,Q9KA20,Q9KQB5,Q9PAH1,Q9PHY1,Q9PL99,Q9RUY3,Q9Z5H8,Q9Z6T6">sucC</protein-id> (TCA cycle) significantly reduces the yield from 3.4 to 2.0 and 2.3 mol <compound-id="6912">xylitol</compound-id> (mol <compound-id="206,5793,64689,79025">glucose</compound-id>)(-1), respectively.	glucose__zwf__interaction	xylitol__sucC__interaction	glucose__sucC__interaction	xylitol__zwf__interaction
18698649-324	In the process studied, the enzyme cellobiose dehydrogenase (<protein-id="P17444,P54223,P60336,P60337,Q01738,Q0TKW1,Q13NG7,Q1BQE2,Q1C932,Q1CFR7,Q1MJU4,Q1QXE1,Q1RFM3,Q2FDP9,Q2FV11,Q2KB43,Q2T6D0,Q2YWJ5,Q39A44,Q3BXK8,Q3JLL7,Q3K5H3,Q48CM7,Q4A0Q1,Q4K4K7,Q4L9D7,Q4UYN5,Q4ZM63,Q5HCU1,Q5HL11,Q62CH8,Q63KK7,Q66D54,Q6D6D9,Q6FDF9,Q6G664,Q6GDJ1,Q6LGH5,Q7MF12,Q88AE7,Q88CW6,Q8BJ64,Q8CMY2,Q8D3K2,Q8FKI9,Q8G1Z8,Q8NE62,Q8NUM0,Q8P5D7,Q8PPG8,Q8UH55,Q8X6C6,Q8YFY2,Q8ZGW0,Q985M5,Q9HTJ2,Q9L4K0,Q9RA05,Q9X2M2">CDH</protein-id>) oxidizes <compound-id="294,6134,84571,440995">lactose</compound-id> at the C-1 position of the reducing sugar moiety to lactobionolactone, which spontaneously hydrolyzes to <compound-id="7314">lactobionic acid</compound-id>.	lactobionic acid__CDH__no_interaction	lactose__CDH__interaction
18698649-325	2,2'-Azino-bis (3-ethylbenzothiazoline-6-<compound-id="104748">sulfonic acid</compound-id>) diammonium salt was used as electron acceptor for <protein-id="P17444,P54223,P60336,P60337,Q01738,Q0TKW1,Q13NG7,Q1BQE2,Q1C932,Q1CFR7,Q1MJU4,Q1QXE1,Q1RFM3,Q2FDP9,Q2FV11,Q2KB43,Q2T6D0,Q2YWJ5,Q39A44,Q3BXK8,Q3JLL7,Q3K5H3,Q48CM7,Q4A0Q1,Q4K4K7,Q4L9D7,Q4UYN5,Q4ZM63,Q5HCU1,Q5HL11,Q62CH8,Q63KK7,Q66D54,Q6D6D9,Q6FDF9,Q6G664,Q6GDJ1,Q6LGH5,Q7MF12,Q88AE7,Q88CW6,Q8BJ64,Q8CMY2,Q8D3K2,Q8FKI9,Q8G1Z8,Q8NE62,Q8NUM0,Q8P5D7,Q8PPG8,Q8UH55,Q8X6C6,Q8YFY2,Q8ZGW0,Q985M5,Q9HTJ2,Q9L4K0,Q9RA05,Q9X2M2">CDH</protein-id> and was continuously regenerated (reoxidized) by <protein-id="Q12570">laccase</protein-id>, a blue multi-copper oxidase.	sulfonic acid__CDH__interaction	sulfonic acid__laccase__interaction
18698649-326	<compound-id="977">Oxygen</compound-id> served as the terminal electron acceptor of the reaction and was fully reduced to water by <protein-id="Q12570">laccase</protein-id>.	Oxygen__laccase__interaction
18699724-117	Immunocytochemical localization of cell surface markers like <compound-id="53262342">SSEA-3</compound-id>, SSEA-4, <compound-id="444212">TRA</compound-id>-1-60, and <compound-id="444212">TRA</compound-id>-1-81, staining for <protein-id="O60109,P81800,P83456">alkaline phosphatase</protein-id> and <protein-id="P03358,P03554,P03555,P03556,P04323,P05400,P09523,P0A3U0,P0A3U1,P10394,P10399,P10400,P10401,P10978,P11283,P11369,P15629,P16423,P19199,P20825,P21325,P21328,P21329,P23070,P23071,P23072,P27502,Q00962,Q02964,Q03269,Q03270,Q03271,Q03272,Q03273,Q03274,Q03275,Q03276,Q03277,Q03278,Q03279,Q05118,Q8I7P9,Q95SX7,Q9NBX4,Q9QC07">reverse transcriptase</protein-id> polymerase chain reaction (RT-<protein-id="O66148,O80333,P15904,Q01289,Q39617,Q41249,Q59987,Q9SDT1">PCR</protein-id>) analysis of pluripotency state markers viz.	TRA__reverse transcriptase__no_interaction	SSEA-3__reverse transcriptase__no_interaction	TRA__alkaline phosphatase__no_interaction	TRA__PCR__no_interaction	SSEA-3__PCR__no_interaction	SSEA-3__alkaline phosphatase__no_interaction
18699774-1334	<compound-id="73611">Solamargine</compound-id> induces apoptosis and enhances susceptibility to trastuzumab and <compound-id="41867">epirubicin</compound-id> in breast cancer cells with low or high expression levels of <protein-id="P04626">HER2</protein-id>/<protein-id="O35657,P06494,P29503,P70424,Q24746">neu</protein-id>.	epirubicin__neu__no_interaction	Solamargine__HER2__no_interaction	epirubicin__HER2__no_interaction	Solamargine__neu__no_interaction
18699774-1335	SM (<compound-id="73611">solamargine</compound-id>), a major <compound-id="452975">steroidal alkaloid</compound-id> glycoside purified from Solanum incanum, triggered apoptosis of breast cancer cells (MCF-7 and SK-BR-3 cells) and non-cancerous breast epithelial cells (HBL-100 cells) within 3 h. To extend the application of trastuzumab in breast cancer patients, the regulation of <protein-id="P04626">HER2</protein-id>/<protein-id="O35657,P06494,P29503,P70424,Q24746">neu</protein-id> expression by SM was investigated.	solamargine__HER2__no_interaction	steroidal alkaloid__neu__no_interaction	solamargine__neu__no_interaction	steroidal alkaloid__HER2__no_interaction
18700056-1486	Since <compound-id="4595">ondansetron</compound-id> completely reversed the effects of <compound-id="4380">clorgyline</compound-id> on DA neuronal activity, the effects of <protein-id="O18851,P21397,P21398,P58027,Q5NU32,Q5RE60,Q6Q2J0">MAOA</protein-id> inhibition appeared to be mediated by <protein-id="O70212,P23979,P35563,P46098">5-HT3</protein-id> receptors.	clorgyline__5-HT3__no_interaction	clorgyline__MAOA__no_interaction	ondansetron__5-HT3__no_interaction	ondansetron__MAOA__no_interaction
18700057-534	The effects of <protein-id="P0A3L5,P0A3L6,P15653,P25018,P46376,Q04590,Q47851,Q80UN9">Ipt</protein-id> were reversed by the mitochondrial KATP blocker, <compound-id="1825">5-hydroxydecanoate</compound-id>, indicating that mitochondrial KATP channels participate in the regulation of astrocyte activation.	5-hydroxydecanoate__Ipt__interaction
18700809-895	The cell proliferation, the up-regulation of pS2, and the down-regulation of <protein-id="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7">ERalpha</protein-id> and <protein-id="O08537,O13012,O93511,P57781,P57782,Q62986,Q92731,Q95171,Q9IAK1,Q9PTU5,Q9PVE2,Q9TTE5,Q9TU15,Q9W6M2,Q9XSB5,Q9XSW2,Q9YH32">ERbeta</protein-id> gene expressions induced by the racemate and enantiomers of o,p'-DDT were all reversed by cotreatment with 10(-6) mol/L <compound-id="104741">ICI 182,780</compound-id>.	ICI 182,780__ERalpha__interaction	ICI 182,780__ERbeta__interaction
18700818-411	While bass in all <compound-id="3017">diazinon</compound-id> treatment groups had significantly inhibited brain <protein-id="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3">AChE</protein-id> activity, only the medium and high treatment groups showed a dose- and time-dependent increase in time to capture prey.	diazinon__AChE__interaction
18701427-85	The aim of this phase 0 study was to investigate whether <compound-id="60750">gemcitabine</compound-id> passes the blood-tumor barrier, and is phosphorylated in the tumor by <protein-id="P27707,P43346,P48769">deoxycytidine kinase</protein-id> (<protein-id="P21974,P27707,P43346,P48769,Q9J579">dCK</protein-id>) to <compound-id="60750">gemcitabine</compound-id> nucleotides in order to enable radiosensitization, and whether it is deaminated by deoxycytidine deaminase (dCDA) to dFdU.	gemcitabine__deoxycytidine kinase__interaction	gemcitabine__dCK__interaction
18701806-1254	The <compound-id="614,8988,145742">proline</compound-id> mutation at amino acid location 164 significantly reduced the initial hydrolysis of either the <protein-id="O97646,O97647,Q28462">amelogenins</protein-id> in solution or the proteins bound on HAP, which was confirmed by amelogenin oligopeptide assays.	proline__amelogenins__interaction
18701809-777	In conclusion, dentin mineralization in a corrected <compound-id="1061,167704,644102">phosphate</compound-id> and <compound-id="5280795">vitamin D</compound-id> environment compensates the adverse effect of <protein-id="P78562">PHEX</protein-id> mutation.	phosphate__PHEX__no_interaction	vitamin D__PHEX__no_interaction
18702173-1549	The considered biological model system consisted of a coating antibody (goat IgG), bovine <protein-id="P21847,P83517">serum albumin</protein-id> (<protein-id="P02769">BSA</protein-id>) as blocking agent, and a complementary antibody labelled with <compound-id="18730">FITC</compound-id> (anti-goat IgG).	FITC__BSA__no_interaction	FITC__serum albumin__no_interaction
18702613-201	Prolonged L-<compound-id="602,4580,5950,71080">alanine</compound-id> exposure induces changes in metabolism, <compound-id="271">Ca(2</compound-id>+) handling and desensitization of <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> secretion in clonal pancreatic beta-cells.	Ca(2__insulin__no_interaction	alanine__insulin__interaction
18702613-203	Collectively, these results illustrate the phenomenon of beta-cell desensitization by amino acids, indicating that prolonged exposure to <compound-id="602,4580,5950,71080">alanine</compound-id> can induce reversible alterations to metabolic flux, <compound-id="271">Ca(2</compound-id>+) handling and <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> secretion.	Ca(2__insulin__no_interaction	alanine__insulin__interaction
18702682-263	Acylation-stimulating protein (<protein-id="P32765,P42127,P45381,P79407,Q03288,Q16937,Q1XGU5,Q1XGU6,Q1XGU7,Q1XGU8,Q1XGU9,Q1XGV0,Q1XGV1,Q1XGV2,Q1XGV3,Q1XGV4,Q1XGV5,Q1XGV6,Q1XGV7,Q29414,Q5UK76,Q6ZYM3,Q865F0,Q95MP2,Q99JA2,Q9H1Y0,Q9NQ94">ASP</protein-id>) has been shown to positively stimulate fatty acid esterification and <compound-id="206,5793,64689,79025">glucose</compound-id> uptake in adipocytes.	glucose__ASP__interaction
18703100-623	Using a set of experiments aimed at manipulate a putative <compound-id="33032">l-glutamate</compound-id>/<compound-id="22880">NMDA</compound-id>/NO signal transduction pathway, we have demonstrated, by quantitative real-time PCR, that <compound-id="22880">NMDA</compound-id> enhances the expression of <protein-id="P27429">GnRH</protein-id> mRNA in a dose-response manner.	l-glutamate__GnRH__interaction	NMDA__GnRH__interaction
18703333-1701	Reaction parameters for the production of XOS from corncob using <protein-id="Q60042">endoxylanase</protein-id> from Aspergillus oryzae MTCC 5154 were optimized and an XOS yield of 10.2+/-0.14 mg ml(-1) corresponding to 81+/-3.9% with 73.5% <compound-id="439538">xylobiose</compound-id> was obtained.	xylobiose__endoxylanase__no_interaction
18703532-1538	<compound-id="2754">Cilostazol</compound-id> inhibits cytokine-induced nuclear factor-kappaB activation via AMP-activated <protein-id="P00513,P25848">protein kinase</protein-id> activation in vascular endothelial cells.	Cilostazol__protein kinase__interaction
18703532-1539	<compound-id="2754">Cilostazol</compound-id> is a selective inhibitor of phosphodiesterase 3 that increases intracellular cyclic AMP (<compound-id="6076">cAMP</compound-id>) levels and activates <protein-id="Q05608,Q9RI12">protein kinase A</protein-id>, thereby inhibiting platelet aggregation and inducing peripheral vasodilation.	cAMP__protein kinase A__no_interaction	Cilostazol__protein kinase A__interaction
18703532-1540	We hypothesized that <compound-id="2754">cilostazol</compound-id> may prevent inflammatory cytokine induced-nuclear factor (NF)-kappaB activation by activating AMP-activated <protein-id="P00513,P25848">protein kinase</protein-id> (<protein-id="P54646,Q09136,Q9Y478">AMPK</protein-id>) in vascular endothelial cells.	cilostazol__AMPK__interaction	cilostazol__protein kinase__interaction
18703622-1294	Serum <compound-id="5757">estradiol</compound-id> (E2) levels were not altered at any time point after <protein-id="P05017,P07455,P08025,P10763,P16545,P17085,P17647,P18254,P33712,P51457,P51458,P51462,Q02815,Q28933,Q68LC0,Q6GUL6,Q6IVA5,Q6JLX1,Q95222">IGF-I</protein-id>, demonstrating that the increased KiSS-1 expression observed was not caused by an elevation in E2.	estradiol__IGF-I__no_interaction
18703794-1209	A2aR stimulation inhibits HA fragment-induced pro-fibrotic genes <protein-id="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1">TNF-alpha</protein-id>, keratinocyte chemoattractant (KC), macrophage inflammatory protein (<protein-id="P06624,P28238,P30301,P35999,P37932,Q01992,Q09734,Q10415,Q6J8I9,Q6RZ07,Q92973,Q99797">MIP</protein-id>)-2, and <protein-id="P10147,P10855,P50229,Q5I1Z0,Q8HYQ3,Q8SQA6">MIP-1alpha</protein-id> while simultaneously synergizing with <compound-id="24759">hyaluronan</compound-id> fragments to up-regulate the TH1 cytokine IL-12.	hyaluronan__TNF-alpha__no_interaction	hyaluronan__MIP__no_interaction	hyaluronan__MIP-1alpha__no_interaction
18703795-1210	In addition, treatment of primary mouse lung fibroblasts with <compound-id="123831">ADMA</compound-id> stimulated <protein-id="O49046,P00812,P0A2X9,P0A2Y0,P0A2Y1,P14012,P33280,P37818,P39138,P40906,P46637,P53608,P60086,P60087,P60088,Q10066,Q12611,Q1E180,Q6G7E9,Q6GER3,Q74ZW4,Q7M0Z3,Q8NVE3">arginase</protein-id> activity and collagen formation in vitro.	ADMA__arginase__interaction
18703795-1211	These data support the idea that <compound-id="123831">ADMA</compound-id> may play a role in airway diseases, including asthma and pulmonary fibrosis, through <protein-id="O54705,O61309,O61608,Q26240,Q28969,Q9I9M2">NOS</protein-id> inhibition and enhancement of <protein-id="O49046,P00812,P0A2X9,P0A2Y0,P0A2Y1,P14012,P33280,P37818,P39138,P40906,P46637,P53608,P60086,P60087,P60088,Q10066,Q12611,Q1E180,Q6G7E9,Q6GER3,Q74ZW4,Q7M0Z3,Q8NVE3">arginase</protein-id> activity.	ADMA__arginase__interaction	ADMA__NOS__interaction
18703867-1272	Osteopontin (<protein-id="P10451,P14287,P31096,Q9XSY9">OPN</protein-id>) inhibits the growth of <compound-id="971">calcium oxalate monohydrate</compound-id> (COM) and other crystal phases in a phosphorylation-dependent manner.	calcium oxalate monohydrate__OPN__interaction
18703992-1333	Prostaglandins D2, E2, and F2alpha were increased in the tissues from mouse pups exposed to &gt;95% <compound-id="977,5359597">O2</compound-id> at 7 d indicating a differential expression of <protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">cyclooxygenase-2</protein-id> products.	O2__cyclooxygenase-2__no_interaction
18704001-1340	<compound-id="206,5793,64689,79025">Glucose</compound-id> replacement to euglycemia causes hypoxia, acidosis, and decreased <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> secretion in fetal sheep with intrauterine growth restriction.	Glucose__insulin__interaction
18704001-1341	<compound-id="206,5793,64689,79025">Glucose</compound-id> stimulated <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> secretion (GSIS) was lower in the Glu group.	Glucose__insulin__interaction
18704095-238	These data confirm that endogenous miR-<compound-id="7248">34a</compound-id> regulates <protein-id="Q14831,Q5RDQ8">GRM7</protein-id> levels and supports the notion that miR-<compound-id="7248">34a</compound-id> contributes to the effects of <compound-id="28486,3028194">lithium</compound-id> and VPA on <protein-id="Q14831,Q5RDQ8">GRM7</protein-id>.	34a__GRM7__interaction	lithium__GRM7__interaction
18704096-1413	These results confirm the therapeutic potential of <protein-id="P31424,P41594">mGluR5</protein-id> blockade on motor symptoms induced by reduced striatal <compound-id="681">dopamine</compound-id> function.	dopamine__mGluR5__interaction
18704096-1414	Further, they demonstrate that <protein-id="P31424,P41594">mGluR5</protein-id> blockade may also have beneficial effects on cognitive deficits induced by <compound-id="681">dopamine</compound-id> depletion.	dopamine__mGluR5__interaction
18704103-600	Here, we found that the addition of glucocorticoids, such as <compound-id="5743">dexamethasone</compound-id> and <compound-id="5754">cortisol</compound-id>, to cultured human keratinocytes increased their <protein-id="O60603,Q2V897,Q689D1,Q95LA9,Q95M53,Q9R1F8">TLR2</protein-id> gene expression.	cortisol__TLR2__interaction	dexamethasone__TLR2__interaction
18704103-601	Gene expression of mitogen-activated protein kinase (<protein-id="O42781,P27638,Q00859">MAPK</protein-id>) phosphatase-1 was also increased by the addition of <compound-id="5743">dexamethasone</compound-id>.	dexamethasone__MAPK__interaction
18704264-1595	Administration of B(a)P (50 mg/kg body weight) to mice resulted in increased lipid peroxides (LPO), lung specific tumor marker <protein-id="P06731">carcinoembryonic antigen</protein-id> (<protein-id="P06731">CEA</protein-id>) and serum marker enzymes aryl hydrocarbon hydroxylase (AHH), gamma glutamyl transpeptidase (<protein-id="P15557,P19440,P20735,Q05053">GGT</protein-id>), <protein-id="P07024,P52307,Q56878,Q9I767,Q9RN37,Q9XZ43">5'nucleotidase</protein-id> (5'ND) and lactate dehydrogenase (<protein-id="P29038,P33571,P93052,Q27797,Q27888,Q95028,Q99289">LDH</protein-id>) with concomitant decrease in the levels of tissue antioxidants like <protein-id="O50258">superoxide dismutase</protein-id> (<protein-id="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64">SOD</protein-id>), <protein-id="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99">catalase</protein-id> (<protein-id="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7">CAT</protein-id>), <protein-id="O32770,O59858,Q00277,Q9CFV1">glutathione peroxidase</protein-id> (GPx), <compound-id="124886">reduced glutathione</compound-id> (<compound-id="124886">GSH</compound-id>), <compound-id="2116,14985,1548900,1742129">vitamin E</compound-id> and <compound-id="54670067">vitamin C</compound-id>.	GSH__SOD__no_interaction	reduced glutathione__SOD__no_interaction	vitamin C__CEA__no_interaction	vitamin C__CAT__no_interaction	GSH__GGT__no_interaction	reduced glutathione__LDH__no_interaction	vitamin C__catalase__no_interaction	reduced glutathione__GGT__no_interaction	vitamin E__CEA__no_interaction	vitamin E__CAT__no_interaction	GSH__CEA__no_interaction	vitamin E__SOD__no_interaction	vitamin E__catalase__no_interaction	GSH__carcinoembryonic antigen__no_interaction	vitamin E__GGT__no_interaction	GSH__CAT__no_interaction	reduced glutathione__CAT__no_interaction	vitamin E__carcinoembryonic antigen__no_interaction	vitamin C__carcinoembryonic antigen__no_interaction	vitamin E__5'nucleotidase__no_interaction	vitamin C__GGT__no_interaction	GSH__glutathione peroxidase__no_interaction	reduced glutathione__5'nucleotidase__no_interaction	reduced glutathione__superoxide dismutase__no_interaction	GSH__superoxide dismutase__no_interaction	vitamin E__glutathione peroxidase__no_interaction	vitamin E__superoxide dismutase__no_interaction	GSH__LDH__no_interaction	reduced glutathione__CEA__no_interaction	reduced glutathione__glutathione peroxidase__no_interaction	reduced glutathione__catalase__no_interaction	GSH__catalase__no_interaction	GSH__5'nucleotidase__no_interaction	vitamin C__superoxide dismutase__no_interaction	vitamin C__glutathione peroxidase__no_interaction	vitamin C__LDH__no_interaction	vitamin C__5'nucleotidase__no_interaction	vitamin C__SOD__no_interaction	reduced glutathione__carcinoembryonic antigen__no_interaction	vitamin E__LDH__no_interaction
18704417-141	Achieving CCgR within 12 months and maintaining it without an increase in <protein-id="P11274">BCR</protein-id>-<protein-id="P00519,P00521,P10447,P11681,Q00022">ABL</protein-id> transcripts might indicate that low-dose <compound-id="5291">imatinib</compound-id> therapy can produce acceptable outcomes without excess toxicity.	imatinib__BCR__interaction	imatinib__ABL__interaction
18704487-89	<protein-id="P40792,P63001,Q6RUV5">Rac1</protein-id> (-/-) platelets displayed defective thrombus formation on collagen under flow conditions which could be fully restored by co-infusion of ADP and the <compound-id="5280497">TxA(2</compound-id>) analog U46619, indicating that impaired <protein-id="P0C191,Q9HCN6">GPVI</protein-id>-, but not G-protein signaling, was responsible for the observed defect.	TxA(2__GPVI__no_interaction	TxA(2__Rac1__no_interaction
18704543-120	<protein-id="P09848,P09849">LCT</protein-id> 13910 CC genotype is associated with <compound-id="294,6134,84571,440995">lactose</compound-id> intolerance, a condition often resulting in reduced milk intake.	lactose__LCT__interaction
18704651-196	Osteointegration of <compound-id="23963">titanium</compound-id> or its alloy with bone can be greatly improved by <compound-id="24441,24456,24632">calcium phosphate</compound-id> coatings, and further enhanced by an extracellular <protein-id="O12705,O18559,O57299,O89341,P03314,P03344,P03419,P03426,P03519,P04876,P04888,P05769,P06157,P06166,P06446,P06502,P06503,P06935,P06942,P06943,P07564,P07720,P07873,P08325,P08671,P09732,P09866,P11206,P12446,P12823,P13616,P13844,P14335,P14336,P14340,P14403,P15200,P16287,P16628,P16629,P17748,P17763,P18356,P18611,P19110,P19692,P19718,P22046,P22338,P24266,P24615,P25058,P25182,P25223,P25224,P26034,P27019,P27020,P27287,P27395,P27663,P27910,P27912,P27913,P27915,P29165,P29837,P29838,P29983,P29984,P29990,P29991,P30026,P31035,P31620,P32886,P33478,P33482,P33515,P35947,P35976,P36355,P36356,P41358,P52637,P62683,P62684,P62685,P62689,P62690,P63117,P63126,P63128,P63130,P63145,P87577,P87889,Q01299,Q01427,Q04538,Q074N0,Q1X880,Q1X881,Q66112,Q6DV88,Q6J3P1,Q7LDI9,Q84131,Q88266,Q88428,Q89277,Q91B74,Q96PI4,Q98803,Q9HDB9,Q9IK90,Q9JAF2,Q9NRZ4,Q9UKH8,Q9YNA8,Q9YRV3">matrix protein</protein-id> layer such as collagen.	titanium__matrix protein__interaction	calcium phosphate__matrix protein__no_interaction
18704653-197	Use of <protein-id="P08587,P21980,P21981,P51176,P52181,Q01841">tissue transglutaminase</protein-id> and <protein-id="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400">fibronectin</protein-id> to influence osteoblast responses to <compound-id="24456">tricalcium phosphate</compound-id> scaffolds.	tricalcium phosphate__tissue transglutaminase__interaction	tricalcium phosphate__fibronectin__interaction
18704653-198	To explore the possibility of controlling cell interaction with biomaterials, <compound-id="24456">tricalcium phosphate</compound-id> scaffolds were modified using the enzyme <protein-id="P08587,P21980,P21981,P51176,P52181,Q01841">tissue transglutaminase</protein-id> (tTgase) in conjunction with <protein-id="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400">fibronectin</protein-id>.	tricalcium phosphate__tissue transglutaminase__interaction	tricalcium phosphate__fibronectin__interaction
18704755-900	A special rigid planar structural octupolar molecule titled 2,4,6-tris(p-methylstyryl)-<compound-id="9262,20437">s-triazine</compound-id> (TMT) was synthesized and its interaction with bovine <protein-id="P21847,P83517">serum albumin</protein-id> (<protein-id="P02769">BSA</protein-id>) were studied by molecular spectroscopy.	s-triazine__BSA__interaction	s-triazine__serum albumin__interaction
18704762-296	<protein-id="Q865F8,Q9NZD4">AHSP</protein-id> inhibits cellular production of the reactive <compound-id="977">oxygen</compound-id> species.	oxygen__AHSP__interaction
18704766-300	Four MPTP monkeys received <compound-id="6047">L-DOPA</compound-id>/<compound-id="2327">Benserazide</compound-id> plus CI-1041 an NMDA antagonist selective for <protein-id="P11605,P11832,P16081,P39865,Q9SML8">NR1</protein-id>/<protein-id="Q00960,Q01097,Q13224">NR2B</protein-id> and four were treated with <compound-id="6047">L-DOPA</compound-id>/<compound-id="2327">Benserazide</compound-id> plus a small dose of <compound-id="54746">cabergoline</compound-id> ; one monkey of each group developed mild dyskinesias at the end of treatment.	Benserazide__NR1__no_interaction	cabergoline__NR1__no_interaction	Benserazide__NR2B__no_interaction	L-DOPA__NR1__no_interaction	cabergoline__NR2B__no_interaction	L-DOPA__NR2B__no_interaction
18704766-304	Hence, MPTP lesion, <compound-id="6047">L-DOPA</compound-id> treatment and prevention of LID with CI-1041 and <compound-id="54746">cabergoline</compound-id>, or reduction with <compound-id="5282337">Ro 61-8048</compound-id> were associated with modulation of <protein-id="Q00960,Q01097,Q13224">NR2B</protein-id>/NMDA glutamate receptors.	Ro 61-8048__NR2B__interaction	L-DOPA__NR2B__interaction	cabergoline__NR2B__interaction
18704940-430	<protein-id="O06222,O07108,O07669,O25236,O51532,O67852,O83873,O84763,P0A089,P0A090,P0A091,P0C0D7,P0C0D8,P14900,P45063,P57313,P57995,P73668,Q03522,Q0SHR9,Q0SQ91,Q0TLQ1,Q0TMJ3,Q0VS04,Q11GS3,Q11RH3,Q12EL7,Q13TZ0,Q14J05,Q163I6,Q182Y7,Q1AVX1,Q1BZG5,Q1C212,Q1CMM9,Q1CU35,Q1D0S8,Q1GAT6,Q1GIV4,Q1GRX7,Q1GYZ9,Q1IKG8,Q1J147,Q1J5S5,Q1JAT4,Q1JG10,Q1JKY4,Q1LIM4,Q1LSW4,Q1ME31,Q1MPC1,Q1Q883,Q1QNU5,Q1QVG5,Q1RGA7,Q1RI52,Q1WT99,Q216E0,Q21MH1,Q21SW7,Q24TE4,Q255W7,Q28NN2,Q2A1Z9,Q2FHQ4,Q2FZ92,Q2G997,Q2IG29,Q2IYL0,Q2JD52,Q2JHP5,Q2JVR9,Q2K6B9,Q2KVF5,Q2LR50,Q2NVV3,Q2P5V2,Q2RK81,Q2RVU2,Q2S530,Q2S9Z0,Q2SZI5,Q2W0H5,Q2Y636,Q2YM69,Q2YXD9,Q313Q5,Q319C4,Q31I61,Q31MM2,Q326E7,Q32K04,Q38XM9,Q39JX2,Q39YM1,Q3A2G4,Q3AAE4,Q3AHP0,Q3ANV5,Q3AZI5,Q3B127,Q3BR29,Q3IG02,Q3J4M6,Q3J787,Q3JND6,Q3K2P4,Q3K742,Q3KKT4,Q3MF19,Q3SMH5,Q3STT0,Q3Z5S1,Q46JA8,Q46WZ2,Q47AA2,Q47QX1,Q47VQ7,Q48EF6,Q48SK8,Q493Q3,Q49WW5,Q4FQ21,Q4JW97,Q4K6J1,Q4L5N4,Q4QLG0,Q4ULT8,Q4UWX9,Q4ZNY8,Q52953,Q57C76,Q57TD2,Q5E2P8,Q5F6L6,Q5FKV3,Q5FUJ7,Q5GSC8,Q5H2Y1,Q5HGP8,Q5HQ09,Q5HW34,Q5L0X7,Q5L521,Q5LIJ5,Q5LU71,Q5M0D5,Q5M4Y2,Q5MZA8,Q5NHK3,Q5NPA7,Q5P6Z4,Q5PBH9,Q5PDC2,Q5R0M3,Q5SJD2,Q5WFG8,Q5WTI5,Q5X1S4,Q5XB04,Q5YYY1,Q5ZSA3,Q604V5,Q62GS5,Q636B4,Q63QJ5,Q64ZL9,Q65JY2,Q65RY4,Q66EK7,Q67QM7,Q68WW9,Q6A9Q4,Q6AE62,Q6AJ52,Q6D0I1,Q6FFC2,Q6G122,Q6G2Q3,Q6GA29,Q6GHQ2,Q6HEQ2,Q6LMF4,Q6MBS4,Q6MIF8,Q6N409,Q6NGC6,Q71XX7,Q728U6,Q72JQ1,Q72NP4,Q732F6,Q73GT3,Q73YQ6,Q748D4,Q74JY5,Q7MNV3,Q7MWM5,Q7N145,Q7NEZ5,Q7NPZ7,Q7U8T1,Q7V0A5,Q7V5V5,Q7VAM1,Q7VEP7,Q7VP56,Q7VQI9,Q7VUQ1,Q7W4B2,Q7WFS0,Q819Q2,Q81WC9,Q821S1,Q82AD8,Q82VS5,Q83F20,Q83GN2,Q83HK0,Q83MF9,Q879A1,Q87EA7,Q87SG6,Q87WY3,Q88N78,Q88V80,Q899G5,Q89AQ2,Q89FU5,Q8A256,Q8CSX6,Q8D2Z4,Q8DEK8,Q8DMN8,Q8DQM2,Q8DVE3,Q8E186,Q8E6P1,Q8E9P6,Q8ER50,Q8F7V4,Q8FL65,Q8FNT8,Q8FZP2,Q8G4Q6,Q8K9T2,Q8KGD2,Q8NX35,Q8P063,Q8P775,Q8PII9,Q8R9G4,Q8RDQ1,Q8UDM6,Q8X9Y9,Q8XHM4,Q8XVI5,Q8Y5M1,Q8YI68,Q8YPS9,Q8Z9H0,Q8ZIF1,Q8ZRU4,Q929Y1,Q92I60,Q97EB9,Q97RU8,Q98KB1,Q9A597,Q9CF91,Q9CPB0,Q9F1N2,Q9HVZ9,Q9JSZ5,Q9K0Y4,Q9K9S8,Q9KPG5,Q9PEB0,Q9PI73,Q9PLG5,Q9RRJ4,Q9S2W9,Q9WY76,Q9Z705,Q9ZDC2,Q9ZLY0">MurD</protein-id> (UDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase), a three-domain bacterial protein, catalyses a highly specific incorporation of D-glutamate to the cytoplasmic intermediate UDP-N-acetyl-muramoyl-L-alanine (<compound-id="5496796">UMA</compound-id>) utilizing ATP hydrolysis to ADP and P(i).	UMA__MurD__interaction
18704940-431	On the basis of structural studies of <protein-id="O06222,O07108,O07669,O25236,O51532,O67852,O83873,O84763,P0A089,P0A090,P0A091,P0C0D7,P0C0D8,P14900,P45063,P57313,P57995,P73668,Q03522,Q0SHR9,Q0SQ91,Q0TLQ1,Q0TMJ3,Q0VS04,Q11GS3,Q11RH3,Q12EL7,Q13TZ0,Q14J05,Q163I6,Q182Y7,Q1AVX1,Q1BZG5,Q1C212,Q1CMM9,Q1CU35,Q1D0S8,Q1GAT6,Q1GIV4,Q1GRX7,Q1GYZ9,Q1IKG8,Q1J147,Q1J5S5,Q1JAT4,Q1JG10,Q1JKY4,Q1LIM4,Q1LSW4,Q1ME31,Q1MPC1,Q1Q883,Q1QNU5,Q1QVG5,Q1RGA7,Q1RI52,Q1WT99,Q216E0,Q21MH1,Q21SW7,Q24TE4,Q255W7,Q28NN2,Q2A1Z9,Q2FHQ4,Q2FZ92,Q2G997,Q2IG29,Q2IYL0,Q2JD52,Q2JHP5,Q2JVR9,Q2K6B9,Q2KVF5,Q2LR50,Q2NVV3,Q2P5V2,Q2RK81,Q2RVU2,Q2S530,Q2S9Z0,Q2SZI5,Q2W0H5,Q2Y636,Q2YM69,Q2YXD9,Q313Q5,Q319C4,Q31I61,Q31MM2,Q326E7,Q32K04,Q38XM9,Q39JX2,Q39YM1,Q3A2G4,Q3AAE4,Q3AHP0,Q3ANV5,Q3AZI5,Q3B127,Q3BR29,Q3IG02,Q3J4M6,Q3J787,Q3JND6,Q3K2P4,Q3K742,Q3KKT4,Q3MF19,Q3SMH5,Q3STT0,Q3Z5S1,Q46JA8,Q46WZ2,Q47AA2,Q47QX1,Q47VQ7,Q48EF6,Q48SK8,Q493Q3,Q49WW5,Q4FQ21,Q4JW97,Q4K6J1,Q4L5N4,Q4QLG0,Q4ULT8,Q4UWX9,Q4ZNY8,Q52953,Q57C76,Q57TD2,Q5E2P8,Q5F6L6,Q5FKV3,Q5FUJ7,Q5GSC8,Q5H2Y1,Q5HGP8,Q5HQ09,Q5HW34,Q5L0X7,Q5L521,Q5LIJ5,Q5LU71,Q5M0D5,Q5M4Y2,Q5MZA8,Q5NHK3,Q5NPA7,Q5P6Z4,Q5PBH9,Q5PDC2,Q5R0M3,Q5SJD2,Q5WFG8,Q5WTI5,Q5X1S4,Q5XB04,Q5YYY1,Q5ZSA3,Q604V5,Q62GS5,Q636B4,Q63QJ5,Q64ZL9,Q65JY2,Q65RY4,Q66EK7,Q67QM7,Q68WW9,Q6A9Q4,Q6AE62,Q6AJ52,Q6D0I1,Q6FFC2,Q6G122,Q6G2Q3,Q6GA29,Q6GHQ2,Q6HEQ2,Q6LMF4,Q6MBS4,Q6MIF8,Q6N409,Q6NGC6,Q71XX7,Q728U6,Q72JQ1,Q72NP4,Q732F6,Q73GT3,Q73YQ6,Q748D4,Q74JY5,Q7MNV3,Q7MWM5,Q7N145,Q7NEZ5,Q7NPZ7,Q7U8T1,Q7V0A5,Q7V5V5,Q7VAM1,Q7VEP7,Q7VP56,Q7VQI9,Q7VUQ1,Q7W4B2,Q7WFS0,Q819Q2,Q81WC9,Q821S1,Q82AD8,Q82VS5,Q83F20,Q83GN2,Q83HK0,Q83MF9,Q879A1,Q87EA7,Q87SG6,Q87WY3,Q88N78,Q88V80,Q899G5,Q89AQ2,Q89FU5,Q8A256,Q8CSX6,Q8D2Z4,Q8DEK8,Q8DMN8,Q8DQM2,Q8DVE3,Q8E186,Q8E6P1,Q8E9P6,Q8ER50,Q8F7V4,Q8FL65,Q8FNT8,Q8FZP2,Q8G4Q6,Q8K9T2,Q8KGD2,Q8NX35,Q8P063,Q8P775,Q8PII9,Q8R9G4,Q8RDQ1,Q8UDM6,Q8X9Y9,Q8XHM4,Q8XVI5,Q8Y5M1,Q8YI68,Q8YPS9,Q8Z9H0,Q8ZIF1,Q8ZRU4,Q929Y1,Q92I60,Q97EB9,Q97RU8,Q98KB1,Q9A597,Q9CF91,Q9CPB0,Q9F1N2,Q9HVZ9,Q9JSZ5,Q9K0Y4,Q9K9S8,Q9KPG5,Q9PEB0,Q9PI73,Q9PLG5,Q9RRJ4,Q9S2W9,Q9WY76,Q9Z705,Q9ZDC2,Q9ZLY0">MurD</protein-id> complexes, a stepwise catalytic mechanism was proposed that commences with a formation of the acyl-<compound-id="1061,167704,644102">phosphate</compound-id> intermediate, followed by a nucleophilic attack of <compound-id="23327">D-glutamate</compound-id> that, through the formation of a tetrahedral reaction intermediate and subsequent <compound-id="1061,167704,644102">phosphate</compound-id> dissociation, affords the final product, UDP-N-acetyl-muramoyl-<compound-id="14534790">L-alanine-D-glutamate</compound-id> (UMAG).	phosphate__MurD__interaction	D-glutamate__MurD__interaction	L-alanine-D-glutamate__MurD__interaction
18704946-1065	Although the overall amino acid identity between <protein-id="P31645,Q9XT49">SERTs</protein-id> and the LeuT(Aa) is only 17%, it increases to above 50% in the first shell of the putative 5-HT binding site, allowing de novo computational docking of <compound-id="1150">tryptamine</compound-id> derivatives in atomic detail.	tryptamine__SERTs__interaction
18704953-1278	Mal-<protein-id="P56862">sCT</protein-id>, prepared by conjugating <protein-id="P56862">sCT</protein-id> via thio-<compound-id="3283,5382654">ether</compound-id> bonds with aqueous-soluble <compound-id="985">palmitic acid</compound-id> derivative at Cys 1 and Cys 7, was reacted with <compound-id="8019">mPEG</compound-id>-<compound-id="11439">succinimide</compound-id> (<compound-id="8019">mPEG</compound-id>-Suc, 5 kDa).	succinimide__sCT__interaction	palmitic acid__sCT__interaction	ether__sCT__interaction	mPEG__sCT__interaction
18704955-1137	Our findings suggest that <protein-id="O12956,P01272,P01273,P01274,P01275,P05110,P06883,P22890,P29794,P55095,P68259,Q06605,Q8MJ25">GLP-1</protein-id> substituted with a PEG of an appropriate Mw at Lys (34) could be used as a promising type 2 anti-diabetic agent to timely control postprandial <compound-id="206,5793,64689,79025">glucose</compound-id> levels.	glucose__GLP-1__interaction
18706130-1404	The antidepressant <compound-id="82148">agomelatine</compound-id> blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (<protein-id="P13591,P13592,P31836">NCAM</protein-id>) expression in the hippocampus of rats.	agomelatine__NCAM__interaction
18706695-1298	<protein-id="P06961,P45269,Q57JQ5,Q5E2K7,Q5F8K9,Q5P3T0,Q5PC82,Q5WT58,Q5X1E5,Q5ZRX9,Q60CQ4,Q62EU1,Q63YC3,Q65Q41,Q665U9,Q6D160,Q6FA38,Q6LV05,Q7M7K5,Q7MAZ9,Q7MBF4,Q821A6,Q82U82,Q87DS9,Q87SK9,Q88A53,Q88QU2,Q8CWL6,Q8CXX6,Q8P5D4,Q8PPG9,Q8XBL4,Q8Y395,Q8Z3M9,Q8ZI64,Q8ZLY4,Q9CP21,Q9I5V3,Q9JUB2,Q9JZ88,Q9KPC6,Q9L7A3,Q9PDL7">Phosphatase</protein-id> activity was also inhibited for all the soils treated with <compound-id="5564">triclosan</compound-id> (from 0.1 to 50mg/kg dry soil), but a declining inhibition was observed after 2 days of incubation.	triclosan__Phosphatase__interaction
18706848-328	The interaction between bovine <protein-id="P21847,P83517">serum albumin</protein-id> (<protein-id="P02769">BSA</protein-id> (5-)) as well as the damage of <protein-id="P02769">BSA</protein-id> in the presence of <compound-id="29936">Fe(III</compound-id>)-<compound-id="875,439655,444305">tartrate</compound-id> complexes under ultrasonic irradiation was studied by UV-vis and fluorescence spectra.	Fe(III__serum albumin__interaction	tartrate__BSA__interaction	tartrate__serum albumin__interaction	Fe(III__BSA__interaction
18706848-329	In addition, the influences of ultrasonic irradiation time, <compound-id="29936">Fe(III</compound-id>)-<compound-id="875,439655,444305">tartrate</compound-id> complex concentration, ionic strength and solution acidity (pH value) were also examined on the damage of <protein-id="P02769">BSA</protein-id>.	tartrate__BSA__interaction	Fe(III__BSA__interaction
18706848-330	Otherwise, under ultrasonic irradiation the <protein-id="P02769">BSA</protein-id> molecules were obviously damaged by the <compound-id="29936">Fe(III</compound-id>)-<compound-id="875,439655,444305">tartrate</compound-id> complexes.	tartrate__BSA__interaction	Fe(III__BSA__interaction
18706940-826	The magnitude of autophagosome formation is tightly regulated by intracellular and extracellular amino acid concentrations and <compound-id="5957">ATP</compound-id> levels via signaling pathways that include the nutrient sensing kinase <protein-id="P51450">TOR</protein-id>.	ATP__TOR__no_interaction
18707755-1088	Normoglycemic (4.72 mmol/L), moderate (11.1 mmol/L) or high grade (16.7 mmol/<compound-id="2724488,10954115">L) glucose</compound-id> clamps were maintained for 6 hours by infusion of <compound-id="206,5793,64689,79025">glucose</compound-id>, <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> and <compound-id="16129681,16129706">somatostatin</compound-id>.	L) glucose__insulin__no_interaction	glucose__insulin__no_interaction	somatostatin__insulin__no_interaction
18708066-1324	or=6 ng/ml) was associated with increased expression of <protein-id="O24999,O35379,O66946,P0AF08,P0AF09,P28667,P32653,P45135,P50863,P53381,P53382,P53383,P65441,P65442,Q92JA4,Q9RVM9,Q9ZE27,Q9ZMM5">mrp</protein-id>-1 and <protein-id="P34712">pgp-1</protein-id> and decreased <compound-id="124886">glutathione</compound-id>, while higher level resistance (10 ng/ml) was primarily associated with the increased expression of P-<protein-id="P08163">glycoproteins</protein-id>.	glutathione__pgp-1__no_interaction	glutathione__glycoproteins__no_interaction	glutathione__mrp__no_interaction
18708157-1383	<compound-id="104729">Co(2</compound-id>+) also induces the release of the pro-apoptotic factors, <protein-id="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3">cytochrome c</protein-id> and <protein-id="O95831">AIF</protein-id>.	Co(2__cytochrome c__interaction	Co(2__AIF__interaction
18708157-1384	Incubation of rat hepatocyte primary cultures with <compound-id="104729">Co(2</compound-id>+) results in apoptosis induction with caspase activation and increased level of expression of <protein-id="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9">HIF-1alpha</protein-id>.	Co(2__HIF-1alpha__interaction
18708158-1385	<compound-id="160355">Roscovitine</compound-id> reduced amounts of the caspase inhibitor XIAP, and API-2 increased amounts of the BH3-only protein <protein-id="O54918,O88498">Bim</protein-id>.	Roscovitine__Bim__no_interaction
18708158-1386	<protein-id="P27297,Q07813,Q63690">Bax</protein-id> accumulated in mitochondria in response to API-2, whereas release of <protein-id="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3">cytochrome c</protein-id> from mitochondria required both API-2 and <compound-id="160355">roscovitine</compound-id>.	roscovitine__Bax__no_interaction	roscovitine__cytochrome c__interaction
18708158-1387	We suggest that <compound-id="160355">roscovitine</compound-id> elicits events that activate <protein-id="P27297,Q07813,Q63690">Bax</protein-id> once it translocates to mitochondria and that inactivation of <protein-id="Q641Z4,Q6GLD8,Q96WV9,Q99J95">cdk9</protein-id> signals these events and the down-regulation of XIAP.	roscovitine__cdk9__interaction	roscovitine__Bax__interaction
18708191-1226	Intravenous <compound-id="738,5961">glutamine</compound-id> enhances <protein-id="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769">COX-2</protein-id> activity giving cardioprotection.	glutamine__COX-2__interaction
18708191-1227	We investigated whether acute intravenous <compound-id="738,5961">glutamine</compound-id>, through an effect on cyclooxygenase (<protein-id="P11353,P36551,P36552,Q9UTE2,Q9V3D2">COX</protein-id>)-2 and heat shock protein (<protein-id="P32590">HSP</protein-id>) 72, might induce preconditioning.	glutamine__HSP__interaction	glutamine__COX__interaction
18708284-1027	Islets from <compound-id="1123">taurine</compound-id>-supplemented mice had: (i) significantly higher <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> content, (ii) increased <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> secretion at stimulatory glucose concentrations, (iii) significantly displaced the dose-response curve for glucose-induced <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> release to the left, (iv) increased glucose metabolism at 5.6 and 11.1-mmol/L concentrations; (v) slowed cytosolic Ca2+ concentration ([Ca2+]i) oscillations in response to stimulatory glucose concentrations; (vi) increased <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>, <protein-id="Q09427,Q09428,Q09429">sulfonylurea receptor-1</protein-id>, <protein-id="O25731,P0A4E1,P0A4E2,P0A6V8,P0A6V9,P17712,P21908,P35557,P52792,P54495,P58616,P58617,P58618,P58619,P64253,P64254,P82680,Q55855,Q56198,Q59171,Q668N7,Q6D7C4,Q7N6Y0,Q83K86,Q87EG6,Q8FFD4,Q8FV09,Q8P8U7,Q8PKU2,Q8UIV7,Q8YDC6,Q92407,Q92T27,Q93IM5,Q98DM2,Q9A6N3,Q9HZ46,Q9KCZ4,Q9PEG4,Q9ZKB0">glucokinase</protein-id>, <protein-id="P12336,P14246">Glut-2</protein-id>, proconvertase and <protein-id="P52945,P52946">pancreas duodenum homeobox-1</protein-id> (<protein-id="P52945">PDX-1</protein-id>) gene expression and (vii) increased <protein-id="P52945">PDX-1</protein-id> expression in the nucleus.	taurine__insulin__interaction	taurine__Glut-2__interaction	taurine__pancreas duodenum homeobox-1__interaction	taurine__glucokinase__interaction	taurine__PDX-1__interaction	taurine__sulfonylurea receptor-1__interaction
18708284-1028	Moreover, <compound-id="1123">taurine</compound-id> supplementation significantly increased both basal and <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> stimulated <compound-id="1153,6057,5460803">tyrosine</compound-id> phosphorylation of the <protein-id="Q28516">insulin receptor</protein-id> in skeletal muscle and liver tissues.	taurine__insulin__interaction	taurine__insulin receptor__interaction	tyrosine__insulin receptor__interaction	tyrosine__insulin__interaction
18708284-1029	These results indicate that <compound-id="1123">taurine</compound-id> controls glucose homeostasis by regulating the expression of genes required for <compound-id="206,5793,64689,79025">glucose</compound-id>-stimulated <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> secretion.	taurine__insulin__interaction	glucose__insulin__interaction
18708284-1030	In addition, <compound-id="1123">taurine</compound-id> enhances peripheral <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> sensitivity.	taurine__insulin__interaction
18708285-1040	Furthermore, treatment of <compound-id="446925">lycopene</compound-id> and EPA also synergistically blocked the activation of downstream <protein-id="P42345,P42346,Q9JLN9">mTOR</protein-id> molecule.	lycopene__mTOR__interaction
18708285-1041	Immunocytochemical staining results revealed that <compound-id="446925">lycopene</compound-id> and EPA could also up-regulate the expression of apoptotic proteins such as <protein-id="P27297,Q07813,Q63690">Bax</protein-id> and <protein-id="P36940,P41047,P48023,P63306,P63307,P63308,Q861W5,Q9BDN1,Q9BEA8">Fas ligand</protein-id> to suppress cell survival.	lycopene__Bax__interaction	lycopene__Fas ligand__interaction
18709446-802	Amino acids (<compound-id="602,4580,5950,71080">alanine</compound-id>, <compound-id="424,5960,83887">aspartic acid</compound-id>, glutamic acid) and <protein-id="P81156">glucose oxidase</protein-id> (GOx) were adsorbed on CNF and the results were compared with those obtained when <compound-id="297">activated carbon</compound-id> (AC) was used as support.	alanine__glucose oxidase__no_interaction	activated carbon__glucose oxidase__no_interaction	aspartic acid__glucose oxidase__no_interaction
18709455-1296	Seven analogues of p-nitrophenyl T-antigen [Galbeta(1--&gt;3)GalNAcalpha(1--&gt;O) <compound-id="980">PNP</compound-id>] have been synthesized as potential substrates for elucidation of the substrate specificity of endo-<protein-id="P83127,Q90744">alpha-N-acetylgalactosaminidase</protein-id>.	PNP__alpha-N-acetylgalactosaminidase__no_interaction
18709646-694	The NSCs and neuroblasts had <protein-id="P55245">epidermal growth factor receptor</protein-id> (<protein-id="P00533,P13387,P55245">EGFR</protein-id>) and platelet-derived growth factor receptor alpha (<protein-id="P16234,P20786,P26618,P26619,Q8AXC7,Q9DE49,Q9PUF6">PDGFRalpha</protein-id>) expressed on the ciliary apparatus and were the only cell types incorporating the proliferation marker <compound-id="6035">BrdU</compound-id>.	BrdU__PDGFRalpha__no_interaction	BrdU__epidermal growth factor receptor__no_interaction	BrdU__EGFR__no_interaction
18709646-695	Ependymal and displaced ependymal cells also expressed <protein-id="P00533,P13387,P55245">EGFR</protein-id> and <protein-id="P16234,P20786,P26618,P26619,Q8AXC7,Q9DE49,Q9PUF6">PDGFRalpha</protein-id> on their cilia but did not incorporate <compound-id="6035">BrdU</compound-id>.	BrdU__PDGFRalpha__no_interaction	BrdU__EGFR__no_interaction
18709647-968	Both 17alpha- and <compound-id="5757">17beta-estradiol</compound-id> elicited rapid phosphorylation of <protein-id="P46672,Q27272,Q8NFH3,Q9SB81">p42</protein-id>/44MAPK, <protein-id="P31750,Q8INB9">Akt</protein-id>, and <protein-id="P18266,P49841,Q5YJC2,Q9WV60">GSK-3beta</protein-id> within 8 min.	17beta-estradiol__Akt__interaction	17beta-estradiol__GSK-3beta__interaction	17beta-estradiol__p42__interaction
18709649-718	Whereas <compound-id="32051">Zn2</compound-id>+-dependent upregulation of <protein-id="O02033,O13257,O18842,O42152,O93571,P02807,P04358,P07216,P08002,P23038,P25127,P25128,P30331,P30565,P51902,P52723,P52725,P52726,P52728,P55945,P55946,P55948,P55951,P55952,P55953,P68494,P68495,P68497,P68498,P68499,P80367,P80593,P84865,Q05890,Q6J1T3,Q6S4N8,Q6XUW5,Q708T3,Q7ZZP9,Q800D3,Q8UVY1,Q94550,Q9IB50,Q9U568">metallothionein</protein-id> may help to counteract excessive astrocyte swelling and production of reactive <compound-id="977">oxygen</compound-id> and <compound-id="945,948,25352,61526,160954,3609161">nitrogen oxide</compound-id> species, stimulation of <protein-id="P16257,P30535,P30536,P50637">PBR</protein-id> expression may augment HE development.	nitrogen oxide__metallothionein__interaction	nitrogen oxide__PBR__no_interaction	Zn2__PBR__no_interaction	oxygen__metallothionein__interaction	oxygen__PBR__no_interaction	Zn2__metallothionein__interaction
18709661-989	Accordingly, the TLR3 agonist <compound-id="32744,213546,274740">poly(I:C</compound-id>) (<compound-id="1854">PIC</compound-id>) induced higher release of <protein-id="O77812,P01574,P01575,P05012,P70499,Q6XZW6,Q9N2J0">IFN-beta</protein-id> in primary and purified astroglia than in microglia.	poly(I:C__IFN-beta__interaction	PIC__IFN-beta__interaction
18709661-990	As siRNA, <compound-id="1854">PIC</compound-id> induced <protein-id="P02778,P17515,P48973">IP-10</protein-id>, <protein-id="P42225">Stat1</protein-id>, <protein-id="P19320,P29533,P29534,Q28260">VCAM-1</protein-id>, and <protein-id="P00411,P24894,P35355,Q05769,Q8HEC3,Q8SEM9">Cox-2</protein-id> and increased <protein-id="O15455,Q0PV50,Q5TJ59">TLR3</protein-id> mRNA expression.	PIC__IP-10__interaction	PIC__VCAM-1__interaction	PIC__Stat1__interaction	PIC__TLR3__interaction	PIC__Cox-2__interaction
18710402-1097	Intracellular concentrations of <compound-id="271">Ca(2</compound-id>+) modulate the strength of signal and alter the outcomes of cytotoxic T-lymphocyte <protein-id="P31522,Q26721,Q56982">antigen-4</protein-id> (<protein-id="P16410">CD152</protein-id>)-<protein-id="P33681,P42070">CD80</protein-id>/<protein-id="P42071,P42081">CD86</protein-id> interactions in CD4 (+) T lymphocytes.	Ca(2__CD80__interaction	Ca(2__CD86__interaction	Ca(2__antigen-4__interaction	Ca(2__CD152__interaction
18710402-1099	During activation with <compound-id="27924,122634,22833501">PMA</compound-id> and low amounts of I, intracellular concentrations of calcium ([<compound-id="271">Ca(2</compound-id>+)](i)) were greatly reduced upon <protein-id="P09793,P16410,P42072,Q9MYX7,Q9XSI1">CTLA-4</protein-id>-<protein-id="P33681,P42070">CD80</protein-id>/<protein-id="P42071,P42081">CD86</protein-id> blockade.	PMA__CD80__interaction	Ca(2__CD86__interaction	PMA__CD86__interaction	PMA__CTLA-4__interaction	Ca(2__CD80__interaction	Ca(2__CTLA-4__interaction
18710402-1100	Further experiments demonstrated that <protein-id="P09793,P16410,P42072,Q9MYX7,Q9XSI1">CTLA-4</protein-id>-<protein-id="P33681,P42070">CD80</protein-id>/<protein-id="P42071,P42081">CD86</protein-id> interactions reduced cell cycling upon activation with <compound-id="27924,122634,22833501">PMA</compound-id> and high amounts of I or TG (high <compound-id="8885">SOS</compound-id>) but the opposite occurred with <compound-id="27924,122634,22833501">PMA</compound-id> and low amounts of I or TG (low <compound-id="8885">SOS</compound-id>).	PMA__CD80__interaction	SOS__CD80__interaction	SOS__CTLA-4__interaction	PMA__CD86__interaction	PMA__CTLA-4__interaction	SOS__CD86__interaction
18710402-1101	Also, <protein-id="P09793,P16410,P42072,Q9MYX7,Q9XSI1">CTLA-4</protein-id>-<protein-id="P33681,P42070">CD80</protein-id>/<protein-id="P42071,P42081">CD86</protein-id> interactions enhanced the generation of reactive <compound-id="977">oxygen</compound-id> species (ROS).	oxygen__CD86__interaction	oxygen__CTLA-4__interaction	oxygen__CD80__interaction
18710604-62	<compound-id="5288258">FSO</compound-id> decreased fasting <compound-id="206,5793,64689,79025">glucose</compound-id> by 20 % and liver weights by 37 % compared with those in the CLA group; it maintained circulating <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id>, HOMA1-IR and HOMA1 for beta cell function at levels found in the control group.	FSO__insulin__no_interaction	glucose__insulin__no_interaction
18710606-240	Animal evidence indicates that <compound-id="4630">green tea</compound-id> may modulate <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> sensitivity, with <compound-id="65064">epigallocatechin-3-gallate</compound-id> (<compound-id="65064">EGCG</compound-id>) proposed as a likely health-promoting component.	EGCG__insulin__no_interaction	epigallocatechin-3-gallate__insulin__no_interaction	green tea__insulin__no_interaction
18710606-241	The purpose of this study was to investigate the effect of dietary supplementation with <compound-id="65064">EGCG</compound-id> on <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> resistance and associated metabolic risk factors in man.	EGCG__insulin__interaction
18710606-242	<compound-id="65064">EGCG</compound-id> treatment had no effect on <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> sensitivity, <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> secretion or <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance but did reduce diastolic blood pressure (mean change: placebo-0.058 (se 0.75) mmHg; <compound-id="65064">EGCG</compound-id>-2.68 (se 0.72) mmHg; P = 0.014).	EGCG__insulin__no_interaction	glucose__insulin__no_interaction
18710606-243	In conclusion, regular intake of <compound-id="65064">EGCG</compound-id> had no effect on <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> resistance but did result in a modest reduction in diastolic blood pressure.	EGCG__insulin__no_interaction
18710702-125	We found that postovulatory administration of 1.5 mg of <compound-id="13109">levonorgestrel</compound-id> to women with a subsequent or existing early pregnancy did not affect the immunohistochemical expressions of <protein-id="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7">estrogen receptors</protein-id> (ER (alpha), ER (beta)), P receptors (PR(B), PR(A+B)), <protein-id="O97775,O97776,O97952,O97960,P10275,P15207,P19091,P49699,Q6QT55,Q7T1K4,Q8MIK0,Q9GKL7,Q9TT90">androgen receptor</protein-id> (AR), or proliferation index Ki67 in the first-trimester decidua and chorionic villi.	levonorgestrel__estrogen receptors__no_interaction	levonorgestrel__androgen receptor__no_interaction
18710819-1300	<compound-id="3385">5-FU</compound-id> effect on HS cell viability was markedly reduced in hypoxic condition without an induction of chemoresistant related protein, P-<protein-id="P08163">glycoprotein</protein-id>.	5-FU__glycoprotein__no_interaction
18710908-298	High-level toxin production occurred after detectable spore germination in all experiments except those with C. difficile PCR ribotype 027 and <compound-id="152946">moxifloxacin</compound-id>, in which marked <protein-id="P07845,P81662">cytotoxin</protein-id> production preceded detectable germination, which coincided with isolate recovery on fluoroquinolone-containing medium.	moxifloxacin__cytotoxin__no_interaction
18711728-143	Furthermore, <protein-id="Q90YJ2,Q99JA8,Q9ER97">Ngb</protein-id> overexpression reduced <compound-id="5359597">superoxide</compound-id> anion generation after H/R, whereas <compound-id="124886">glutathione</compound-id> levels were significantly improved compared with WT controls.	superoxide__Ngb__interaction	glutathione__Ngb__interaction
18711746-961	Our previous studies have shown that <compound-id="5202">serotonin</compound-id> (<compound-id="5202">5-HT</compound-id>) altered under diabetic condition was accompanied by alterations of <protein-id="P13678,Q25378">protein kinase C</protein-id>-alpha (<protein-id="P04409,P05696,P10102,P17252,P20444">PKC-alpha</protein-id>) and <protein-id="Q00168">CaMKII</protein-id>, and those alterations were reversed after <protein-id="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7">insulin</protein-id> administration.	serotonin__PKC-alpha__interaction	serotonin__insulin__interaction	5-HT__PKC-alpha__interaction	5-HT__CaMKII__interaction	5-HT__protein kinase C__interaction	5-HT__insulin__interaction	serotonin__protein kinase C__interaction	serotonin__CaMKII__interaction
18711746-962	The current study showed that <compound-id="5781">alloxan</compound-id>-induced diabetic animals revealed hyperglycemia and was associated with an increase in the content of <compound-id="5202">5-HT</compound-id>, <protein-id="P04409,P05696,P10102,P17252,P20444">PKC-alpha</protein-id> expression and <protein-id="P05130,P13677,P13678,P34722">PKC</protein-id> 0.05) simultaneously in striatum (ST), midbrain (MB), <protein-id="P52430,P55159">pons</protein-id> medulla (PM), cerebellum (CB), and cerebral cortex (CCX) from 7 days to 60 days.	5-HT__PKC-alpha__no_interaction	alloxan__pons__no_interaction	5-HT__PKC__no_interaction	5-HT__pons__no_interaction	alloxan__PKC-alpha__no_interaction	alloxan__PKC__no_interaction
18711746-963	Although the <compound-id="5202">5-HT</compound-id> levels in hippocampus (HC) and hypothalamus (HT) were not altered, the <protein-id="P04409,P05696,P10102,P17252,P20444">PKC-alpha</protein-id> expression and <protein-id="P05130,P13677,P13678,P34722">PKC</protein-id> 0.05) in level in HC.	5-HT__PKC-alpha__no_interaction	5-HT__PKC__no_interaction
18711749-1020	We tested the hypothesis that a <compound-id="145068">nitric oxide</compound-id> donor, <compound-id="1606">DETA-NONOate</compound-id>, up-regulates stromal cell-derived factor-1 (<protein-id="O62657,P48061">SDF1</protein-id>) and angiopoietin 1 (<protein-id="P21570">Ang1</protein-id>) in the ischemic brain and their respective receptors chemokine CXC motif receptor 4 (<protein-id="O62747,P25930,P56491,P56498,P61072,P61073,P79394,Q28474,Q28553,Q3LSL6,Q764M9,Q7YS92,Q8HZU0,Q8HZU1,Q9TSQ8">CXCR4</protein-id>) and <protein-id="O73791,Q02858">Tie2</protein-id> in the subventricular zone (SVZ) and thereby promote SVZ neuroblast cell migration after stroke.	DETA-NONOate__CXCR4__interaction	DETA-NONOate__SDF1__interaction	nitric oxide__Tie2__no_interaction	nitric oxide__SDF1__no_interaction	nitric oxide__Ang1__no_interaction	DETA-NONOate__Tie2__interaction	DETA-NONOate__Ang1__interaction	nitric oxide__CXCR4__no_interaction
18711749-1021	To elucidate whether <protein-id="O62657,P48061">SDF1</protein-id>/CXCR4 and Ang1/Tie2 pathways mediate <compound-id="1606">DETA-NONOate</compound-id>-induced SVZ migration after stroke, SDF1alpha, Ang1 <compound-id="52944803">peptide, a</compound-id> specific antagonist of CXCR4 (<compound-id="65015">AMD3100</compound-id>), and a neutralizing antibody of Tie2 (anti-Tie2) were used in vitro.	AMD3100__SDF1__interaction	DETA-NONOate__SDF1__interaction	peptide, a__SDF1__interaction
18711749-1023	<compound-id="1606">DETA-NONOate</compound-id> significantly increased the expression of <protein-id="O62657,P48061">SDF1</protein-id> and <protein-id="P21570">Ang1</protein-id> in the ischemic border and up-regulated <protein-id="O62747,P25930,P56491,P56498,P61072,P61073,P79394,Q28474,Q28553,Q3LSL6,Q764M9,Q7YS92,Q8HZU0,Q8HZU1,Q9TSQ8">CXCR4</protein-id> and <protein-id="O73791,Q02858">Tie2</protein-id> in the SVZ compared with MCAo control.	DETA-NONOate__CXCR4__interaction	DETA-NONOate__Tie2__interaction	DETA-NONOate__SDF1__interaction	DETA-NONOate__Ang1__interaction
18711749-1025	Our data indicate that treatment of stroke with a <compound-id="145068">nitric oxide</compound-id> donor up-regulates <protein-id="O62657,P48061">SDF1</protein-id>/<protein-id="O62747,P25930,P56491,P56498,P61072,P61073,P79394,Q28474,Q28553,Q3LSL6,Q764M9,Q7YS92,Q8HZU0,Q8HZU1,Q9TSQ8">CXCR4</protein-id> and <protein-id="P21570">Ang1</protein-id>/<protein-id="O73791,Q02858">Tie2</protein-id> pathways and thereby likely increases SVZ neuroblast cell migration.	nitric oxide__Tie2__interaction	nitric oxide__Ang1__interaction	nitric oxide__SDF1__interaction	nitric oxide__CXCR4__interaction
18711750-1026	The MEK inhibitor <compound-id="4713">PD98059</compound-id> did not inhibit neurite outgrowth, and Y-27632 and <compound-id="5279,44259,451705,5311103,5459111,6419748,6711321,9956178,44299148">staurosporine</compound-id> did not induce <protein-id="P29323">ERK</protein-id> phosphorylation, suggesting that the inhibitory effect of <compound-id="1456">ODQ</compound-id> on neurite outgrowth is independent of the <protein-id="P29323">ERK</protein-id> signaling pathway.	PD98059__ERK__no_interaction	ODQ__ERK__no_interaction	staurosporine__ERK__no_interaction
18712272-1403	We used this model to identify a potent competitive inhibitor, N1,N7-dihexyl-1,7-diamino-4-azaheptane, and to develop an affinity column, 1,16-diamino4,13-diazahexadecane-linked <compound-id="11966311">Sepharose</compound-id>, which was useful for the purification of <protein-id="O64411,Q6QHF9,Q865R1,Q9FYC2">PAO</protein-id>.	Sepharose__PAO__no_interaction
18712288-246	Rapid determination of <compound-id="5961,145815">L-glutamine</compound-id> using engineered Escherichia coli overexpressing <protein-id="O00088,O04867,O08467,O27612,O29313,O58097,O59648,O66514,P00964,P04773,P07804,P09606,P0A039,P0A040,P0A1P6,P0A1P7,P0A9C5,P0A9C6,P0A9C7,P0A9C8,P10583,P10656,P11600,P12424,P12425,P13499,P15103,P15104,P15105,P15106,P15124,P15623,P16580,P19064,P19904,P20479,P21154,P22248,P23712,P23794,P25821,P28605,P28786,P32288,P33035,P36205,P43386,P43518,P43794,P45627,P46410,P51120,P51121,P60890,P77961,P94126,P94845,P99095,Q04831,Q05650,Q05907,Q06378,Q09179,Q12613,Q4R7U3,Q5HGC3,Q5HPN2,Q60182,Q6B4U7,Q6C3E0,Q6FMT6,Q6G9Q4,Q6GHC6,Q75BT9,Q86ZF9,Q86ZU6,Q874T6,Q8CSR8,Q8HZM5,Q8J1R3,Q8X169,Q96UG9,Q96UV5,Q96V52,Q9C2U9,Q9CDL9,Q9CLP2,Q9HH09,Q9HNI2,Q9HU65,Q9KNJ2,Q9QY94,Q9UUN6,Q9UY99,Q9ZLW5">glutamine synthetase</protein-id>.	L-glutamine__glutamine synthetase__interaction
